{
    "640f857d201352f04a00002b_0001": [
        {
            "start_logit": 1.4912109375,
            "end_logit": 0.348876953125,
            "text": " systematic Reviews of prediction Modelling Studies (CHARMS)",
            "probability": 0.1873779296875
        },
        {
            "start_logit": 1.4697265625,
            "end_logit": 0.348876953125,
            "text": " data extraction for systematic Reviews of prediction Modelling Studies (CHARMS)",
            "probability": 0.183349609375
        },
        {
            "start_logit": 1.4912109375,
            "end_logit": 0.0633544921875,
            "text": " systematic Reviews of prediction Modelling Studies (CHARMS).",
            "probability": 0.140869140625
        },
        {
            "start_logit": 1.4697265625,
            "end_logit": 0.0633544921875,
            "text": " data extraction for systematic Reviews of prediction Modelling Studies (CHARMS).",
            "probability": 0.137939453125
        },
        {
            "start_logit": 1.4697265625,
            "end_logit": -0.8994140625,
            "text": " data extraction",
            "probability": 0.05267333984375
        },
        {
            "start_logit": 1.4912109375,
            "end_logit": -1.19140625,
            "text": " systematic Reviews of prediction Modelling Studies",
            "probability": 0.0401611328125
        },
        {
            "start_logit": 1.4697265625,
            "end_logit": -1.19140625,
            "text": " data extraction for systematic Reviews of prediction Modelling Studies",
            "probability": 0.039337158203125
        },
        {
            "start_logit": -0.292236328125,
            "end_logit": 0.348876953125,
            "text": " critical Appraisal and data extraction for systematic Reviews of prediction Modelling Studies (CHARMS)",
            "probability": 0.031494140625
        },
        {
            "start_logit": 1.4912109375,
            "end_logit": -1.6142578125,
            "text": " systematic Reviews of prediction Modelling Studies (CHARMS",
            "probability": 0.026336669921875
        },
        {
            "start_logit": 1.4697265625,
            "end_logit": -1.6142578125,
            "text": " data extraction for systematic Reviews of prediction Modelling Studies (CHARMS",
            "probability": 0.0257568359375
        },
        {
            "start_logit": -0.292236328125,
            "end_logit": 0.0633544921875,
            "text": " critical Appraisal and data extraction for systematic Reviews of prediction Modelling Studies (CHARMS).",
            "probability": 0.023681640625
        },
        {
            "start_logit": -0.5107421875,
            "end_logit": 0.0633544921875,
            "text": ".",
            "probability": 0.0190277099609375
        },
        {
            "start_logit": 1.4912109375,
            "end_logit": -2.259765625,
            "text": " systematic Reviews of prediction Modelling",
            "probability": 0.0137939453125
        },
        {
            "start_logit": 1.4697265625,
            "end_logit": -2.259765625,
            "text": " data extraction for systematic Reviews of prediction Modelling",
            "probability": 0.013519287109375
        },
        {
            "start_logit": 1.4912109375,
            "end_logit": -2.40234375,
            "text": " systematic Reviews of prediction",
            "probability": 0.0119781494140625
        },
        {
            "start_logit": 1.4697265625,
            "end_logit": -2.40234375,
            "text": " data extraction for systematic Reviews of prediction",
            "probability": 0.0117034912109375
        },
        {
            "start_logit": 1.4912109375,
            "end_logit": -2.42578125,
            "text": " systematic Reviews",
            "probability": 0.0117034912109375
        },
        {
            "start_logit": 1.4697265625,
            "end_logit": -2.42578125,
            "text": " data extraction for systematic Reviews",
            "probability": 0.01143646240234375
        },
        {
            "start_logit": -0.292236328125,
            "end_logit": -0.8994140625,
            "text": " critical Appraisal and data extraction",
            "probability": 0.00904083251953125
        },
        {
            "start_logit": -1.572265625,
            "end_logit": 0.348876953125,
            "text": "(CHARMS)",
            "probability": 0.00876617431640625
        }
    ],
    "640f857d201352f04a00002b_0002": [
        {
            "start_logit": 3.951171875,
            "end_logit": 0.50341796875,
            "text": " Systematic Reviews of Prediction Modeling Studies (CHARMS)",
            "probability": 0.52978515625
        },
        {
            "start_logit": 3.951171875,
            "end_logit": -0.83642578125,
            "text": " Systematic Reviews of Prediction Modeling Studies",
            "probability": 0.1390380859375
        },
        {
            "start_logit": 3.951171875,
            "end_logit": -0.94775390625,
            "text": " Systematic Reviews of Prediction Modeling Studies (CHARMS),",
            "probability": 0.12432861328125
        },
        {
            "start_logit": 3.951171875,
            "end_logit": -1.8046875,
            "text": " Systematic Reviews of Prediction Modeling Studies (CHARMS",
            "probability": 0.052764892578125
        },
        {
            "start_logit": 3.951171875,
            "end_logit": -2.29296875,
            "text": " Systematic Reviews",
            "probability": 0.032379150390625
        },
        {
            "start_logit": 1.0517578125,
            "end_logit": 0.50341796875,
            "text": "\u00a0Critical Appraisal and Data Extraction for Systematic Reviews of Prediction Modeling Studies (CHARMS)",
            "probability": 0.0291900634765625
        },
        {
            "start_logit": 3.951171875,
            "end_logit": -2.888671875,
            "text": " Systematic Reviews of Prediction Modeling",
            "probability": 0.017852783203125
        },
        {
            "start_logit": 3.951171875,
            "end_logit": -3.365234375,
            "text": " Systematic",
            "probability": 0.01108551025390625
        },
        {
            "start_logit": 3.951171875,
            "end_logit": -3.3671875,
            "text": " Systematic Reviews of Prediction",
            "probability": 0.01105499267578125
        },
        {
            "start_logit": 0.031707763671875,
            "end_logit": 0.50341796875,
            "text": " Checklist for\u00a0Critical Appraisal and Data Extraction for Systematic Reviews of Prediction Modeling Studies (CHARMS)",
            "probability": 0.01053619384765625
        },
        {
            "start_logit": 3.951171875,
            "end_logit": -3.697265625,
            "text": " Systematic Reviews of Prediction Modeling Studies (CHARMS), ",
            "probability": 0.0079498291015625
        },
        {
            "start_logit": 1.0517578125,
            "end_logit": -0.83642578125,
            "text": "\u00a0Critical Appraisal and Data Extraction for Systematic Reviews of Prediction Modeling Studies",
            "probability": 0.007648468017578125
        },
        {
            "start_logit": 1.0517578125,
            "end_logit": -0.94775390625,
            "text": "\u00a0Critical Appraisal and Data Extraction for Systematic Reviews of Prediction Modeling Studies (CHARMS),",
            "probability": 0.006855010986328125
        },
        {
            "start_logit": -1.1796875,
            "end_logit": 0.50341796875,
            "text": " the Checklist for\u00a0Critical Appraisal and Data Extraction for Systematic Reviews of Prediction Modeling Studies (CHARMS)",
            "probability": 0.0031375885009765625
        },
        {
            "start_logit": -1.2314453125,
            "end_logit": 0.50341796875,
            "text": " data based on the Checklist for\u00a0Critical Appraisal and Data Extraction for Systematic Reviews of Prediction Modeling Studies (CHARMS)",
            "probability": 0.00298309326171875
        },
        {
            "start_logit": 1.0517578125,
            "end_logit": -1.8046875,
            "text": "\u00a0Critical Appraisal and Data Extraction for Systematic Reviews of Prediction Modeling Studies (CHARMS",
            "probability": 0.0029010772705078125
        },
        {
            "start_logit": 0.031707763671875,
            "end_logit": -0.83642578125,
            "text": " Checklist for\u00a0Critical Appraisal and Data Extraction for Systematic Reviews of Prediction Modeling Studies",
            "probability": 0.002758026123046875
        },
        {
            "start_logit": -1.3095703125,
            "end_logit": 0.50341796875,
            "text": " extract data based on the Checklist for\u00a0Critical Appraisal and Data Extraction for Systematic Reviews of Prediction Modeling Studies (CHARMS)",
            "probability": 0.002758026123046875
        },
        {
            "start_logit": -1.3681640625,
            "end_logit": 0.50341796875,
            "text": " Data Extraction for Systematic Reviews of Prediction Modeling Studies (CHARMS)",
            "probability": 0.00260162353515625
        },
        {
            "start_logit": 0.031707763671875,
            "end_logit": -0.94775390625,
            "text": " Checklist for\u00a0Critical Appraisal and Data Extraction for Systematic Reviews of Prediction Modeling Studies (CHARMS),",
            "probability": 0.002471923828125
        }
    ],
    "640f857d201352f04a00002b_0003": [
        {
            "start_logit": 3.453125,
            "end_logit": 2.568359375,
            "text": "CHARMS-PF",
            "probability": 0.72119140625
        },
        {
            "start_logit": 3.453125,
            "end_logit": 0.7392578125,
            "text": "CHARMS-PF)",
            "probability": 0.11541748046875
        },
        {
            "start_logit": 3.453125,
            "end_logit": 0.08880615234375,
            "text": "CHARMS-PF).",
            "probability": 0.06024169921875
        },
        {
            "start_logit": 3.453125,
            "end_logit": -0.88525390625,
            "text": "CHARMS",
            "probability": 0.0227813720703125
        },
        {
            "start_logit": -0.167236328125,
            "end_logit": 2.568359375,
            "text": " Data Extraction for Systematic Reviews of Prediction Modeling Studies (CHARMS-PF",
            "probability": 0.019256591796875
        },
        {
            "start_logit": -0.5341796875,
            "end_logit": 2.568359375,
            "text": "(CHARMS-PF",
            "probability": 0.01335906982421875
        },
        {
            "start_logit": -0.69775390625,
            "end_logit": 2.568359375,
            "text": " Systematic Reviews of Prediction Modeling Studies (CHARMS-PF",
            "probability": 0.01134490966796875
        },
        {
            "start_logit": -0.85400390625,
            "end_logit": 2.568359375,
            "text": " Critical Appraisal and Data Extraction for Systematic Reviews of Prediction Modeling Studies (CHARMS-PF",
            "probability": 0.00969696044921875
        },
        {
            "start_logit": -1.134765625,
            "end_logit": 2.568359375,
            "text": "PF",
            "probability": 0.00732421875
        },
        {
            "start_logit": -0.167236328125,
            "end_logit": 0.7392578125,
            "text": " Data Extraction for Systematic Reviews of Prediction Modeling Studies (CHARMS-PF)",
            "probability": 0.00308990478515625
        },
        {
            "start_logit": -0.5341796875,
            "end_logit": 0.7392578125,
            "text": "(CHARMS-PF)",
            "probability": 0.0021381378173828125
        },
        {
            "start_logit": -2.435546875,
            "end_logit": 2.568359375,
            "text": " Prediction Modeling Studies (CHARMS-PF",
            "probability": 0.001995086669921875
        },
        {
            "start_logit": -2.498046875,
            "end_logit": 2.568359375,
            "text": "-PF",
            "probability": 0.001873016357421875
        },
        {
            "start_logit": -0.69775390625,
            "end_logit": 0.7392578125,
            "text": " Systematic Reviews of Prediction Modeling Studies (CHARMS-PF)",
            "probability": 0.0018224716186523438
        },
        {
            "start_logit": -0.167236328125,
            "end_logit": 0.08880615234375,
            "text": " Data Extraction for Systematic Reviews of Prediction Modeling Studies (CHARMS-PF).",
            "probability": 0.0016145706176757812
        },
        {
            "start_logit": -0.85400390625,
            "end_logit": 0.7392578125,
            "text": " Critical Appraisal and Data Extraction for Systematic Reviews of Prediction Modeling Studies (CHARMS-PF)",
            "probability": 0.001560211181640625
        },
        {
            "start_logit": 3.453125,
            "end_logit": -3.572265625,
            "text": "CHAR",
            "probability": 0.001552581787109375
        },
        {
            "start_logit": -2.87109375,
            "end_logit": 2.568359375,
            "text": "Checklist for Critical Appraisal and Data Extraction for Systematic Reviews of Prediction Modeling Studies (CHARMS-PF",
            "probability": 0.0012874603271484375
        },
        {
            "start_logit": -1.134765625,
            "end_logit": 0.7392578125,
            "text": "PF)",
            "probability": 0.0011768341064453125
        },
        {
            "start_logit": -0.5341796875,
            "end_logit": 0.08880615234375,
            "text": "(CHARMS-PF).",
            "probability": 0.0011186599731445312
        }
    ],
    "640f857d201352f04a00002b_0004": [
        {
            "start_logit": 4.43359375,
            "end_logit": 0.74658203125,
            "text": "Critical Appraisal and Data Extraction for Systematic Reviews of Prediction Modeling Studies (CHARMS)",
            "probability": 0.432861328125
        },
        {
            "start_logit": 4.43359375,
            "end_logit": 0.0692138671875,
            "text": "Critical Appraisal and Data Extraction",
            "probability": 0.22021484375
        },
        {
            "start_logit": 4.43359375,
            "end_logit": -0.58056640625,
            "text": "Critical Appraisal and Data Extraction for Systematic Reviews of Prediction Modeling Studies",
            "probability": 0.1148681640625
        },
        {
            "start_logit": 2.435546875,
            "end_logit": 0.74658203125,
            "text": " Systematic Reviews of Prediction Modeling Studies (CHARMS)",
            "probability": 0.058685302734375
        },
        {
            "start_logit": 4.43359375,
            "end_logit": -1.9365234375,
            "text": "Critical Appraisal",
            "probability": 0.0295562744140625
        },
        {
            "start_logit": 4.43359375,
            "end_logit": -2.021484375,
            "text": "Critical Appraisal and Data Extraction for Systematic Reviews of Prediction Modeling",
            "probability": 0.0271759033203125
        },
        {
            "start_logit": 4.43359375,
            "end_logit": -2.373046875,
            "text": "Critical Appraisal and Data Extraction for Systematic Reviews",
            "probability": 0.0191192626953125
        },
        {
            "start_logit": 4.43359375,
            "end_logit": -2.3828125,
            "text": "Critical Appraisal and Data Extraction for Systematic Reviews of Prediction",
            "probability": 0.0189361572265625
        },
        {
            "start_logit": 4.43359375,
            "end_logit": -2.396484375,
            "text": "Critical Appraisal and Data Extraction for Systematic Reviews of Prediction Modeling Studies (CHARMS",
            "probability": 0.0186920166015625
        },
        {
            "start_logit": 2.435546875,
            "end_logit": -0.58056640625,
            "text": " Systematic Reviews of Prediction Modeling Studies",
            "probability": 0.01558685302734375
        },
        {
            "start_logit": 4.43359375,
            "end_logit": -2.927734375,
            "text": "Critical Appraisal and Data",
            "probability": 0.01097869873046875
        },
        {
            "start_logit": 4.43359375,
            "end_logit": -3.310546875,
            "text": "Critical",
            "probability": 0.007503509521484375
        },
        {
            "start_logit": 4.43359375,
            "end_logit": -3.677734375,
            "text": "Critical Appraisal and Data Extraction for",
            "probability": 0.00519561767578125
        },
        {
            "start_logit": -0.2218017578125,
            "end_logit": 0.74658203125,
            "text": " Data Extraction for Systematic Reviews of Prediction Modeling Studies (CHARMS)",
            "probability": 0.00411224365234375
        },
        {
            "start_logit": 2.435546875,
            "end_logit": -2.021484375,
            "text": " Systematic Reviews of Prediction Modeling",
            "probability": 0.00368499755859375
        },
        {
            "start_logit": 4.43359375,
            "end_logit": -4.140625,
            "text": "Critical Appraisal and Data Extraction for Systematic",
            "probability": 0.003265380859375
        },
        {
            "start_logit": 2.435546875,
            "end_logit": -2.373046875,
            "text": " Systematic Reviews",
            "probability": 0.002593994140625
        },
        {
            "start_logit": 2.435546875,
            "end_logit": -2.3828125,
            "text": " Systematic Reviews of Prediction",
            "probability": 0.0025730133056640625
        },
        {
            "start_logit": 2.435546875,
            "end_logit": -2.396484375,
            "text": " Systematic Reviews of Prediction Modeling Studies (CHARMS",
            "probability": 0.0025348663330078125
        },
        {
            "start_logit": -0.2218017578125,
            "end_logit": 0.0692138671875,
            "text": " Data Extraction",
            "probability": 0.0020923614501953125
        }
    ],
    "6410eb95201352f04a00002e_0001": [
        {
            "start_logit": 2.53125,
            "end_logit": 2.978515625,
            "text": " brain",
            "probability": 0.489501953125
        },
        {
            "start_logit": 2.53125,
            "end_logit": 1.859375,
            "text": " brain and heart",
            "probability": 0.16015625
        },
        {
            "start_logit": 1.658203125,
            "end_logit": 1.859375,
            "text": " heart",
            "probability": 0.06689453125
        },
        {
            "start_logit": 0.391845703125,
            "end_logit": 2.978515625,
            "text": " AS is fundamental to organ development, especially for the brain",
            "probability": 0.057769775390625
        },
        {
            "start_logit": 0.337890625,
            "end_logit": 2.978515625,
            "text": " intricate interplay of programs controlling gene expression levels and AS is fundamental to organ development, especially for the brain",
            "probability": 0.0546875
        },
        {
            "start_logit": -0.338623046875,
            "end_logit": 2.978515625,
            "text": " organ development, especially for the brain",
            "probability": 0.02783203125
        },
        {
            "start_logit": 2.53125,
            "end_logit": -0.1435546875,
            "text": " brain and heart.",
            "probability": 0.0215911865234375
        },
        {
            "start_logit": 0.391845703125,
            "end_logit": 1.859375,
            "text": " AS is fundamental to organ development, especially for the brain and heart",
            "probability": 0.01885986328125
        },
        {
            "start_logit": 0.337890625,
            "end_logit": 1.859375,
            "text": " intricate interplay of programs controlling gene expression levels and AS is fundamental to organ development, especially for the brain and heart",
            "probability": 0.0178680419921875
        },
        {
            "start_logit": -0.88525390625,
            "end_logit": 2.978515625,
            "text": " programs controlling gene expression levels and AS is fundamental to organ development, especially for the brain",
            "probability": 0.0160980224609375
        },
        {
            "start_logit": -0.338623046875,
            "end_logit": 1.859375,
            "text": " organ development, especially for the brain and heart",
            "probability": 0.009063720703125
        },
        {
            "start_logit": 1.658203125,
            "end_logit": -0.1435546875,
            "text": " heart.",
            "probability": 0.00904083251953125
        },
        {
            "start_logit": -1.501953125,
            "end_logit": 2.978515625,
            "text": " interplay of programs controlling gene expression levels and AS is fundamental to organ development, especially for the brain",
            "probability": 0.00868988037109375
        },
        {
            "start_logit": 0.391845703125,
            "end_logit": 0.826171875,
            "text": " AS",
            "probability": 0.0067138671875
        },
        {
            "start_logit": -1.7841796875,
            "end_logit": 2.978515625,
            "text": " fundamental to organ development, especially for the brain",
            "probability": 0.006557464599609375
        },
        {
            "start_logit": -1.7958984375,
            "end_logit": 2.978515625,
            "text": ", especially for the brain",
            "probability": 0.006481170654296875
        },
        {
            "start_logit": 0.337890625,
            "end_logit": 0.826171875,
            "text": " intricate interplay of programs controlling gene expression levels and AS",
            "probability": 0.00635528564453125
        },
        {
            "start_logit": -1.98828125,
            "end_logit": 2.978515625,
            "text": " the brain",
            "probability": 0.0053558349609375
        },
        {
            "start_logit": -1.9921875,
            "end_logit": 2.978515625,
            "text": " gene expression levels and AS is fundamental to organ development, especially for the brain",
            "probability": 0.00531005859375
        },
        {
            "start_logit": -0.88525390625,
            "end_logit": 1.859375,
            "text": " programs controlling gene expression levels and AS is fundamental to organ development, especially for the brain and heart",
            "probability": 0.0052490234375
        }
    ],
    "6410eb95201352f04a00002e_0002": [
        {
            "start_logit": 7.296875,
            "end_logit": 6.9609375,
            "text": "Srrm4",
            "probability": 0.39013671875
        },
        {
            "start_logit": 7.296875,
            "end_logit": 6.83203125,
            "text": "Srrm4 and Nova1",
            "probability": 0.341552734375
        },
        {
            "start_logit": 7.0234375,
            "end_logit": 6.83203125,
            "text": "Nova1",
            "probability": 0.261962890625
        },
        {
            "start_logit": 7.296875,
            "end_logit": 1.2666015625,
            "text": "Srrm4 and Nova",
            "probability": 0.0013113021850585938
        },
        {
            "start_logit": 7.0234375,
            "end_logit": 1.2666015625,
            "text": "Nova",
            "probability": 0.0009984970092773438
        },
        {
            "start_logit": 0.72900390625,
            "end_logit": 6.9609375,
            "text": " tissue-specific splicing factors Srrm4",
            "probability": 0.0005488395690917969
        },
        {
            "start_logit": 7.296875,
            "end_logit": 0.28955078125,
            "text": "S",
            "probability": 0.0004940032958984375
        },
        {
            "start_logit": 0.72900390625,
            "end_logit": 6.83203125,
            "text": " tissue-specific splicing factors Srrm4 and Nova1",
            "probability": 0.00048279762268066406
        },
        {
            "start_logit": 0.57568359375,
            "end_logit": 6.9609375,
            "text": "Bioinformatical analysis pointed to the tissue-specific splicing factors Srrm4",
            "probability": 0.0004696846008300781
        },
        {
            "start_logit": 0.57568359375,
            "end_logit": 6.83203125,
            "text": "Bioinformatical analysis pointed to the tissue-specific splicing factors Srrm4 and Nova1",
            "probability": 0.0004127025604248047
        },
        {
            "start_logit": 7.296875,
            "end_logit": -0.04345703125,
            "text": "Srrm4 and Nova1 as likely upstream regulators of the observed splicing changes in the PLN-R14del cardiomyocytes.",
            "probability": 0.00035452842712402344
        },
        {
            "start_logit": 7.296875,
            "end_logit": -0.2252197265625,
            "text": "Srrm",
            "probability": 0.0002949237823486328
        },
        {
            "start_logit": 7.0234375,
            "end_logit": -0.04345703125,
            "text": "Nova1 as likely upstream regulators of the observed splicing changes in the PLN-R14del cardiomyocytes.",
            "probability": 0.0002696514129638672
        },
        {
            "start_logit": -0.2900390625,
            "end_logit": 6.9609375,
            "text": "4",
            "probability": 0.00019800662994384766
        },
        {
            "start_logit": -0.2900390625,
            "end_logit": 6.83203125,
            "text": "4 and Nova1",
            "probability": 0.00017404556274414062
        },
        {
            "start_logit": -0.309814453125,
            "end_logit": 6.83203125,
            "text": "1",
            "probability": 0.00017070770263671875
        },
        {
            "start_logit": 7.296875,
            "end_logit": -1.5966796875,
            "text": "Srrm4 and Nova1 as likely upstream regulators",
            "probability": 7.456541061401367e-05
        },
        {
            "start_logit": 7.296875,
            "end_logit": -1.64453125,
            "text": "Srrm4 and Nova1 as likely upstream regulators of the observed splicing changes in the PLN-R14del cardiomyocytes",
            "probability": 7.11679458618164e-05
        },
        {
            "start_logit": 7.296875,
            "end_logit": -1.6533203125,
            "text": "Srr",
            "probability": 7.11679458618164e-05
        },
        {
            "start_logit": 7.0234375,
            "end_logit": -1.5966796875,
            "text": "Nova1 as likely upstream regulators",
            "probability": 5.716085433959961e-05
        }
    ],
    "64162fb0690f196b5100001a_0001": [
        {
            "start_logit": 6.45703125,
            "end_logit": 6.3203125,
            "text": " point mutations",
            "probability": 0.40380859375
        },
        {
            "start_logit": 5.73828125,
            "end_logit": 6.3203125,
            "text": " deletions, 18% duplications and 18% point mutations",
            "probability": 0.19677734375
        },
        {
            "start_logit": 5.62890625,
            "end_logit": 6.3203125,
            "text": " duplications and 18% point mutations",
            "probability": 0.1763916015625
        },
        {
            "start_logit": 5.73828125,
            "end_logit": 5.33984375,
            "text": " deletions, 18% duplications",
            "probability": 0.07354736328125
        },
        {
            "start_logit": 5.73828125,
            "end_logit": 5.328125,
            "text": " deletions",
            "probability": 0.0723876953125
        },
        {
            "start_logit": 5.62890625,
            "end_logit": 5.33984375,
            "text": " duplications",
            "probability": 0.06591796875
        },
        {
            "start_logit": 1.0712890625,
            "end_logit": 6.3203125,
            "text": " 64% deletions, 18% duplications and 18% point mutations",
            "probability": 0.0018405914306640625
        },
        {
            "start_logit": 6.45703125,
            "end_logit": 0.67822265625,
            "text": " point",
            "probability": 0.0014276504516601562
        },
        {
            "start_logit": 0.6513671875,
            "end_logit": 6.3203125,
            "text": " 18% point mutations",
            "probability": 0.0012121200561523438
        },
        {
            "start_logit": 0.465576171875,
            "end_logit": 6.3203125,
            "text": " 18% duplications and 18% point mutations",
            "probability": 0.0010051727294921875
        },
        {
            "start_logit": 0.138427734375,
            "end_logit": 6.3203125,
            "text": " mutations",
            "probability": 0.0007233619689941406
        },
        {
            "start_logit": 6.45703125,
            "end_logit": -0.0261688232421875,
            "text": " point mutations.",
            "probability": 0.0007042884826660156
        },
        {
            "start_logit": 5.73828125,
            "end_logit": 0.67822265625,
            "text": " deletions, 18% duplications and 18% point",
            "probability": 0.0006957054138183594
        },
        {
            "start_logit": 1.0712890625,
            "end_logit": 5.33984375,
            "text": " 64% deletions, 18% duplications",
            "probability": 0.000690460205078125
        },
        {
            "start_logit": 1.0712890625,
            "end_logit": 5.328125,
            "text": " 64% deletions",
            "probability": 0.0006823539733886719
        },
        {
            "start_logit": 5.62890625,
            "end_logit": 0.67822265625,
            "text": " duplications and 18% point",
            "probability": 0.0006237030029296875
        },
        {
            "start_logit": 0.465576171875,
            "end_logit": 5.33984375,
            "text": " 18% duplications",
            "probability": 0.0003769397735595703
        },
        {
            "start_logit": 5.73828125,
            "end_logit": -0.0261688232421875,
            "text": " deletions, 18% duplications and 18% point mutations.",
            "probability": 0.00034332275390625
        },
        {
            "start_logit": 5.62890625,
            "end_logit": -0.0261688232421875,
            "text": " duplications and 18% point mutations.",
            "probability": 0.0003075599670410156
        },
        {
            "start_logit": 5.73828125,
            "end_logit": -0.51220703125,
            "text": " deletions,",
            "probability": 0.00021135807037353516
        }
    ],
    "64162fb0690f196b5100001a_0002": [
        {
            "start_logit": 5.5859375,
            "end_logit": 5.33984375,
            "text": " exonic duplications",
            "probability": 0.28515625
        },
        {
            "start_logit": 5.578125,
            "end_logit": 5.33984375,
            "text": " exonic deletions, 64 (11.1%) were exonic duplications",
            "probability": 0.28515625
        },
        {
            "start_logit": 5.578125,
            "end_logit": 5.22265625,
            "text": " exonic deletions",
            "probability": 0.251708984375
        },
        {
            "start_logit": 5.5859375,
            "end_logit": 3.6171875,
            "text": " exonic duplications, and one was a deletion/duplication complex rearrangement",
            "probability": 0.0511474609375
        },
        {
            "start_logit": 5.578125,
            "end_logit": 3.6171875,
            "text": " exonic deletions, 64 (11.1%) were exonic duplications, and one was a deletion/duplication complex rearrangement",
            "probability": 0.05072021484375
        },
        {
            "start_logit": 4.828125,
            "end_logit": 3.3671875,
            "text": " nonsense/frameshift types",
            "probability": 0.0186614990234375
        },
        {
            "start_logit": 4.828125,
            "end_logit": 2.599609375,
            "text": " nonsense/frameshift",
            "probability": 0.0086822509765625
        },
        {
            "start_logit": 4.828125,
            "end_logit": 2.400390625,
            "text": " nonsense/frameshift types (75.2%). Mutations in splice sites",
            "probability": 0.007083892822265625
        },
        {
            "start_logit": 5.5859375,
            "end_logit": 1.556640625,
            "text": " exonic duplications, and one was a deletion/duplication complex",
            "probability": 0.006504058837890625
        },
        {
            "start_logit": 5.578125,
            "end_logit": 1.556640625,
            "text": " exonic deletions, 64 (11.1%) were exonic duplications, and one was a deletion/duplication complex",
            "probability": 0.006450653076171875
        },
        {
            "start_logit": 3.513671875,
            "end_logit": 3.6171875,
            "text": " deletion/duplication complex rearrangement",
            "probability": 0.006450653076171875
        },
        {
            "start_logit": 5.5859375,
            "end_logit": 1.458984375,
            "text": " exonic duplications, and one was a deletion/duplication complex rearrangement (0.2%)",
            "probability": 0.00592041015625
        },
        {
            "start_logit": 5.5859375,
            "end_logit": 1.056640625,
            "text": " exonic duplications, and one was a deletion/duplication",
            "probability": 0.00394439697265625
        },
        {
            "start_logit": 5.578125,
            "end_logit": 1.056640625,
            "text": " exonic deletions, 64 (11.1%) were exonic duplications, and one was a deletion/duplication",
            "probability": 0.00391387939453125
        },
        {
            "start_logit": 5.5859375,
            "end_logit": 0.304443359375,
            "text": " exonic duplications,",
            "probability": 0.0018625259399414062
        },
        {
            "start_logit": 5.578125,
            "end_logit": 0.304443359375,
            "text": " exonic deletions, 64 (11.1%) were exonic duplications,",
            "probability": 0.0018482208251953125
        },
        {
            "start_logit": 0.267822265625,
            "end_logit": 5.33984375,
            "text": " duplications",
            "probability": 0.0014057159423828125
        },
        {
            "start_logit": 5.5859375,
            "end_logit": -0.1622314453125,
            "text": " exonic duplications, and one was a deletion/duplication complex rearrangement (0.2%).",
            "probability": 0.0011653900146484375
        },
        {
            "start_logit": 0.052276611328125,
            "end_logit": 5.33984375,
            "text": " deletions, 64 (11.1%) were exonic duplications",
            "probability": 0.001129150390625
        },
        {
            "start_logit": -0.03619384765625,
            "end_logit": 5.33984375,
            "text": " 406 (70.5%) were exonic deletions, 64 (11.1%) were exonic duplications",
            "probability": 0.0010366439819335938
        }
    ],
    "64162fb0690f196b5100001a_0003": [
        {
            "start_logit": 6.14453125,
            "end_logit": 6.1640625,
            "text": " gene duplication",
            "probability": 0.49609375
        },
        {
            "start_logit": 5.5546875,
            "end_logit": 6.1640625,
            "text": "gene deletion rate was 54.3% (391/720), and gene duplication",
            "probability": 0.27392578125
        },
        {
            "start_logit": 5.5546875,
            "end_logit": 5.87109375,
            "text": "gene deletion",
            "probability": 0.20361328125
        },
        {
            "start_logit": 1.7421875,
            "end_logit": 6.1640625,
            "text": " deletion rate was 54.3% (391/720), and gene duplication",
            "probability": 0.006053924560546875
        },
        {
            "start_logit": 1.7421875,
            "end_logit": 5.87109375,
            "text": " deletion",
            "probability": 0.0045166015625
        },
        {
            "start_logit": 1.3037109375,
            "end_logit": 6.1640625,
            "text": " 54.3% (391/720), and gene duplication",
            "probability": 0.003910064697265625
        },
        {
            "start_logit": 1.2666015625,
            "end_logit": 6.1640625,
            "text": " duplication",
            "probability": 0.0037593841552734375
        },
        {
            "start_logit": 6.14453125,
            "end_logit": 0.60693359375,
            "text": " gene duplication rate was 10.6%",
            "probability": 0.0019044876098632812
        },
        {
            "start_logit": 5.5546875,
            "end_logit": 0.81982421875,
            "text": "gene deletion rate was 54.3%",
            "probability": 0.001308441162109375
        },
        {
            "start_logit": 5.5546875,
            "end_logit": 0.60693359375,
            "text": "gene deletion rate was 54.3% (391/720), and gene duplication rate was 10.6%",
            "probability": 0.0010557174682617188
        },
        {
            "start_logit": 6.14453125,
            "end_logit": -0.005084991455078125,
            "text": " gene duplication rate was 10.6% (76/720)",
            "probability": 0.0010356903076171875
        },
        {
            "start_logit": 5.5546875,
            "end_logit": 0.0238037109375,
            "text": "gene deletion rate was 54.3% (391/720)",
            "probability": 0.0005898475646972656
        },
        {
            "start_logit": 6.14453125,
            "end_logit": -0.99365234375,
            "text": " gene duplication rate",
            "probability": 0.000385284423828125
        },
        {
            "start_logit": 5.5546875,
            "end_logit": -0.41845703125,
            "text": "gene deletion rate",
            "probability": 0.0003795623779296875
        },
        {
            "start_logit": 6.14453125,
            "end_logit": -1.431640625,
            "text": " gene",
            "probability": 0.000247955322265625
        },
        {
            "start_logit": 5.5546875,
            "end_logit": -0.95166015625,
            "text": "gene deletion rate was 54.3% (391/720),",
            "probability": 0.00022220611572265625
        },
        {
            "start_logit": -1.58203125,
            "end_logit": 6.1640625,
            "text": "391/720), and gene duplication",
            "probability": 0.00021791458129882812
        },
        {
            "start_logit": 5.5546875,
            "end_logit": -0.99365234375,
            "text": "gene deletion rate was 54.3% (391/720), and gene duplication rate",
            "probability": 0.00021374225616455078
        },
        {
            "start_logit": -1.662109375,
            "end_logit": 6.1640625,
            "text": "3% (391/720), and gene duplication",
            "probability": 0.00020074844360351562
        },
        {
            "start_logit": -1.6669921875,
            "end_logit": 6.1640625,
            "text": " and gene duplication",
            "probability": 0.00020003318786621094
        }
    ],
    "64162fb0690f196b5100001a_0004": [
        {
            "start_logit": 4.4921875,
            "end_logit": 5.08984375,
            "text": " gene duplication",
            "probability": 0.4365234375
        },
        {
            "start_logit": 3.626953125,
            "end_logit": 5.08984375,
            "text": " gene deletion patients; meanwhile, the rate of gene duplication",
            "probability": 0.184814453125
        },
        {
            "start_logit": 4.16796875,
            "end_logit": 3.98828125,
            "text": " deletion",
            "probability": 0.10528564453125
        },
        {
            "start_logit": 4.16796875,
            "end_logit": 3.85546875,
            "text": " deletion mutant occurred in Exon 45-54 was 71.9% (281/391) in all gene deletion",
            "probability": 0.09222412109375
        },
        {
            "start_logit": 3.626953125,
            "end_logit": 3.85546875,
            "text": " gene deletion",
            "probability": 0.053802490234375
        },
        {
            "start_logit": 4.16796875,
            "end_logit": 3.080078125,
            "text": " deletion mutant",
            "probability": 0.04254150390625
        },
        {
            "start_logit": 1.3388671875,
            "end_logit": 5.08984375,
            "text": " duplication",
            "probability": 0.0187225341796875
        },
        {
            "start_logit": 4.4921875,
            "end_logit": 1.693359375,
            "text": " gene duplication occurred in Exon 1-40 was 82.9% (63/76) in all gene duplication",
            "probability": 0.01470947265625
        },
        {
            "start_logit": 0.57470703125,
            "end_logit": 5.08984375,
            "text": " all gene deletion patients; meanwhile, the rate of gene duplication",
            "probability": 0.0087127685546875
        },
        {
            "start_logit": 0.556640625,
            "end_logit": 5.08984375,
            "text": " 71.9% (281/391) in all gene deletion patients; meanwhile, the rate of gene duplication",
            "probability": 0.008575439453125
        },
        {
            "start_logit": 0.36767578125,
            "end_logit": 5.08984375,
            "text": " deletion patients; meanwhile, the rate of gene duplication",
            "probability": 0.007080078125
        },
        {
            "start_logit": 4.16796875,
            "end_logit": 0.92822265625,
            "text": " deletion mutant occurred in Exon 45-54 was 71.9% (281/391)",
            "probability": 0.00494384765625
        },
        {
            "start_logit": 4.4921875,
            "end_logit": 0.356689453125,
            "text": " gene duplication occurred in Exon 1-40 was 82.9% (63/76) in all gene duplication ones",
            "probability": 0.003849029541015625
        },
        {
            "start_logit": 4.16796875,
            "end_logit": 0.56787109375,
            "text": " deletion mutant occurred in Exon 45-54 was 71.9% (281/391) in all gene",
            "probability": 0.00344085693359375
        },
        {
            "start_logit": 4.4921875,
            "end_logit": 0.08367919921875,
            "text": " gene duplication occurred in Exon 1-40 was 82.9% (63/76)",
            "probability": 0.0029296875
        },
        {
            "start_logit": 0.57470703125,
            "end_logit": 3.85546875,
            "text": " all gene deletion",
            "probability": 0.002536773681640625
        },
        {
            "start_logit": 0.556640625,
            "end_logit": 3.85546875,
            "text": " 71.9% (281/391) in all gene deletion",
            "probability": 0.0024967193603515625
        },
        {
            "start_logit": 4.16796875,
            "end_logit": 0.2283935546875,
            "text": " deletion mutant occurred in Exon 45-54 was 71.9% (281/391) in all gene deletion patients",
            "probability": 0.0024471282958984375
        },
        {
            "start_logit": 4.4921875,
            "end_logit": -0.12152099609375,
            "text": " gene duplication occurred in Exon 1-40 was 82.9% (63/76) in all gene duplication ones.",
            "probability": 0.002391815185546875
        },
        {
            "start_logit": 4.16796875,
            "end_logit": 0.197265625,
            "text": " deletion mutant occurred in Exon 45-54",
            "probability": 0.00238037109375
        }
    ],
    "64162fb0690f196b5100001a_0005": [
        {
            "start_logit": 5.8671875,
            "end_logit": 4.8203125,
            "text": "BMD",
            "probability": 0.310546875
        },
        {
            "start_logit": 4.5625,
            "end_logit": 5.1796875,
            "text": " gene deletion and duplication",
            "probability": 0.12066650390625
        },
        {
            "start_logit": 4.7421875,
            "end_logit": 4.8203125,
            "text": " IMD was 90.6% (423/467), and BMD",
            "probability": 0.100830078125
        },
        {
            "start_logit": 4.64453125,
            "end_logit": 4.8203125,
            "text": "DMD and IMD was 90.6% (423/467), and BMD",
            "probability": 0.091796875
        },
        {
            "start_logit": 4.7421875,
            "end_logit": 4.30078125,
            "text": " IMD",
            "probability": 0.0601806640625
        },
        {
            "start_logit": 4.64453125,
            "end_logit": 4.30078125,
            "text": "DMD and IMD",
            "probability": 0.05438232421875
        },
        {
            "start_logit": 4.5625,
            "end_logit": 4.30078125,
            "text": " gene deletion and duplication, the rate of DMD and IMD",
            "probability": 0.0499267578125
        },
        {
            "start_logit": 4.5625,
            "end_logit": 4.2265625,
            "text": " gene deletion",
            "probability": 0.0465087890625
        },
        {
            "start_logit": 3.1875,
            "end_logit": 5.1796875,
            "text": " duplication",
            "probability": 0.030517578125
        },
        {
            "start_logit": 4.64453125,
            "end_logit": 3.54296875,
            "text": "DMD",
            "probability": 0.025482177734375
        },
        {
            "start_logit": 4.5625,
            "end_logit": 3.54296875,
            "text": " gene deletion and duplication, the rate of DMD",
            "probability": 0.0235748291015625
        },
        {
            "start_logit": 3.1875,
            "end_logit": 4.8203125,
            "text": " duplication, the rate of DMD and IMD was 90.6% (423/467), and BMD",
            "probability": 0.02130126953125
        },
        {
            "start_logit": 2.541015625,
            "end_logit": 5.1796875,
            "text": " deletion and duplication",
            "probability": 0.0159454345703125
        },
        {
            "start_logit": 3.1875,
            "end_logit": 4.30078125,
            "text": " duplication, the rate of DMD and IMD",
            "probability": 0.01267242431640625
        },
        {
            "start_logit": 5.8671875,
            "end_logit": 1.4140625,
            "text": "BMD, 9.4% (44/467)",
            "probability": 0.0102996826171875
        },
        {
            "start_logit": 2.541015625,
            "end_logit": 4.30078125,
            "text": " deletion and duplication, the rate of DMD and IMD",
            "probability": 0.00664520263671875
        },
        {
            "start_logit": 2.541015625,
            "end_logit": 4.2265625,
            "text": " deletion",
            "probability": 0.0061492919921875
        },
        {
            "start_logit": 3.1875,
            "end_logit": 3.54296875,
            "text": " duplication, the rate of DMD",
            "probability": 0.0059356689453125
        },
        {
            "start_logit": 5.8671875,
            "end_logit": 0.4248046875,
            "text": "BM",
            "probability": 0.0038318634033203125
        },
        {
            "start_logit": 2.541015625,
            "end_logit": 3.54296875,
            "text": " deletion and duplication, the rate of DMD",
            "probability": 0.0031147003173828125
        }
    ],
    "64162fb0690f196b5100001a_0006": [
        {
            "start_logit": 5.84765625,
            "end_logit": 5.78515625,
            "text": " point mutations",
            "probability": 0.3349609375
        },
        {
            "start_logit": 5.03515625,
            "end_logit": 5.78515625,
            "text": " duplications, about 26% point mutations",
            "probability": 0.148681640625
        },
        {
            "start_logit": 4.91015625,
            "end_logit": 5.78515625,
            "text": " deletions, about 7% duplications, about 26% point mutations",
            "probability": 0.131103515625
        },
        {
            "start_logit": 5.03515625,
            "end_logit": 5.14453125,
            "text": " duplications",
            "probability": 0.07830810546875
        },
        {
            "start_logit": 5.84765625,
            "end_logit": 4.328125,
            "text": " point mutations and about 2% unknown mutations",
            "probability": 0.07769775390625
        },
        {
            "start_logit": 4.91015625,
            "end_logit": 5.14453125,
            "text": " deletions, about 7% duplications",
            "probability": 0.069091796875
        },
        {
            "start_logit": 4.91015625,
            "end_logit": 4.86328125,
            "text": " deletions",
            "probability": 0.052154541015625
        },
        {
            "start_logit": 5.03515625,
            "end_logit": 4.328125,
            "text": " duplications, about 26% point mutations and about 2% unknown mutations",
            "probability": 0.03448486328125
        },
        {
            "start_logit": 4.91015625,
            "end_logit": 4.328125,
            "text": " deletions, about 7% duplications, about 26% point mutations and about 2% unknown mutations",
            "probability": 0.030426025390625
        },
        {
            "start_logit": 2.5546875,
            "end_logit": 5.78515625,
            "text": " Xlinked dystrophin gene (about 65% deletions, about 7% duplications, about 26% point mutations",
            "probability": 0.01248931884765625
        },
        {
            "start_logit": 3.478515625,
            "end_logit": 4.328125,
            "text": " unknown mutations",
            "probability": 0.007282257080078125
        },
        {
            "start_logit": 2.5546875,
            "end_logit": 5.14453125,
            "text": " Xlinked dystrophin gene (about 65% deletions, about 7% duplications",
            "probability": 0.00655364990234375
        },
        {
            "start_logit": 2.5546875,
            "end_logit": 4.86328125,
            "text": " Xlinked dystrophin gene (about 65% deletions",
            "probability": 0.004947662353515625
        },
        {
            "start_logit": 2.5546875,
            "end_logit": 4.328125,
            "text": " Xlinked dystrophin gene (about 65% deletions, about 7% duplications, about 26% point mutations and about 2% unknown mutations",
            "probability": 0.0028972625732421875
        },
        {
            "start_logit": 5.84765625,
            "end_logit": 0.9130859375,
            "text": " point",
            "probability": 0.0025653839111328125
        },
        {
            "start_logit": 5.84765625,
            "end_logit": 0.72705078125,
            "text": " point mutations and about 2% unknown",
            "probability": 0.00212860107421875
        },
        {
            "start_logit": 5.84765625,
            "end_logit": 0.1285400390625,
            "text": " point mutations and about 2% unknown mutations)",
            "probability": 0.001171112060546875
        },
        {
            "start_logit": 5.03515625,
            "end_logit": 0.9130859375,
            "text": " duplications, about 26% point",
            "probability": 0.0011386871337890625
        },
        {
            "start_logit": 0.07159423828125,
            "end_logit": 5.78515625,
            "text": " mutations",
            "probability": 0.00103759765625
        },
        {
            "start_logit": 4.91015625,
            "end_logit": 0.9130859375,
            "text": " deletions, about 7% duplications, about 26% point",
            "probability": 0.0010051727294921875
        }
    ],
    "63eef3ebf36125a42600000a_0001": [
        {
            "start_logit": 7.0859375,
            "end_logit": 6.41015625,
            "text": "BDCA2",
            "probability": 0.994140625
        },
        {
            "start_logit": 7.0859375,
            "end_logit": -0.00930023193359375,
            "text": "BDCA2 Antibody",
            "probability": 0.0016164779663085938
        },
        {
            "start_logit": 7.0859375,
            "end_logit": -0.0518798828125,
            "text": "BDCA2 Antibody Litifilimab for Cutaneous Lupus Erythematosus.",
            "probability": 0.0015478134155273438
        },
        {
            "start_logit": 7.0859375,
            "end_logit": -0.95166015625,
            "text": "B",
            "probability": 0.0006279945373535156
        },
        {
            "start_logit": 7.0859375,
            "end_logit": -1.36328125,
            "text": "BDCA",
            "probability": 0.00041675567626953125
        },
        {
            "start_logit": 7.0859375,
            "end_logit": -1.712890625,
            "text": "BDCA2 Antibody Litifilimab for Cutaneous Lupus Erythematosus",
            "probability": 0.0002944469451904297
        },
        {
            "start_logit": -1.09765625,
            "end_logit": 6.41015625,
            "text": "DCA2",
            "probability": 0.00027632713317871094
        },
        {
            "start_logit": 7.0859375,
            "end_logit": -1.806640625,
            "text": "BD",
            "probability": 0.00026798248291015625
        },
        {
            "start_logit": -1.4326171875,
            "end_logit": 6.41015625,
            "text": "2",
            "probability": 0.00019752979278564453
        },
        {
            "start_logit": -1.8642578125,
            "end_logit": 6.41015625,
            "text": "CA2",
            "probability": 0.00012862682342529297
        },
        {
            "start_logit": -1.8916015625,
            "end_logit": 6.41015625,
            "text": "Trial of Anti-BDCA2",
            "probability": 0.0001246929168701172
        },
        {
            "start_logit": 7.0859375,
            "end_logit": -3.484375,
            "text": "BDCA2 Antibody Litifilimab",
            "probability": 4.9948692321777344e-05
        },
        {
            "start_logit": 7.0859375,
            "end_logit": -3.513671875,
            "text": "BDCA2 Antibody Litifilimab for Cutaneous Lupus",
            "probability": 4.839897155761719e-05
        },
        {
            "start_logit": -2.951171875,
            "end_logit": 6.41015625,
            "text": " Anti-BDCA2",
            "probability": 4.3451786041259766e-05
        },
        {
            "start_logit": -3.017578125,
            "end_logit": 6.41015625,
            "text": "-BDCA2",
            "probability": 4.0471553802490234e-05
        },
        {
            "start_logit": 7.0859375,
            "end_logit": -4.0078125,
            "text": "BDCA2 Antibody Litifili",
            "probability": 2.962350845336914e-05
        },
        {
            "start_logit": 7.0859375,
            "end_logit": -4.19140625,
            "text": "BDCA2 Antibody ",
            "probability": 2.4557113647460938e-05
        },
        {
            "start_logit": 7.0859375,
            "end_logit": -4.20703125,
            "text": "BDCA2 Antibody Litif",
            "probability": 2.4199485778808594e-05
        },
        {
            "start_logit": -3.64453125,
            "end_logit": 6.41015625,
            "text": " of Anti-BDCA2",
            "probability": 2.1636486053466797e-05
        },
        {
            "start_logit": -0.50146484375,
            "end_logit": -0.0518798828125,
            "text": ".",
            "probability": 7.748603820800781e-07
        }
    ],
    "63eef3ebf36125a42600000a_0002": [
        {
            "start_logit": 7.63671875,
            "end_logit": 7.0390625,
            "text": "BDCA2",
            "probability": 0.998046875
        },
        {
            "start_logit": 7.63671875,
            "end_logit": -0.1981201171875,
            "text": "BDCA2, would be efficacious in reducing disease activity in patients with cutaneous lupus erythematosus has not been extensively studied.",
            "probability": 0.0007200241088867188
        },
        {
            "start_logit": 7.63671875,
            "end_logit": -0.9814453125,
            "text": "B",
            "probability": 0.0003294944763183594
        },
        {
            "start_logit": 7.63671875,
            "end_logit": -1.09765625,
            "text": "BDCA2,",
            "probability": 0.0002932548522949219
        },
        {
            "start_logit": 7.63671875,
            "end_logit": -1.3544921875,
            "text": "BDCA",
            "probability": 0.00022649765014648438
        },
        {
            "start_logit": 7.63671875,
            "end_logit": -2.076171875,
            "text": "BD",
            "probability": 0.00011038780212402344
        },
        {
            "start_logit": -1.5185546875,
            "end_logit": 7.0390625,
            "text": "DCA2",
            "probability": 0.00010538101196289062
        },
        {
            "start_logit": -1.6162109375,
            "end_logit": 7.0390625,
            "text": "2",
            "probability": 9.590387344360352e-05
        },
        {
            "start_logit": 7.63671875,
            "end_logit": -2.673828125,
            "text": "BDCA2, would be efficacious in reducing disease activity in patients with cutaneous lupus erythematosus",
            "probability": 6.0498714447021484e-05
        },
        {
            "start_logit": -2.23828125,
            "end_logit": 7.0390625,
            "text": "CA2",
            "probability": 5.131959915161133e-05
        },
        {
            "start_logit": -2.333984375,
            "end_logit": 7.0390625,
            "text": ", a humanized monoclonal antibody against BDCA2",
            "probability": 4.673004150390625e-05
        },
        {
            "start_logit": 7.63671875,
            "end_logit": -3.474609375,
            "text": "BDCA2, would be efficacious in",
            "probability": 2.7239322662353516e-05
        },
        {
            "start_logit": -2.9453125,
            "end_logit": 7.0390625,
            "text": " monoclonal antibody against BDCA2",
            "probability": 2.5391578674316406e-05
        },
        {
            "start_logit": -3.095703125,
            "end_logit": 7.0390625,
            "text": "litifilimab, a humanized monoclonal antibody against BDCA2",
            "probability": 2.187490463256836e-05
        },
        {
            "start_logit": -3.224609375,
            "end_logit": 7.0390625,
            "text": " treatment with litifilimab, a humanized monoclonal antibody against BDCA2",
            "probability": 1.919269561767578e-05
        },
        {
            "start_logit": -3.232421875,
            "end_logit": 7.0390625,
            "text": " humanized monoclonal antibody against BDCA2",
            "probability": 1.901388168334961e-05
        },
        {
            "start_logit": 7.63671875,
            "end_logit": -3.966796875,
            "text": "BDCA2, would be efficacious in reducing disease activity in patients with cutaneous lupus",
            "probability": 1.6629695892333984e-05
        },
        {
            "start_logit": 7.63671875,
            "end_logit": -4.23828125,
            "text": "BDCA2, would be efficacious in reducing disease activity",
            "probability": 1.2695789337158203e-05
        },
        {
            "start_logit": -3.666015625,
            "end_logit": 7.0390625,
            "text": " a humanized monoclonal antibody against BDCA2",
            "probability": 1.239776611328125e-05
        },
        {
            "start_logit": -3.767578125,
            "end_logit": 7.0390625,
            "text": " antibody against BDCA2",
            "probability": 1.1205673217773438e-05
        }
    ],
    "63eef3ebf36125a42600000a_0003": [
        {
            "start_logit": 7.0546875,
            "end_logit": 6.44921875,
            "text": "BDCA2",
            "probability": 0.994140625
        },
        {
            "start_logit": 7.0546875,
            "end_logit": 0.055633544921875,
            "text": "BDCA2 Antibody",
            "probability": 0.0016679763793945312
        },
        {
            "start_logit": 7.0546875,
            "end_logit": -0.055755615234375,
            "text": "BDCA2 Antibody Litifilimab for Systemic Lupus Erythematosus.",
            "probability": 0.0014944076538085938
        },
        {
            "start_logit": 7.0546875,
            "end_logit": -0.95751953125,
            "text": "B",
            "probability": 0.000606536865234375
        },
        {
            "start_logit": 7.0546875,
            "end_logit": -1.3701171875,
            "text": "BDCA",
            "probability": 0.00040078163146972656
        },
        {
            "start_logit": -1.0791015625,
            "end_logit": 6.44921875,
            "text": "DCA2",
            "probability": 0.0002944469451904297
        },
        {
            "start_logit": 7.0546875,
            "end_logit": -1.794921875,
            "text": "BD",
            "probability": 0.0002617835998535156
        },
        {
            "start_logit": 7.0546875,
            "end_logit": -2.0234375,
            "text": "BDCA2 Antibody Litifilimab for Systemic Lupus Erythematosus",
            "probability": 0.00020873546600341797
        },
        {
            "start_logit": -1.416015625,
            "end_logit": 6.44921875,
            "text": "2",
            "probability": 0.00020873546600341797
        },
        {
            "start_logit": -1.833984375,
            "end_logit": 6.44921875,
            "text": "CA2",
            "probability": 0.0001379251480102539
        },
        {
            "start_logit": -1.8837890625,
            "end_logit": 6.44921875,
            "text": "Trial of Anti-BDCA2",
            "probability": 0.00013065338134765625
        },
        {
            "start_logit": 7.0546875,
            "end_logit": -3.49609375,
            "text": "BDCA2 Antibody Litifilimab",
            "probability": 4.8041343688964844e-05
        },
        {
            "start_logit": -2.95703125,
            "end_logit": 6.44921875,
            "text": " Anti-BDCA2",
            "probability": 4.482269287109375e-05
        },
        {
            "start_logit": -3.064453125,
            "end_logit": 6.44921875,
            "text": "-BDCA2",
            "probability": 4.011392593383789e-05
        },
        {
            "start_logit": 7.0546875,
            "end_logit": -3.7421875,
            "text": "BDCA2 Antibody Litifilimab for Systemic Lupus",
            "probability": 3.737211227416992e-05
        },
        {
            "start_logit": 7.0546875,
            "end_logit": -4.1640625,
            "text": "BDCA2 Antibody Litifili",
            "probability": 2.4557113647460938e-05
        },
        {
            "start_logit": 7.0546875,
            "end_logit": -4.19921875,
            "text": "BDCA2 Antibody ",
            "probability": 2.378225326538086e-05
        },
        {
            "start_logit": -3.623046875,
            "end_logit": 6.44921875,
            "text": " of Anti-BDCA2",
            "probability": 2.3066997528076172e-05
        },
        {
            "start_logit": 7.0546875,
            "end_logit": -4.29296875,
            "text": "BDCA2 Antibody Litif",
            "probability": 2.1636486053466797e-05
        },
        {
            "start_logit": -0.497314453125,
            "end_logit": -0.055755615234375,
            "text": ".",
            "probability": 7.748603820800781e-07
        }
    ],
    "63eef3ebf36125a42600000a_0004": [
        {
            "start_logit": 7.61328125,
            "end_logit": 7.0625,
            "text": "BDCA2",
            "probability": 0.998046875
        },
        {
            "start_logit": 7.61328125,
            "end_logit": -0.2265625,
            "text": "BDCA2, in patients with SLE have not been extensively studied.",
            "probability": 0.0006842613220214844
        },
        {
            "start_logit": 7.61328125,
            "end_logit": -1.0859375,
            "text": "B",
            "probability": 0.00029087066650390625
        },
        {
            "start_logit": 7.61328125,
            "end_logit": -1.42578125,
            "text": "BDCA2,",
            "probability": 0.00020635128021240234
        },
        {
            "start_logit": 7.61328125,
            "end_logit": -1.4443359375,
            "text": "BDCA",
            "probability": 0.00020313262939453125
        },
        {
            "start_logit": 7.61328125,
            "end_logit": -1.896484375,
            "text": "BDCA2, in patients with SLE",
            "probability": 0.0001291036605834961
        },
        {
            "start_logit": 7.61328125,
            "end_logit": -1.955078125,
            "text": "BD",
            "probability": 0.00012123584747314453
        },
        {
            "start_logit": -1.642578125,
            "end_logit": 7.0625,
            "text": "2",
            "probability": 9.590387344360352e-05
        },
        {
            "start_logit": -1.8203125,
            "end_logit": 7.0625,
            "text": "DCA2",
            "probability": 8.0108642578125e-05
        },
        {
            "start_logit": -2.400390625,
            "end_logit": 7.0625,
            "text": "CA2",
            "probability": 4.500150680541992e-05
        },
        {
            "start_logit": -2.466796875,
            "end_logit": 7.0625,
            "text": " subcutaneous litifilimab, a humanized monoclonal antibody that binds to BDCA2",
            "probability": 4.190206527709961e-05
        },
        {
            "start_logit": -2.529296875,
            "end_logit": 7.0625,
            "text": ", a humanized monoclonal antibody that binds to BDCA2",
            "probability": 3.93986701965332e-05
        },
        {
            "start_logit": -2.572265625,
            "end_logit": 7.0625,
            "text": "litifilimab, a humanized monoclonal antibody that binds to BDCA2",
            "probability": 3.784894943237305e-05
        },
        {
            "start_logit": -2.859375,
            "end_logit": 7.0625,
            "text": " safety and efficacy of subcutaneous litifilimab, a humanized monoclonal antibody that binds to BDCA2",
            "probability": 2.8371810913085938e-05
        },
        {
            "start_logit": -2.86328125,
            "end_logit": 7.0625,
            "text": " monoclonal antibody that binds to BDCA2",
            "probability": 2.8371810913085938e-05
        },
        {
            "start_logit": -2.984375,
            "end_logit": 7.0625,
            "text": " humanized monoclonal antibody that binds to BDCA2",
            "probability": 2.5033950805664062e-05
        },
        {
            "start_logit": -2.9921875,
            "end_logit": 7.0625,
            "text": " binds to BDCA2",
            "probability": 2.47955322265625e-05
        },
        {
            "start_logit": -3.166015625,
            "end_logit": 7.0625,
            "text": " antibody that binds to BDCA2",
            "probability": 2.086162567138672e-05
        },
        {
            "start_logit": -3.4140625,
            "end_logit": 7.0625,
            "text": " a humanized monoclonal antibody that binds to BDCA2",
            "probability": 1.627206802368164e-05
        },
        {
            "start_logit": -0.74560546875,
            "end_logit": -0.2265625,
            "text": ".",
            "probability": 1.7881393432617188e-07
        }
    ],
    "64136fbf201352f04a00003d_0001": [
        {
            "start_logit": 4.4921875,
            "end_logit": 1.236328125,
            "text": " area under the receiver operator characteristics curve",
            "probability": 0.458740234375
        },
        {
            "start_logit": 4.4921875,
            "end_logit": 0.36669921875,
            "text": " area under the receiver operator characteristics curve (area under the receiver operating characteristic curve)",
            "probability": 0.1927490234375
        },
        {
            "start_logit": 3.16796875,
            "end_logit": 1.236328125,
            "text": " The area under the receiver operator characteristics curve",
            "probability": 0.12255859375
        },
        {
            "start_logit": 4.4921875,
            "end_logit": -0.365478515625,
            "text": " area under the receiver operator characteristics curve (area under the receiver operating characteristic curve",
            "probability": 0.09246826171875
        },
        {
            "start_logit": 3.16796875,
            "end_logit": 0.36669921875,
            "text": " The area under the receiver operator characteristics curve (area under the receiver operating characteristic curve)",
            "probability": 0.05126953125
        },
        {
            "start_logit": 3.16796875,
            "end_logit": -0.365478515625,
            "text": " The area under the receiver operator characteristics curve (area under the receiver operating characteristic curve",
            "probability": 0.024658203125
        },
        {
            "start_logit": 4.4921875,
            "end_logit": -1.982421875,
            "text": " area under the receiver operator characteristics",
            "probability": 0.0183868408203125
        },
        {
            "start_logit": 0.2421875,
            "end_logit": 1.236328125,
            "text": " receiver operator characteristics curve",
            "probability": 0.0065460205078125
        },
        {
            "start_logit": 4.4921875,
            "end_logit": -3.017578125,
            "text": " area under the receiver operator characteristics curve (area under the receiver operating characteristic",
            "probability": 0.0065460205078125
        },
        {
            "start_logit": 4.4921875,
            "end_logit": -3.12109375,
            "text": " area",
            "probability": 0.005886077880859375
        },
        {
            "start_logit": 3.16796875,
            "end_logit": -1.982421875,
            "text": " The area under the receiver operator characteristics",
            "probability": 0.004901885986328125
        },
        {
            "start_logit": 0.2421875,
            "end_logit": 0.36669921875,
            "text": " receiver operator characteristics curve (area under the receiver operating characteristic curve)",
            "probability": 0.0027484893798828125
        },
        {
            "start_logit": 4.4921875,
            "end_logit": -3.958984375,
            "text": " area under the receiver operator characteristics curve (area under",
            "probability": 0.0025424957275390625
        },
        {
            "start_logit": 3.16796875,
            "end_logit": -3.017578125,
            "text": " The area under the receiver operator characteristics curve (area under the receiver operating characteristic",
            "probability": 0.0017347335815429688
        },
        {
            "start_logit": 3.16796875,
            "end_logit": -3.12109375,
            "text": " The area",
            "probability": 0.0015659332275390625
        },
        {
            "start_logit": 4.4921875,
            "end_logit": -4.50390625,
            "text": " area under the receiver operator characteristics curve (area",
            "probability": 0.0014772415161132812
        },
        {
            "start_logit": 4.4921875,
            "end_logit": -4.5703125,
            "text": " area under",
            "probability": 0.0013828277587890625
        },
        {
            "start_logit": 4.4921875,
            "end_logit": -4.578125,
            "text": " area under the",
            "probability": 0.0013723373413085938
        },
        {
            "start_logit": 0.2421875,
            "end_logit": -0.365478515625,
            "text": " receiver operator characteristics curve (area under the receiver operating characteristic curve",
            "probability": 0.00131988525390625
        },
        {
            "start_logit": 4.4921875,
            "end_logit": -4.8125,
            "text": " area under the receiver",
            "probability": 0.0010852813720703125
        }
    ],
    "64136fbf201352f04a00003d_0002": [
        {
            "start_logit": 5.05078125,
            "end_logit": 2.908203125,
            "text": "area under receiver operator curve",
            "probability": 0.94482421875
        },
        {
            "start_logit": 5.05078125,
            "end_logit": -0.77294921875,
            "text": "area under receiver operator curve [area under the receiver operating characteristic curve",
            "probability": 0.02374267578125
        },
        {
            "start_logit": 5.05078125,
            "end_logit": -1.1396484375,
            "text": "area under receiver operator curve [area under the receiver operating characteristic curve]",
            "probability": 0.016448974609375
        },
        {
            "start_logit": 5.05078125,
            "end_logit": -2.748046875,
            "text": "area under receiver operator curve [area under the receiver operating characteristic",
            "probability": 0.00330352783203125
        },
        {
            "start_logit": 5.05078125,
            "end_logit": -3.048828125,
            "text": "area",
            "probability": 0.00243377685546875
        },
        {
            "start_logit": 5.05078125,
            "end_logit": -3.099609375,
            "text": "area under receiver operator",
            "probability": 0.002323150634765625
        },
        {
            "start_logit": -1.33984375,
            "end_logit": 2.908203125,
            "text": " receiver operator curve",
            "probability": 0.0015850067138671875
        },
        {
            "start_logit": -1.9287109375,
            "end_logit": 2.908203125,
            "text": " operator curve",
            "probability": 0.0008783340454101562
        },
        {
            "start_logit": -2.021484375,
            "end_logit": 2.908203125,
            "text": " under receiver operator curve",
            "probability": 0.0008001327514648438
        },
        {
            "start_logit": 5.05078125,
            "end_logit": -4.21484375,
            "text": "area under receiver operator curve [area",
            "probability": 0.0007605552673339844
        },
        {
            "start_logit": 5.05078125,
            "end_logit": -4.36328125,
            "text": "area under receiver operator curve [area under the receiver operating characteristic curve] ",
            "probability": 0.0006551742553710938
        },
        {
            "start_logit": 5.05078125,
            "end_logit": -4.609375,
            "text": "area under receiver",
            "probability": 0.0005121231079101562
        },
        {
            "start_logit": 5.05078125,
            "end_logit": -4.7578125,
            "text": "area under receiver operator curve [area under",
            "probability": 0.00044155120849609375
        },
        {
            "start_logit": 5.05078125,
            "end_logit": -4.8125,
            "text": "area under receiver operator curve [",
            "probability": 0.0004181861877441406
        },
        {
            "start_logit": 5.05078125,
            "end_logit": -4.8671875,
            "text": "area under",
            "probability": 0.0003960132598876953
        },
        {
            "start_logit": 5.05078125,
            "end_logit": -5.00390625,
            "text": "area under receiver operator curve [area under the receiver",
            "probability": 0.0003452301025390625
        },
        {
            "start_logit": -0.63818359375,
            "end_logit": -0.77294921875,
            "text": "[area under the receiver operating characteristic curve",
            "probability": 8.0108642578125e-05
        },
        {
            "start_logit": -0.63818359375,
            "end_logit": -1.1396484375,
            "text": "[area under the receiver operating characteristic curve]",
            "probability": 5.5909156799316406e-05
        },
        {
            "start_logit": -1.32421875,
            "end_logit": -0.77294921875,
            "text": " receiver operating characteristic curve",
            "probability": 4.029273986816406e-05
        },
        {
            "start_logit": -1.33984375,
            "end_logit": -0.77294921875,
            "text": " receiver operator curve [area under the receiver operating characteristic curve",
            "probability": 3.9637088775634766e-05
        }
    ],
    "64136fbf201352f04a00003d_0003": [
        {
            "start_logit": 4.25,
            "end_logit": 1.8740234375,
            "text": " area under the receiver operating characteristic curve",
            "probability": 0.68017578125
        },
        {
            "start_logit": 4.25,
            "end_logit": 0.16845703125,
            "text": " area under the receiver operating characteristic curve (area under the receiver operating characteristic curve",
            "probability": 0.1234130859375
        },
        {
            "start_logit": 4.25,
            "end_logit": 0.119384765625,
            "text": " area under the receiver operating characteristic curve (area under the receiver operating characteristic curve)",
            "probability": 0.1177978515625
        },
        {
            "start_logit": 0.8212890625,
            "end_logit": 1.8740234375,
            "text": " receiver operating characteristic curve",
            "probability": 0.0220489501953125
        },
        {
            "start_logit": 4.25,
            "end_logit": -2.337890625,
            "text": " area",
            "probability": 0.01009368896484375
        },
        {
            "start_logit": 4.25,
            "end_logit": -2.587890625,
            "text": " area under the receiver operating characteristic",
            "probability": 0.0078582763671875
        },
        {
            "start_logit": 4.25,
            "end_logit": -3.091796875,
            "text": " area under the receiver operating characteristic curve (area under the receiver operating characteristic",
            "probability": 0.004730224609375
        },
        {
            "start_logit": -0.8720703125,
            "end_logit": 1.8740234375,
            "text": " the area under the receiver operating characteristic curve",
            "probability": 0.004047393798828125
        },
        {
            "start_logit": 0.8212890625,
            "end_logit": 0.16845703125,
            "text": " receiver operating characteristic curve (area under the receiver operating characteristic curve",
            "probability": 0.003997802734375
        },
        {
            "start_logit": -0.89404296875,
            "end_logit": 1.8740234375,
            "text": " evaluated using the area under the receiver operating characteristic curve",
            "probability": 0.00396728515625
        },
        {
            "start_logit": 0.8212890625,
            "end_logit": 0.119384765625,
            "text": " receiver operating characteristic curve (area under the receiver operating characteristic curve)",
            "probability": 0.003814697265625
        },
        {
            "start_logit": 4.25,
            "end_logit": -3.521484375,
            "text": " area under the receiver operating characteristic curve (area under",
            "probability": 0.003078460693359375
        },
        {
            "start_logit": -1.2060546875,
            "end_logit": 1.8740234375,
            "text": "The model performance was evaluated using the area under the receiver operating characteristic curve",
            "probability": 0.0029010772705078125
        },
        {
            "start_logit": 4.25,
            "end_logit": -3.619140625,
            "text": " area under the receiver operating characteristic curve (area",
            "probability": 0.002803802490234375
        },
        {
            "start_logit": 4.25,
            "end_logit": -3.80078125,
            "text": " area under",
            "probability": 0.0023326873779296875
        },
        {
            "start_logit": -1.4921875,
            "end_logit": 1.8740234375,
            "text": " the receiver operating characteristic curve",
            "probability": 0.0021820068359375
        },
        {
            "start_logit": -2.005859375,
            "end_logit": 1.8740234375,
            "text": " model performance was evaluated using the area under the receiver operating characteristic curve",
            "probability": 0.0013027191162109375
        },
        {
            "start_logit": -2.015625,
            "end_logit": 1.8740234375,
            "text": " using the area under the receiver operating characteristic curve",
            "probability": 0.001293182373046875
        },
        {
            "start_logit": -2.271484375,
            "end_logit": 1.8740234375,
            "text": " characteristic curve",
            "probability": 0.00099945068359375
        },
        {
            "start_logit": -0.6142578125,
            "end_logit": 0.119384765625,
            "text": ")",
            "probability": 0.0009064674377441406
        }
    ],
    "64136664201352f04a00003b_0001": [
        {
            "start_logit": 5.6875,
            "end_logit": 5.2265625,
            "text": " sensory disturbances",
            "probability": 0.465576171875
        },
        {
            "start_logit": 5.73046875,
            "end_logit": 4.2265625,
            "text": " autonomic dysfunction",
            "probability": 0.1781005859375
        },
        {
            "start_logit": 5.6875,
            "end_logit": 4.2265625,
            "text": " sensory disturbances, or autonomic dysfunction",
            "probability": 0.1712646484375
        },
        {
            "start_logit": 5.73046875,
            "end_logit": 2.703125,
            "text": " autonomic",
            "probability": 0.03912353515625
        },
        {
            "start_logit": 3.208984375,
            "end_logit": 5.2265625,
            "text": " pain, sensory disturbances",
            "probability": 0.03912353515625
        },
        {
            "start_logit": 5.6875,
            "end_logit": 2.703125,
            "text": " sensory disturbances, or autonomic",
            "probability": 0.037322998046875
        },
        {
            "start_logit": 3.208984375,
            "end_logit": 4.2265625,
            "text": " pain, sensory disturbances, or autonomic dysfunction",
            "probability": 0.0143890380859375
        },
        {
            "start_logit": 5.73046875,
            "end_logit": 1.4912109375,
            "text": " autonomic dysfunction. T",
            "probability": 0.01160430908203125
        },
        {
            "start_logit": 5.6875,
            "end_logit": 1.4912109375,
            "text": " sensory disturbances, or autonomic dysfunction. T",
            "probability": 0.0111236572265625
        },
        {
            "start_logit": 3.208984375,
            "end_logit": 3.568359375,
            "text": " pain",
            "probability": 0.007434844970703125
        },
        {
            "start_logit": 5.6875,
            "end_logit": 0.71044921875,
            "text": " sensory disturbances,",
            "probability": 0.005092620849609375
        },
        {
            "start_logit": 0.9951171875,
            "end_logit": 5.2265625,
            "text": " large fiber affection) manifests with pain, sensory disturbances",
            "probability": 0.004268646240234375
        },
        {
            "start_logit": 3.208984375,
            "end_logit": 2.703125,
            "text": " pain, sensory disturbances, or autonomic",
            "probability": 0.00313568115234375
        },
        {
            "start_logit": 5.73046875,
            "end_logit": -0.0241546630859375,
            "text": " autonomic dysfunction.",
            "probability": 0.0025501251220703125
        },
        {
            "start_logit": 5.6875,
            "end_logit": -0.0241546630859375,
            "text": " sensory disturbances, or autonomic dysfunction.",
            "probability": 0.0024433135986328125
        },
        {
            "start_logit": 5.6875,
            "end_logit": -0.10894775390625,
            "text": " sensory",
            "probability": 0.0022411346435546875
        },
        {
            "start_logit": 0.9951171875,
            "end_logit": 4.2265625,
            "text": " large fiber affection) manifests with pain, sensory disturbances, or autonomic dysfunction",
            "probability": 0.0015707015991210938
        },
        {
            "start_logit": -0.08404541015625,
            "end_logit": 5.2265625,
            "text": " disturbances",
            "probability": 0.0014467239379882812
        },
        {
            "start_logit": -0.137939453125,
            "end_logit": 5.2265625,
            "text": " Selective small fiber neuropathy (without large fiber affection) manifests with pain, sensory disturbances",
            "probability": 0.0013751983642578125
        },
        {
            "start_logit": 3.208984375,
            "end_logit": 1.4912109375,
            "text": " pain, sensory disturbances, or autonomic dysfunction. T",
            "probability": 0.0009303092956542969
        }
    ],
    "64136664201352f04a00003b_0002": [
        {
            "start_logit": 5.3515625,
            "end_logit": 4.1796875,
            "text": " Restless legs syndrome",
            "probability": 0.414306640625
        },
        {
            "start_logit": 4.78125,
            "end_logit": 4.53515625,
            "text": "Neuropathic pain (Neuropathic pain)",
            "probability": 0.3330078125
        },
        {
            "start_logit": 3.05078125,
            "end_logit": 4.53515625,
            "text": "Neuropathic pain)",
            "probability": 0.0592041015625
        },
        {
            "start_logit": 5.3515625,
            "end_logit": 2.201171875,
            "text": " Restless legs syndrome (Restless legs syndrome",
            "probability": 0.057403564453125
        },
        {
            "start_logit": 4.78125,
            "end_logit": 2.744140625,
            "text": "Neuropathic pain",
            "probability": 0.055633544921875
        },
        {
            "start_logit": 5.3515625,
            "end_logit": 1.5869140625,
            "text": " Restless legs syndrome (Restless legs syndrome)",
            "probability": 0.030975341796875
        },
        {
            "start_logit": 4.78125,
            "end_logit": 1.0888671875,
            "text": "Neuropathic pain (Neuropathic pain) is a main feature of Fabry disease (Fabry disease)",
            "probability": 0.01065826416015625
        },
        {
            "start_logit": 4.78125,
            "end_logit": 0.494384765625,
            "text": "Neuropathic pain (Neuropathic pain",
            "probability": 0.005886077880859375
        },
        {
            "start_logit": 4.78125,
            "end_logit": 0.449462890625,
            "text": "Neuropathic pain (Neuropathic pain) is a main feature of Fabry disease",
            "probability": 0.005615234375
        },
        {
            "start_logit": 0.732421875,
            "end_logit": 4.1796875,
            "text": " Fabry disease (Fabry disease) as consequence of small fiber neuropathy. Restless legs syndrome",
            "probability": 0.004093170166015625
        },
        {
            "start_logit": 5.3515625,
            "end_logit": -0.74560546875,
            "text": " Restless legs syndrome (Restless legs syndrome) in Fabry disease was not described,",
            "probability": 0.0030059814453125
        },
        {
            "start_logit": 2.392578125,
            "end_logit": 2.201171875,
            "text": "Restless legs syndrome",
            "probability": 0.002971649169921875
        },
        {
            "start_logit": 4.78125,
            "end_logit": -0.207763671875,
            "text": "Neuropathic pain (Neuropathic pain) is a main feature of Fabry disease (Fabry disease) as consequence of small fiber neuropathy",
            "probability": 0.0029144287109375
        },
        {
            "start_logit": 5.3515625,
            "end_logit": -0.8798828125,
            "text": " Restless legs",
            "probability": 0.00263214111328125
        },
        {
            "start_logit": 5.3515625,
            "end_logit": -1.0751953125,
            "text": " Restless legs syndrome (Restless legs",
            "probability": 0.0021648406982421875
        },
        {
            "start_logit": -0.282470703125,
            "end_logit": 4.53515625,
            "text": "(Neuropathic pain)",
            "probability": 0.0021152496337890625
        },
        {
            "start_logit": 5.3515625,
            "end_logit": -1.1767578125,
            "text": " Restless legs syndrome (Restless legs syndrome) in Fabry disease was not described",
            "probability": 0.001956939697265625
        },
        {
            "start_logit": 3.05078125,
            "end_logit": 1.0888671875,
            "text": "Neuropathic pain) is a main feature of Fabry disease (Fabry disease)",
            "probability": 0.001888275146484375
        },
        {
            "start_logit": -0.08856201171875,
            "end_logit": 4.1796875,
            "text": " consequence of small fiber neuropathy. Restless legs syndrome",
            "probability": 0.0017948150634765625
        },
        {
            "start_logit": 2.392578125,
            "end_logit": 1.5869140625,
            "text": "Restless legs syndrome)",
            "probability": 0.00160980224609375
        }
    ],
    "64136664201352f04a00003b_0003": [
        {
            "start_logit": 2.005859375,
            "end_logit": 1.25390625,
            "text": " trisulfated heparan disaccharide (Trisulfated Heparin Disaccharide) antigen",
            "probability": 0.202880859375
        },
        {
            "start_logit": 2.068359375,
            "end_logit": 0.80419921875,
            "text": "mall fiber neuropathy (small fiber neuropathy)",
            "probability": 0.1378173828125
        },
        {
            "start_logit": 2.068359375,
            "end_logit": 0.74267578125,
            "text": "mall fiber neuropathy",
            "probability": 0.1295166015625
        },
        {
            "start_logit": 2.068359375,
            "end_logit": 0.3076171875,
            "text": "mall fiber neuropathy (small fiber neuropathy) can be associated with autoantibodies",
            "probability": 0.083740234375
        },
        {
            "start_logit": 2.005859375,
            "end_logit": 0.217529296875,
            "text": " trisulfated heparan disaccharide (Trisulfated Heparin Disaccharide)",
            "probability": 0.0718994140625
        },
        {
            "start_logit": 0.951171875,
            "end_logit": 1.25390625,
            "text": "Trisulfated Heparin Disaccharide) antigen",
            "probability": 0.0706787109375
        },
        {
            "start_logit": 2.005859375,
            "end_logit": -0.056915283203125,
            "text": " trisulfated heparan disaccharide (Trisulfated Heparin Disaccharide) antigen.",
            "probability": 0.054718017578125
        },
        {
            "start_logit": 2.068359375,
            "end_logit": -0.374267578125,
            "text": "mall fiber neuropathy (small fiber neuropathy) can be associated with autoantibodies,",
            "probability": 0.042388916015625
        },
        {
            "start_logit": 2.005859375,
            "end_logit": -0.6796875,
            "text": " trisulfated heparan disaccharide (Trisulfated Heparin Disaccharide",
            "probability": 0.0293426513671875
        },
        {
            "start_logit": 2.068359375,
            "end_logit": -0.77197265625,
            "text": "mall fiber neuropathy (small fiber neuropathy",
            "probability": 0.02850341796875
        },
        {
            "start_logit": 2.068359375,
            "end_logit": -0.8203125,
            "text": "mall fiber neuropathy (small fiber neuropathy) can be associated with autoantibodies, including those of IgM",
            "probability": 0.0271453857421875
        },
        {
            "start_logit": 0.951171875,
            "end_logit": 0.217529296875,
            "text": "Trisulfated Heparin Disaccharide)",
            "probability": 0.0251007080078125
        },
        {
            "start_logit": 0.951171875,
            "end_logit": -0.056915283203125,
            "text": "Trisulfated Heparin Disaccharide) antigen.",
            "probability": 0.0190582275390625
        },
        {
            "start_logit": -0.51513671875,
            "end_logit": 1.25390625,
            "text": "IgM class with specificity for the trisulfated heparan disaccharide (Trisulfated Heparin Disaccharide) antigen",
            "probability": 0.01629638671875
        },
        {
            "start_logit": 2.068359375,
            "end_logit": -1.564453125,
            "text": "mall fiber neuropathy (small fiber neuropathy) can be associated with autoantibodies, including those of IgM class",
            "probability": 0.01288604736328125
        },
        {
            "start_logit": 2.005859375,
            "end_logit": -1.556640625,
            "text": " trisulfated heparan disaccharide",
            "probability": 0.01220703125
        },
        {
            "start_logit": 0.951171875,
            "end_logit": -0.6796875,
            "text": "Trisulfated Heparin Disaccharide",
            "probability": 0.010223388671875
        },
        {
            "start_logit": -1.1201171875,
            "end_logit": 1.25390625,
            "text": " associated with autoantibodies, including those of IgM class with specificity for the trisulfated heparan disaccharide (Trisulfated Heparin Disaccharide) antigen",
            "probability": 0.0089111328125
        },
        {
            "start_logit": -1.16015625,
            "end_logit": 1.25390625,
            "text": " disaccharide (Trisulfated Heparin Disaccharide) antigen",
            "probability": 0.00855255126953125
        },
        {
            "start_logit": -1.166015625,
            "end_logit": 1.25390625,
            "text": " specificity for the trisulfated heparan disaccharide (Trisulfated Heparin Disaccharide) antigen",
            "probability": 0.00850677490234375
        }
    ],
    "64136664201352f04a00003b_0004": [
        {
            "start_logit": 2.14453125,
            "end_logit": 1.3271484375,
            "text": " fibroblast growth factor receptor 3",
            "probability": 0.149658203125
        },
        {
            "start_logit": 2.025390625,
            "end_logit": 1.3271484375,
            "text": " Trisulfated Heparin Disaccharide (Trisulfated Heparin Disaccharide) and fibroblast growth factor receptor 3",
            "probability": 0.132568359375
        },
        {
            "start_logit": 2.025390625,
            "end_logit": 1.0634765625,
            "text": " Trisulfated Heparin Disaccharide",
            "probability": 0.10205078125
        },
        {
            "start_logit": 1.759765625,
            "end_logit": 1.3271484375,
            "text": "Trisulfated Heparin Disaccharide) and fibroblast growth factor receptor 3",
            "probability": 0.10162353515625
        },
        {
            "start_logit": 2.14453125,
            "end_logit": 0.7392578125,
            "text": " fibroblast growth factor receptor 3 (FGFR-3",
            "probability": 0.08294677734375
        },
        {
            "start_logit": 2.025390625,
            "end_logit": 0.7392578125,
            "text": " Trisulfated Heparin Disaccharide (Trisulfated Heparin Disaccharide) and fibroblast growth factor receptor 3 (FGFR-3",
            "probability": 0.07379150390625
        },
        {
            "start_logit": 2.025390625,
            "end_logit": 0.48046875,
            "text": " Trisulfated Heparin Disaccharide (Trisulfated Heparin Disaccharide)",
            "probability": 0.056915283203125
        },
        {
            "start_logit": 1.759765625,
            "end_logit": 0.7392578125,
            "text": "Trisulfated Heparin Disaccharide) and fibroblast growth factor receptor 3 (FGFR-3",
            "probability": 0.05657958984375
        },
        {
            "start_logit": 1.759765625,
            "end_logit": 0.48046875,
            "text": "Trisulfated Heparin Disaccharide)",
            "probability": 0.043609619140625
        },
        {
            "start_logit": 2.14453125,
            "end_logit": -0.1346435546875,
            "text": " fibroblast growth factor receptor 3 (FGFR-3)",
            "probability": 0.034637451171875
        },
        {
            "start_logit": 2.025390625,
            "end_logit": -0.1346435546875,
            "text": " Trisulfated Heparin Disaccharide (Trisulfated Heparin Disaccharide) and fibroblast growth factor receptor 3 (FGFR-3)",
            "probability": 0.03076171875
        },
        {
            "start_logit": 0.67431640625,
            "end_logit": 1.0634765625,
            "text": " small fiber neuropathy (small fiber neuropathy) cases are idiopathic, but novel antibodies to Trisulfated Heparin Disaccharide",
            "probability": 0.0264129638671875
        },
        {
            "start_logit": 1.759765625,
            "end_logit": -0.1346435546875,
            "text": "Trisulfated Heparin Disaccharide) and fibroblast growth factor receptor 3 (FGFR-3)",
            "probability": 0.0235748291015625
        },
        {
            "start_logit": 2.025390625,
            "end_logit": -0.8310546875,
            "text": " Trisulfated Heparin Disaccharide (Trisulfated Heparin Disaccharide",
            "probability": 0.01534271240234375
        },
        {
            "start_logit": 0.67431640625,
            "end_logit": 0.48046875,
            "text": " small fiber neuropathy (small fiber neuropathy) cases are idiopathic, but novel antibodies to Trisulfated Heparin Disaccharide (Trisulfated Heparin Disaccharide)",
            "probability": 0.01473236083984375
        },
        {
            "start_logit": 1.759765625,
            "end_logit": -0.8310546875,
            "text": "Trisulfated Heparin Disaccharide",
            "probability": 0.0117645263671875
        },
        {
            "start_logit": -0.400390625,
            "end_logit": 1.3271484375,
            "text": " antibodies to Trisulfated Heparin Disaccharide (Trisulfated Heparin Disaccharide) and fibroblast growth factor receptor 3",
            "probability": 0.01171875
        },
        {
            "start_logit": 2.14453125,
            "end_logit": -1.234375,
            "text": " fibroblast growth factor receptor 3 (FGFR-3) have been implicated in half of",
            "probability": 0.01153564453125
        },
        {
            "start_logit": 0.67431640625,
            "end_logit": 0.1512451171875,
            "text": " small fiber neuropathy",
            "probability": 0.01061248779296875
        },
        {
            "start_logit": -0.400390625,
            "end_logit": 1.0634765625,
            "text": " antibodies to Trisulfated Heparin Disaccharide",
            "probability": 0.00902557373046875
        }
    ],
    "6415c53e690f196b51000012_0001": [
        {
            "start_logit": 6.4375,
            "end_logit": 6.7578125,
            "text": " October 24, 2016",
            "probability": 0.96337890625
        },
        {
            "start_logit": 2.916015625,
            "end_logit": 6.7578125,
            "text": " 2016",
            "probability": 0.028411865234375
        },
        {
            "start_logit": 0.28662109375,
            "end_logit": 6.7578125,
            "text": "On October 24, 2016",
            "probability": 0.0020503997802734375
        },
        {
            "start_logit": 6.4375,
            "end_logit": 0.59912109375,
            "text": " October 24, 2016,",
            "probability": 0.002033233642578125
        },
        {
            "start_logit": 6.4375,
            "end_logit": 0.35400390625,
            "text": " October 24,",
            "probability": 0.0015964508056640625
        },
        {
            "start_logit": 6.4375,
            "end_logit": -0.2073974609375,
            "text": " October 24, 2016, the U.S. Food and Drug Administration (Food and Drug Administration) approved pembrolizumab",
            "probability": 0.0009098052978515625
        },
        {
            "start_logit": -0.6435546875,
            "end_logit": 6.7578125,
            "text": " 24, 2016",
            "probability": 0.0008091926574707031
        },
        {
            "start_logit": 6.4375,
            "end_logit": -0.59423828125,
            "text": " October 24",
            "probability": 0.0006184577941894531
        },
        {
            "start_logit": 6.4375,
            "end_logit": -1.2509765625,
            "text": " Octo",
            "probability": 0.00032067298889160156
        },
        {
            "start_logit": 2.916015625,
            "end_logit": 0.59912109375,
            "text": " 2016,",
            "probability": 6.026029586791992e-05
        },
        {
            "start_logit": 2.916015625,
            "end_logit": -0.2073974609375,
            "text": " 2016, the U.S. Food and Drug Administration (Food and Drug Administration) approved pembrolizumab",
            "probability": 2.6941299438476562e-05
        },
        {
            "start_logit": 0.28662109375,
            "end_logit": 0.59912109375,
            "text": "On October 24, 2016,",
            "probability": 4.291534423828125e-06
        },
        {
            "start_logit": 0.28662109375,
            "end_logit": 0.35400390625,
            "text": "On October 24,",
            "probability": 3.3974647521972656e-06
        },
        {
            "start_logit": 0.28662109375,
            "end_logit": -0.2073974609375,
            "text": "On October 24, 2016, the U.S. Food and Drug Administration (Food and Drug Administration) approved pembrolizumab",
            "probability": 1.9669532775878906e-06
        },
        {
            "start_logit": -0.6435546875,
            "end_logit": 0.59912109375,
            "text": " 24, 2016,",
            "probability": 1.7285346984863281e-06
        },
        {
            "start_logit": -0.6435546875,
            "end_logit": 0.35400390625,
            "text": " 24,",
            "probability": 1.3113021850585938e-06
        },
        {
            "start_logit": 0.28662109375,
            "end_logit": -0.59423828125,
            "text": "On October 24",
            "probability": 1.3113021850585938e-06
        },
        {
            "start_logit": -0.6435546875,
            "end_logit": -0.2073974609375,
            "text": " 24, 2016, the U.S. Food and Drug Administration (Food and Drug Administration) approved pembrolizumab",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": 0.28662109375,
            "end_logit": -1.2509765625,
            "text": "On Octo",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": -0.6435546875,
            "end_logit": -0.59423828125,
            "text": " 24",
            "probability": 5.364418029785156e-07
        }
    ],
    "6417949d690f196b51000035_0001": [
        {
            "start_logit": 2.318359375,
            "end_logit": 1.921875,
            "text": " trying to reverse or block the pathophysiological processes of the disease, such as inflammation",
            "probability": 0.216064453125
        },
        {
            "start_logit": 2.318359375,
            "end_logit": 1.5849609375,
            "text": " trying to reverse or block the pathophysiological processes of the disease, such as inflammation, fibrosis",
            "probability": 0.15380859375
        },
        {
            "start_logit": 2.318359375,
            "end_logit": 1.556640625,
            "text": " trying to reverse or block the pathophysiological processes of the disease, such as inflammation, fibrosis, muscle regeneration",
            "probability": 0.149658203125
        },
        {
            "start_logit": 1.669921875,
            "end_logit": 1.921875,
            "text": " inflammation",
            "probability": 0.11279296875
        },
        {
            "start_logit": 1.669921875,
            "end_logit": 1.5849609375,
            "text": " inflammation, fibrosis",
            "probability": 0.0804443359375
        },
        {
            "start_logit": 1.669921875,
            "end_logit": 1.556640625,
            "text": " inflammation, fibrosis, muscle regeneration",
            "probability": 0.0782470703125
        },
        {
            "start_logit": 1.10546875,
            "end_logit": 1.5849609375,
            "text": " fibrosis",
            "probability": 0.045806884765625
        },
        {
            "start_logit": 1.10546875,
            "end_logit": 1.556640625,
            "text": " fibrosis, muscle regeneration",
            "probability": 0.04449462890625
        },
        {
            "start_logit": 2.318359375,
            "end_logit": -0.4326171875,
            "text": " trying to reverse or block the pathophysiological processes of the disease, such as inflammation, fibrosis, muscle regeneration, etc.",
            "probability": 0.0204925537109375
        },
        {
            "start_logit": -0.56982421875,
            "end_logit": 1.921875,
            "text": " block the pathophysiological processes of the disease, such as inflammation",
            "probability": 0.01200103759765625
        },
        {
            "start_logit": 1.669921875,
            "end_logit": -0.4326171875,
            "text": " inflammation, fibrosis, muscle regeneration, etc.",
            "probability": 0.010711669921875
        },
        {
            "start_logit": 2.318359375,
            "end_logit": -1.1220703125,
            "text": " trying to reverse or block the pathophysiological processes",
            "probability": 0.01026153564453125
        },
        {
            "start_logit": 2.318359375,
            "end_logit": -1.197265625,
            "text": " trying to reverse or block the pathophysiological processes of the disease,",
            "probability": 0.00952911376953125
        },
        {
            "start_logit": -0.451416015625,
            "end_logit": 1.556640625,
            "text": " muscle regeneration",
            "probability": 0.0093841552734375
        },
        {
            "start_logit": -0.56982421875,
            "end_logit": 1.5849609375,
            "text": " block the pathophysiological processes of the disease, such as inflammation, fibrosis",
            "probability": 0.008575439453125
        },
        {
            "start_logit": -0.56982421875,
            "end_logit": 1.556640625,
            "text": " block the pathophysiological processes of the disease, such as inflammation, fibrosis, muscle regeneration",
            "probability": 0.00832366943359375
        },
        {
            "start_logit": -0.939453125,
            "end_logit": 1.921875,
            "text": " gene therapies and 2) trying to reverse or block the pathophysiological processes of the disease, such as inflammation",
            "probability": 0.00829315185546875
        },
        {
            "start_logit": -0.6416015625,
            "end_logit": 1.556640625,
            "text": " regeneration",
            "probability": 0.007747650146484375
        },
        {
            "start_logit": 2.318359375,
            "end_logit": -1.48046875,
            "text": " trying to reverse or block the pathophysiological processes of the disease, such as inflammation, fibrosis, muscle regeneration,",
            "probability": 0.00717926025390625
        },
        {
            "start_logit": 2.318359375,
            "end_logit": -1.5537109375,
            "text": " trying to reverse or block the pathophysiological processes of the disease, such as inflammation, fibrosis,",
            "probability": 0.006679534912109375
        }
    ],
    "6417949d690f196b51000035_0002": [
        {
            "start_logit": 6.75,
            "end_logit": 6.23046875,
            "text": " suppression of stop codons",
            "probability": 0.2249755859375
        },
        {
            "start_logit": 6.625,
            "end_logit": 6.25390625,
            "text": " exon skipping",
            "probability": 0.20166015625
        },
        {
            "start_logit": 6.625,
            "end_logit": 6.23046875,
            "text": " exon skipping, suppression of stop codons",
            "probability": 0.198486328125
        },
        {
            "start_logit": 6.15625,
            "end_logit": 6.25390625,
            "text": " gene replacement, exon skipping",
            "probability": 0.126220703125
        },
        {
            "start_logit": 6.15625,
            "end_logit": 6.23046875,
            "text": " gene replacement, exon skipping, suppression of stop codons",
            "probability": 0.12420654296875
        },
        {
            "start_logit": 6.15625,
            "end_logit": 6.1328125,
            "text": " gene replacement",
            "probability": 0.11224365234375
        },
        {
            "start_logit": 6.75,
            "end_logit": 1.349609375,
            "text": " suppression",
            "probability": 0.0017042160034179688
        },
        {
            "start_logit": 6.625,
            "end_logit": 1.349609375,
            "text": " exon skipping, suppression",
            "probability": 0.0015039443969726562
        },
        {
            "start_logit": 6.625,
            "end_logit": 1.1376953125,
            "text": " exon",
            "probability": 0.00121307373046875
        },
        {
            "start_logit": 6.15625,
            "end_logit": 1.373046875,
            "text": " gene",
            "probability": 0.0009636878967285156
        },
        {
            "start_logit": 1.2607421875,
            "end_logit": 6.25390625,
            "text": " replacement, exon skipping",
            "probability": 0.0009484291076660156
        },
        {
            "start_logit": 6.15625,
            "end_logit": 1.349609375,
            "text": " gene replacement, exon skipping, suppression",
            "probability": 0.0009412765502929688
        },
        {
            "start_logit": 1.2607421875,
            "end_logit": 6.23046875,
            "text": " replacement, exon skipping, suppression of stop codons",
            "probability": 0.000926971435546875
        },
        {
            "start_logit": 1.2607421875,
            "end_logit": 6.1328125,
            "text": " replacement",
            "probability": 0.0008406639099121094
        },
        {
            "start_logit": 6.15625,
            "end_logit": 1.1376953125,
            "text": " gene replacement, exon",
            "probability": 0.000759124755859375
        },
        {
            "start_logit": 0.93896484375,
            "end_logit": 6.25390625,
            "text": " skipping",
            "probability": 0.0006861686706542969
        },
        {
            "start_logit": 0.93896484375,
            "end_logit": 6.23046875,
            "text": " skipping, suppression of stop codons",
            "probability": 0.0006699562072753906
        },
        {
            "start_logit": 6.625,
            "end_logit": 0.435302734375,
            "text": " exon skipping,",
            "probability": 0.0006008148193359375
        },
        {
            "start_logit": 6.75,
            "end_logit": -0.072998046875,
            "text": " suppression of stop codons.",
            "probability": 0.0004096031188964844
        },
        {
            "start_logit": 6.75,
            "end_logit": -0.1534423828125,
            "text": " suppression of stop",
            "probability": 0.0003788471221923828
        }
    ],
    "6417949d690f196b51000035_0003": [
        {
            "start_logit": 7.66796875,
            "end_logit": 7.13671875,
            "text": "CRISPR/Cas9",
            "probability": 0.9970703125
        },
        {
            "start_logit": 7.66796875,
            "end_logit": -0.1068115234375,
            "text": "CRISPR/Cas9 offers exciting perspectives for restoring dystrophin expression in patients with DMD.",
            "probability": 0.0007138252258300781
        },
        {
            "start_logit": 7.66796875,
            "end_logit": -0.486328125,
            "text": "CRIS",
            "probability": 0.00048661231994628906
        },
        {
            "start_logit": 7.66796875,
            "end_logit": -1.28515625,
            "text": "CRISPR/Cas9 offers exciting perspectives for restoring dystrophin expression",
            "probability": 0.00021946430206298828
        },
        {
            "start_logit": -0.7744140625,
            "end_logit": 7.13671875,
            "text": " referred to as CRISPR/Cas9",
            "probability": 0.00021600723266601562
        },
        {
            "start_logit": 7.66796875,
            "end_logit": -1.44921875,
            "text": "CRISPR/Cas",
            "probability": 0.00018608570098876953
        },
        {
            "start_logit": 7.66796875,
            "end_logit": -1.7216796875,
            "text": "CRISPR",
            "probability": 0.0001417398452758789
        },
        {
            "start_logit": 7.66796875,
            "end_logit": -1.806640625,
            "text": "CRISPR/Cas9 offers exciting perspectives",
            "probability": 0.00012993812561035156
        },
        {
            "start_logit": -1.435546875,
            "end_logit": 7.13671875,
            "text": "9",
            "probability": 0.0001112222671508789
        },
        {
            "start_logit": -1.5830078125,
            "end_logit": 7.13671875,
            "text": " to as CRISPR/Cas9",
            "probability": 9.578466415405273e-05
        },
        {
            "start_logit": -1.6943359375,
            "end_logit": 7.13671875,
            "text": " a promising gene editing tool referred to as CRISPR/Cas9",
            "probability": 8.589029312133789e-05
        },
        {
            "start_logit": 7.66796875,
            "end_logit": -2.294921875,
            "text": "CRISPR/Cas9 offers exciting perspectives for restoring dystrophin expression in patients with DMD",
            "probability": 8.004903793334961e-05
        },
        {
            "start_logit": -1.8583984375,
            "end_logit": 7.13671875,
            "text": "Cas9",
            "probability": 7.230043411254883e-05
        },
        {
            "start_logit": -1.9033203125,
            "end_logit": 7.13671875,
            "text": "PR/Cas9",
            "probability": 6.961822509765625e-05
        },
        {
            "start_logit": -1.935546875,
            "end_logit": 7.13671875,
            "text": ", a promising gene editing tool referred to as CRISPR/Cas9",
            "probability": 6.747245788574219e-05
        },
        {
            "start_logit": 7.66796875,
            "end_logit": -2.482421875,
            "text": "CRISPR/Cas9 offers exciting perspectives for restoring dystrophin",
            "probability": 6.639957427978516e-05
        },
        {
            "start_logit": -1.951171875,
            "end_logit": 7.13671875,
            "text": "More recently, a promising gene editing tool referred to as CRISPR/Cas9",
            "probability": 6.639957427978516e-05
        },
        {
            "start_logit": -1.9609375,
            "end_logit": 7.13671875,
            "text": " promising gene editing tool referred to as CRISPR/Cas9",
            "probability": 6.586313247680664e-05
        },
        {
            "start_logit": -2.23046875,
            "end_logit": 7.13671875,
            "text": " gene editing tool referred to as CRISPR/Cas9",
            "probability": 5.0127506256103516e-05
        },
        {
            "start_logit": 7.66796875,
            "end_logit": -2.84375,
            "text": "CRISPR/Cas9 offers exciting",
            "probability": 4.601478576660156e-05
        }
    ],
    "6417949d690f196b51000035_0004": [
        {
            "start_logit": 6.8203125,
            "end_logit": 4.51953125,
            "text": "Adeno-associated virus-vectorized gene therapies to restore dystrophin protein expression using gene replacement or antisense oligonucleotide-mediated pre-mRNA splicing modulation",
            "probability": 0.465087890625
        },
        {
            "start_logit": 6.8203125,
            "end_logit": 3.404296875,
            "text": "Adeno-associated virus",
            "probability": 0.152099609375
        },
        {
            "start_logit": 6.8203125,
            "end_logit": 3.357421875,
            "text": "Adeno-associated virus-vectorized gene therapies to restore dystrophin protein expression using gene replacement",
            "probability": 0.145263671875
        },
        {
            "start_logit": 6.8203125,
            "end_logit": 2.517578125,
            "text": "Adeno-associated virus-vectorized gene therapies",
            "probability": 0.06243896484375
        },
        {
            "start_logit": 6.8203125,
            "end_logit": 2.5,
            "text": "Adeno-associated virus-vectorized gene therapies to restore dystrophin protein expression using gene replacement or antisense oligonucleotide",
            "probability": 0.061492919921875
        },
        {
            "start_logit": 4.7421875,
            "end_logit": 4.51953125,
            "text": " antisense oligonucleotide-mediated pre-mRNA splicing modulation",
            "probability": 0.058197021484375
        },
        {
            "start_logit": 6.8203125,
            "end_logit": 0.56640625,
            "text": "Adeno-associated virus-vectorized gene therapies to restore dystrophin protein expression",
            "probability": 0.00888824462890625
        },
        {
            "start_logit": 4.7421875,
            "end_logit": 2.5,
            "text": " antisense oligonucleotide",
            "probability": 0.0076904296875
        },
        {
            "start_logit": 6.8203125,
            "end_logit": 0.3916015625,
            "text": "Adeno-associated virus-vectorized gene therapies to restore dystrophin protein expression using gene replacement or antisense oligonucleotide-mediated pre-mRNA splicing",
            "probability": 0.007457733154296875
        },
        {
            "start_logit": 6.8203125,
            "end_logit": 0.0355224609375,
            "text": "Adeno-associated virus-vectorized gene therapies to restore dystrophin protein expression using gene replacement or antisense oligonucleotide-mediated pre",
            "probability": 0.00522613525390625
        },
        {
            "start_logit": 2.18359375,
            "end_logit": 4.51953125,
            "text": " gene replacement or antisense oligonucleotide-mediated pre-mRNA splicing modulation",
            "probability": 0.004489898681640625
        },
        {
            "start_logit": 6.8203125,
            "end_logit": -0.279052734375,
            "text": "Adeno-associated virus-vectorized gene therapies to restore dystrophin protein",
            "probability": 0.0038242340087890625
        },
        {
            "start_logit": 6.8203125,
            "end_logit": -0.556640625,
            "text": "Adeno-associated virus-vectorized gene therapies to restore dystrophin protein expression using gene replacement or antisense",
            "probability": 0.002899169921875
        },
        {
            "start_logit": 1.748046875,
            "end_logit": 4.51953125,
            "text": " pre-mRNA splicing modulation",
            "probability": 0.002899169921875
        },
        {
            "start_logit": 6.8203125,
            "end_logit": -0.5947265625,
            "text": "Adeno-associated virus-vectorized",
            "probability": 0.0027866363525390625
        },
        {
            "start_logit": 6.8203125,
            "end_logit": -0.7822265625,
            "text": "Adeno-associated virus-vector",
            "probability": 0.0023097991943359375
        },
        {
            "start_logit": 6.8203125,
            "end_logit": -0.896484375,
            "text": "Adeno-associated virus-vectorized gene therapies to restore dystrophin protein expression using",
            "probability": 0.0020542144775390625
        },
        {
            "start_logit": 6.8203125,
            "end_logit": -0.99658203125,
            "text": "Adeno-associated virus-vectorized gene therapies to restore dystrophin protein expression using gene",
            "probability": 0.0018644332885742188
        },
        {
            "start_logit": 6.8203125,
            "end_logit": -1.1748046875,
            "text": "Adeno",
            "probability": 0.0015573501586914062
        },
        {
            "start_logit": 2.18359375,
            "end_logit": 3.357421875,
            "text": " gene replacement",
            "probability": 0.0014019012451171875
        }
    ],
    "641368ee201352f04a00003c_0001": [
        {
            "start_logit": 6.15234375,
            "end_logit": 6.03515625,
            "text": " oligodendroglioma",
            "probability": 0.379638671875
        },
        {
            "start_logit": 5.31640625,
            "end_logit": 6.03515625,
            "text": " astrocytoma, isocitrate dehydrogenase (isocitrate dehydrogenase)-mutant, oligodendroglioma",
            "probability": 0.1644287109375
        },
        {
            "start_logit": 5.31640625,
            "end_logit": 5.48046875,
            "text": " astrocytoma",
            "probability": 0.094482421875
        },
        {
            "start_logit": 4.57421875,
            "end_logit": 6.03515625,
            "text": " isocitrate dehydrogenase (isocitrate dehydrogenase)-mutant, oligodendroglioma",
            "probability": 0.078369140625
        },
        {
            "start_logit": 6.15234375,
            "end_logit": 4.3828125,
            "text": " oligodendroglioma, isocitrate dehydrogenase-mutant and 1p/19q codeleted, and glioblastoma, isocitrate dehydrogenase-wildtype",
            "probability": 0.0723876953125
        },
        {
            "start_logit": 6.15234375,
            "end_logit": 3.703125,
            "text": " oligodendroglioma, isocitrate dehydrogenase-mutant",
            "probability": 0.0369873046875
        },
        {
            "start_logit": 5.15234375,
            "end_logit": 4.3828125,
            "text": " glioblastoma, isocitrate dehydrogenase-wildtype",
            "probability": 0.026641845703125
        },
        {
            "start_logit": 6.15234375,
            "end_logit": 3.361328125,
            "text": " oligodendroglioma, isocitrate dehydrogenase-mutant and 1p/19q codeleted",
            "probability": 0.0262451171875
        },
        {
            "start_logit": 4.82421875,
            "end_logit": 4.3828125,
            "text": " isocitrate dehydrogenase-wildtype",
            "probability": 0.019195556640625
        },
        {
            "start_logit": 4.69921875,
            "end_logit": 4.3828125,
            "text": " isocitrate dehydrogenase-mutant and 1p/19q codeleted, and glioblastoma, isocitrate dehydrogenase-wildtype",
            "probability": 0.016937255859375
        },
        {
            "start_logit": 5.31640625,
            "end_logit": 3.703125,
            "text": " astrocytoma, isocitrate dehydrogenase (isocitrate dehydrogenase)-mutant, oligodendroglioma, isocitrate dehydrogenase-mutant",
            "probability": 0.0159149169921875
        },
        {
            "start_logit": 4.4375,
            "end_logit": 4.3828125,
            "text": " 1p/19q codeleted, and glioblastoma, isocitrate dehydrogenase-wildtype",
            "probability": 0.013092041015625
        },
        {
            "start_logit": 5.31640625,
            "end_logit": 3.361328125,
            "text": " astrocytoma, isocitrate dehydrogenase (isocitrate dehydrogenase)-mutant, oligodendroglioma, isocitrate dehydrogenase-mutant and 1p/19q codeleted",
            "probability": 0.01137542724609375
        },
        {
            "start_logit": 4.69921875,
            "end_logit": 3.703125,
            "text": " isocitrate dehydrogenase-mutant",
            "probability": 0.0086517333984375
        },
        {
            "start_logit": 4.57421875,
            "end_logit": 3.703125,
            "text": " isocitrate dehydrogenase (isocitrate dehydrogenase)-mutant, oligodendroglioma, isocitrate dehydrogenase-mutant",
            "probability": 0.007633209228515625
        },
        {
            "start_logit": 6.15234375,
            "end_logit": 1.916015625,
            "text": " oligodendroglioma, isocitrate dehydrogenase-mutant and 1p/19q codeleted, and glioblastoma",
            "probability": 0.006183624267578125
        },
        {
            "start_logit": 4.69921875,
            "end_logit": 3.361328125,
            "text": " isocitrate dehydrogenase-mutant and 1p/19q codeleted",
            "probability": 0.006134033203125
        },
        {
            "start_logit": 4.57421875,
            "end_logit": 3.361328125,
            "text": " isocitrate dehydrogenase (isocitrate dehydrogenase)-mutant, oligodendroglioma, isocitrate dehydrogenase-mutant and 1p/19q codeleted",
            "probability": 0.005413055419921875
        },
        {
            "start_logit": 6.15234375,
            "end_logit": 1.751953125,
            "text": " oligodendroglioma, isocitrate dehydrogenase-mutant and 1p/19q codeleted, and glioblastoma,",
            "probability": 0.005245208740234375
        },
        {
            "start_logit": 5.31640625,
            "end_logit": 2.498046875,
            "text": " astrocytoma, isocitrate dehydrogenase (isocitrate dehydrogenase)-mutant",
            "probability": 0.0047760009765625
        }
    ],
    "641368ee201352f04a00003c_0002": [
        {
            "start_logit": 5.3046875,
            "end_logit": 5.4375,
            "text": " low-risk, expecting oligodendroglioma",
            "probability": 0.1724853515625
        },
        {
            "start_logit": 5.12109375,
            "end_logit": 5.40625,
            "text": " intermediate-risk, expecting astrocytoma, isocitrate dehydrogenase-mutant; and (3) high-risk, expecting glioblastoma",
            "probability": 0.1397705078125
        },
        {
            "start_logit": 4.90234375,
            "end_logit": 5.4375,
            "text": " oligodendroglioma",
            "probability": 0.1158447265625
        },
        {
            "start_logit": 5.12109375,
            "end_logit": 5.04296875,
            "text": " intermediate-risk, expecting astrocytoma",
            "probability": 0.0968017578125
        },
        {
            "start_logit": 4.73046875,
            "end_logit": 5.40625,
            "text": " high-risk, expecting glioblastoma",
            "probability": 0.094482421875
        },
        {
            "start_logit": 5.3046875,
            "end_logit": 4.50390625,
            "text": " low-risk",
            "probability": 0.068115234375
        },
        {
            "start_logit": 5.12109375,
            "end_logit": 4.4296875,
            "text": " intermediate-risk",
            "probability": 0.05218505859375
        },
        {
            "start_logit": 4.09375,
            "end_logit": 5.4375,
            "text": " expecting oligodendroglioma",
            "probability": 0.0513916015625
        },
        {
            "start_logit": 3.693359375,
            "end_logit": 5.40625,
            "text": " glioblastoma",
            "probability": 0.033447265625
        },
        {
            "start_logit": 3.517578125,
            "end_logit": 5.40625,
            "text": " expecting glioblastoma",
            "probability": 0.0279388427734375
        },
        {
            "start_logit": 4.1484375,
            "end_logit": 4.4296875,
            "text": " isocitrate dehydrogenase (isocitrate dehydrogenase)-mutant, and 1p/19q-codeleted; (2) intermediate-risk",
            "probability": 0.0198211669921875
        },
        {
            "start_logit": 4.73046875,
            "end_logit": 3.8125,
            "text": " high-risk, expecting glioblastoma, isocitrate dehydrogenase-wildtype",
            "probability": 0.0192108154296875
        },
        {
            "start_logit": 5.3046875,
            "end_logit": 3.126953125,
            "text": " low-risk, expecting",
            "probability": 0.0170745849609375
        },
        {
            "start_logit": 5.3046875,
            "end_logit": 3.05078125,
            "text": " low-risk, expecting oligodendroglioma, isocitrate dehydrogenase (isocitrate dehydrogenase)",
            "probability": 0.0159149169921875
        },
        {
            "start_logit": 5.12109375,
            "end_logit": 3.162109375,
            "text": " intermediate-risk, expecting astrocytoma, isocitrate dehydrogenase-mutant",
            "probability": 0.01471710205078125
        },
        {
            "start_logit": 2.861328125,
            "end_logit": 5.40625,
            "text": " expecting astrocytoma, isocitrate dehydrogenase-mutant; and (3) high-risk, expecting glioblastoma",
            "probability": 0.014495849609375
        },
        {
            "start_logit": 2.8515625,
            "end_logit": 5.40625,
            "text": " isocitrate dehydrogenase-mutant; and (3) high-risk, expecting glioblastoma",
            "probability": 0.01438140869140625
        },
        {
            "start_logit": 4.20703125,
            "end_logit": 3.8125,
            "text": " isocitrate dehydrogenase-wildtype",
            "probability": 0.01128387451171875
        },
        {
            "start_logit": 4.90234375,
            "end_logit": 3.05078125,
            "text": " oligodendroglioma, isocitrate dehydrogenase (isocitrate dehydrogenase)",
            "probability": 0.0106048583984375
        },
        {
            "start_logit": 2.861328125,
            "end_logit": 5.04296875,
            "text": " expecting astrocytoma",
            "probability": 0.0101165771484375
        }
    ],
    "6415bc8d690f196b5100000f_0001": [
        {
            "start_logit": 7.63671875,
            "end_logit": 7.01953125,
            "text": " 8%",
            "probability": 0.9853515625
        },
        {
            "start_logit": 7.63671875,
            "end_logit": 2.099609375,
            "text": " 8% and 10-12%",
            "probability": 0.00717926025390625
        },
        {
            "start_logit": 7.63671875,
            "end_logit": 0.9033203125,
            "text": " 8% and 10-12",
            "probability": 0.0021724700927734375
        },
        {
            "start_logit": 7.63671875,
            "end_logit": 0.74072265625,
            "text": " 8% and 10",
            "probability": 0.0018444061279296875
        },
        {
            "start_logit": 7.63671875,
            "end_logit": -0.068115234375,
            "text": " 8% and 10-12%, respectively.",
            "probability": 0.0008249282836914062
        },
        {
            "start_logit": 7.63671875,
            "end_logit": -0.2412109375,
            "text": " 8% and 10-12%,",
            "probability": 0.0006918907165527344
        },
        {
            "start_logit": -0.044830322265625,
            "end_logit": 7.01953125,
            "text": " costs by online counseling with about 8%",
            "probability": 0.0004553794860839844
        },
        {
            "start_logit": 7.63671875,
            "end_logit": -0.71533203125,
            "text": " 8",
            "probability": 0.00043129920959472656
        },
        {
            "start_logit": 7.63671875,
            "end_logit": -1.505859375,
            "text": " 8% and 10-12%, respectively",
            "probability": 0.0001958608627319336
        },
        {
            "start_logit": -0.9326171875,
            "end_logit": 7.01953125,
            "text": "%",
            "probability": 0.000186920166015625
        },
        {
            "start_logit": -2.0625,
            "end_logit": 7.01953125,
            "text": "We estimated reduced time and costs by online counseling with about 8%",
            "probability": 6.020069122314453e-05
        },
        {
            "start_logit": -2.087890625,
            "end_logit": 7.01953125,
            "text": " online counseling with about 8%",
            "probability": 5.882978439331055e-05
        },
        {
            "start_logit": -2.177734375,
            "end_logit": 7.01953125,
            "text": " about 8%",
            "probability": 5.4001808166503906e-05
        },
        {
            "start_logit": -2.20703125,
            "end_logit": 7.01953125,
            "text": " estimated reduced time and costs by online counseling with about 8%",
            "probability": 5.227327346801758e-05
        },
        {
            "start_logit": -2.4140625,
            "end_logit": 7.01953125,
            "text": " reduced time and costs by online counseling with about 8%",
            "probability": 4.273653030395508e-05
        },
        {
            "start_logit": 2.341796875,
            "end_logit": 2.099609375,
            "text": "12%",
            "probability": 3.594160079956055e-05
        },
        {
            "start_logit": 2.326171875,
            "end_logit": 2.099609375,
            "text": " 10-12%",
            "probability": 3.540515899658203e-05
        },
        {
            "start_logit": -2.759765625,
            "end_logit": 7.01953125,
            "text": " with about 8%",
            "probability": 3.0040740966796875e-05
        },
        {
            "start_logit": 7.63671875,
            "end_logit": -3.44921875,
            "text": " 8% and",
            "probability": 2.8014183044433594e-05
        },
        {
            "start_logit": 7.63671875,
            "end_logit": -3.615234375,
            "text": " 8% and 10-",
            "probability": 2.378225326538086e-05
        }
    ],
    "6402bc2d201352f04a000005_0001": [
        {
            "start_logit": 6.890625,
            "end_logit": 6.81640625,
            "text": "CD20",
            "probability": 0.368896484375
        },
        {
            "start_logit": 6.890625,
            "end_logit": 6.703125,
            "text": "CD20 on B cells and engage T cells via CD3",
            "probability": 0.330810546875
        },
        {
            "start_logit": 6.74609375,
            "end_logit": 6.703125,
            "text": "CD3",
            "probability": 0.287353515625
        },
        {
            "start_logit": 2.41796875,
            "end_logit": 6.703125,
            "text": " T cells via CD3",
            "probability": 0.00379180908203125
        },
        {
            "start_logit": 1.4892578125,
            "end_logit": 6.703125,
            "text": "B cells and engage T cells via CD3",
            "probability": 0.001495361328125
        },
        {
            "start_logit": 6.890625,
            "end_logit": 1.0498046875,
            "text": "CD20 on B cells",
            "probability": 0.0011606216430664062
        },
        {
            "start_logit": 0.86279296875,
            "end_logit": 6.703125,
            "text": "3",
            "probability": 0.0007977485656738281
        },
        {
            "start_logit": 6.890625,
            "end_logit": 0.59521484375,
            "text": "CD20 on B cells and engage T cells via CD3 in a 1:1 or 2:1 CD20:CD3",
            "probability": 0.0007343292236328125
        },
        {
            "start_logit": 6.890625,
            "end_logit": 0.59130859375,
            "text": "CD20 on B cells and engage T cells",
            "probability": 0.0007319450378417969
        },
        {
            "start_logit": 6.74609375,
            "end_logit": 0.59521484375,
            "text": "CD3 in a 1:1 or 2:1 CD20:CD3",
            "probability": 0.0006356239318847656
        },
        {
            "start_logit": 6.890625,
            "end_logit": 0.366455078125,
            "text": "CD20 on B cells and engage T cells via CD",
            "probability": 0.0005855560302734375
        },
        {
            "start_logit": 6.74609375,
            "end_logit": 0.366455078125,
            "text": "CD",
            "probability": 0.0005068778991699219
        },
        {
            "start_logit": 6.890625,
            "end_logit": 0.11016845703125,
            "text": "CD",
            "probability": 0.0004527568817138672
        },
        {
            "start_logit": 0.0809326171875,
            "end_logit": 6.81640625,
            "text": "20",
            "probability": 0.0004088878631591797
        },
        {
            "start_logit": 0.0809326171875,
            "end_logit": 6.703125,
            "text": "20 on B cells and engage T cells via CD3",
            "probability": 0.00036525726318359375
        },
        {
            "start_logit": 6.890625,
            "end_logit": -0.1922607421875,
            "text": "CD20 on B cells and engage T",
            "probability": 0.0003349781036376953
        },
        {
            "start_logit": 6.74609375,
            "end_logit": -0.127197265625,
            "text": "CD3 in a 1:1 or 2:1 CD20:CD3 antigen binding fragment (Fab) format.",
            "probability": 0.00030875205993652344
        },
        {
            "start_logit": 6.890625,
            "end_logit": -0.58251953125,
            "text": "CD20 on B",
            "probability": 0.00022673606872558594
        },
        {
            "start_logit": 6.74609375,
            "end_logit": -0.6318359375,
            "text": "CD3 in a 1:1 or 2:1 CD20:CD3 antigen binding fragment",
            "probability": 0.00018644332885742188
        },
        {
            "start_logit": 6.74609375,
            "end_logit": -0.7099609375,
            "text": "CD3 in a 1:1 or 2:1 CD20:CD3 antigen binding fragment (Fab)",
            "probability": 0.00017249584197998047
        }
    ],
    "6402bc2d201352f04a000005_0002": [
        {
            "start_logit": 7.15625,
            "end_logit": 6.9296875,
            "text": "CD20/CD3",
            "probability": 0.341796875
        },
        {
            "start_logit": 7.15625,
            "end_logit": 6.91015625,
            "text": "CD20",
            "probability": 0.333984375
        },
        {
            "start_logit": 7.06640625,
            "end_logit": 6.9296875,
            "text": "CD3",
            "probability": 0.3134765625
        },
        {
            "start_logit": 7.15625,
            "end_logit": 1.90234375,
            "text": "CD20/CD3 T-cell engaging",
            "probability": 0.0022487640380859375
        },
        {
            "start_logit": 7.06640625,
            "end_logit": 1.90234375,
            "text": "CD3 T-cell engaging",
            "probability": 0.002048492431640625
        },
        {
            "start_logit": 7.15625,
            "end_logit": 0.86962890625,
            "text": "CD20/CD3 T-cell engaging bispecific",
            "probability": 0.0007958412170410156
        },
        {
            "start_logit": 7.06640625,
            "end_logit": 0.86962890625,
            "text": "CD3 T-cell engaging bispecific",
            "probability": 0.0007300376892089844
        },
        {
            "start_logit": 7.15625,
            "end_logit": 0.6865234375,
            "text": "CD20/CD3 T-cell engaging bispecific antibody",
            "probability": 0.0006647109985351562
        },
        {
            "start_logit": 7.06640625,
            "end_logit": 0.6865234375,
            "text": "CD3 T-cell engaging bispecific antibody",
            "probability": 0.0006079673767089844
        },
        {
            "start_logit": 7.15625,
            "end_logit": 0.2049560546875,
            "text": "CD",
            "probability": 0.00040984153747558594
        },
        {
            "start_logit": 0.418212890625,
            "end_logit": 6.9296875,
            "text": "3",
            "probability": 0.0004048347473144531
        },
        {
            "start_logit": 7.15625,
            "end_logit": 0.1488037109375,
            "text": "CD20/CD",
            "probability": 0.0003879070281982422
        },
        {
            "start_logit": 7.15625,
            "end_logit": 0.06982421875,
            "text": "CD20/CD3 T-cell",
            "probability": 0.00035881996154785156
        },
        {
            "start_logit": 7.06640625,
            "end_logit": 0.1488037109375,
            "text": "CD",
            "probability": 0.00035452842712402344
        },
        {
            "start_logit": 7.06640625,
            "end_logit": 0.06982421875,
            "text": "CD3 T-cell",
            "probability": 0.00032782554626464844
        },
        {
            "start_logit": 0.09942626953125,
            "end_logit": 6.9296875,
            "text": "20/CD3",
            "probability": 0.00029397010803222656
        },
        {
            "start_logit": 0.09942626953125,
            "end_logit": 6.91015625,
            "text": "20",
            "probability": 0.00028824806213378906
        },
        {
            "start_logit": 7.15625,
            "end_logit": -0.1995849609375,
            "text": "CD20/CD3 T-cell engaging bispecific antibody, is being developed by Roche for the treatment of relapsed or refractory follicular lymphoma.",
            "probability": 0.0002739429473876953
        },
        {
            "start_logit": 7.15625,
            "end_logit": -0.212646484375,
            "text": "CD20/CD3 T-cell engaging bispecific antibody,",
            "probability": 0.00027060508728027344
        },
        {
            "start_logit": 7.15625,
            "end_logit": -0.259033203125,
            "text": "CD20/CD3 T-cell engaging bispecific antibody, is being developed by Roche for the treatment of relapsed or refractory follicular lymphoma",
            "probability": 0.0002582073211669922
        }
    ],
    "6402bc2d201352f04a000005_0003": [
        {
            "start_logit": 7.140625,
            "end_logit": 6.89453125,
            "text": "CD20\u2009\u00d7\u2009CD3",
            "probability": 0.340087890625
        },
        {
            "start_logit": 7.12109375,
            "end_logit": 6.89453125,
            "text": "CD3",
            "probability": 0.334716796875
        },
        {
            "start_logit": 7.140625,
            "end_logit": 6.83203125,
            "text": "CD20",
            "probability": 0.3193359375
        },
        {
            "start_logit": 7.140625,
            "end_logit": 0.91015625,
            "text": "CD20\u2009\u00d7\u2009CD3 T-cell-engaging",
            "probability": 0.0008559226989746094
        },
        {
            "start_logit": 7.12109375,
            "end_logit": 0.91015625,
            "text": "CD3 T-cell-engaging",
            "probability": 0.000843048095703125
        },
        {
            "start_logit": 7.140625,
            "end_logit": 0.4951171875,
            "text": "CD20\u2009\u00d7\u2009CD3 T-cell-engaging bispecific",
            "probability": 0.0005679130554199219
        },
        {
            "start_logit": 7.12109375,
            "end_logit": 0.4951171875,
            "text": "CD3 T-cell-engaging bispecific",
            "probability": 0.00055694580078125
        },
        {
            "start_logit": 7.140625,
            "end_logit": 0.08636474609375,
            "text": "CD20\u2009\u00d7\u2009CD",
            "probability": 0.00037670135498046875
        },
        {
            "start_logit": 7.12109375,
            "end_logit": 0.08636474609375,
            "text": "CD",
            "probability": 0.0003695487976074219
        },
        {
            "start_logit": 0.26953125,
            "end_logit": 6.89453125,
            "text": "3",
            "probability": 0.0003540515899658203
        },
        {
            "start_logit": 7.140625,
            "end_logit": -0.062042236328125,
            "text": "CD20\u2009\u00d7\u2009CD3 T-cell-engaging bispecific monoclonal antibody that redirects T cells to eliminate malignant B cells.",
            "probability": 0.0003249645233154297
        },
        {
            "start_logit": 7.12109375,
            "end_logit": -0.062042236328125,
            "text": "CD3 T-cell-engaging bispecific monoclonal antibody that redirects T cells to eliminate malignant B cells.",
            "probability": 0.0003185272216796875
        },
        {
            "start_logit": 7.140625,
            "end_logit": -0.296630859375,
            "text": "CD",
            "probability": 0.0002570152282714844
        },
        {
            "start_logit": 7.140625,
            "end_logit": -0.325927734375,
            "text": "CD20\u2009\u00d7\u2009CD3 T-cell-engaging bispecific monoclonal antibody",
            "probability": 0.00025010108947753906
        },
        {
            "start_logit": -0.092529296875,
            "end_logit": 6.89453125,
            "text": "20\u2009\u00d7\u2009CD3",
            "probability": 0.00024628639221191406
        },
        {
            "start_logit": 7.12109375,
            "end_logit": -0.325927734375,
            "text": "CD3 T-cell-engaging bispecific monoclonal antibody",
            "probability": 0.0002453327178955078
        },
        {
            "start_logit": -0.092529296875,
            "end_logit": 6.83203125,
            "text": "20",
            "probability": 0.0002313852310180664
        },
        {
            "start_logit": -0.39990234375,
            "end_logit": 6.89453125,
            "text": "BACKGROUND: Mosunetuzumab is a CD20\u2009\u00d7\u2009CD3",
            "probability": 0.00018155574798583984
        },
        {
            "start_logit": -0.39990234375,
            "end_logit": 6.83203125,
            "text": "BACKGROUND: Mosunetuzumab is a CD20",
            "probability": 0.00017058849334716797
        },
        {
            "start_logit": 7.140625,
            "end_logit": -1.021484375,
            "text": "CD20\u2009\u00d7\u2009CD3 T-cell-eng",
            "probability": 0.00012421607971191406
        }
    ],
    "6402bc2d201352f04a000005_0004": [
        {
            "start_logit": 6.765625,
            "end_logit": 6.7734375,
            "text": "CD3",
            "probability": 0.46875
        },
        {
            "start_logit": 6.3671875,
            "end_logit": 6.7734375,
            "text": "CD20 \u00d7 CD3",
            "probability": 0.314697265625
        },
        {
            "start_logit": 6.3671875,
            "end_logit": 6.22265625,
            "text": "CD20",
            "probability": 0.1822509765625
        },
        {
            "start_logit": 6.765625,
            "end_logit": 3.111328125,
            "text": "CD3 BsAbs including odron",
            "probability": 0.01201629638671875
        },
        {
            "start_logit": 6.3671875,
            "end_logit": 3.111328125,
            "text": "CD20 \u00d7 CD3 BsAbs including odron",
            "probability": 0.0080718994140625
        },
        {
            "start_logit": 6.765625,
            "end_logit": 2.060546875,
            "text": "CD3 BsAbs including odronextamab",
            "probability": 0.00421905517578125
        },
        {
            "start_logit": 6.3671875,
            "end_logit": 2.060546875,
            "text": "CD20 \u00d7 CD3 BsAbs including odronextamab",
            "probability": 0.00283050537109375
        },
        {
            "start_logit": 6.765625,
            "end_logit": 1.3466796875,
            "text": "CD3 BsAbs including odronextam",
            "probability": 0.0020542144775390625
        },
        {
            "start_logit": 6.3671875,
            "end_logit": 1.3466796875,
            "text": "CD20 \u00d7 CD3 BsAbs including odronextam",
            "probability": 0.0013856887817382812
        },
        {
            "start_logit": 6.765625,
            "end_logit": 0.25,
            "text": "CD3 BsAbs including odronextamab, mosunetuzumab, glofitamab",
            "probability": 0.0006885528564453125
        },
        {
            "start_logit": 6.765625,
            "end_logit": 0.046417236328125,
            "text": "CD3 BsAbs",
            "probability": 0.0005621910095214844
        },
        {
            "start_logit": 6.3671875,
            "end_logit": 0.25,
            "text": "CD20 \u00d7 CD3 BsAbs including odronextamab, mosunetuzumab, glofitamab",
            "probability": 0.0004622936248779297
        },
        {
            "start_logit": 6.3671875,
            "end_logit": 0.046417236328125,
            "text": "CD20 \u00d7 CD3 BsAbs",
            "probability": 0.00037741661071777344
        },
        {
            "start_logit": 6.765625,
            "end_logit": -0.3818359375,
            "text": "CD",
            "probability": 0.0003657341003417969
        },
        {
            "start_logit": -0.62255859375,
            "end_logit": 6.7734375,
            "text": "3",
            "probability": 0.0002903938293457031
        },
        {
            "start_logit": 6.3671875,
            "end_logit": -0.3818359375,
            "text": "CD20 \u00d7 CD",
            "probability": 0.0002455711364746094
        },
        {
            "start_logit": 6.765625,
            "end_logit": -0.86572265625,
            "text": "CD3 BsAbs including odronextamab,",
            "probability": 0.00022530555725097656
        },
        {
            "start_logit": 2.64453125,
            "end_logit": 3.111328125,
            "text": "odron",
            "probability": 0.0001957416534423828
        },
        {
            "start_logit": 6.765625,
            "end_logit": -1.0126953125,
            "text": "CD3 BsAbs including odronextamab, mosunetuzumab,",
            "probability": 0.00019490718841552734
        },
        {
            "start_logit": 6.765625,
            "end_logit": -1.056640625,
            "text": "CD3 BsAbs including odronextamab, mosunetuzumab, glofitamab,",
            "probability": 0.00018680095672607422
        }
    ],
    "6415c6b6690f196b51000015_0001": [
        {
            "start_logit": 0.84033203125,
            "end_logit": 1.251953125,
            "text": " KEYNOTE-024",
            "probability": 0.303466796875
        },
        {
            "start_logit": 0.466552734375,
            "end_logit": 1.3388671875,
            "text": " KEYNOTE-010",
            "probability": 0.2279052734375
        },
        {
            "start_logit": -0.1612548828125,
            "end_logit": 1.251953125,
            "text": " overall survival (overall survival) for patients randomized to pembrolizumab compared with chemotherapy. In KEYNOTE-024",
            "probability": 0.11151123046875
        },
        {
            "start_logit": 0.6533203125,
            "end_logit": -0.10675048828125,
            "text": " docetaxel",
            "probability": 0.06475830078125
        },
        {
            "start_logit": 0.6533203125,
            "end_logit": -0.322021484375,
            "text": " docetaxel 75 mg/m2 every 3 weeks.",
            "probability": 0.052154541015625
        },
        {
            "start_logit": -1.302734375,
            "end_logit": 1.251953125,
            "text": " pembrolizumab compared with chemotherapy. In KEYNOTE-024",
            "probability": 0.035614013671875
        },
        {
            "start_logit": -1.55859375,
            "end_logit": 1.251953125,
            "text": " chemotherapy. In KEYNOTE-024",
            "probability": 0.027587890625
        },
        {
            "start_logit": 0.84033203125,
            "end_logit": -1.26171875,
            "text": " KEYNOTE-024, patients with previously untreated metastatic non-small cell lung cancer",
            "probability": 0.0245819091796875
        },
        {
            "start_logit": -1.791015625,
            "end_logit": 1.251953125,
            "text": ". In KEYNOTE-024",
            "probability": 0.0218658447265625
        },
        {
            "start_logit": -0.1612548828125,
            "end_logit": -0.51611328125,
            "text": " overall survival",
            "probability": 0.0190277099609375
        },
        {
            "start_logit": -0.1612548828125,
            "end_logit": -0.7001953125,
            "text": " overall survival (overall survival) for patients randomized to pembrolizumab compared with chemotherapy.",
            "probability": 0.015838623046875
        },
        {
            "start_logit": -0.55419921875,
            "end_logit": -0.39990234375,
            "text": " progression-free survival (progression-free survival)",
            "probability": 0.0144195556640625
        },
        {
            "start_logit": -0.55419921875,
            "end_logit": -0.51611328125,
            "text": " progression-free survival (progression-free survival) and overall survival",
            "probability": 0.012847900390625
        },
        {
            "start_logit": -0.55419921875,
            "end_logit": -0.53271484375,
            "text": " progression-free survival",
            "probability": 0.01262664794921875
        },
        {
            "start_logit": -0.1612548828125,
            "end_logit": -1.0673828125,
            "text": " overall survival (overall survival) for patients randomized to pembrolizumab",
            "probability": 0.01096343994140625
        },
        {
            "start_logit": -0.55419921875,
            "end_logit": -0.7001953125,
            "text": " progression-free survival (progression-free survival) and overall survival (overall survival) for patients randomized to pembrolizumab compared with chemotherapy.",
            "probability": 0.0106964111328125
        },
        {
            "start_logit": -0.96728515625,
            "end_logit": -0.39990234375,
            "text": " statistically significant improvements in progression-free survival (progression-free survival)",
            "probability": 0.009552001953125
        },
        {
            "start_logit": -0.96728515625,
            "end_logit": -0.51611328125,
            "text": " statistically significant improvements in progression-free survival (progression-free survival) and overall survival",
            "probability": 0.00850677490234375
        },
        {
            "start_logit": -0.96728515625,
            "end_logit": -0.53271484375,
            "text": " statistically significant improvements in progression-free survival",
            "probability": 0.00836181640625
        },
        {
            "start_logit": -0.55419921875,
            "end_logit": -1.0673828125,
            "text": " progression-free survival (progression-free survival) and overall survival (overall survival) for patients randomized to pembrolizumab",
            "probability": 0.00740814208984375
        }
    ],
    "640c8309201352f04a000024_0001": [
        {
            "start_logit": 6.76171875,
            "end_logit": 6.3828125,
            "text": " alkaline phosphatase",
            "probability": 0.97265625
        },
        {
            "start_logit": 6.76171875,
            "end_logit": 1.6708984375,
            "text": " alkaline phosphatase that is 1.67-times higher than the upper limit of normal",
            "probability": 0.00875091552734375
        },
        {
            "start_logit": 1.7822265625,
            "end_logit": 6.3828125,
            "text": " bile acid retention, whether within the hepatocyte or in the bile ducts of any caliber. Biochemically, it is defined by a level of alkaline phosphatase",
            "probability": 0.00670623779296875
        },
        {
            "start_logit": 3.326171875,
            "end_logit": 3.94140625,
            "text": " bilirubin",
            "probability": 0.0027313232421875
        },
        {
            "start_logit": 0.21484375,
            "end_logit": 6.3828125,
            "text": " bile ducts of any caliber. Biochemically, it is defined by a level of alkaline phosphatase",
            "probability": 0.001399993896484375
        },
        {
            "start_logit": 6.76171875,
            "end_logit": -0.297119140625,
            "text": " alkaline phosphatase that is 1.67-times higher than the upper limit of normal.",
            "probability": 0.0012264251708984375
        },
        {
            "start_logit": 2.3828125,
            "end_logit": 3.94140625,
            "text": " serum bilirubin",
            "probability": 0.0010652542114257812
        },
        {
            "start_logit": 2.255859375,
            "end_logit": 3.94140625,
            "text": "jaundice (yellowing of the skin and mucus membranes, associated with elevated serum bilirubin",
            "probability": 0.0009365081787109375
        },
        {
            "start_logit": -0.417236328125,
            "end_logit": 6.3828125,
            "text": " a level of alkaline phosphatase",
            "probability": 0.000743865966796875
        },
        {
            "start_logit": -0.63037109375,
            "end_logit": 6.3828125,
            "text": " phosphatase",
            "probability": 0.0006022453308105469
        },
        {
            "start_logit": 6.76171875,
            "end_logit": -1.0419921875,
            "text": " alkaline",
            "probability": 0.0005812644958496094
        },
        {
            "start_logit": -0.7294921875,
            "end_logit": 6.3828125,
            "text": " Biochemically, it is defined by a level of alkaline phosphatase",
            "probability": 0.0005445480346679688
        },
        {
            "start_logit": 6.76171875,
            "end_logit": -1.220703125,
            "text": " alkaline phosphatase that is 1.67-times higher than the upper limit of normal. Cholestatic diseases can be associated with an inflammatory process of the liver",
            "probability": 0.0004858970642089844
        },
        {
            "start_logit": -0.92529296875,
            "end_logit": 6.3828125,
            "text": ". Biochemically, it is defined by a level of alkaline phosphatase",
            "probability": 0.0004477500915527344
        },
        {
            "start_logit": -0.98681640625,
            "end_logit": 6.3828125,
            "text": " level of alkaline phosphatase",
            "probability": 0.00042057037353515625
        },
        {
            "start_logit": 0.6220703125,
            "end_logit": 3.94140625,
            "text": " mucus membranes, associated with elevated serum bilirubin",
            "probability": 0.00018310546875
        },
        {
            "start_logit": 2.255859375,
            "end_logit": 2.1328125,
            "text": "jaundice",
            "probability": 0.00015401840209960938
        },
        {
            "start_logit": 3.326171875,
            "end_logit": 0.98583984375,
            "text": " bilirubin levels",
            "probability": 0.0001424551010131836
        },
        {
            "start_logit": 0.053375244140625,
            "end_logit": 3.94140625,
            "text": "yellowing of the skin and mucus membranes, associated with elevated serum bilirubin",
            "probability": 0.00010347366333007812
        },
        {
            "start_logit": -0.07904052734375,
            "end_logit": 3.94140625,
            "text": "hepatitis), withjaundice (yellowing of the skin and mucus membranes, associated with elevated serum bilirubin",
            "probability": 9.059906005859375e-05
        }
    ],
    "640c8309201352f04a000024_0002": [
        {
            "start_logit": 6.37890625,
            "end_logit": 6.28125,
            "text": " alkaline phosphatase",
            "probability": 0.4443359375
        },
        {
            "start_logit": 6.37890625,
            "end_logit": 5.69921875,
            "text": " alkaline phosphatase, and conjugated bilirubin",
            "probability": 0.2493896484375
        },
        {
            "start_logit": 5.87109375,
            "end_logit": 5.69921875,
            "text": " conjugated bilirubin",
            "probability": 0.1500244140625
        },
        {
            "start_logit": 4.33203125,
            "end_logit": 6.28125,
            "text": " liver transaminases, alkaline phosphatase",
            "probability": 0.057403564453125
        },
        {
            "start_logit": 4.33203125,
            "end_logit": 5.69921875,
            "text": " liver transaminases, alkaline phosphatase, and conjugated bilirubin",
            "probability": 0.032196044921875
        },
        {
            "start_logit": 3.15625,
            "end_logit": 6.28125,
            "text": " transaminases, alkaline phosphatase",
            "probability": 0.0177764892578125
        },
        {
            "start_logit": 3.15625,
            "end_logit": 5.69921875,
            "text": " transaminases, alkaline phosphatase, and conjugated bilirubin",
            "probability": 0.009979248046875
        },
        {
            "start_logit": 4.33203125,
            "end_logit": 4.44140625,
            "text": " liver transaminases",
            "probability": 0.0091552734375
        },
        {
            "start_logit": 2.224609375,
            "end_logit": 6.28125,
            "text": " elevated liver transaminases, alkaline phosphatase",
            "probability": 0.00701904296875
        },
        {
            "start_logit": 6.37890625,
            "end_logit": 2.0625,
            "text": " alkaline phosphatase,",
            "probability": 0.006542205810546875
        },
        {
            "start_logit": 2.224609375,
            "end_logit": 5.69921875,
            "text": " elevated liver transaminases, alkaline phosphatase, and conjugated bilirubin",
            "probability": 0.00390625
        },
        {
            "start_logit": 3.15625,
            "end_logit": 4.44140625,
            "text": " transaminases",
            "probability": 0.0028247833251953125
        },
        {
            "start_logit": 4.33203125,
            "end_logit": 3.1484375,
            "text": " liver transaminase",
            "probability": 0.0025119781494140625
        },
        {
            "start_logit": 0.51025390625,
            "end_logit": 6.28125,
            "text": " phosphatase",
            "probability": 0.001262664794921875
        },
        {
            "start_logit": 2.224609375,
            "end_logit": 4.44140625,
            "text": " elevated liver transaminases",
            "probability": 0.001110076904296875
        },
        {
            "start_logit": 6.37890625,
            "end_logit": 0.28271484375,
            "text": " alkaline phosphatase, and conjugated",
            "probability": 0.00110626220703125
        },
        {
            "start_logit": 6.37890625,
            "end_logit": 0.0770263671875,
            "text": " alkaline",
            "probability": 0.0009026527404785156
        },
        {
            "start_logit": 4.33203125,
            "end_logit": 2.0625,
            "text": " liver transaminases, alkaline phosphatase,",
            "probability": 0.0008482933044433594
        },
        {
            "start_logit": 3.15625,
            "end_logit": 3.1484375,
            "text": " transaminase",
            "probability": 0.0007753372192382812
        },
        {
            "start_logit": 0.51025390625,
            "end_logit": 5.69921875,
            "text": " phosphatase, and conjugated bilirubin",
            "probability": 0.000705718994140625
        }
    ],
    "640c8309201352f04a000024_0003": [
        {
            "start_logit": 6.5390625,
            "end_logit": 6.4375,
            "text": " alkaline phosphatase",
            "probability": 0.449951171875
        },
        {
            "start_logit": 6.1953125,
            "end_logit": 6.4375,
            "text": " conjugated bilirubin and alkaline phosphatase",
            "probability": 0.319091796875
        },
        {
            "start_logit": 6.1953125,
            "end_logit": 5.94140625,
            "text": " conjugated bilirubin",
            "probability": 0.1949462890625
        },
        {
            "start_logit": 6.5390625,
            "end_logit": 2.998046875,
            "text": " alkaline phosphatase suggestive of cholestatic jaundice",
            "probability": 0.01445770263671875
        },
        {
            "start_logit": 6.1953125,
            "end_logit": 2.998046875,
            "text": " conjugated bilirubin and alkaline phosphatase suggestive of cholestatic jaundice",
            "probability": 0.01025390625
        },
        {
            "start_logit": 1.2958984375,
            "end_logit": 6.4375,
            "text": " elevated conjugated bilirubin and alkaline phosphatase",
            "probability": 0.0023784637451171875
        },
        {
            "start_logit": 1.2958984375,
            "end_logit": 5.94140625,
            "text": " elevated conjugated bilirubin",
            "probability": 0.0014486312866210938
        },
        {
            "start_logit": 0.5888671875,
            "end_logit": 6.4375,
            "text": " bilirubin and alkaline phosphatase",
            "probability": 0.0011730194091796875
        },
        {
            "start_logit": 0.36328125,
            "end_logit": 6.4375,
            "text": " phosphatase",
            "probability": 0.0009355545043945312
        },
        {
            "start_logit": 0.5888671875,
            "end_logit": 5.94140625,
            "text": " bilirubin",
            "probability": 0.0007143020629882812
        },
        {
            "start_logit": 6.1953125,
            "end_logit": 0.275634765625,
            "text": " conjugated",
            "probability": 0.0006737709045410156
        },
        {
            "start_logit": 6.5390625,
            "end_logit": -0.0809326171875,
            "text": " alkaline phosphatase suggestive of cholestatic jaundice.",
            "probability": 0.0006632804870605469
        },
        {
            "start_logit": -0.00801849365234375,
            "end_logit": 6.4375,
            "text": " liver enzymes with elevated conjugated bilirubin and alkaline phosphatase",
            "probability": 0.0006451606750488281
        },
        {
            "start_logit": -0.160888671875,
            "end_logit": 6.4375,
            "text": " abnormal liver enzymes with elevated conjugated bilirubin and alkaline phosphatase",
            "probability": 0.0005545616149902344
        },
        {
            "start_logit": 6.5390625,
            "end_logit": -0.268310546875,
            "text": " alkaline",
            "probability": 0.0005502700805664062
        },
        {
            "start_logit": 6.1953125,
            "end_logit": -0.0809326171875,
            "text": " conjugated bilirubin and alkaline phosphatase suggestive of cholestatic jaundice.",
            "probability": 0.00047016143798828125
        },
        {
            "start_logit": -0.00801849365234375,
            "end_logit": 5.94140625,
            "text": " liver enzymes with elevated conjugated bilirubin",
            "probability": 0.000392913818359375
        },
        {
            "start_logit": 6.1953125,
            "end_logit": -0.268310546875,
            "text": " conjugated bilirubin and alkaline",
            "probability": 0.00039005279541015625
        },
        {
            "start_logit": -0.160888671875,
            "end_logit": 5.94140625,
            "text": " abnormal liver enzymes with elevated conjugated bilirubin",
            "probability": 0.00033736228942871094
        },
        {
            "start_logit": -0.74462890625,
            "end_logit": 6.4375,
            "text": ". Initial laboratory tests showed abnormal liver enzymes with elevated conjugated bilirubin and alkaline phosphatase",
            "probability": 0.0003085136413574219
        }
    ],
    "640c8309201352f04a000024_0004": [
        {
            "start_logit": 6.421875,
            "end_logit": 5.98828125,
            "text": " alanine aminotransferase",
            "probability": 0.1151123046875
        },
        {
            "start_logit": 6.421875,
            "end_logit": 5.92578125,
            "text": " alanine aminotransferase, aspartate aminotransferase",
            "probability": 0.108154296875
        },
        {
            "start_logit": 6.35546875,
            "end_logit": 5.92578125,
            "text": " aspartate aminotransferase",
            "probability": 0.1015625
        },
        {
            "start_logit": 6.421875,
            "end_logit": 5.8125,
            "text": " alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase",
            "probability": 0.096923828125
        },
        {
            "start_logit": 6.35546875,
            "end_logit": 5.8125,
            "text": " aspartate aminotransferase, alkaline phosphatase",
            "probability": 0.091064453125
        },
        {
            "start_logit": 6.08203125,
            "end_logit": 5.8125,
            "text": " alkaline phosphatase",
            "probability": 0.0687255859375
        },
        {
            "start_logit": 6.421875,
            "end_logit": 5.24609375,
            "text": " alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, gamma-glutamyl transpeptidase",
            "probability": 0.055206298828125
        },
        {
            "start_logit": 6.35546875,
            "end_logit": 5.24609375,
            "text": " aspartate aminotransferase, alkaline phosphatase, gamma-glutamyl transpeptidase",
            "probability": 0.051483154296875
        },
        {
            "start_logit": 6.08203125,
            "end_logit": 5.24609375,
            "text": " alkaline phosphatase, gamma-glutamyl transpeptidase",
            "probability": 0.0391845703125
        },
        {
            "start_logit": 6.35546875,
            "end_logit": 4.84375,
            "text": " aspartate aminotransferase, alkaline phosphatase, gamma-glutamyl transpeptidase, cholesterol, total serum tasting bile acids and total and conjugated bilirubin",
            "probability": 0.034576416015625
        },
        {
            "start_logit": 5.92578125,
            "end_logit": 5.24609375,
            "text": " gamma-glutamyl transpeptidase",
            "probability": 0.03350830078125
        },
        {
            "start_logit": 6.421875,
            "end_logit": 4.6875,
            "text": " alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, gamma-glutamyl transpeptidase, cholesterol, total serum tasting bile acids",
            "probability": 0.031463623046875
        },
        {
            "start_logit": 6.35546875,
            "end_logit": 4.6875,
            "text": " aspartate aminotransferase, alkaline phosphatase, gamma-glutamyl transpeptidase, cholesterol, total serum tasting bile acids",
            "probability": 0.0295562744140625
        },
        {
            "start_logit": 6.08203125,
            "end_logit": 4.84375,
            "text": " alkaline phosphatase, gamma-glutamyl transpeptidase, cholesterol, total serum tasting bile acids and total and conjugated bilirubin",
            "probability": 0.026092529296875
        },
        {
            "start_logit": 6.08203125,
            "end_logit": 4.6875,
            "text": " alkaline phosphatase, gamma-glutamyl transpeptidase, cholesterol, total serum tasting bile acids",
            "probability": 0.022308349609375
        },
        {
            "start_logit": 5.92578125,
            "end_logit": 4.84375,
            "text": " gamma-glutamyl transpeptidase, cholesterol, total serum tasting bile acids and total and conjugated bilirubin",
            "probability": 0.022308349609375
        },
        {
            "start_logit": 6.421875,
            "end_logit": 4.25,
            "text": " alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, gamma-glutamyl transpeptidase, cholesterol",
            "probability": 0.02032470703125
        },
        {
            "start_logit": 6.35546875,
            "end_logit": 4.25,
            "text": " aspartate aminotransferase, alkaline phosphatase, gamma-glutamyl transpeptidase, cholesterol",
            "probability": 0.0190887451171875
        },
        {
            "start_logit": 5.92578125,
            "end_logit": 4.6875,
            "text": " gamma-glutamyl transpeptidase, cholesterol, total serum tasting bile acids",
            "probability": 0.0190887451171875
        },
        {
            "start_logit": 6.08203125,
            "end_logit": 4.25,
            "text": " alkaline phosphatase, gamma-glutamyl transpeptidase, cholesterol",
            "probability": 0.014404296875
        }
    ],
    "6415c599690f196b51000013_0001": [
        {
            "start_logit": 7.484375,
            "end_logit": 6.16796875,
            "text": "Merck & Co.",
            "probability": 0.8203125
        },
        {
            "start_logit": 7.484375,
            "end_logit": 4.14453125,
            "text": "Merck",
            "probability": 0.107666015625
        },
        {
            "start_logit": 7.484375,
            "end_logit": 3.033203125,
            "text": "Merck & Co., Inc.",
            "probability": 0.035491943359375
        },
        {
            "start_logit": 7.484375,
            "end_logit": 2.916015625,
            "text": "Merck & Co., Inc",
            "probability": 0.031585693359375
        },
        {
            "start_logit": 7.484375,
            "end_logit": -0.81884765625,
            "text": "Merck & Co., Inc.,",
            "probability": 0.0007538795471191406
        },
        {
            "start_logit": 7.484375,
            "end_logit": -0.94091796875,
            "text": "Mer",
            "probability": 0.0006680488586425781
        },
        {
            "start_logit": 7.484375,
            "end_logit": -0.96875,
            "text": "Merck & Co., In",
            "probability": 0.0006499290466308594
        },
        {
            "start_logit": 0.072021484375,
            "end_logit": 6.16796875,
            "text": " Co.",
            "probability": 0.0004925727844238281
        },
        {
            "start_logit": 7.484375,
            "end_logit": -1.447265625,
            "text": "Merck & Co., Inc., https://www.merck.com",
            "probability": 0.0004038810729980469
        },
        {
            "start_logit": -0.1673583984375,
            "end_logit": 6.16796875,
            "text": " pembrolizumab (Keytruda; Merck & Co.",
            "probability": 0.00038814544677734375
        },
        {
            "start_logit": 7.484375,
            "end_logit": -1.7197265625,
            "text": "Merck & Co.,",
            "probability": 0.0003070831298828125
        },
        {
            "start_logit": 7.484375,
            "end_logit": -2.06640625,
            "text": "Merck & Co",
            "probability": 0.00021767616271972656
        },
        {
            "start_logit": -1.1171875,
            "end_logit": 6.16796875,
            "text": " Food and Drug Administration (Food and Drug Administration) approved pembrolizumab (Keytruda; Merck & Co.",
            "probability": 0.00014960765838623047
        },
        {
            "start_logit": 1.2158203125,
            "end_logit": 3.033203125,
            "text": " Inc.",
            "probability": 6.74128532409668e-05
        },
        {
            "start_logit": 1.2158203125,
            "end_logit": 2.916015625,
            "text": " Inc",
            "probability": 6.002187728881836e-05
        },
        {
            "start_logit": 0.99755859375,
            "end_logit": 3.033203125,
            "text": "c.",
            "probability": 5.418062210083008e-05
        },
        {
            "start_logit": -0.1673583984375,
            "end_logit": 4.14453125,
            "text": " pembrolizumab (Keytruda; Merck",
            "probability": 5.131959915161133e-05
        },
        {
            "start_logit": -2.21484375,
            "end_logit": 6.16796875,
            "text": " Administration (Food and Drug Administration) approved pembrolizumab (Keytruda; Merck & Co.",
            "probability": 5.0127506256103516e-05
        },
        {
            "start_logit": 0.99755859375,
            "end_logit": 2.916015625,
            "text": "c",
            "probability": 4.8220157623291016e-05
        },
        {
            "start_logit": -2.4453125,
            "end_logit": 6.16796875,
            "text": ".",
            "probability": 3.9637088775634766e-05
        }
    ],
    "6414638c201352f04a000047_0001": [
        {
            "start_logit": 6.3203125,
            "end_logit": 6.6484375,
            "text": " thalidomide",
            "probability": 0.98291015625
        },
        {
            "start_logit": 6.3203125,
            "end_logit": 2.380859375,
            "text": " thalidomide and its derivatives",
            "probability": 0.01380157470703125
        },
        {
            "start_logit": 6.3203125,
            "end_logit": -0.216064453125,
            "text": " thalidomide and its derivatives.",
            "probability": 0.0010271072387695312
        },
        {
            "start_logit": -0.98388671875,
            "end_logit": 6.6484375,
            "text": " well-known target of thalidomide",
            "probability": 0.0006608963012695312
        },
        {
            "start_logit": -1.1630859375,
            "end_logit": 6.6484375,
            "text": "Cereblon is a well-known target of thalidomide",
            "probability": 0.0005521774291992188
        },
        {
            "start_logit": -1.9541015625,
            "end_logit": 6.6484375,
            "text": " of thalidomide",
            "probability": 0.00025081634521484375
        },
        {
            "start_logit": -2.34765625,
            "end_logit": 6.6484375,
            "text": " a well-known target of thalidomide",
            "probability": 0.00016832351684570312
        },
        {
            "start_logit": 6.3203125,
            "end_logit": -2.25390625,
            "text": " thalidomide and its",
            "probability": 0.00013315677642822266
        },
        {
            "start_logit": -2.880859375,
            "end_logit": 6.6484375,
            "text": "Cereblon is a well-known target of thalidomide",
            "probability": 9.900331497192383e-05
        },
        {
            "start_logit": -3.044921875,
            "end_logit": 6.6484375,
            "text": " target of thalidomide",
            "probability": 8.398294448852539e-05
        },
        {
            "start_logit": -3.197265625,
            "end_logit": 6.6484375,
            "text": "known target of thalidomide",
            "probability": 7.241964340209961e-05
        },
        {
            "start_logit": 6.3203125,
            "end_logit": -2.984375,
            "text": " thalidomide and",
            "probability": 6.443262100219727e-05
        },
        {
            "start_logit": -0.826171875,
            "end_logit": 2.380859375,
            "text": " derivatives",
            "probability": 1.0848045349121094e-05
        },
        {
            "start_logit": -0.974609375,
            "end_logit": 2.380859375,
            "text": " its derivatives",
            "probability": 9.357929229736328e-06
        },
        {
            "start_logit": -0.98388671875,
            "end_logit": 2.380859375,
            "text": " well-known target of thalidomide and its derivatives",
            "probability": 9.238719940185547e-06
        },
        {
            "start_logit": -1.1630859375,
            "end_logit": 2.380859375,
            "text": "Cereblon is a well-known target of thalidomide and its derivatives",
            "probability": 7.748603820800781e-06
        },
        {
            "start_logit": -1.9541015625,
            "end_logit": 2.380859375,
            "text": " of thalidomide and its derivatives",
            "probability": 3.516674041748047e-06
        },
        {
            "start_logit": -2.34765625,
            "end_logit": 2.380859375,
            "text": " a well-known target of thalidomide and its derivatives",
            "probability": 2.3245811462402344e-06
        },
        {
            "start_logit": -2.880859375,
            "end_logit": 2.380859375,
            "text": "Cereblon is a well-known target of thalidomide and its derivatives",
            "probability": 1.430511474609375e-06
        },
        {
            "start_logit": -3.044921875,
            "end_logit": 2.380859375,
            "text": " target of thalidomide and its derivatives",
            "probability": 1.1920928955078125e-06
        }
    ],
    "6414638c201352f04a000047_0002": [
        {
            "start_logit": 4.51953125,
            "end_logit": 3.4921875,
            "text": "cereblon inhibitors, namely DHFO and its analogs, with structural features that are slightly different from thalidomide",
            "probability": 0.33544921875
        },
        {
            "start_logit": 4.51953125,
            "end_logit": 3.23046875,
            "text": "cereblon inhibitors, namely DHFO",
            "probability": 0.25732421875
        },
        {
            "start_logit": 4.51953125,
            "end_logit": 2.396484375,
            "text": "cereblon inhibitors",
            "probability": 0.11151123046875
        },
        {
            "start_logit": 3.21484375,
            "end_logit": 3.4921875,
            "text": "DHFO and its analogs, with structural features that are slightly different from thalidomide",
            "probability": 0.0906982421875
        },
        {
            "start_logit": 2.97265625,
            "end_logit": 3.4921875,
            "text": " thalidomide",
            "probability": 0.0711669921875
        },
        {
            "start_logit": 3.21484375,
            "end_logit": 3.23046875,
            "text": "DHFO",
            "probability": 0.06976318359375
        },
        {
            "start_logit": 4.51953125,
            "end_logit": 0.55810546875,
            "text": "cereblon inhibitors, namely DHFO and its analogs",
            "probability": 0.017791748046875
        },
        {
            "start_logit": 4.51953125,
            "end_logit": -0.06463623046875,
            "text": "cereblon inhibitors,",
            "probability": 0.00951385498046875
        },
        {
            "start_logit": 4.51953125,
            "end_logit": -0.255126953125,
            "text": "cereblon inhibitors, namely DH",
            "probability": 0.0078887939453125
        },
        {
            "start_logit": 3.21484375,
            "end_logit": 0.55810546875,
            "text": "DHFO and its analogs",
            "probability": 0.00482177734375
        },
        {
            "start_logit": 4.51953125,
            "end_logit": -1.052734375,
            "text": "cereblon inhibitors, namely DHFO and its analogs,",
            "probability": 0.0035552978515625
        },
        {
            "start_logit": 3.21484375,
            "end_logit": 0.0863037109375,
            "text": "DHFO and its analogs, with structural features that are slightly different from thalidomide but stronger cereblon-binding affinity",
            "probability": 0.0030078887939453125
        },
        {
            "start_logit": -0.2088623046875,
            "end_logit": 3.4921875,
            "text": " novel cereblon inhibitors, namely DHFO and its analogs, with structural features that are slightly different from thalidomide",
            "probability": 0.002948760986328125
        },
        {
            "start_logit": 3.21484375,
            "end_logit": -0.143310546875,
            "text": "DHFO and its analogs, with structural features that are slightly different from thalidomide but stronger cereblon-binding affinity.",
            "probability": 0.00238800048828125
        },
        {
            "start_logit": 2.97265625,
            "end_logit": 0.0863037109375,
            "text": " thalidomide but stronger cereblon-binding affinity",
            "probability": 0.0023593902587890625
        },
        {
            "start_logit": -0.2088623046875,
            "end_logit": 3.23046875,
            "text": " novel cereblon inhibitors, namely DHFO",
            "probability": 0.002277374267578125
        },
        {
            "start_logit": 3.21484375,
            "end_logit": -0.255126953125,
            "text": "DH",
            "probability": 0.002140045166015625
        },
        {
            "start_logit": 2.97265625,
            "end_logit": -0.143310546875,
            "text": " thalidomide but stronger cereblon-binding affinity.",
            "probability": 0.0018739700317382812
        },
        {
            "start_logit": -0.67822265625,
            "end_logit": 3.4921875,
            "text": "We have identified novel cereblon inhibitors, namely DHFO and its analogs, with structural features that are slightly different from thalidomide",
            "probability": 0.0018453598022460938
        },
        {
            "start_logit": 4.51953125,
            "end_logit": -1.7333984375,
            "text": "cereblon inhibitors, namely",
            "probability": 0.0017957687377929688
        }
    ],
    "6414638c201352f04a000047_0003": [
        {
            "start_logit": 7.0546875,
            "end_logit": 5.98828125,
            "text": "immunomodulatory drugs",
            "probability": 0.61474609375
        },
        {
            "start_logit": 7.0546875,
            "end_logit": 4.671875,
            "text": "immunomodulatory drugs (immunomodulatory drugs) thalidomide",
            "probability": 0.1641845703125
        },
        {
            "start_logit": 7.0546875,
            "end_logit": 4.47265625,
            "text": "immunomodulatory drugs (immunomodulatory drugs) thalidomide, lenalidomide",
            "probability": 0.135009765625
        },
        {
            "start_logit": 7.0546875,
            "end_logit": 2.703125,
            "text": "immunomodulatory drugs (immunomodulatory drugs)",
            "probability": 0.022918701171875
        },
        {
            "start_logit": 7.0546875,
            "end_logit": 2.595703125,
            "text": "immunomodulatory drugs (immunomodulatory drugs) thalidomide, lenalidomide, and po",
            "probability": 0.020538330078125
        },
        {
            "start_logit": 4.29296875,
            "end_logit": 4.671875,
            "text": " thalidomide",
            "probability": 0.01041412353515625
        },
        {
            "start_logit": 4.29296875,
            "end_logit": 4.47265625,
            "text": " thalidomide, lenalidomide",
            "probability": 0.0084991455078125
        },
        {
            "start_logit": 7.0546875,
            "end_logit": 1.314453125,
            "text": "immunomodulatory drugs (immunomodulatory drugs",
            "probability": 0.005706787109375
        },
        {
            "start_logit": 3.841796875,
            "end_logit": 4.47265625,
            "text": " lenalidomide",
            "probability": 0.005401611328125
        },
        {
            "start_logit": 7.0546875,
            "end_logit": 0.58203125,
            "text": "immunomodulatory",
            "probability": 0.0027484893798828125
        },
        {
            "start_logit": 7.0546875,
            "end_logit": -0.04254150390625,
            "text": "immunomodulatory drugs (immunomodulatory drugs) thalidomide, lenalidomide, and pomalidomide",
            "probability": 0.0014715194702148438
        },
        {
            "start_logit": 7.0546875,
            "end_logit": -0.051513671875,
            "text": "immunomodulatory drugs (immunomodulatory drugs) thalidomide, lenalidomide,",
            "probability": 0.0014591217041015625
        },
        {
            "start_logit": 7.0546875,
            "end_logit": -0.09576416015625,
            "text": "immunomodulatory drugs (immunomodulatory drugs) thalidomide,",
            "probability": 0.001392364501953125
        },
        {
            "start_logit": 7.0546875,
            "end_logit": -0.1484375,
            "text": "immunomodulatory drugs (immunomodulatory drugs) thalidomide, lenalidomide, and pomalidomide.",
            "probability": 0.001323699951171875
        },
        {
            "start_logit": 4.29296875,
            "end_logit": 2.595703125,
            "text": " thalidomide, lenalidomide, and po",
            "probability": 0.0013036727905273438
        },
        {
            "start_logit": 3.84765625,
            "end_logit": 2.595703125,
            "text": "po",
            "probability": 0.0008349418640136719
        },
        {
            "start_logit": 3.841796875,
            "end_logit": 2.595703125,
            "text": " lenalidomide, and po",
            "probability": 0.0008282661437988281
        },
        {
            "start_logit": 7.0546875,
            "end_logit": -0.93408203125,
            "text": "immunomodulatory drugs (immunomodulatory drugs) thalidomide, lenalidomide, and pomalido",
            "probability": 0.0006036758422851562
        },
        {
            "start_logit": 7.0546875,
            "end_logit": -1.0234375,
            "text": "immunomodulatory drugs (immunomodulatory drugs) thalidomide, lenalidomide, and pomalidomide. immunomodulatory drugs",
            "probability": 0.0005517005920410156
        },
        {
            "start_logit": -0.32958984375,
            "end_logit": 5.98828125,
            "text": " the immunomodulatory drugs",
            "probability": 0.0003807544708251953
        }
    ],
    "6414638c201352f04a000047_0004": [
        {
            "start_logit": 3.763671875,
            "end_logit": 5.01953125,
            "text": "immunomodulatory agents",
            "probability": 0.640625
        },
        {
            "start_logit": 3.763671875,
            "end_logit": 2.853515625,
            "text": "immunomodulatory agents (immunomodulatory drugs\u00ae)",
            "probability": 0.07354736328125
        },
        {
            "start_logit": 3.763671875,
            "end_logit": 2.50390625,
            "text": "immunomodulatory agents (immunomodulatory drugs\u00ae) lenalidomide",
            "probability": 0.0517578125
        },
        {
            "start_logit": 3.763671875,
            "end_logit": 2.328125,
            "text": "immunomodulatory agents (immunomodulatory drugs\u00ae) lenalidomide (Lenacapavir) and pomalidomide",
            "probability": 0.0435791015625
        },
        {
            "start_logit": 3.763671875,
            "end_logit": 2.064453125,
            "text": "immunomodulatory agents (immunomodulatory drugs\u00ae) lenalidomide (Lenacapavir",
            "probability": 0.033416748046875
        },
        {
            "start_logit": 0.68701171875,
            "end_logit": 5.01953125,
            "text": "Cereblon (cereblon)-targeting immunomodulatory agents",
            "probability": 0.02960205078125
        },
        {
            "start_logit": 3.763671875,
            "end_logit": 1.5263671875,
            "text": "immunomodulatory agents (immunomodulatory drugs\u00ae) lenalidomide (Lenacapavir)",
            "probability": 0.019500732421875
        },
        {
            "start_logit": 3.763671875,
            "end_logit": 1.25390625,
            "text": "immunomodulatory agents (immunomodulatory drugs\u00ae) lenalidomide (Lenacapavir) and pomalidomide (pomalidomide)",
            "probability": 0.01482391357421875
        },
        {
            "start_logit": 2.626953125,
            "end_logit": 2.328125,
            "text": "pomalidomide",
            "probability": 0.01392364501953125
        },
        {
            "start_logit": -0.13623046875,
            "end_logit": 5.01953125,
            "text": "cereblon)-targeting immunomodulatory agents",
            "probability": 0.0129852294921875
        },
        {
            "start_logit": 3.763671875,
            "end_logit": 1.001953125,
            "text": "immunomodulatory agents (immunomodulatory drugs",
            "probability": 0.0115509033203125
        },
        {
            "start_logit": 2.1484375,
            "end_logit": 2.50390625,
            "text": " lenalidomide",
            "probability": 0.01030731201171875
        },
        {
            "start_logit": 3.763671875,
            "end_logit": 0.71875,
            "text": "immunomodulatory agents (immunomodulatory drugs\u00ae",
            "probability": 0.0087127685546875
        },
        {
            "start_logit": 2.1484375,
            "end_logit": 2.328125,
            "text": " lenalidomide (Lenacapavir) and pomalidomide",
            "probability": 0.0086517333984375
        },
        {
            "start_logit": 2.1484375,
            "end_logit": 2.064453125,
            "text": " lenalidomide (Lenacapavir",
            "probability": 0.00662994384765625
        },
        {
            "start_logit": 2.626953125,
            "end_logit": 1.25390625,
            "text": "pomalidomide (pomalidomide)",
            "probability": 0.0047760009765625
        },
        {
            "start_logit": 1.4716796875,
            "end_logit": 2.328125,
            "text": "Lenacapavir) and pomalidomide",
            "probability": 0.004398345947265625
        },
        {
            "start_logit": -1.2685546875,
            "end_logit": 5.01953125,
            "text": "targeting immunomodulatory agents",
            "probability": 0.004180908203125
        },
        {
            "start_logit": 2.1484375,
            "end_logit": 1.5263671875,
            "text": " lenalidomide (Lenacapavir)",
            "probability": 0.00388336181640625
        },
        {
            "start_logit": 3.763671875,
            "end_logit": -0.1475830078125,
            "text": "immunomodulatory agents (immunomodulatory drugs\u00ae) lenalidomide (Lenacapavir) and po",
            "probability": 0.003662109375
        }
    ],
    "6414638c201352f04a000047_0005": [
        {
            "start_logit": 4.52734375,
            "end_logit": 4.21875,
            "text": " multiple myeloma",
            "probability": 0.919921875
        },
        {
            "start_logit": 0.400634765625,
            "end_logit": 4.21875,
            "text": " potent teratogenicity, has been re-evaluated as a clinically effective drug for the treatment of multiple myeloma",
            "probability": 0.01480865478515625
        },
        {
            "start_logit": 4.52734375,
            "end_logit": -0.0002541542053222656,
            "text": " multiple myeloma. Although the direct target of thalidomide",
            "probability": 0.01348114013671875
        },
        {
            "start_logit": 4.52734375,
            "end_logit": -0.2337646484375,
            "text": " multiple myeloma.",
            "probability": 0.0106658935546875
        },
        {
            "start_logit": -0.252685546875,
            "end_logit": 4.21875,
            "text": " treatment of multiple myeloma",
            "probability": 0.00771331787109375
        },
        {
            "start_logit": 4.52734375,
            "end_logit": -0.69775390625,
            "text": " multiple myeloma. Although the direct target of thalidomide had been unclear until recently, we identified cereblon (cereblon)",
            "probability": 0.006702423095703125
        },
        {
            "start_logit": 4.52734375,
            "end_logit": -1.3857421875,
            "text": " multiple myeloma. Although the direct target of thalidomide had been unclear until recently, we identified cereblon",
            "probability": 0.0033702850341796875
        },
        {
            "start_logit": -1.23828125,
            "end_logit": 4.21875,
            "text": " teratogenicity, has been re-evaluated as a clinically effective drug for the treatment of multiple myeloma",
            "probability": 0.0028705596923828125
        },
        {
            "start_logit": 4.52734375,
            "end_logit": -1.638671875,
            "text": " multiple myeloma. Although the direct target of thalidomide had been unclear until recently,",
            "probability": 0.00262451171875
        },
        {
            "start_logit": -1.3662109375,
            "end_logit": 4.21875,
            "text": " clinically effective drug for the treatment of multiple myeloma",
            "probability": 0.00252532958984375
        },
        {
            "start_logit": 4.52734375,
            "end_logit": -1.751953125,
            "text": " multiple",
            "probability": 0.0023345947265625
        },
        {
            "start_logit": -1.61328125,
            "end_logit": 4.21875,
            "text": " myeloma",
            "probability": 0.0019741058349609375
        },
        {
            "start_logit": -1.73828125,
            "end_logit": 4.21875,
            "text": " its potent teratogenicity, has been re-evaluated as a clinically effective drug for the treatment of multiple myeloma",
            "probability": 0.0017414093017578125
        },
        {
            "start_logit": 4.52734375,
            "end_logit": -2.1328125,
            "text": " multiple myeloma. Although the direct target of thalidomide had been unclear until recently, we identified cereblon (cereblon",
            "probability": 0.001598358154296875
        },
        {
            "start_logit": -1.8564453125,
            "end_logit": 4.21875,
            "text": " re-evaluated as a clinically effective drug for the treatment of multiple myeloma",
            "probability": 0.0015497207641601562
        },
        {
            "start_logit": -1.978515625,
            "end_logit": 4.21875,
            "text": ", has been re-evaluated as a clinically effective drug for the treatment of multiple myeloma",
            "probability": 0.0013723373413085938
        },
        {
            "start_logit": -2.099609375,
            "end_logit": 4.21875,
            "text": ", well known for its potent teratogenicity, has been re-evaluated as a clinically effective drug for the treatment of multiple myeloma",
            "probability": 0.0012111663818359375
        },
        {
            "start_logit": -2.177734375,
            "end_logit": 4.21875,
            "text": " well known for its potent teratogenicity, has been re-evaluated as a clinically effective drug for the treatment of multiple myeloma",
            "probability": 0.0011205673217773438
        },
        {
            "start_logit": 0.400634765625,
            "end_logit": 1.6064453125,
            "text": " potent teratogenicity",
            "probability": 0.0010852813720703125
        },
        {
            "start_logit": -2.41796875,
            "end_logit": 4.21875,
            "text": " effective drug for the treatment of multiple myeloma",
            "probability": 0.0008826255798339844
        }
    ],
    "6414638c201352f04a000047_0006": [
        {
            "start_logit": 7.5234375,
            "end_logit": 6.83984375,
            "text": "immunomodulatory drugs",
            "probability": 0.998046875
        },
        {
            "start_logit": 7.5234375,
            "end_logit": -0.479248046875,
            "text": "immunomodulatory",
            "probability": 0.0006632804870605469
        },
        {
            "start_logit": 7.5234375,
            "end_logit": -0.77099609375,
            "text": "immunomodulatory drugs remained unclear for a long time until 2010 when the protein cereblon (cereblon)",
            "probability": 0.0004968643188476562
        },
        {
            "start_logit": 7.5234375,
            "end_logit": -1.80078125,
            "text": "immunomodulatory drugs remained unclear for a long time until 2010 when the protein cereblon",
            "probability": 0.00017642974853515625
        },
        {
            "start_logit": -1.63671875,
            "end_logit": 6.83984375,
            "text": " drugs",
            "probability": 0.00010538101196289062
        },
        {
            "start_logit": 7.5234375,
            "end_logit": -2.640625,
            "text": "immunomodulatory drugs remained unclear for a long time until 2010 when the protein cereblon (cereblon) was identified as a primary direct target",
            "probability": 7.647275924682617e-05
        },
        {
            "start_logit": -2.015625,
            "end_logit": 6.83984375,
            "text": "The molecular mechanism of action of immunomodulatory drugs",
            "probability": 7.241964340209961e-05
        },
        {
            "start_logit": 7.5234375,
            "end_logit": -2.74609375,
            "text": "immunomodulatory drugs remained unclear for a long time until 2010",
            "probability": 6.908178329467773e-05
        },
        {
            "start_logit": 7.5234375,
            "end_logit": -2.783203125,
            "text": "immunomodulatory drugs remained unclear for a long time until 2010 when the protein cereblon (cereblon",
            "probability": 6.645917892456055e-05
        },
        {
            "start_logit": 0.195556640625,
            "end_logit": 0.252197265625,
            "text": "immunomodulatory drugs",
            "probability": 8.940696716308594e-07
        },
        {
            "start_logit": -0.451171875,
            "end_logit": 0.252197265625,
            "text": "cereblon (cereblon) was identified as a primary direct target. immunomodulatory drugs",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": -0.451171875,
            "end_logit": -0.181640625,
            "text": "cereblon (cereblon) was identified as a primary direct target.",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -0.884765625,
            "end_logit": 0.252197265625,
            "text": ". immunomodulatory drugs",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 0.195556640625,
            "end_logit": -1.1220703125,
            "text": "immunomodulatory drugs binds to cereblon and alters the substrate specificity of the cereblon E3 ubiquitin ligase complex",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -0.884765625,
            "end_logit": -0.181640625,
            "text": ".",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -0.451171875,
            "end_logit": -0.77099609375,
            "text": "cereblon (cereblon)",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -1.54296875,
            "end_logit": 0.252197265625,
            "text": " 2010 when the protein cereblon (cereblon) was identified as a primary direct target. immunomodulatory drugs",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 0.195556640625,
            "end_logit": -1.76953125,
            "text": "immunomodulatory drugs binds to cereblon and alters the substrate specificity of the cereblon E3 ubiquitin ligase complex,",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 0.195556640625,
            "end_logit": -1.826171875,
            "text": "immunomodulatory drugs binds to cereblon and alters the substrate specificity of the cereblon E3",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -1.54296875,
            "end_logit": -0.181640625,
            "text": " 2010 when the protein cereblon (cereblon) was identified as a primary direct target.",
            "probability": 1.1920928955078125e-07
        }
    ],
    "63f03a20f36125a42600001c_0001": [
        {
            "start_logit": 6.890625,
            "end_logit": 6.62109375,
            "text": "tixagevimab [AZD8895] and cilgavimab",
            "probability": 0.338134765625
        },
        {
            "start_logit": 6.890625,
            "end_logit": 6.59375,
            "text": "tixagevimab",
            "probability": 0.327880859375
        },
        {
            "start_logit": 6.84375,
            "end_logit": 6.62109375,
            "text": "cilgavimab",
            "probability": 0.32275390625
        },
        {
            "start_logit": 6.890625,
            "end_logit": 1.1357421875,
            "text": "ti",
            "probability": 0.0013933181762695312
        },
        {
            "start_logit": 6.890625,
            "end_logit": 1.009765625,
            "text": "tixage",
            "probability": 0.0012292861938476562
        },
        {
            "start_logit": 6.890625,
            "end_logit": 0.96435546875,
            "text": "tix",
            "probability": 0.0011777877807617188
        },
        {
            "start_logit": 6.890625,
            "end_logit": 0.87255859375,
            "text": "tixagevimab [AZD8895] and cil",
            "probability": 0.001071929931640625
        },
        {
            "start_logit": 6.84375,
            "end_logit": 0.87255859375,
            "text": "cil",
            "probability": 0.0010232925415039062
        },
        {
            "start_logit": 6.890625,
            "end_logit": 0.494873046875,
            "text": "tixagevimab [AZD8895]",
            "probability": 0.0007367134094238281
        },
        {
            "start_logit": 6.890625,
            "end_logit": 0.342529296875,
            "text": "tixagevimab [AZD8895] and cilgavimab [AZD1061]",
            "probability": 0.0006327629089355469
        },
        {
            "start_logit": 6.84375,
            "end_logit": 0.342529296875,
            "text": "cilgavimab [AZD1061]",
            "probability": 0.0006036758422851562
        },
        {
            "start_logit": 0.5224609375,
            "end_logit": 6.62109375,
            "text": "xagevimab [AZD8895] and cilgavimab",
            "probability": 0.0005784034729003906
        },
        {
            "start_logit": 0.5224609375,
            "end_logit": 6.59375,
            "text": "xagevimab",
            "probability": 0.0005626678466796875
        },
        {
            "start_logit": 6.890625,
            "end_logit": 0.09564208984375,
            "text": "tixagevi",
            "probability": 0.0004925727844238281
        },
        {
            "start_logit": 6.890625,
            "end_logit": -0.13671875,
            "text": "tixagevimab [AZD8895] and cilgavimab [AZD1061]),",
            "probability": 0.00039124488830566406
        },
        {
            "start_logit": 6.84375,
            "end_logit": -0.13671875,
            "text": "cilgavimab [AZD1061]),",
            "probability": 0.0003733634948730469
        },
        {
            "start_logit": 6.890625,
            "end_logit": -0.296875,
            "text": "tixagevimab [AZD8895",
            "probability": 0.00033354759216308594
        },
        {
            "start_logit": -0.12158203125,
            "end_logit": 6.62109375,
            "text": " long-acting monoclonal antibodies (tixagevimab [AZD8895] and cilgavimab",
            "probability": 0.0003037452697753906
        },
        {
            "start_logit": -0.12158203125,
            "end_logit": 6.59375,
            "text": " long-acting monoclonal antibodies (tixagevimab",
            "probability": 0.00029540061950683594
        },
        {
            "start_logit": -0.3818359375,
            "end_logit": 6.62109375,
            "text": "mab [AZD8895] and cilgavimab",
            "probability": 0.00023365020751953125
        }
    ],
    "63f03a20f36125a42600001c_0002": [
        {
            "start_logit": 6.87109375,
            "end_logit": 6.57421875,
            "text": "tixagevimab-cilgavimab",
            "probability": 0.335693359375
        },
        {
            "start_logit": 6.87109375,
            "end_logit": 6.5625,
            "text": "tixagevimab",
            "probability": 0.3330078125
        },
        {
            "start_logit": 6.8125,
            "end_logit": 6.57421875,
            "text": "cilgavimab",
            "probability": 0.31787109375
        },
        {
            "start_logit": 6.87109375,
            "end_logit": 1.1845703125,
            "text": "tixagevimab-cil",
            "probability": 0.0015306472778320312
        },
        {
            "start_logit": 6.87109375,
            "end_logit": 1.17578125,
            "text": "ti",
            "probability": 0.0015192031860351562
        },
        {
            "start_logit": 6.8125,
            "end_logit": 1.1845703125,
            "text": "cil",
            "probability": 0.0014438629150390625
        },
        {
            "start_logit": 6.87109375,
            "end_logit": 1.0869140625,
            "text": "tixage",
            "probability": 0.0013885498046875
        },
        {
            "start_logit": 6.87109375,
            "end_logit": 0.95263671875,
            "text": "tix",
            "probability": 0.0012149810791015625
        },
        {
            "start_logit": 6.87109375,
            "end_logit": 0.375732421875,
            "text": "tixagevi",
            "probability": 0.0006818771362304688
        },
        {
            "start_logit": 0.669921875,
            "end_logit": 6.57421875,
            "text": "xagevimab-cilgavimab",
            "probability": 0.0006794929504394531
        },
        {
            "start_logit": 0.669921875,
            "end_logit": 6.5625,
            "text": "xagevimab",
            "probability": 0.0006737709045410156
        },
        {
            "start_logit": 6.87109375,
            "end_logit": 0.3544921875,
            "text": "tixagevimab-cilgavimab) for prevention of Covid-19",
            "probability": 0.0006685256958007812
        },
        {
            "start_logit": 6.8125,
            "end_logit": 0.3544921875,
            "text": "cilgavimab) for prevention of Covid-19",
            "probability": 0.0006308555603027344
        },
        {
            "start_logit": 6.87109375,
            "end_logit": -0.031829833984375,
            "text": "tixagevimab-cilgavimab) for prevention of Covid-19.",
            "probability": 0.0004544258117675781
        },
        {
            "start_logit": 6.8125,
            "end_logit": -0.031829833984375,
            "text": "cilgavimab) for prevention of Covid-19.",
            "probability": 0.0004284381866455078
        },
        {
            "start_logit": 0.05096435546875,
            "end_logit": 6.57421875,
            "text": "mab-cilgavimab",
            "probability": 0.0003662109375
        },
        {
            "start_logit": 0.05096435546875,
            "end_logit": 6.5625,
            "text": "mab",
            "probability": 0.00036215782165527344
        },
        {
            "start_logit": 6.87109375,
            "end_logit": -0.365478515625,
            "text": "tixagevimab-cilgavi",
            "probability": 0.0003247261047363281
        },
        {
            "start_logit": 6.8125,
            "end_logit": -0.365478515625,
            "text": "cilgavi",
            "probability": 0.00030612945556640625
        },
        {
            "start_logit": -0.1544189453125,
            "end_logit": 6.57421875,
            "text": "mab",
            "probability": 0.0002980232238769531
        }
    ],
    "63f03a20f36125a42600001c_0003": [
        {
            "start_logit": 6.84765625,
            "end_logit": 6.578125,
            "text": "Cilgavimab",
            "probability": 0.327880859375
        },
        {
            "start_logit": 6.84765625,
            "end_logit": 6.578125,
            "text": "Tixagevimab-Cilgavimab",
            "probability": 0.327880859375
        },
        {
            "start_logit": 6.84765625,
            "end_logit": 6.5703125,
            "text": "Tixagevimab",
            "probability": 0.327880859375
        },
        {
            "start_logit": 6.84765625,
            "end_logit": 1.9794921875,
            "text": "Tixage",
            "probability": 0.0033168792724609375
        },
        {
            "start_logit": 6.84765625,
            "end_logit": 1.2900390625,
            "text": "Tix",
            "probability": 0.001667022705078125
        },
        {
            "start_logit": 6.84765625,
            "end_logit": 1.259765625,
            "text": "Ti",
            "probability": 0.0016155242919921875
        },
        {
            "start_logit": 6.84765625,
            "end_logit": 1.1083984375,
            "text": "Cil",
            "probability": 0.0013875961303710938
        },
        {
            "start_logit": 6.84765625,
            "end_logit": 1.1083984375,
            "text": "Tixagevimab-Cil",
            "probability": 0.0013875961303710938
        },
        {
            "start_logit": 6.84765625,
            "end_logit": 1.0234375,
            "text": "Tixagevi",
            "probability": 0.0012731552124023438
        },
        {
            "start_logit": 1.0908203125,
            "end_logit": 6.578125,
            "text": "xagevimab-Cilgavimab",
            "probability": 0.0010395050048828125
        },
        {
            "start_logit": 1.0908203125,
            "end_logit": 6.5703125,
            "text": "xagevimab",
            "probability": 0.0010309219360351562
        },
        {
            "start_logit": 6.84765625,
            "end_logit": 0.3486328125,
            "text": "Cilgavimab) Administration",
            "probability": 0.0006475448608398438
        },
        {
            "start_logit": 6.84765625,
            "end_logit": 0.3486328125,
            "text": "Tixagevimab-Cilgavimab) Administration",
            "probability": 0.0006475448608398438
        },
        {
            "start_logit": 6.84765625,
            "end_logit": 0.04901123046875,
            "text": "Cilgavi",
            "probability": 0.0004813671112060547
        },
        {
            "start_logit": 6.84765625,
            "end_logit": 0.04901123046875,
            "text": "Tixagevimab-Cilgavi",
            "probability": 0.0004813671112060547
        },
        {
            "start_logit": 0.19091796875,
            "end_logit": 6.578125,
            "text": "vimab-Cilgavimab",
            "probability": 0.00042319297790527344
        },
        {
            "start_logit": 0.19091796875,
            "end_logit": 6.5703125,
            "text": "vimab",
            "probability": 0.00041985511779785156
        },
        {
            "start_logit": 6.84765625,
            "end_logit": -0.159423828125,
            "text": "Cilgavimab) Administration and Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection, Hospitalization, and Mortality.",
            "probability": 0.0003898143768310547
        },
        {
            "start_logit": 0.0733642578125,
            "end_logit": 6.578125,
            "text": "mab-Cilgavimab",
            "probability": 0.0003764629364013672
        },
        {
            "start_logit": 0.0733642578125,
            "end_logit": 6.5703125,
            "text": "mab",
            "probability": 0.00037360191345214844
        }
    ],
    "63f03a20f36125a42600001c_0004": [
        {
            "start_logit": 6.83984375,
            "end_logit": 6.68359375,
            "text": "Tixagevimab",
            "probability": 0.33056640625
        },
        {
            "start_logit": 6.83984375,
            "end_logit": 6.68359375,
            "text": "Tixagevimab-Cilgavimab",
            "probability": 0.33056640625
        },
        {
            "start_logit": 6.82421875,
            "end_logit": 6.68359375,
            "text": "Cilgavimab",
            "probability": 0.325439453125
        },
        {
            "start_logit": 6.83984375,
            "end_logit": 1.431640625,
            "text": "Tixage",
            "probability": 0.0017347335815429688
        },
        {
            "start_logit": 6.83984375,
            "end_logit": 1.3115234375,
            "text": "Tix",
            "probability": 0.0015306472778320312
        },
        {
            "start_logit": 1.1279296875,
            "end_logit": 6.68359375,
            "text": "xagevimab",
            "probability": 0.0010938644409179688
        },
        {
            "start_logit": 1.1279296875,
            "end_logit": 6.68359375,
            "text": "xagevimab-Cilgavimab",
            "probability": 0.0010938644409179688
        },
        {
            "start_logit": 6.83984375,
            "end_logit": 0.8671875,
            "text": "Ti",
            "probability": 0.00098419189453125
        },
        {
            "start_logit": 6.83984375,
            "end_logit": 0.86328125,
            "text": "Tixagevimab-Cil",
            "probability": 0.000980377197265625
        },
        {
            "start_logit": 6.82421875,
            "end_logit": 0.86328125,
            "text": "Cil",
            "probability": 0.000965118408203125
        },
        {
            "start_logit": 6.83984375,
            "end_logit": 0.625,
            "text": "Tixagevimab-Cilgavimab, (Evusheld",
            "probability": 0.0007729530334472656
        },
        {
            "start_logit": 6.82421875,
            "end_logit": 0.625,
            "text": "Cilgavimab, (Evusheld",
            "probability": 0.0007610321044921875
        },
        {
            "start_logit": 6.83984375,
            "end_logit": 0.5478515625,
            "text": "Tixagevi",
            "probability": 0.0007147789001464844
        },
        {
            "start_logit": 6.83984375,
            "end_logit": 0.22314453125,
            "text": "Tixagevimab-Cilgavimab,",
            "probability": 0.0005164146423339844
        },
        {
            "start_logit": 6.82421875,
            "end_logit": 0.22314453125,
            "text": "Cilgavimab,",
            "probability": 0.0005087852478027344
        },
        {
            "start_logit": 6.83984375,
            "end_logit": 0.11669921875,
            "text": "Tixagevimab-Cilgavi",
            "probability": 0.0004649162292480469
        },
        {
            "start_logit": 6.82421875,
            "end_logit": 0.11669921875,
            "text": "Cilgavi",
            "probability": 0.000457763671875
        },
        {
            "start_logit": -0.10076904296875,
            "end_logit": 6.68359375,
            "text": "mab",
            "probability": 0.0003197193145751953
        },
        {
            "start_logit": -0.10076904296875,
            "end_logit": 6.68359375,
            "text": "mab-Cilgavimab",
            "probability": 0.0003197193145751953
        },
        {
            "start_logit": -0.287109375,
            "end_logit": 6.68359375,
            "text": "vimab",
            "probability": 0.00026607513427734375
        }
    ],
    "640ddd9d201352f04a000028_0001": [
        {
            "start_logit": 6.0625,
            "end_logit": 6.02734375,
            "text": " Nivolumab and Pembrolizumab",
            "probability": 0.345703125
        },
        {
            "start_logit": 6.0625,
            "end_logit": 6.02734375,
            "text": " Nivolumab",
            "probability": 0.345703125
        },
        {
            "start_logit": 5.94140625,
            "end_logit": 6.02734375,
            "text": " Pembrolizumab",
            "probability": 0.304931640625
        },
        {
            "start_logit": -0.431396484375,
            "end_logit": 6.02734375,
            "text": " programmed cell death protein 1 (programmed death 1) inhibitors, Nivolumab and Pembrolizumab",
            "probability": 0.0005221366882324219
        },
        {
            "start_logit": -0.431396484375,
            "end_logit": 6.02734375,
            "text": " programmed cell death protein 1 (programmed death 1) inhibitors, Nivolumab",
            "probability": 0.0005221366882324219
        },
        {
            "start_logit": 6.0625,
            "end_logit": -0.5048828125,
            "text": " Nivolumab and Pembrolizumab.",
            "probability": 0.0005016326904296875
        },
        {
            "start_logit": -0.51953125,
            "end_logit": 6.02734375,
            "text": " different programmed cell death protein 1 (programmed death 1) inhibitors, Nivolumab and Pembrolizumab",
            "probability": 0.00047707557678222656
        },
        {
            "start_logit": -0.51953125,
            "end_logit": 6.02734375,
            "text": " different programmed cell death protein 1 (programmed death 1) inhibitors, Nivolumab",
            "probability": 0.00047707557678222656
        },
        {
            "start_logit": 5.94140625,
            "end_logit": -0.5048828125,
            "text": " Pembrolizumab.",
            "probability": 0.0004444122314453125
        },
        {
            "start_logit": -1.822265625,
            "end_logit": 6.02734375,
            "text": ", Nivolumab and Pembrolizumab",
            "probability": 0.00012946128845214844
        },
        {
            "start_logit": -1.822265625,
            "end_logit": 6.02734375,
            "text": ", Nivolumab",
            "probability": 0.00012946128845214844
        },
        {
            "start_logit": -2.046875,
            "end_logit": 6.02734375,
            "text": "2 different programmed cell death protein 1 (programmed death 1) inhibitors, Nivolumab and Pembrolizumab",
            "probability": 0.00010395050048828125
        },
        {
            "start_logit": -2.046875,
            "end_logit": 6.02734375,
            "text": "2 different programmed cell death protein 1 (programmed death 1) inhibitors, Nivolumab",
            "probability": 0.00010395050048828125
        },
        {
            "start_logit": -2.548828125,
            "end_logit": 6.02734375,
            "text": ") inhibitors, Nivolumab and Pembrolizumab",
            "probability": 6.258487701416016e-05
        },
        {
            "start_logit": -2.548828125,
            "end_logit": 6.02734375,
            "text": ") inhibitors, Nivolumab",
            "probability": 6.258487701416016e-05
        },
        {
            "start_logit": -2.5703125,
            "end_logit": 6.02734375,
            "text": "programmed death 1) inhibitors, Nivolumab and Pembrolizumab",
            "probability": 6.109476089477539e-05
        },
        {
            "start_logit": -2.5703125,
            "end_logit": 6.02734375,
            "text": "programmed death 1) inhibitors, Nivolumab",
            "probability": 6.109476089477539e-05
        },
        {
            "start_logit": -3.34375,
            "end_logit": 6.02734375,
            "text": " and Pembrolizumab",
            "probability": 2.8431415557861328e-05
        },
        {
            "start_logit": 6.0625,
            "end_logit": -3.44140625,
            "text": " Nivolumab and",
            "probability": 2.6702880859375e-05
        },
        {
            "start_logit": -3.7421875,
            "end_logit": 6.02734375,
            "text": " death 1) inhibitors, Nivolumab and Pembrolizumab",
            "probability": 1.895427703857422e-05
        }
    ],
    "640ddd9d201352f04a000028_0002": [
        {
            "start_logit": 6.01953125,
            "end_logit": 6.1171875,
            "text": " nivolumab",
            "probability": 0.36181640625
        },
        {
            "start_logit": 6.01953125,
            "end_logit": 6.04296875,
            "text": " nivolumab and pembrolizumab",
            "probability": 0.334716796875
        },
        {
            "start_logit": 5.890625,
            "end_logit": 6.04296875,
            "text": " pembrolizumab",
            "probability": 0.29541015625
        },
        {
            "start_logit": 0.81494140625,
            "end_logit": 6.1171875,
            "text": " programmed death 1 (programmed death 1) receptor, nivolumab",
            "probability": 0.0019817352294921875
        },
        {
            "start_logit": 0.81494140625,
            "end_logit": 6.04296875,
            "text": " programmed death 1 (programmed death 1) receptor, nivolumab and pembrolizumab",
            "probability": 0.0018396377563476562
        },
        {
            "start_logit": 6.01953125,
            "end_logit": -0.1817626953125,
            "text": " nivolumab and pembrolizumab,",
            "probability": 0.0006613731384277344
        },
        {
            "start_logit": 5.890625,
            "end_logit": -0.1817626953125,
            "text": " pembrolizumab,",
            "probability": 0.0005812644958496094
        },
        {
            "start_logit": -0.84912109375,
            "end_logit": 6.1171875,
            "text": " receptor, nivolumab",
            "probability": 0.00037550926208496094
        },
        {
            "start_logit": -0.84912109375,
            "end_logit": 6.04296875,
            "text": " receptor, nivolumab and pembrolizumab",
            "probability": 0.0003485679626464844
        },
        {
            "start_logit": -0.939453125,
            "end_logit": 6.1171875,
            "text": " immune checkpoint programmed death 1 (programmed death 1) receptor, nivolumab",
            "probability": 0.00034308433532714844
        },
        {
            "start_logit": -0.939453125,
            "end_logit": 6.04296875,
            "text": " immune checkpoint programmed death 1 (programmed death 1) receptor, nivolumab and pembrolizumab",
            "probability": 0.0003173351287841797
        },
        {
            "start_logit": -1.2177734375,
            "end_logit": 6.1171875,
            "text": "programmed death 1) receptor, nivolumab",
            "probability": 0.0002589225769042969
        },
        {
            "start_logit": -1.2177734375,
            "end_logit": 6.04296875,
            "text": "programmed death 1) receptor, nivolumab and pembrolizumab",
            "probability": 0.00024056434631347656
        },
        {
            "start_logit": -1.4765625,
            "end_logit": 6.1171875,
            "text": ", nivolumab",
            "probability": 0.00020015239715576172
        },
        {
            "start_logit": -1.4765625,
            "end_logit": 6.04296875,
            "text": ", nivolumab and pembrolizumab",
            "probability": 0.00018584728240966797
        },
        {
            "start_logit": -1.6005859375,
            "end_logit": 6.1171875,
            "text": " checkpoint programmed death 1 (programmed death 1) receptor, nivolumab",
            "probability": 0.00017654895782470703
        },
        {
            "start_logit": -1.6005859375,
            "end_logit": 6.04296875,
            "text": " checkpoint programmed death 1 (programmed death 1) receptor, nivolumab and pembrolizumab",
            "probability": 0.000164031982421875
        },
        {
            "start_logit": -1.7431640625,
            "end_logit": 6.1171875,
            "text": " monoclonal antibodies against the immune checkpoint programmed death 1 (programmed death 1) receptor, nivolumab",
            "probability": 0.00015342235565185547
        },
        {
            "start_logit": -1.7431640625,
            "end_logit": 6.04296875,
            "text": " monoclonal antibodies against the immune checkpoint programmed death 1 (programmed death 1) receptor, nivolumab and pembrolizumab",
            "probability": 0.0001424551010131836
        },
        {
            "start_logit": -2.021484375,
            "end_logit": 6.1171875,
            "text": ") receptor, nivolumab",
            "probability": 0.00011587142944335938
        }
    ],
    "640ddd9d201352f04a000028_0003": [
        {
            "start_logit": 5.99609375,
            "end_logit": 6.0625,
            "text": " nivolumab",
            "probability": 0.343017578125
        },
        {
            "start_logit": 5.99609375,
            "end_logit": 6.04296875,
            "text": " nivolumab and pembrolizumab",
            "probability": 0.3349609375
        },
        {
            "start_logit": 5.93359375,
            "end_logit": 6.04296875,
            "text": " pembrolizumab",
            "probability": 0.314697265625
        },
        {
            "start_logit": 0.345947265625,
            "end_logit": 6.0625,
            "text": " programmed cell death protein 1 (programmed death 1) inhibitors, nivolumab",
            "probability": 0.0012035369873046875
        },
        {
            "start_logit": 0.345947265625,
            "end_logit": 6.04296875,
            "text": " programmed cell death protein 1 (programmed death 1) inhibitors, nivolumab and pembrolizumab",
            "probability": 0.0011796951293945312
        },
        {
            "start_logit": 5.99609375,
            "end_logit": -0.0423583984375,
            "text": " nivolumab and pembrolizumab,",
            "probability": 0.0007619857788085938
        },
        {
            "start_logit": 5.93359375,
            "end_logit": -0.0423583984375,
            "text": " pembrolizumab,",
            "probability": 0.0007157325744628906
        },
        {
            "start_logit": -0.31103515625,
            "end_logit": 6.0625,
            "text": "e programmed cell death protein 1 (programmed death 1) inhibitors, nivolumab",
            "probability": 0.0006222724914550781
        },
        {
            "start_logit": -0.31103515625,
            "end_logit": 6.04296875,
            "text": "e programmed cell death protein 1 (programmed death 1) inhibitors, nivolumab and pembrolizumab",
            "probability": 0.0006098747253417969
        },
        {
            "start_logit": 5.99609375,
            "end_logit": -0.4208984375,
            "text": " nivolumab and pembrolizumab, have quickly been incorporated into clinical trials for first- and second-line therapy of Hodgkin lymphoma.",
            "probability": 0.0005216598510742188
        },
        {
            "start_logit": 5.93359375,
            "end_logit": -0.4208984375,
            "text": " pembrolizumab, have quickly been incorporated into clinical trials for first- and second-line therapy of Hodgkin lymphoma.",
            "probability": 0.0004897117614746094
        },
        {
            "start_logit": 5.99609375,
            "end_logit": -1.1533203125,
            "text": " nivolumab and pembrolizumab, have quickly been incorporated into clinical trials for first- and second-line therapy of Hodgkin lymphoma",
            "probability": 0.0002512931823730469
        },
        {
            "start_logit": -1.24609375,
            "end_logit": 6.0625,
            "text": ") inhibitors, nivolumab",
            "probability": 0.00024437904357910156
        },
        {
            "start_logit": -1.24609375,
            "end_logit": 6.04296875,
            "text": ") inhibitors, nivolumab and pembrolizumab",
            "probability": 0.0002397298812866211
        },
        {
            "start_logit": 5.93359375,
            "end_logit": -1.1533203125,
            "text": " pembrolizumab, have quickly been incorporated into clinical trials for first- and second-line therapy of Hodgkin lymphoma",
            "probability": 0.00023615360260009766
        },
        {
            "start_logit": -1.83203125,
            "end_logit": 6.0625,
            "text": ", nivolumab",
            "probability": 0.0001360177993774414
        },
        {
            "start_logit": -1.83203125,
            "end_logit": 6.04296875,
            "text": ", nivolumab and pembrolizumab",
            "probability": 0.00013339519500732422
        },
        {
            "start_logit": -2.24609375,
            "end_logit": 6.0625,
            "text": "programmed death 1) inhibitors, nivolumab",
            "probability": 8.958578109741211e-05
        },
        {
            "start_logit": -2.24609375,
            "end_logit": 6.04296875,
            "text": "programmed death 1) inhibitors, nivolumab and pembrolizumab",
            "probability": 8.821487426757812e-05
        },
        {
            "start_logit": -2.4921875,
            "end_logit": 6.0625,
            "text": " inhibitors, nivolumab",
            "probability": 7.033348083496094e-05
        }
    ],
    "640ddd9d201352f04a000028_0004": [
        {
            "start_logit": 5.89453125,
            "end_logit": 6.2109375,
            "text": " pembrolizumab",
            "probability": 0.50439453125
        },
        {
            "start_logit": 5.89453125,
            "end_logit": 5.74609375,
            "text": " pembrolizumab, was recently approved by the United States Food and Drug Administration for the treatment of melanoma; nivolumab",
            "probability": 0.315673828125
        },
        {
            "start_logit": 5.3203125,
            "end_logit": 5.74609375,
            "text": " nivolumab",
            "probability": 0.177001953125
        },
        {
            "start_logit": 5.89453125,
            "end_logit": -0.263427734375,
            "text": " pembrolizumab,",
            "probability": 0.0007762908935546875
        },
        {
            "start_logit": 5.89453125,
            "end_logit": -0.53662109375,
            "text": " pembrolizumab, was recently approved by the United States Food and Drug Administration for the treatment of melanoma; nivolumab was previously approved in Japan.",
            "probability": 0.0005903244018554688
        },
        {
            "start_logit": 5.3203125,
            "end_logit": -0.53662109375,
            "text": " nivolumab was previously approved in Japan.",
            "probability": 0.0003325939178466797
        },
        {
            "start_logit": -1.705078125,
            "end_logit": 6.2109375,
            "text": "The first programmed death 1 (programmed death 1) inhibitor, pembrolizumab",
            "probability": 0.00025200843811035156
        },
        {
            "start_logit": -2.017578125,
            "end_logit": 6.2109375,
            "text": " first programmed death 1 (programmed death 1) inhibitor, pembrolizumab",
            "probability": 0.0001842975616455078
        },
        {
            "start_logit": -2.041015625,
            "end_logit": 6.2109375,
            "text": " programmed death 1 (programmed death 1) inhibitor, pembrolizumab",
            "probability": 0.00018012523651123047
        },
        {
            "start_logit": -2.044921875,
            "end_logit": 6.2109375,
            "text": ", pembrolizumab",
            "probability": 0.0001785755157470703
        },
        {
            "start_logit": -1.837890625,
            "end_logit": 5.74609375,
            "text": ", was recently approved by the United States Food and Drug Administration for the treatment of melanoma; nivolumab",
            "probability": 0.0001380443572998047
        },
        {
            "start_logit": -2.044921875,
            "end_logit": 5.74609375,
            "text": ", pembrolizumab, was recently approved by the United States Food and Drug Administration for the treatment of melanoma; nivolumab",
            "probability": 0.00011271238327026367
        },
        {
            "start_logit": 5.89453125,
            "end_logit": -2.255859375,
            "text": " pembrolizumab, was recently approved by the United States Food and Drug Administration for the treatment of melanoma",
            "probability": 0.00010585784912109375
        },
        {
            "start_logit": -2.119140625,
            "end_logit": 5.74609375,
            "text": " melanoma; nivolumab",
            "probability": 0.0001042485237121582
        },
        {
            "start_logit": -2.763671875,
            "end_logit": 6.2109375,
            "text": "programmed death 1) inhibitor, pembrolizumab",
            "probability": 8.70823860168457e-05
        },
        {
            "start_logit": -2.376953125,
            "end_logit": 5.74609375,
            "text": " United States Food and Drug Administration for the treatment of melanoma; nivolumab",
            "probability": 8.052587509155273e-05
        },
        {
            "start_logit": 5.89453125,
            "end_logit": -2.603515625,
            "text": " pembrolizumab, was recently approved by the United States Food and Drug Administration for the treatment of melanoma; nivolumab was previously approved in Japan",
            "probability": 7.444620132446289e-05
        },
        {
            "start_logit": 5.89453125,
            "end_logit": -2.841796875,
            "text": " pembrolizumab, was recently approved by the United States Food and Drug Administration for the treatment of melanoma;",
            "probability": 5.888938903808594e-05
        },
        {
            "start_logit": -2.73046875,
            "end_logit": 5.74609375,
            "text": "; nivolumab",
            "probability": 5.6624412536621094e-05
        },
        {
            "start_logit": -2.763671875,
            "end_logit": 5.74609375,
            "text": "programmed death 1) inhibitor, pembrolizumab, was recently approved by the United States Food and Drug Administration for the treatment of melanoma; nivolumab",
            "probability": 5.4895877838134766e-05
        }
    ],
    "6414c4cf690f196b51000006_0001": [
        {
            "start_logit": 3.15234375,
            "end_logit": 1.15625,
            "text": " skin picking",
            "probability": 0.1961669921875
        },
        {
            "start_logit": 3.15234375,
            "end_logit": 1.0927734375,
            "text": " skin picking disorder (skin picking disorder)",
            "probability": 0.184326171875
        },
        {
            "start_logit": 3.15234375,
            "end_logit": 0.52294921875,
            "text": " skin picking disorder",
            "probability": 0.10418701171875
        },
        {
            "start_logit": 3.15234375,
            "end_logit": 0.51904296875,
            "text": " skin picking disorder (skin picking disorder) is a chronic, recurrent, and treatment resistant neuropsychiatric disorder with an underestimated prevalence",
            "probability": 0.103759765625
        },
        {
            "start_logit": 1.9404296875,
            "end_logit": 1.15625,
            "text": "Dermatillomania or skin picking",
            "probability": 0.058441162109375
        },
        {
            "start_logit": 1.9404296875,
            "end_logit": 1.0927734375,
            "text": "Dermatillomania or skin picking disorder (skin picking disorder)",
            "probability": 0.054779052734375
        },
        {
            "start_logit": 3.15234375,
            "end_logit": -0.22265625,
            "text": " skin picking disorder (skin picking disorder) is a chronic, recurrent, and treatment resistant",
            "probability": 0.0494384765625
        },
        {
            "start_logit": 3.15234375,
            "end_logit": -0.6123046875,
            "text": " skin picking disorder (skin picking disorder) is a chronic, recurrent, and treatment resistant neuropsychiatric disorder",
            "probability": 0.033416748046875
        },
        {
            "start_logit": 1.9404296875,
            "end_logit": 0.52294921875,
            "text": "Dermatillomania or skin picking disorder",
            "probability": 0.0309906005859375
        },
        {
            "start_logit": 3.15234375,
            "end_logit": -0.73681640625,
            "text": " skin picking disorder (skin picking disorder) is a chronic,",
            "probability": 0.0295562744140625
        },
        {
            "start_logit": 3.15234375,
            "end_logit": -0.9697265625,
            "text": " skin picking disorder (skin picking disorder) is a chronic, recurrent,",
            "probability": 0.0234375
        },
        {
            "start_logit": 3.15234375,
            "end_logit": -1.0087890625,
            "text": " skin picking disorder (skin picking disorder",
            "probability": 0.0225372314453125
        },
        {
            "start_logit": 3.15234375,
            "end_logit": -1.2265625,
            "text": " skin picking disorder (skin picking disorder) is a chronic, recurrent",
            "probability": 0.018096923828125
        },
        {
            "start_logit": 1.2578125,
            "end_logit": 0.51904296875,
            "text": " treatment resistant neuropsychiatric disorder with an underestimated prevalence",
            "probability": 0.0156097412109375
        },
        {
            "start_logit": 1.9404296875,
            "end_logit": -0.22265625,
            "text": "Dermatillomania or skin picking disorder (skin picking disorder) is a chronic, recurrent, and treatment resistant",
            "probability": 0.01471710205078125
        },
        {
            "start_logit": 3.15234375,
            "end_logit": -1.4658203125,
            "text": " skin picking disorder (skin picking",
            "probability": 0.01425933837890625
        },
        {
            "start_logit": 3.15234375,
            "end_logit": -1.5751953125,
            "text": " skin picking disorder (skin picking disorder) is a chronic, recurrent, and treatment resistant neuropsychiatric",
            "probability": 0.012786865234375
        },
        {
            "start_logit": 1.9404296875,
            "end_logit": -0.432861328125,
            "text": "Dermatillomania",
            "probability": 0.0119171142578125
        },
        {
            "start_logit": 0.95703125,
            "end_logit": 0.51904296875,
            "text": " recurrent, and treatment resistant neuropsychiatric disorder with an underestimated prevalence",
            "probability": 0.0115509033203125
        },
        {
            "start_logit": 1.9404296875,
            "end_logit": -0.6123046875,
            "text": "Dermatillomania or skin picking disorder (skin picking disorder) is a chronic, recurrent, and treatment resistant neuropsychiatric disorder",
            "probability": 0.0099639892578125
        }
    ],
    "63eefa3bf36125a426000012_0001": [
        {
            "start_logit": 6.64453125,
            "end_logit": 5.90625,
            "text": "R. japonica",
            "probability": 0.96875
        },
        {
            "start_logit": 1.75390625,
            "end_logit": 5.90625,
            "text": "Japanese spotted fever (Japanese spotted fever), R. japonica",
            "probability": 0.0073089599609375
        },
        {
            "start_logit": 4.70703125,
            "end_logit": 2.7421875,
            "text": "Rickettsia species LON",
            "probability": 0.00592041015625
        },
        {
            "start_logit": 4.70703125,
            "end_logit": 2.4765625,
            "text": "Rickettsia species LON strains closely related to an agent of Japanese spotted fever",
            "probability": 0.00453948974609375
        },
        {
            "start_logit": 6.64453125,
            "end_logit": -0.07611083984375,
            "text": "R. japonica, were isolated in Japan from Haemaphysalis longicornis ticks in 2001.",
            "probability": 0.0024566650390625
        },
        {
            "start_logit": 6.64453125,
            "end_logit": -0.092529296875,
            "text": "R. japonica,",
            "probability": 0.002410888671875
        },
        {
            "start_logit": 4.70703125,
            "end_logit": 1.7568359375,
            "text": "Rickettsia species",
            "probability": 0.0022125244140625
        },
        {
            "start_logit": 4.70703125,
            "end_logit": 1.2041015625,
            "text": "Rickettsia species LON strains closely related to an agent of Japanese spotted fever (Japanese spotted fever)",
            "probability": 0.001270294189453125
        },
        {
            "start_logit": 6.64453125,
            "end_logit": -1.1875,
            "text": "R",
            "probability": 0.0008072853088378906
        },
        {
            "start_logit": 4.70703125,
            "end_logit": 0.74658203125,
            "text": "Rickettsia species LON strains",
            "probability": 0.0008044242858886719
        },
        {
            "start_logit": -0.52099609375,
            "end_logit": 5.90625,
            "text": "LON strains closely related to an agent of Japanese spotted fever (Japanese spotted fever), R. japonica",
            "probability": 0.0007524490356445312
        },
        {
            "start_logit": 4.70703125,
            "end_logit": 0.1529541015625,
            "text": "Rickettsia species LON strains closely related to an agent of Japanese spotted fever (Japanese spotted fever",
            "probability": 0.00044417381286621094
        },
        {
            "start_logit": -1.2421875,
            "end_logit": 5.90625,
            "text": " strains closely related to an agent of Japanese spotted fever (Japanese spotted fever), R. japonica",
            "probability": 0.0003654956817626953
        },
        {
            "start_logit": -1.4541015625,
            "end_logit": 5.90625,
            "text": " fever (Japanese spotted fever), R. japonica",
            "probability": 0.00029587745666503906
        },
        {
            "start_logit": 4.70703125,
            "end_logit": -0.272705078125,
            "text": "Rickettsia",
            "probability": 0.0002913475036621094
        },
        {
            "start_logit": -1.501953125,
            "end_logit": 5.90625,
            "text": " spotted fever (Japanese spotted fever), R. japonica",
            "probability": 0.00028228759765625
        },
        {
            "start_logit": -1.5771484375,
            "end_logit": 5.90625,
            "text": " japonica",
            "probability": 0.0002613067626953125
        },
        {
            "start_logit": -1.626953125,
            "end_logit": 5.90625,
            "text": " an agent of Japanese spotted fever (Japanese spotted fever), R. japonica",
            "probability": 0.0002491474151611328
        },
        {
            "start_logit": -1.6650390625,
            "end_logit": 5.90625,
            "text": " closely related to an agent of Japanese spotted fever (Japanese spotted fever), R. japonica",
            "probability": 0.00023949146270751953
        },
        {
            "start_logit": 1.75390625,
            "end_logit": 2.4765625,
            "text": "Japanese spotted fever",
            "probability": 0.0002377033233642578
        }
    ],
    "63eefa3bf36125a426000012_0002": [
        {
            "start_logit": 6.75390625,
            "end_logit": 4.35546875,
            "text": "rickettsiosis",
            "probability": 0.8857421875
        },
        {
            "start_logit": 6.75390625,
            "end_logit": 1.0185546875,
            "text": "rickettsiosis) are tick-borne zoonose",
            "probability": 0.031524658203125
        },
        {
            "start_logit": 6.75390625,
            "end_logit": 0.90576171875,
            "text": "rickettsiosis) are tick-borne zoonoses",
            "probability": 0.02813720703125
        },
        {
            "start_logit": 6.75390625,
            "end_logit": 0.319091796875,
            "text": "rickettsiosis) are tick-borne zoo",
            "probability": 0.0156707763671875
        },
        {
            "start_logit": 2.216796875,
            "end_logit": 4.35546875,
            "text": " group rickettsiosis",
            "probability": 0.00946044921875
        },
        {
            "start_logit": 2.060546875,
            "end_logit": 4.35546875,
            "text": "Japanese spotted fever (Japanese spotted fever; a spotted fever group rickettsiosis",
            "probability": 0.00809478759765625
        },
        {
            "start_logit": 6.75390625,
            "end_logit": -0.6689453125,
            "text": "rickettsiosis)",
            "probability": 0.005828857421875
        },
        {
            "start_logit": 6.75390625,
            "end_logit": -1.1962890625,
            "text": "ricketts",
            "probability": 0.00344085693359375
        },
        {
            "start_logit": 0.72705078125,
            "end_logit": 4.35546875,
            "text": " spotted fever group rickettsiosis",
            "probability": 0.0021381378173828125
        },
        {
            "start_logit": 6.75390625,
            "end_logit": -1.7392578125,
            "text": "rick",
            "probability": 0.0019989013671875
        },
        {
            "start_logit": 2.021484375,
            "end_logit": 2.1796875,
            "text": "Severe fever with thrombocytopenia",
            "probability": 0.0008869171142578125
        },
        {
            "start_logit": 2.017578125,
            "end_logit": 2.1796875,
            "text": "thrombocytopenia",
            "probability": 0.0008802413940429688
        },
        {
            "start_logit": 2.060546875,
            "end_logit": 2.087890625,
            "text": "Japanese spotted fever",
            "probability": 0.0008401870727539062
        },
        {
            "start_logit": 2.021484375,
            "end_logit": 2.087890625,
            "text": "Severe fever with thrombocytopenia syndrome (SFTS) and Japanese spotted fever",
            "probability": 0.0008077621459960938
        },
        {
            "start_logit": 2.017578125,
            "end_logit": 2.087890625,
            "text": "thrombocytopenia syndrome (SFTS) and Japanese spotted fever",
            "probability": 0.0008044242858886719
        },
        {
            "start_logit": 1.9033203125,
            "end_logit": 2.1796875,
            "text": " fever with thrombocytopenia",
            "probability": 0.00078582763671875
        },
        {
            "start_logit": 2.060546875,
            "end_logit": 1.9609375,
            "text": "Japanese spotted fever (Japanese spotted fever; a spotted fever",
            "probability": 0.0007414817810058594
        },
        {
            "start_logit": 1.9033203125,
            "end_logit": 2.087890625,
            "text": " fever with thrombocytopenia syndrome (SFTS) and Japanese spotted fever",
            "probability": 0.0007185935974121094
        },
        {
            "start_logit": 2.017578125,
            "end_logit": 1.9609375,
            "text": "thrombocytopenia syndrome (SFTS) and Japanese spotted fever (Japanese spotted fever; a spotted fever",
            "probability": 0.0007076263427734375
        },
        {
            "start_logit": -0.47705078125,
            "end_logit": 4.35546875,
            "text": " a spotted fever group rickettsiosis",
            "probability": 0.0006418228149414062
        }
    ],
    "63eefa3bf36125a426000012_0003": [
        {
            "start_logit": 6.4375,
            "end_logit": 6.08203125,
            "text": "Rickettsia japonica",
            "probability": 0.9873046875
        },
        {
            "start_logit": 6.4375,
            "end_logit": 0.7216796875,
            "text": "Rickettsia japonica is a member of SFG rickettsiae",
            "probability": 0.00466156005859375
        },
        {
            "start_logit": 6.4375,
            "end_logit": 0.431884765625,
            "text": "Rickettsia japonica is a member of SFG rickettsiae causing Japanese spotted fever",
            "probability": 0.0034923553466796875
        },
        {
            "start_logit": 6.4375,
            "end_logit": -0.76416015625,
            "text": "Rickettsia",
            "probability": 0.0010528564453125
        },
        {
            "start_logit": 6.4375,
            "end_logit": -1.30078125,
            "text": "Rick",
            "probability": 0.0006165504455566406
        },
        {
            "start_logit": -1.4609375,
            "end_logit": 6.08203125,
            "text": " japonica",
            "probability": 0.0003681182861328125
        },
        {
            "start_logit": -1.54296875,
            "end_logit": 6.08203125,
            "text": "ettsia japonica",
            "probability": 0.0003390312194824219
        },
        {
            "start_logit": 6.4375,
            "end_logit": -1.99609375,
            "text": "Rickettsia japonica is a member of SFG ricketts",
            "probability": 0.0003063678741455078
        },
        {
            "start_logit": 6.4375,
            "end_logit": -2.146484375,
            "text": "Rickettsia japonica is a member of SFG rickettsiae causing",
            "probability": 0.00026416778564453125
        },
        {
            "start_logit": 6.4375,
            "end_logit": -2.259765625,
            "text": "Rickettsia japonica is",
            "probability": 0.00023674964904785156
        },
        {
            "start_logit": 6.4375,
            "end_logit": -2.330078125,
            "text": "Rickettsia japonica is a member of SF",
            "probability": 0.0002206563949584961
        },
        {
            "start_logit": 6.4375,
            "end_logit": -2.47265625,
            "text": "Rickettsia japonica is a member of SFG",
            "probability": 0.00019180774688720703
        },
        {
            "start_logit": 6.4375,
            "end_logit": -2.4921875,
            "text": "Rickettsia japonica is a member of SFG rick",
            "probability": 0.00018727779388427734
        },
        {
            "start_logit": 6.4375,
            "end_logit": -2.537109375,
            "text": "Rickettsia japonica is a member of SFG rickettsiae causing Japanese spotted",
            "probability": 0.0001786947250366211
        },
        {
            "start_logit": 0.4814453125,
            "end_logit": 0.7216796875,
            "text": "SFG rickettsiae",
            "probability": 1.2040138244628906e-05
        },
        {
            "start_logit": 0.2049560546875,
            "end_logit": 0.7216796875,
            "text": "rickettsiae",
            "probability": 9.179115295410156e-06
        },
        {
            "start_logit": 0.4814453125,
            "end_logit": 0.431884765625,
            "text": "SFG rickettsiae causing Japanese spotted fever",
            "probability": 9.059906005859375e-06
        },
        {
            "start_logit": 0.35888671875,
            "end_logit": 0.431884765625,
            "text": "Japanese spotted fever",
            "probability": 7.927417755126953e-06
        },
        {
            "start_logit": 0.2049560546875,
            "end_logit": 0.431884765625,
            "text": "rickettsiae causing Japanese spotted fever",
            "probability": 6.9141387939453125e-06
        },
        {
            "start_logit": 0.35888671875,
            "end_logit": -0.043975830078125,
            "text": "Japanese spotted fever (Japanese spotted fever) and can transmit to humans via infected ticks.",
            "probability": 4.947185516357422e-06
        }
    ],
    "6414c0f7690f196b51000001_0001": [
        {
            "start_logit": 6.8515625,
            "end_logit": 6.2421875,
            "text": " hyperammonaemic encephalopathy",
            "probability": 0.9697265625
        },
        {
            "start_logit": 2.701171875,
            "end_logit": 6.2421875,
            "text": " neonatal presentation with hyperammonaemic encephalopathy",
            "probability": 0.01531219482421875
        },
        {
            "start_logit": 1.5205078125,
            "end_logit": 6.2421875,
            "text": " asymptomatic carrier state to severe neonatal presentation with hyperammonaemic encephalopathy",
            "probability": 0.004688262939453125
        },
        {
            "start_logit": 1.421875,
            "end_logit": 6.2421875,
            "text": " carrier state to severe neonatal presentation with hyperammonaemic encephalopathy",
            "probability": 0.00424957275390625
        },
        {
            "start_logit": 6.8515625,
            "end_logit": -0.044769287109375,
            "text": " hyperammonaemic encephalopathy.",
            "probability": 0.0018072128295898438
        },
        {
            "start_logit": -0.110107421875,
            "end_logit": 6.2421875,
            "text": " severe neonatal presentation with hyperammonaemic encephalopathy",
            "probability": 0.0009198188781738281
        },
        {
            "start_logit": 6.8515625,
            "end_logit": -1.1611328125,
            "text": " hyper",
            "probability": 0.000591278076171875
        },
        {
            "start_logit": -0.69775390625,
            "end_logit": 6.2421875,
            "text": ". The disease severity ranges from asymptomatic carrier state to severe neonatal presentation with hyperammonaemic encephalopathy",
            "probability": 0.0005097389221191406
        },
        {
            "start_logit": 6.8515625,
            "end_logit": -1.45703125,
            "text": " hyperammonaemic",
            "probability": 0.0004394054412841797
        },
        {
            "start_logit": -1.1298828125,
            "end_logit": 6.2421875,
            "text": " encephalopathy",
            "probability": 0.000331878662109375
        },
        {
            "start_logit": -1.1591796875,
            "end_logit": 6.2421875,
            "text": " urea cycle defect. The disease severity ranges from asymptomatic carrier state to severe neonatal presentation with hyperammonaemic encephalopathy",
            "probability": 0.00032019615173339844
        },
        {
            "start_logit": -1.2685546875,
            "end_logit": 6.2421875,
            "text": "ammonaemic encephalopathy",
            "probability": 0.00028705596923828125
        },
        {
            "start_logit": -1.416015625,
            "end_logit": 6.2421875,
            "text": " from asymptomatic carrier state to severe neonatal presentation with hyperammonaemic encephalopathy",
            "probability": 0.0002493858337402344
        },
        {
            "start_logit": -1.498046875,
            "end_logit": 6.2421875,
            "text": " state to severe neonatal presentation with hyperammonaemic encephalopathy",
            "probability": 0.0002288818359375
        },
        {
            "start_logit": -1.845703125,
            "end_logit": 6.2421875,
            "text": "aemic encephalopathy",
            "probability": 0.00016224384307861328
        },
        {
            "start_logit": -1.91015625,
            "end_logit": 6.2421875,
            "text": " most common urea cycle defect. The disease severity ranges from asymptomatic carrier state to severe neonatal presentation with hyperammonaemic encephalopathy",
            "probability": 0.0001512765884399414
        },
        {
            "start_logit": -2.0625,
            "end_logit": 6.2421875,
            "text": " The disease severity ranges from asymptomatic carrier state to severe neonatal presentation with hyperammonaemic encephalopathy",
            "probability": 0.0001304149627685547
        },
        {
            "start_logit": 2.701171875,
            "end_logit": 0.2388916015625,
            "text": " neonatal presentation",
            "probability": 3.7670135498046875e-05
        },
        {
            "start_logit": 2.701171875,
            "end_logit": -0.044769287109375,
            "text": " neonatal presentation with hyperammonaemic encephalopathy.",
            "probability": 2.8431415557861328e-05
        },
        {
            "start_logit": 1.5205078125,
            "end_logit": 1.087890625,
            "text": " asymptomatic carrier state",
            "probability": 2.7120113372802734e-05
        }
    ],
    "6414c0f7690f196b51000001_0002": [
        {
            "start_logit": 6.28125,
            "end_logit": 4.421875,
            "text": " neonatal hyperammonemic events",
            "probability": 0.802734375
        },
        {
            "start_logit": 6.28125,
            "end_logit": 2.072265625,
            "text": " neonatal hyperammonemic events to moderate symptoms",
            "probability": 0.076416015625
        },
        {
            "start_logit": 6.28125,
            "end_logit": 1.0791015625,
            "text": " neonatal hyperammonemic events to moderate symptoms and even asymptomatic individual",
            "probability": 0.0283355712890625
        },
        {
            "start_logit": 6.28125,
            "end_logit": 0.9375,
            "text": " neonatal hyperammonemic events to moderate symptoms and even asymptomatic",
            "probability": 0.0246124267578125
        },
        {
            "start_logit": 6.28125,
            "end_logit": 0.405517578125,
            "text": " neonatal hyperammonemic",
            "probability": 0.01447296142578125
        },
        {
            "start_logit": 6.28125,
            "end_logit": 0.183349609375,
            "text": " neonatal hyper",
            "probability": 0.0115814208984375
        },
        {
            "start_logit": 1.9140625,
            "end_logit": 4.421875,
            "text": " hyperammonemic events",
            "probability": 0.01018524169921875
        },
        {
            "start_logit": 6.28125,
            "end_logit": -0.03680419921875,
            "text": " neonatal hyperammonemic events to moderate",
            "probability": 0.009307861328125
        },
        {
            "start_logit": 1.3515625,
            "end_logit": 4.421875,
            "text": " high phenotypic heterogeneity, ranging from lethal neonatal hyperammonemic events",
            "probability": 0.005802154541015625
        },
        {
            "start_logit": 6.28125,
            "end_logit": -0.83984375,
            "text": " neonatal",
            "probability": 0.004161834716796875
        },
        {
            "start_logit": 6.28125,
            "end_logit": -0.8583984375,
            "text": " neonatal hyperammon",
            "probability": 0.00408172607421875
        },
        {
            "start_logit": 0.61474609375,
            "end_logit": 4.421875,
            "text": " lethal neonatal hyperammonemic events",
            "probability": 0.0027713775634765625
        },
        {
            "start_logit": 1.9140625,
            "end_logit": 2.072265625,
            "text": " hyperammonemic events to moderate symptoms",
            "probability": 0.0009698867797851562
        },
        {
            "start_logit": -0.64013671875,
            "end_logit": 4.421875,
            "text": " urea cycle disorder. Due to high phenotypic heterogeneity, ranging from lethal neonatal hyperammonemic events",
            "probability": 0.0007915496826171875
        },
        {
            "start_logit": -0.66845703125,
            "end_logit": 4.421875,
            "text": " Due to high phenotypic heterogeneity, ranging from lethal neonatal hyperammonemic events",
            "probability": 0.0007700920104980469
        },
        {
            "start_logit": -0.796875,
            "end_logit": 4.421875,
            "text": " phenotypic heterogeneity, ranging from lethal neonatal hyperammonemic events",
            "probability": 0.0006771087646484375
        },
        {
            "start_logit": -0.80517578125,
            "end_logit": 4.421875,
            "text": ". Due to high phenotypic heterogeneity, ranging from lethal neonatal hyperammonemic events",
            "probability": 0.00067138671875
        },
        {
            "start_logit": -0.84814453125,
            "end_logit": 4.421875,
            "text": " X-linked metabolic disease and the most common urea cycle disorder. Due to high phenotypic heterogeneity, ranging from lethal neonatal hyperammonemic events",
            "probability": 0.0006432533264160156
        },
        {
            "start_logit": 1.3515625,
            "end_logit": 2.072265625,
            "text": " high phenotypic heterogeneity, ranging from lethal neonatal hyperammonemic events to moderate symptoms",
            "probability": 0.0005526542663574219
        },
        {
            "start_logit": 1.9140625,
            "end_logit": 1.0791015625,
            "text": " hyperammonemic events to moderate symptoms and even asymptomatic individual",
            "probability": 0.00035953521728515625
        }
    ],
    "6414c0f7690f196b51000001_0003": [
        {
            "start_logit": 6.91796875,
            "end_logit": 6.3046875,
            "text": " hyperammonemia",
            "probability": 0.99609375
        },
        {
            "start_logit": -0.10150146484375,
            "end_logit": 6.3046875,
            "text": " urea cycle, results in hyperammonemia",
            "probability": 0.0008945465087890625
        },
        {
            "start_logit": 6.91796875,
            "end_logit": -1.0458984375,
            "text": " hyper",
            "probability": 0.0006418228149414062
        },
        {
            "start_logit": -0.6875,
            "end_logit": 6.3046875,
            "text": "ornithine transcarbamylase, an enzyme in the urea cycle, results in hyperammonemia",
            "probability": 0.0004978179931640625
        },
        {
            "start_logit": -0.85009765625,
            "end_logit": 6.3046875,
            "text": " results in hyperammonemia",
            "probability": 0.00042247772216796875
        },
        {
            "start_logit": 6.91796875,
            "end_logit": -1.6708984375,
            "text": " hyperammon",
            "probability": 0.00034332275390625
        },
        {
            "start_logit": -1.1083984375,
            "end_logit": 6.3046875,
            "text": "ammonemia",
            "probability": 0.00032639503479003906
        },
        {
            "start_logit": -1.3671875,
            "end_logit": 6.3046875,
            "text": "emia",
            "probability": 0.0002522468566894531
        },
        {
            "start_logit": -1.66015625,
            "end_logit": 6.3046875,
            "text": " in hyperammonemia",
            "probability": 0.0001875162124633789
        },
        {
            "start_logit": -1.91015625,
            "end_logit": 6.3046875,
            "text": ", results in hyperammonemia",
            "probability": 0.00014591217041015625
        },
        {
            "start_logit": -2.4453125,
            "end_logit": 6.3046875,
            "text": ", an enzyme in the urea cycle, results in hyperammonemia",
            "probability": 8.577108383178711e-05
        },
        {
            "start_logit": -2.494140625,
            "end_logit": 6.3046875,
            "text": "Deficiency of ornithine transcarbamylase, an enzyme in the urea cycle, results in hyperammonemia",
            "probability": 8.189678192138672e-05
        },
        {
            "start_logit": -2.876953125,
            "end_logit": 6.3046875,
            "text": "carbamylase, an enzyme in the urea cycle, results in hyperammonemia",
            "probability": 5.5849552154541016e-05
        },
        {
            "start_logit": -2.978515625,
            "end_logit": 6.3046875,
            "text": " transcarbamylase, an enzyme in the urea cycle, results in hyperammonemia",
            "probability": 5.048513412475586e-05
        },
        {
            "start_logit": -3.0546875,
            "end_logit": 6.3046875,
            "text": " cycle, results in hyperammonemia",
            "probability": 4.667043685913086e-05
        },
        {
            "start_logit": -3.21484375,
            "end_logit": 6.3046875,
            "text": " an enzyme in the urea cycle, results in hyperammonemia",
            "probability": 3.987550735473633e-05
        },
        {
            "start_logit": -3.330078125,
            "end_logit": 6.3046875,
            "text": " the urea cycle, results in hyperammonemia",
            "probability": 3.552436828613281e-05
        },
        {
            "start_logit": -0.10150146484375,
            "end_logit": -0.62060546875,
            "text": " urea cycle",
            "probability": 8.940696716308594e-07
        },
        {
            "start_logit": -0.10150146484375,
            "end_logit": -0.81298828125,
            "text": " urea cycle,",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": -0.10150146484375,
            "end_logit": -1.0458984375,
            "text": " urea cycle, results in hyper",
            "probability": 5.960464477539062e-07
        }
    ],
    "6414c0f7690f196b51000001_0004": [
        {
            "start_logit": 5.59375,
            "end_logit": 5.1484375,
            "text": " developmental delay",
            "probability": 0.1253662109375
        },
        {
            "start_logit": 5.19140625,
            "end_logit": 5.2421875,
            "text": " vomiting",
            "probability": 0.0924072265625
        },
        {
            "start_logit": 5.59375,
            "end_logit": 4.55078125,
            "text": " developmental delay (38 percent), and seizures",
            "probability": 0.06866455078125
        },
        {
            "start_logit": 5.19140625,
            "end_logit": 4.890625,
            "text": " vomiting and lethargy (100 percent), protein avoidance (92 percent), ataxia (77 percent), Stage II coma",
            "probability": 0.06451416015625
        },
        {
            "start_logit": 5.19140625,
            "end_logit": 4.796875,
            "text": " vomiting and lethargy",
            "probability": 0.05877685546875
        },
        {
            "start_logit": 4.83203125,
            "end_logit": 5.1484375,
            "text": " ataxia (77 percent), Stage II coma (46 percent), delayed physical growth (38 percent), developmental delay",
            "probability": 0.05877685546875
        },
        {
            "start_logit": 5.19140625,
            "end_logit": 4.78515625,
            "text": " vomiting and lethargy (100 percent), protein avoidance (92 percent), ataxia",
            "probability": 0.058319091796875
        },
        {
            "start_logit": 5.19140625,
            "end_logit": 4.7421875,
            "text": " vomiting and lethargy (100 percent), protein avoidance",
            "probability": 0.056060791015625
        },
        {
            "start_logit": 4.69921875,
            "end_logit": 5.1484375,
            "text": " coma (46 percent), delayed physical growth (38 percent), developmental delay",
            "probability": 0.051055908203125
        },
        {
            "start_logit": 4.83203125,
            "end_logit": 4.890625,
            "text": " ataxia (77 percent), Stage II coma",
            "probability": 0.0450439453125
        },
        {
            "start_logit": 4.55859375,
            "end_logit": 5.1484375,
            "text": " delayed physical growth (38 percent), developmental delay",
            "probability": 0.044342041015625
        },
        {
            "start_logit": 4.83203125,
            "end_logit": 4.78515625,
            "text": " ataxia",
            "probability": 0.04071044921875
        },
        {
            "start_logit": 4.69921875,
            "end_logit": 4.890625,
            "text": " coma",
            "probability": 0.039764404296875
        },
        {
            "start_logit": 4.4609375,
            "end_logit": 4.890625,
            "text": " lethargy (100 percent), protein avoidance (92 percent), ataxia (77 percent), Stage II coma",
            "probability": 0.0312042236328125
        },
        {
            "start_logit": 4.4609375,
            "end_logit": 4.796875,
            "text": " lethargy",
            "probability": 0.028411865234375
        },
        {
            "start_logit": 4.69921875,
            "end_logit": 4.55078125,
            "text": " coma (46 percent), delayed physical growth (38 percent), developmental delay (38 percent), and seizures",
            "probability": 0.0281829833984375
        },
        {
            "start_logit": 4.4609375,
            "end_logit": 4.78515625,
            "text": " lethargy (100 percent), protein avoidance (92 percent), ataxia",
            "probability": 0.0281829833984375
        },
        {
            "start_logit": 4.35546875,
            "end_logit": 4.890625,
            "text": " protein avoidance (92 percent), ataxia (77 percent), Stage II coma",
            "probability": 0.0281829833984375
        },
        {
            "start_logit": 4.4609375,
            "end_logit": 4.7421875,
            "text": " lethargy (100 percent), protein avoidance",
            "probability": 0.0269012451171875
        },
        {
            "start_logit": 4.35546875,
            "end_logit": 4.78515625,
            "text": " protein avoidance (92 percent), ataxia",
            "probability": 0.0252685546875
        }
    ],
    "63eef60ef36125a42600000c_0001": [
        {
            "start_logit": 7.61328125,
            "end_logit": 7.5078125,
            "text": " rheumatoid arthritis",
            "probability": 0.9990234375
        },
        {
            "start_logit": 7.61328125,
            "end_logit": -0.429931640625,
            "text": " rheumatoid arthritis inadequately controlled by methotrexate: efficacy and safety results of a randomised controlled phase III study.",
            "probability": 0.0003554821014404297
        },
        {
            "start_logit": 7.61328125,
            "end_logit": -0.66064453125,
            "text": " rheumatoid",
            "probability": 0.00028228759765625
        },
        {
            "start_logit": -0.755859375,
            "end_logit": 7.5078125,
            "text": " arthritis",
            "probability": 0.00023031234741210938
        },
        {
            "start_logit": 7.61328125,
            "end_logit": -1.8486328125,
            "text": " rheumatoid arthritis inadequately controlled by methotrexate",
            "probability": 8.606910705566406e-05
        },
        {
            "start_logit": -1.853515625,
            "end_logit": 7.5078125,
            "text": " interleukin 6, in combination with methotrexate in patients with rheumatoid arthritis",
            "probability": 7.718801498413086e-05
        },
        {
            "start_logit": -2.234375,
            "end_logit": 7.5078125,
            "text": " methotrexate in patients with rheumatoid arthritis",
            "probability": 5.263090133666992e-05
        },
        {
            "start_logit": -2.42578125,
            "end_logit": 7.5078125,
            "text": ", in combination with methotrexate in patients with rheumatoid arthritis",
            "probability": 4.3272972106933594e-05
        },
        {
            "start_logit": -2.611328125,
            "end_logit": 7.5078125,
            "text": "Olokizumab, a monoclonal antibody against interleukin 6, in combination with methotrexate in patients with rheumatoid arthritis",
            "probability": 3.612041473388672e-05
        },
        {
            "start_logit": 7.61328125,
            "end_logit": -2.826171875,
            "text": " rheumatoid arthritis inadequately controlled by methotrexate: efficacy and safety results of a randomised controlled phase III study",
            "probability": 3.236532211303711e-05
        },
        {
            "start_logit": -2.779296875,
            "end_logit": 7.5078125,
            "text": " 6, in combination with methotrexate in patients with rheumatoid arthritis",
            "probability": 3.045797348022461e-05
        },
        {
            "start_logit": 7.61328125,
            "end_logit": -2.896484375,
            "text": " rheumatoid arthritis inadequately controlled",
            "probability": 3.0219554901123047e-05
        },
        {
            "start_logit": -2.876953125,
            "end_logit": 7.5078125,
            "text": ", a monoclonal antibody against interleukin 6, in combination with methotrexate in patients with rheumatoid arthritis",
            "probability": 2.777576446533203e-05
        },
        {
            "start_logit": -3.11328125,
            "end_logit": 7.5078125,
            "text": " patients with rheumatoid arthritis",
            "probability": 2.1755695343017578e-05
        },
        {
            "start_logit": -3.234375,
            "end_logit": 7.5078125,
            "text": " combination with methotrexate in patients with rheumatoid arthritis",
            "probability": 1.9371509552001953e-05
        },
        {
            "start_logit": 7.61328125,
            "end_logit": -3.45703125,
            "text": " rheumatoid arthritis inadequately controlled by methotrexate:",
            "probability": 1.722574234008789e-05
        },
        {
            "start_logit": 7.61328125,
            "end_logit": -3.97265625,
            "text": " rheumatoid arthritis inadequately controlled by methotrexate: efficacy and safety results of a",
            "probability": 1.0311603546142578e-05
        },
        {
            "start_logit": 7.61328125,
            "end_logit": -4.02734375,
            "text": " rheumatoid arthritis inadequately controlled by methotrexate: efficacy and safety",
            "probability": 9.715557098388672e-06
        },
        {
            "start_logit": -0.755859375,
            "end_logit": -0.429931640625,
            "text": " arthritis inadequately controlled by methotrexate: efficacy and safety results of a randomised controlled phase III study.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.0966796875,
            "end_logit": -0.429931640625,
            "text": ".",
            "probability": 5.960464477539063e-08
        }
    ],
    "63eef60ef36125a42600000c_0002": [
        {
            "start_logit": 7.70703125,
            "end_logit": 7.5,
            "text": " rheumatoid arthritis",
            "probability": 0.998046875
        },
        {
            "start_logit": -0.121826171875,
            "end_logit": 7.5,
            "text": " active rheumatoid arthritis",
            "probability": 0.0003991127014160156
        },
        {
            "start_logit": 7.70703125,
            "end_logit": -0.418212890625,
            "text": " rheumatoid arthritis despite treatment with methotrexate (methotrexate).",
            "probability": 0.0003647804260253906
        },
        {
            "start_logit": 7.70703125,
            "end_logit": -0.6669921875,
            "text": " rheumatoid",
            "probability": 0.0002841949462890625
        },
        {
            "start_logit": -1.111328125,
            "end_logit": 7.5,
            "text": " arthritis",
            "probability": 0.00014865398406982422
        },
        {
            "start_logit": 7.70703125,
            "end_logit": -1.994140625,
            "text": " rheumatoid arthritis despite treatment with methotrexate (methotrexate)",
            "probability": 7.534027099609375e-05
        },
        {
            "start_logit": -2.05078125,
            "end_logit": 7.5,
            "text": "OBJECTIVE: To evaluate the efficacy and safety of olokizumab (olokizumab) in patients with active rheumatoid arthritis",
            "probability": 5.817413330078125e-05
        },
        {
            "start_logit": -2.328125,
            "end_logit": 7.5,
            "text": "olokizumab (olokizumab) in patients with active rheumatoid arthritis",
            "probability": 4.392862319946289e-05
        },
        {
            "start_logit": -2.494140625,
            "end_logit": 7.5,
            "text": " safety of olokizumab (olokizumab) in patients with active rheumatoid arthritis",
            "probability": 3.731250762939453e-05
        },
        {
            "start_logit": 7.70703125,
            "end_logit": -3.15234375,
            "text": " rheumatoid arthritis despite treatment with methotrexate",
            "probability": 2.3663043975830078e-05
        },
        {
            "start_logit": -2.994140625,
            "end_logit": 7.5,
            "text": " patients with active rheumatoid arthritis",
            "probability": 2.2590160369873047e-05
        },
        {
            "start_logit": -3.15234375,
            "end_logit": 7.5,
            "text": " efficacy and safety of olokizumab (olokizumab) in patients with active rheumatoid arthritis",
            "probability": 1.919269561767578e-05
        },
        {
            "start_logit": -3.265625,
            "end_logit": 7.5,
            "text": " evaluate the efficacy and safety of olokizumab (olokizumab) in patients with active rheumatoid arthritis",
            "probability": 1.71661376953125e-05
        },
        {
            "start_logit": 7.70703125,
            "end_logit": -3.802734375,
            "text": " rheumatoid arthritis despite treatment",
            "probability": 1.239776611328125e-05
        },
        {
            "start_logit": -3.62890625,
            "end_logit": 7.5,
            "text": "olokizumab) in patients with active rheumatoid arthritis",
            "probability": 1.2040138244628906e-05
        },
        {
            "start_logit": -3.66015625,
            "end_logit": 7.5,
            "text": " with active rheumatoid arthritis",
            "probability": 1.1682510375976562e-05
        },
        {
            "start_logit": -3.732421875,
            "end_logit": 7.5,
            "text": ") in patients with active rheumatoid arthritis",
            "probability": 1.0788440704345703e-05
        },
        {
            "start_logit": 7.70703125,
            "end_logit": -3.998046875,
            "text": " rheumatoid arthritis despite treatment with methotrexate (methotrexate",
            "probability": 1.0192394256591797e-05
        },
        {
            "start_logit": -3.9453125,
            "end_logit": 7.5,
            "text": ": To evaluate the efficacy and safety of olokizumab (olokizumab) in patients with active rheumatoid arthritis",
            "probability": 8.761882781982422e-06
        },
        {
            "start_logit": -0.121826171875,
            "end_logit": -0.418212890625,
            "text": " active rheumatoid arthritis despite treatment with methotrexate (methotrexate).",
            "probability": 1.1920928955078125e-07
        }
    ],
    "63eef60ef36125a42600000c_0003": [
        {
            "start_logit": 7.62890625,
            "end_logit": 7.52734375,
            "text": " rheumatoid arthritis",
            "probability": 0.998046875
        },
        {
            "start_logit": 7.62890625,
            "end_logit": -0.375732421875,
            "text": " rheumatoid arthritis without discernible differences between the two regimens.",
            "probability": 0.00036907196044921875
        },
        {
            "start_logit": 7.62890625,
            "end_logit": -0.493896484375,
            "text": " rheumatoid",
            "probability": 0.0003294944763183594
        },
        {
            "start_logit": -0.54931640625,
            "end_logit": 7.52734375,
            "text": "CONCLUSIONS: Treatment with olokizumab was associated with significant improvement in signs, symptoms and physical function of rheumatoid arthritis",
            "probability": 0.0002799034118652344
        },
        {
            "start_logit": -0.607421875,
            "end_logit": 7.52734375,
            "text": " arthritis",
            "probability": 0.00026488304138183594
        },
        {
            "start_logit": -1.169921875,
            "end_logit": 7.52734375,
            "text": " signs, symptoms and physical function of rheumatoid arthritis",
            "probability": 0.00015091896057128906
        },
        {
            "start_logit": -1.861328125,
            "end_logit": 7.52734375,
            "text": " function of rheumatoid arthritis",
            "probability": 7.534027099609375e-05
        },
        {
            "start_logit": -1.9501953125,
            "end_logit": 7.52734375,
            "text": " associated with significant improvement in signs, symptoms and physical function of rheumatoid arthritis",
            "probability": 6.908178329467773e-05
        },
        {
            "start_logit": -1.9599609375,
            "end_logit": 7.52734375,
            "text": " physical function of rheumatoid arthritis",
            "probability": 6.80088996887207e-05
        },
        {
            "start_logit": -2.189453125,
            "end_logit": 7.52734375,
            "text": "olokizumab was associated with significant improvement in signs, symptoms and physical function of rheumatoid arthritis",
            "probability": 5.424022674560547e-05
        },
        {
            "start_logit": -2.294921875,
            "end_logit": 7.52734375,
            "text": ", symptoms and physical function of rheumatoid arthritis",
            "probability": 4.8995018005371094e-05
        },
        {
            "start_logit": -2.400390625,
            "end_logit": 7.52734375,
            "text": " symptoms and physical function of rheumatoid arthritis",
            "probability": 4.392862319946289e-05
        },
        {
            "start_logit": -2.59765625,
            "end_logit": 7.52734375,
            "text": " significant improvement in signs, symptoms and physical function of rheumatoid arthritis",
            "probability": 3.612041473388672e-05
        },
        {
            "start_logit": -2.669921875,
            "end_logit": 7.52734375,
            "text": " improvement in signs, symptoms and physical function of rheumatoid arthritis",
            "probability": 3.36766242980957e-05
        },
        {
            "start_logit": -2.9375,
            "end_logit": 7.52734375,
            "text": " Treatment with olokizumab was associated with significant improvement in signs, symptoms and physical function of rheumatoid arthritis",
            "probability": 2.580881118774414e-05
        },
        {
            "start_logit": -3.39453125,
            "end_logit": 7.52734375,
            "text": " of rheumatoid arthritis",
            "probability": 1.627206802368164e-05
        },
        {
            "start_logit": 7.62890625,
            "end_logit": -3.591796875,
            "text": " rheumatoid arthritis without discernible differences between the two regimens",
            "probability": 1.4841556549072266e-05
        },
        {
            "start_logit": 7.62890625,
            "end_logit": -3.87109375,
            "text": " rheumatoid arthritis without discernible",
            "probability": 1.1205673217773438e-05
        },
        {
            "start_logit": -0.607421875,
            "end_logit": -0.375732421875,
            "text": " arthritis without discernible differences between the two regimens.",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -0.54931640625,
            "end_logit": -0.493896484375,
            "text": "CONCLUSIONS: Treatment with olokizumab was associated with significant improvement in signs, symptoms and physical function of rheumatoid",
            "probability": 1.1920928955078125e-07
        }
    ],
    "63eef60ef36125a42600000c_0004": [
        {
            "start_logit": 7.16015625,
            "end_logit": 7.07421875,
            "text": " Rheumatoid Arthritis",
            "probability": 0.998046875
        },
        {
            "start_logit": 7.16015625,
            "end_logit": -0.1812744140625,
            "text": " Rheumatoid Arthritis.",
            "probability": 0.0007061958312988281
        },
        {
            "start_logit": -0.67578125,
            "end_logit": 7.07421875,
            "text": " Arthritis",
            "probability": 0.00039458274841308594
        },
        {
            "start_logit": 7.16015625,
            "end_logit": -0.77734375,
            "text": " Rheumatoid",
            "probability": 0.0003883838653564453
        },
        {
            "start_logit": -1.4091796875,
            "end_logit": 7.07421875,
            "text": " Adalimumab in Rheumatoid Arthritis",
            "probability": 0.00018930435180664062
        },
        {
            "start_logit": -1.7666015625,
            "end_logit": 7.07421875,
            "text": "Olokizumab versus Placebo or Adalimumab in Rheumatoid Arthritis",
            "probability": 0.00013315677642822266
        },
        {
            "start_logit": -1.7919921875,
            "end_logit": 7.07421875,
            "text": " Placebo or Adalimumab in Rheumatoid Arthritis",
            "probability": 0.0001291036605834961
        },
        {
            "start_logit": -3.021484375,
            "end_logit": 7.07421875,
            "text": " in Rheumatoid Arthritis",
            "probability": 3.784894943237305e-05
        },
        {
            "start_logit": -3.451171875,
            "end_logit": 7.07421875,
            "text": " or Adalimumab in Rheumatoid Arthritis",
            "probability": 2.4616718292236328e-05
        },
        {
            "start_logit": -3.45703125,
            "end_logit": 7.07421875,
            "text": "zumab versus Placebo or Adalimumab in Rheumatoid Arthritis",
            "probability": 2.4437904357910156e-05
        },
        {
            "start_logit": -3.5078125,
            "end_logit": 7.07421875,
            "text": " versus Placebo or Adalimumab in Rheumatoid Arthritis",
            "probability": 2.3126602172851562e-05
        },
        {
            "start_logit": -3.912109375,
            "end_logit": 7.07421875,
            "text": "Olokizumab versus Placebo or Adalimumab in Rheumatoid Arthritis",
            "probability": 1.5497207641601562e-05
        },
        {
            "start_logit": -4.07421875,
            "end_logit": 7.07421875,
            "text": "kizumab versus Placebo or Adalimumab in Rheumatoid Arthritis",
            "probability": 1.3232231140136719e-05
        },
        {
            "start_logit": -0.5703125,
            "end_logit": -0.1812744140625,
            "text": ".",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -0.67578125,
            "end_logit": -0.1812744140625,
            "text": " Arthritis.",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -1.4091796875,
            "end_logit": -0.1812744140625,
            "text": " Adalimumab in Rheumatoid Arthritis.",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -1.7666015625,
            "end_logit": -0.1812744140625,
            "text": "Olokizumab versus Placebo or Adalimumab in Rheumatoid Arthritis.",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -1.7919921875,
            "end_logit": -0.1812744140625,
            "text": " Placebo or Adalimumab in Rheumatoid Arthritis.",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -1.4091796875,
            "end_logit": -0.77734375,
            "text": " Adalimumab in Rheumatoid",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.7666015625,
            "end_logit": -0.77734375,
            "text": "Olokizumab versus Placebo or Adalimumab in Rheumatoid",
            "probability": 5.960464477539063e-08
        }
    ],
    "63eef60ef36125a42600000c_0005": [
        {
            "start_logit": 7.57421875,
            "end_logit": 7.34375,
            "text": " rheumatoid arthritis",
            "probability": 0.994140625
        },
        {
            "start_logit": 7.57421875,
            "end_logit": 1.5458984375,
            "text": " rheumatoid arthritis. Olokizumab, a humanized monoclonal antibody targeting the interleukin-6 cytokine directly, is being tested for the treatment of rheumatoid arthritis",
            "probability": 0.0029964447021484375
        },
        {
            "start_logit": 7.57421875,
            "end_logit": -0.25537109375,
            "text": " rheumatoid arthritis.",
            "probability": 0.0004968643188476562
        },
        {
            "start_logit": 7.57421875,
            "end_logit": -0.55126953125,
            "text": " rheumatoid arthritis. Olokizumab, a humanized monoclonal antibody targeting the interleukin-6 cytokine directly, is being tested for the treatment of rheumatoid arthritis.",
            "probability": 0.00036907196044921875
        },
        {
            "start_logit": 7.57421875,
            "end_logit": -0.6396484375,
            "text": " rheumatoid",
            "probability": 0.0003376007080078125
        },
        {
            "start_logit": -0.9306640625,
            "end_logit": 7.34375,
            "text": "BACKGROUND: The cytokine interleukin-6 is involved in the pathogenesis of rheumatoid arthritis",
            "probability": 0.00020074844360351562
        },
        {
            "start_logit": -0.95556640625,
            "end_logit": 7.34375,
            "text": " arthritis",
            "probability": 0.00019598007202148438
        },
        {
            "start_logit": 7.57421875,
            "end_logit": -1.1904296875,
            "text": " rheumatoid arthritis. Olokizumab, a humanized monoclonal antibody targeting the interleukin-6 cytokine directly",
            "probability": 0.00019443035125732422
        },
        {
            "start_logit": 7.57421875,
            "end_logit": -1.4033203125,
            "text": " rheumatoid arthritis. Olokizumab, a humanized monoclonal antibody targeting the interleukin-6 cytokine directly,",
            "probability": 0.00015747547149658203
        },
        {
            "start_logit": 7.57421875,
            "end_logit": -1.890625,
            "text": " rheumatoid arthritis. Olokizumab,",
            "probability": 9.703636169433594e-05
        },
        {
            "start_logit": 7.57421875,
            "end_logit": -1.9130859375,
            "text": " rheumatoid arthritis. Olokizumab, a humanized monoclonal antibody targeting the interleukin-6 cytokine directly, is being tested for the treatment of rheumatoid",
            "probability": 9.40561294555664e-05
        },
        {
            "start_logit": -1.9111328125,
            "end_logit": 7.34375,
            "text": " interleukin-6 is involved in the pathogenesis of rheumatoid arthritis",
            "probability": 7.56382942199707e-05
        },
        {
            "start_logit": 7.57421875,
            "end_logit": -2.154296875,
            "text": " rheumatoid arthritis. Olokizumab, a humanized monoclonal antibody targeting the interleukin-6 cytokine directly, is being tested for the treatment",
            "probability": 7.444620132446289e-05
        },
        {
            "start_logit": 7.57421875,
            "end_logit": -2.521484375,
            "text": " rheumatoid arthritis. Olokizumab, a humanized monoclonal antibody targeting the interleukin-6 cytokine",
            "probability": 5.155801773071289e-05
        },
        {
            "start_logit": -2.30078125,
            "end_logit": 7.34375,
            "text": " pathogenesis of rheumatoid arthritis",
            "probability": 5.1140785217285156e-05
        },
        {
            "start_logit": -2.861328125,
            "end_logit": 7.34375,
            "text": " cytokine interleukin-6 is involved in the pathogenesis of rheumatoid arthritis",
            "probability": 2.9146671295166016e-05
        },
        {
            "start_logit": -2.880859375,
            "end_logit": 7.34375,
            "text": " involved in the pathogenesis of rheumatoid arthritis",
            "probability": 2.8431415557861328e-05
        },
        {
            "start_logit": 1.11328125,
            "end_logit": 1.5458984375,
            "text": " rheumatoid arthritis",
            "probability": 4.708766937255859e-06
        },
        {
            "start_logit": -0.90234375,
            "end_logit": 1.5458984375,
            "text": ". Olokizumab, a humanized monoclonal antibody targeting the interleukin-6 cytokine directly, is being tested for the treatment of rheumatoid arthritis",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": -0.95556640625,
            "end_logit": 1.5458984375,
            "text": " arthritis. Olokizumab, a humanized monoclonal antibody targeting the interleukin-6 cytokine directly, is being tested for the treatment of rheumatoid arthritis",
            "probability": 5.960464477539062e-07
        }
    ],
    "63eef60ef36125a42600000c_0006": [
        {
            "start_logit": 7.6640625,
            "end_logit": 7.42578125,
            "text": " rheumatoid arthritis",
            "probability": 0.9990234375
        },
        {
            "start_logit": 7.6640625,
            "end_logit": -0.53125,
            "text": " rheumatoid",
            "probability": 0.0003485679626464844
        },
        {
            "start_logit": -0.64208984375,
            "end_logit": 7.42578125,
            "text": "CONCLUSIONS: In patients with rheumatoid arthritis",
            "probability": 0.00024509429931640625
        },
        {
            "start_logit": -0.91357421875,
            "end_logit": 7.42578125,
            "text": " arthritis",
            "probability": 0.00018799304962158203
        },
        {
            "start_logit": 7.6640625,
            "end_logit": -1.3955078125,
            "text": " rheumatoid arthritis who were receiving maintenance methotrexate,",
            "probability": 0.00014638900756835938
        },
        {
            "start_logit": 7.6640625,
            "end_logit": -2.5625,
            "text": " rheumatoid arthritis who were receiving maintenance methotrexate, olokizumab was superior to placebo and noninferior to adalimumab",
            "probability": 4.571676254272461e-05
        },
        {
            "start_logit": 7.6640625,
            "end_logit": -2.58203125,
            "text": " rheumatoid arthritis who were receiving maintenance methotrexate, olokizumab was superior to placebo and noninferior to adalimumab in producing an ACR20",
            "probability": 4.464387893676758e-05
        },
        {
            "start_logit": 7.6640625,
            "end_logit": -2.599609375,
            "text": " rheumatoid arthritis who were receiving maintenance methotrexate, olokizumab was superior to placebo and noninferior to adalimumab in producing an ACR20 response",
            "probability": 4.392862319946289e-05
        },
        {
            "start_logit": 7.6640625,
            "end_logit": -2.787109375,
            "text": " rheumatoid arthritis who were receiving maintenance methotrexate",
            "probability": 3.641843795776367e-05
        },
        {
            "start_logit": 7.6640625,
            "end_logit": -2.916015625,
            "text": " rheumatoid arthritis who were receiving maintenance methotrexate, olokizumab was superior to placebo",
            "probability": 3.212690353393555e-05
        },
        {
            "start_logit": -3.060546875,
            "end_logit": 7.42578125,
            "text": " patients with rheumatoid arthritis",
            "probability": 2.193450927734375e-05
        },
        {
            "start_logit": 0.6669921875,
            "end_logit": 1.181640625,
            "text": " rheumatoid arthritis",
            "probability": 1.7881393432617188e-06
        },
        {
            "start_logit": -1.05078125,
            "end_logit": 1.181640625,
            "text": ". Larger and longer trials are required to determine the efficacy and safety of olokizumab in patients with rheumatoid arthritis",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 0.6669921875,
            "end_logit": -0.548828125,
            "text": " rheumatoid arthritis.",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -2.09765625,
            "end_logit": 1.181640625,
            "text": "ACR20 response at 12 weeks. Larger and longer trials are required to determine the efficacy and safety of olokizumab in patients with rheumatoid arthritis",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -0.64208984375,
            "end_logit": -0.53125,
            "text": "CONCLUSIONS: In patients with rheumatoid",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.05078125,
            "end_logit": -0.240478515625,
            "text": ".",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.05078125,
            "end_logit": -0.548828125,
            "text": ". Larger and longer trials are required to determine the efficacy and safety of olokizumab in patients with rheumatoid arthritis.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -2.80078125,
            "end_logit": 1.181640625,
            "text": " 12 weeks. Larger and longer trials are required to determine the efficacy and safety of olokizumab in patients with rheumatoid arthritis",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -2.83984375,
            "end_logit": 1.181640625,
            "text": " Larger and longer trials are required to determine the efficacy and safety of olokizumab in patients with rheumatoid arthritis",
            "probability": 5.960464477539063e-08
        }
    ],
    "63f03fc8f36125a426000021_0001": [
        {
            "start_logit": 6.515625,
            "end_logit": 5.10546875,
            "text": " human immunodeficiency virus",
            "probability": 0.92822265625
        },
        {
            "start_logit": 6.515625,
            "end_logit": 1.833984375,
            "text": " human immunodeficiency virus type 1",
            "probability": 0.03515625
        },
        {
            "start_logit": 6.515625,
            "end_logit": 1.203125,
            "text": " human immunodeficiency",
            "probability": 0.0186767578125
        },
        {
            "start_logit": 6.515625,
            "end_logit": -0.07427978515625,
            "text": " human immunodeficiency virus type 1 Capsid Inhibitor Lenacapavir.",
            "probability": 0.005207061767578125
        },
        {
            "start_logit": 6.515625,
            "end_logit": -0.8193359375,
            "text": " human immunodeficiency virus type 1 Capsid Inhibitor",
            "probability": 0.002468109130859375
        },
        {
            "start_logit": 0.08038330078125,
            "end_logit": 5.10546875,
            "text": " Viral Resistance to human immunodeficiency virus",
            "probability": 0.0014858245849609375
        },
        {
            "start_logit": -0.0399169921875,
            "end_logit": 5.10546875,
            "text": "immunodeficiency virus",
            "probability": 0.001316070556640625
        },
        {
            "start_logit": 6.515625,
            "end_logit": -1.462890625,
            "text": " human immunodeficiency virus type 1 Capsid",
            "probability": 0.001300811767578125
        },
        {
            "start_logit": 6.515625,
            "end_logit": -1.5927734375,
            "text": " human",
            "probability": 0.0011396408081054688
        },
        {
            "start_logit": 6.515625,
            "end_logit": -1.7001953125,
            "text": " human immunodeficiency virus type",
            "probability": 0.0010251998901367188
        },
        {
            "start_logit": 6.515625,
            "end_logit": -1.7333984375,
            "text": " human ",
            "probability": 0.0009899139404296875
        },
        {
            "start_logit": -0.499755859375,
            "end_logit": 5.10546875,
            "text": "Structural and Mechanistic Bases of Viral Resistance to human immunodeficiency virus",
            "probability": 0.0008301734924316406
        },
        {
            "start_logit": 6.515625,
            "end_logit": -2.373046875,
            "text": " human immunodeficiency virus type 1 Capsid Inhibitor Lenacapavir",
            "probability": 0.0005216598510742188
        },
        {
            "start_logit": -1.5791015625,
            "end_logit": 5.10546875,
            "text": " Mechanistic Bases of Viral Resistance to human immunodeficiency virus",
            "probability": 0.0002834796905517578
        },
        {
            "start_logit": -1.642578125,
            "end_logit": 5.10546875,
            "text": " virus",
            "probability": 0.00026416778564453125
        },
        {
            "start_logit": -2.01953125,
            "end_logit": 5.10546875,
            "text": " Resistance to human immunodeficiency virus",
            "probability": 0.00018155574798583984
        },
        {
            "start_logit": -2.0703125,
            "end_logit": 5.10546875,
            "text": " immunodeficiency virus",
            "probability": 0.00017201900482177734
        },
        {
            "start_logit": -2.12109375,
            "end_logit": 5.10546875,
            "text": " Bases of Viral Resistance to human immunodeficiency virus",
            "probability": 0.00016415119171142578
        },
        {
            "start_logit": -3.072265625,
            "end_logit": 5.10546875,
            "text": " to human immunodeficiency virus",
            "probability": 6.324052810668945e-05
        },
        {
            "start_logit": -3.1171875,
            "end_logit": 5.10546875,
            "text": " of Viral Resistance to human immunodeficiency virus",
            "probability": 6.03795051574707e-05
        }
    ],
    "63f03fc8f36125a426000021_0002": [
        {
            "start_logit": 7.21484375,
            "end_logit": 5.97265625,
            "text": " human immunodeficiency virus",
            "probability": 0.97265625
        },
        {
            "start_logit": 7.21484375,
            "end_logit": 1.91796875,
            "text": " human immunodeficiency virus type 1",
            "probability": 0.0168609619140625
        },
        {
            "start_logit": 7.21484375,
            "end_logit": 0.475341796875,
            "text": " human immunodeficiency",
            "probability": 0.00399017333984375
        },
        {
            "start_logit": 7.21484375,
            "end_logit": -0.288818359375,
            "text": " human immunodeficiency virus type 1 capsid (capsid) inhibitor.",
            "probability": 0.0018558502197265625
        },
        {
            "start_logit": 7.21484375,
            "end_logit": -0.73876953125,
            "text": " human immunodeficiency virus type 1 capsid",
            "probability": 0.0011844635009765625
        },
        {
            "start_logit": 7.21484375,
            "end_logit": -0.98046875,
            "text": " human immunodeficiency virus type 1 capsid (capsid) inhibitor",
            "probability": 0.0009293556213378906
        },
        {
            "start_logit": 7.21484375,
            "end_logit": -1.517578125,
            "text": " human",
            "probability": 0.0005421638488769531
        },
        {
            "start_logit": 7.21484375,
            "end_logit": -2.00390625,
            "text": " human ",
            "probability": 0.0003337860107421875
        },
        {
            "start_logit": 7.21484375,
            "end_logit": -2.1484375,
            "text": " human immunodeficiency virus type",
            "probability": 0.0002880096435546875
        },
        {
            "start_logit": -1.25390625,
            "end_logit": 5.97265625,
            "text": "immunodeficiency virus",
            "probability": 0.00020420551300048828
        },
        {
            "start_logit": -1.4873046875,
            "end_logit": 5.97265625,
            "text": "Lenacapavir (Lenacapavir) is a long-acting, highly potent human immunodeficiency virus",
            "probability": 0.0001615285873413086
        },
        {
            "start_logit": 7.21484375,
            "end_logit": -2.83203125,
            "text": " human immunodeficiency virus type 1 capsid ",
            "probability": 0.00014591217041015625
        },
        {
            "start_logit": -1.6708984375,
            "end_logit": 5.97265625,
            "text": " virus",
            "probability": 0.00013387203216552734
        },
        {
            "start_logit": 7.21484375,
            "end_logit": -3.04296875,
            "text": " human immunodeficiency virus type 1 capsid (capsid)",
            "probability": 0.00011813640594482422
        },
        {
            "start_logit": -1.865234375,
            "end_logit": 5.97265625,
            "text": " highly potent human immunodeficiency virus",
            "probability": 0.00011098384857177734
        },
        {
            "start_logit": -2.216796875,
            "end_logit": 5.97265625,
            "text": " long-acting, highly potent human immunodeficiency virus",
            "probability": 7.808208465576172e-05
        },
        {
            "start_logit": -2.3515625,
            "end_logit": 5.97265625,
            "text": ", highly potent human immunodeficiency virus",
            "probability": 6.842613220214844e-05
        },
        {
            "start_logit": -2.951171875,
            "end_logit": 5.97265625,
            "text": " immunodeficiency virus",
            "probability": 3.743171691894531e-05
        },
        {
            "start_logit": -3.298828125,
            "end_logit": 5.97265625,
            "text": " potent human immunodeficiency virus",
            "probability": 2.6345252990722656e-05
        },
        {
            "start_logit": -3.31640625,
            "end_logit": 5.97265625,
            "text": "Lenacapavir) is a long-acting, highly potent human immunodeficiency virus",
            "probability": 2.5987625122070312e-05
        }
    ],
    "63f03fc8f36125a426000021_0003": [
        {
            "start_logit": 6.765625,
            "end_logit": 5.23046875,
            "text": " human immunodeficiency virus",
            "probability": 0.9111328125
        },
        {
            "start_logit": 6.765625,
            "end_logit": 2.431640625,
            "text": " human immunodeficiency",
            "probability": 0.055145263671875
        },
        {
            "start_logit": 6.765625,
            "end_logit": 1.392578125,
            "text": " human immunodeficiency virus type 1",
            "probability": 0.019500732421875
        },
        {
            "start_logit": 6.765625,
            "end_logit": -0.132080078125,
            "text": " human immunodeficiency virus type 1 inside the nucleus without displacing the tightly bound cellular cofactor from virus cores.",
            "probability": 0.00424957275390625
        },
        {
            "start_logit": 6.765625,
            "end_logit": -0.59716796875,
            "text": " human immunodeficiency virus type 1 inside the nucleus without displacing the tightly bound cellular cofactor from virus cores",
            "probability": 0.0026702880859375
        },
        {
            "start_logit": 6.765625,
            "end_logit": -1.384765625,
            "text": " human immunodeficiency virus type 1 inside the nucleus without displacing the tightly bound cellular cofactor from virus",
            "probability": 0.0012178421020507812
        },
        {
            "start_logit": 6.765625,
            "end_logit": -1.5478515625,
            "text": " human immunodeficiency virus type 1 inside the nucleus without displacing the tightly bound cellular cofactor",
            "probability": 0.001033782958984375
        },
        {
            "start_logit": 6.765625,
            "end_logit": -1.6875,
            "text": " human ",
            "probability": 0.0008983612060546875
        },
        {
            "start_logit": 6.765625,
            "end_logit": -1.779296875,
            "text": " human immunodeficiency virus type 1 inside the nucleus",
            "probability": 0.0008177757263183594
        },
        {
            "start_logit": 6.765625,
            "end_logit": -1.904296875,
            "text": " human",
            "probability": 0.0007214546203613281
        },
        {
            "start_logit": 6.765625,
            "end_logit": -2.08203125,
            "text": " human immunodeficiency virus type",
            "probability": 0.0006055831909179688
        },
        {
            "start_logit": 6.765625,
            "end_logit": -2.443359375,
            "text": " human immunodeficiency virus type 1 inside",
            "probability": 0.0004210472106933594
        },
        {
            "start_logit": -0.9189453125,
            "end_logit": 5.23046875,
            "text": " complex to potently impair human immunodeficiency virus",
            "probability": 0.0004177093505859375
        },
        {
            "start_logit": -1.021484375,
            "end_logit": 5.23046875,
            "text": "immunodeficiency virus",
            "probability": 0.0003771781921386719
        },
        {
            "start_logit": 6.765625,
            "end_logit": -2.986328125,
            "text": " human immunodeficiency virus type 1 inside the nucleus without ",
            "probability": 0.0002455711364746094
        },
        {
            "start_logit": -1.515625,
            "end_logit": 5.23046875,
            "text": " the complex to potently impair human immunodeficiency virus",
            "probability": 0.00023066997528076172
        },
        {
            "start_logit": -1.587890625,
            "end_logit": 5.23046875,
            "text": " potently impair human immunodeficiency virus",
            "probability": 0.00021338462829589844
        },
        {
            "start_logit": -2.048828125,
            "end_logit": 5.23046875,
            "text": "The investigational drug lenacapavir accesses unoccupied hydrophobic pockets in the complex to potently impair human immunodeficiency virus",
            "probability": 0.00013458728790283203
        },
        {
            "start_logit": -2.060546875,
            "end_logit": 5.23046875,
            "text": " accesses unoccupied hydrophobic pockets in the complex to potently impair human immunodeficiency virus",
            "probability": 0.000133514404296875
        },
        {
            "start_logit": -2.130859375,
            "end_logit": 5.23046875,
            "text": " virus",
            "probability": 0.00012445449829101562
        }
    ],
    "63f03fc8f36125a426000021_0004": [
        {
            "start_logit": 7.12109375,
            "end_logit": 5.38671875,
            "text": " human immunodeficiency virus",
            "probability": 0.87353515625
        },
        {
            "start_logit": 7.12109375,
            "end_logit": 2.728515625,
            "text": " human immunodeficiency virus type\u00a01",
            "probability": 0.06134033203125
        },
        {
            "start_logit": 7.12109375,
            "end_logit": 2.4921875,
            "text": " human immunodeficiency",
            "probability": 0.04815673828125
        },
        {
            "start_logit": 7.12109375,
            "end_logit": -0.035125732421875,
            "text": " human immunodeficiency virus type\u00a01 (human immunodeficiency virus type 1",
            "probability": 0.0038604736328125
        },
        {
            "start_logit": 7.12109375,
            "end_logit": -0.1893310546875,
            "text": " human immunodeficiency virus type\u00a01 (human immunodeficiency virus type 1) being developed by Gilead Sciences Inc.",
            "probability": 0.003314971923828125
        },
        {
            "start_logit": 7.12109375,
            "end_logit": -0.60498046875,
            "text": " human immunodeficiency virus type\u00a01 (human immunodeficiency virus type 1)",
            "probability": 0.0021839141845703125
        },
        {
            "start_logit": 7.12109375,
            "end_logit": -0.66015625,
            "text": " human immunodeficiency virus type\u00a01 (human immunodeficiency",
            "probability": 0.0020656585693359375
        },
        {
            "start_logit": 7.12109375,
            "end_logit": -0.82763671875,
            "text": " human immunodeficiency virus type\u00a01 (human immunodeficiency virus",
            "probability": 0.0017461776733398438
        },
        {
            "start_logit": 7.12109375,
            "end_logit": -1.5400390625,
            "text": " human",
            "probability": 0.000858306884765625
        },
        {
            "start_logit": 7.12109375,
            "end_logit": -1.9921875,
            "text": " human ",
            "probability": 0.000545501708984375
        },
        {
            "start_logit": 7.12109375,
            "end_logit": -2.173828125,
            "text": " human immunodeficiency virus type",
            "probability": 0.00045418739318847656
        },
        {
            "start_logit": 7.12109375,
            "end_logit": -2.2890625,
            "text": " human immunodeficiency virus type\u00a01 (human immunodeficiency virus type 1) being developed by Gilead Sciences Inc",
            "probability": 0.00040531158447265625
        },
        {
            "start_logit": 7.12109375,
            "end_logit": -2.560546875,
            "text": " human immunodeficiency virus type\u00a01 ",
            "probability": 0.0003094673156738281
        },
        {
            "start_logit": -1.03515625,
            "end_logit": 5.38671875,
            "text": "immunodeficiency virus",
            "probability": 0.0002505779266357422
        },
        {
            "start_logit": -1.5712890625,
            "end_logit": 5.38671875,
            "text": "Lenacapavir (Sunlenca\u00ae) is a long-acting capsid inhibitor of human immunodeficiency virus",
            "probability": 0.00014734268188476562
        },
        {
            "start_logit": -1.7265625,
            "end_logit": 5.38671875,
            "text": " long-acting capsid inhibitor of human immunodeficiency virus",
            "probability": 0.00012600421905517578
        },
        {
            "start_logit": -2.03125,
            "end_logit": 5.38671875,
            "text": " virus",
            "probability": 9.22083854675293e-05
        },
        {
            "start_logit": -2.568359375,
            "end_logit": 5.38671875,
            "text": " capsid inhibitor of human immunodeficiency virus",
            "probability": 5.424022674560547e-05
        },
        {
            "start_logit": -2.73046875,
            "end_logit": 5.38671875,
            "text": " a long-acting capsid inhibitor of human immunodeficiency virus",
            "probability": 4.601478576660156e-05
        },
        {
            "start_logit": -2.861328125,
            "end_logit": 5.38671875,
            "text": " immunodeficiency virus",
            "probability": 4.029273986816406e-05
        }
    ],
    "63f03fc8f36125a426000021_0005": [
        {
            "start_logit": 7.46875,
            "end_logit": 6.7421875,
            "text": " human immunodeficiency virus type 1 infection",
            "probability": 0.9716796875
        },
        {
            "start_logit": 7.46875,
            "end_logit": 3.083984375,
            "text": " human immunodeficiency virus",
            "probability": 0.0251007080078125
        },
        {
            "start_logit": 7.46875,
            "end_logit": -0.2822265625,
            "text": " human immunodeficiency virus type 1 infection.",
            "probability": 0.0008654594421386719
        },
        {
            "start_logit": 3.107421875,
            "end_logit": 3.98046875,
            "text": " HIV infection",
            "probability": 0.000782012939453125
        },
        {
            "start_logit": 7.46875,
            "end_logit": -0.654296875,
            "text": " human immunodeficiency virus type 1",
            "probability": 0.0005946159362792969
        },
        {
            "start_logit": 7.46875,
            "end_logit": -1.0712890625,
            "text": " human immunodeficiency",
            "probability": 0.00039315223693847656
        },
        {
            "start_logit": 7.46875,
            "end_logit": -1.59375,
            "text": " human",
            "probability": 0.00023293495178222656
        },
        {
            "start_logit": -0.9091796875,
            "end_logit": 6.7421875,
            "text": "immunodeficiency virus type 1 infection",
            "probability": 0.00022399425506591797
        },
        {
            "start_logit": -1.818359375,
            "end_logit": 6.7421875,
            "text": " infection",
            "probability": 8.982419967651367e-05
        },
        {
            "start_logit": -1.818359375,
            "end_logit": 6.7421875,
            "text": " type 1 infection",
            "probability": 8.982419967651367e-05
        },
        {
            "start_logit": 0.7060546875,
            "end_logit": 3.98046875,
            "text": " infection",
            "probability": 7.104873657226562e-05
        },
        {
            "start_logit": -0.603515625,
            "end_logit": 3.98046875,
            "text": " EU for use in combination with other antiretroviral(s) in adults with multi-drug resistant HIV infection",
            "probability": 1.913309097290039e-05
        },
        {
            "start_logit": 3.107421875,
            "end_logit": -0.058502197265625,
            "text": " HIV",
            "probability": 1.3768672943115234e-05
        },
        {
            "start_logit": 3.107421875,
            "end_logit": -0.1802978515625,
            "text": " HIV infection, for whom it is otherwise not possible to construct a suppressive anti-viral regimen.",
            "probability": 1.2278556823730469e-05
        },
        {
            "start_logit": -1.416015625,
            "end_logit": 3.98046875,
            "text": "IV infection",
            "probability": 8.52346420288086e-06
        },
        {
            "start_logit": -1.5126953125,
            "end_logit": 3.98046875,
            "text": " the EU for use in combination with other antiretroviral(s) in adults with multi-drug resistant HIV infection",
            "probability": 7.68899917602539e-06
        },
        {
            "start_logit": 3.107421875,
            "end_logit": -0.642578125,
            "text": " H",
            "probability": 7.62939453125e-06
        },
        {
            "start_logit": -1.6494140625,
            "end_logit": 3.98046875,
            "text": " multi-drug resistant HIV infection",
            "probability": 6.794929504394531e-06
        },
        {
            "start_logit": -1.6982421875,
            "end_logit": 3.98046875,
            "text": " resistant HIV infection",
            "probability": 6.4373016357421875e-06
        },
        {
            "start_logit": -0.9091796875,
            "end_logit": 3.083984375,
            "text": "immunodeficiency virus",
            "probability": 5.781650543212891e-06
        }
    ],
    "63f03fc8f36125a426000021_0006": [
        {
            "start_logit": 7.29296875,
            "end_logit": 6.203125,
            "text": " human immunodeficiency virus",
            "probability": 0.97607421875
        },
        {
            "start_logit": 7.29296875,
            "end_logit": 1.986328125,
            "text": " human immunodeficiency virus type 1",
            "probability": 0.01436614990234375
        },
        {
            "start_logit": 7.29296875,
            "end_logit": 1.0849609375,
            "text": " human immunodeficiency",
            "probability": 0.00580596923828125
        },
        {
            "start_logit": 7.29296875,
            "end_logit": -0.24951171875,
            "text": " human immunodeficiency virus type 1 capsid inhibitor.",
            "probability": 0.0015325546264648438
        },
        {
            "start_logit": 7.29296875,
            "end_logit": -1.2490234375,
            "text": " human immunodeficiency virus type 1 capsid inhibitor",
            "probability": 0.0005636215209960938
        },
        {
            "start_logit": 7.29296875,
            "end_logit": -1.626953125,
            "text": " human immunodeficiency virus type 1 capsid",
            "probability": 0.0003857612609863281
        },
        {
            "start_logit": 7.29296875,
            "end_logit": -1.626953125,
            "text": " human",
            "probability": 0.0003857612609863281
        },
        {
            "start_logit": 7.29296875,
            "end_logit": -1.8369140625,
            "text": " human ",
            "probability": 0.00031256675720214844
        },
        {
            "start_logit": 7.29296875,
            "end_logit": -2.21875,
            "text": " human immunodeficiency virus type",
            "probability": 0.0002148151397705078
        },
        {
            "start_logit": -1.41796875,
            "end_logit": 6.203125,
            "text": "immunodeficiency virus",
            "probability": 0.0001595020294189453
        },
        {
            "start_logit": -1.7900390625,
            "end_logit": 6.203125,
            "text": " virus",
            "probability": 0.00011056661605834961
        },
        {
            "start_logit": -2.08984375,
            "end_logit": 6.203125,
            "text": "Lenacapavir: a first-in-class human immunodeficiency virus",
            "probability": 8.153915405273438e-05
        },
        {
            "start_logit": -2.9765625,
            "end_logit": 6.203125,
            "text": " immunodeficiency virus",
            "probability": 3.36766242980957e-05
        },
        {
            "start_logit": -3.69921875,
            "end_logit": 6.203125,
            "text": "class human immunodeficiency virus",
            "probability": 1.627206802368164e-05
        },
        {
            "start_logit": -3.71484375,
            "end_logit": 6.203125,
            "text": " a first-in-class human immunodeficiency virus",
            "probability": 1.6033649444580078e-05
        },
        {
            "start_logit": -4.06640625,
            "end_logit": 6.203125,
            "text": " first-in-class human immunodeficiency virus",
            "probability": 1.138448715209961e-05
        },
        {
            "start_logit": -4.25,
            "end_logit": 6.203125,
            "text": "-class human immunodeficiency virus",
            "probability": 9.417533874511719e-06
        },
        {
            "start_logit": -4.37109375,
            "end_logit": 6.203125,
            "text": "avir: a first-in-class human immunodeficiency virus",
            "probability": 8.344650268554688e-06
        },
        {
            "start_logit": -4.4296875,
            "end_logit": 6.203125,
            "text": "capavir: a first-in-class human immunodeficiency virus",
            "probability": 7.867813110351562e-06
        },
        {
            "start_logit": -1.41796875,
            "end_logit": 1.986328125,
            "text": "immunodeficiency virus type 1",
            "probability": 2.384185791015625e-06
        }
    ],
    "63f03fc8f36125a426000021_0007": [
        {
            "start_logit": 7.3203125,
            "end_logit": 6.4140625,
            "text": " human immunodeficiency virus",
            "probability": 0.96533203125
        },
        {
            "start_logit": 7.3203125,
            "end_logit": 2.64453125,
            "text": " human immunodeficiency virus type 1",
            "probability": 0.0223388671875
        },
        {
            "start_logit": 7.3203125,
            "end_logit": 1.3359375,
            "text": " human immunodeficiency",
            "probability": 0.006015777587890625
        },
        {
            "start_logit": 7.3203125,
            "end_logit": 0.421875,
            "text": " human immunodeficiency virus type 1. In persons with human immunodeficiency virus",
            "probability": 0.002410888671875
        },
        {
            "start_logit": 7.3203125,
            "end_logit": -0.021484375,
            "text": " human immunodeficiency virus type 1. In persons with human immunodeficiency virus type 1",
            "probability": 0.0015439987182617188
        },
        {
            "start_logit": 7.3203125,
            "end_logit": -0.447265625,
            "text": " human immunodeficiency virus type 1.",
            "probability": 0.0010137557983398438
        },
        {
            "start_logit": 7.3203125,
            "end_logit": -1.009765625,
            "text": " human immunodeficiency virus type 1. In persons with human immunodeficiency",
            "probability": 0.0005769729614257812
        },
        {
            "start_logit": 7.3203125,
            "end_logit": -1.482421875,
            "text": " human",
            "probability": 0.00035834312438964844
        },
        {
            "start_logit": 7.3203125,
            "end_logit": -2.009765625,
            "text": " human ",
            "probability": 0.0002124309539794922
        },
        {
            "start_logit": 7.3203125,
            "end_logit": -2.01171875,
            "text": " human immunodeficiency virus type 1. In persons with human immunodeficiency virus type 1,",
            "probability": 0.0002124309539794922
        },
        {
            "start_logit": -1.2265625,
            "end_logit": 6.4140625,
            "text": " persons with human immunodeficiency virus",
            "probability": 0.00018739700317382812
        },
        {
            "start_logit": -1.7392578125,
            "end_logit": 6.4140625,
            "text": "immunodeficiency virus",
            "probability": 0.0001118779182434082
        },
        {
            "start_logit": -1.9912109375,
            "end_logit": 6.4140625,
            "text": " virus",
            "probability": 8.71419906616211e-05
        },
        {
            "start_logit": -2.32421875,
            "end_logit": 6.4140625,
            "text": " picomolar potency in vitro with no cross resistance to existing antiretroviral classes and potent antiviral activity in persons with human immunodeficiency virus",
            "probability": 6.276369094848633e-05
        },
        {
            "start_logit": -2.515625,
            "end_logit": 6.4140625,
            "text": " potent antiviral activity in persons with human immunodeficiency virus",
            "probability": 5.161762237548828e-05
        },
        {
            "start_logit": -1.2265625,
            "end_logit": 2.64453125,
            "text": " persons with human immunodeficiency virus type 1",
            "probability": 4.291534423828125e-06
        },
        {
            "start_logit": 0.908203125,
            "end_logit": 0.421875,
            "text": " human immunodeficiency virus",
            "probability": 3.993511199951172e-06
        },
        {
            "start_logit": -1.7392578125,
            "end_logit": 2.64453125,
            "text": "immunodeficiency virus type 1",
            "probability": 2.562999725341797e-06
        },
        {
            "start_logit": 0.908203125,
            "end_logit": -0.021484375,
            "text": " human immunodeficiency virus type 1",
            "probability": 2.5033950805664062e-06
        },
        {
            "start_logit": -1.9912109375,
            "end_logit": 2.64453125,
            "text": " virus type 1",
            "probability": 2.0265579223632812e-06
        }
    ],
    "63f03fc8f36125a426000021_0008": [
        {
            "start_logit": 7.51171875,
            "end_logit": 6.57421875,
            "text": " human immunodeficiency virus",
            "probability": 0.90625
        },
        {
            "start_logit": 7.51171875,
            "end_logit": 4.15625,
            "text": " human immunodeficiency virus type 1",
            "probability": 0.0810546875
        },
        {
            "start_logit": 7.51171875,
            "end_logit": 1.4970703125,
            "text": " human immunodeficiency",
            "probability": 0.005649566650390625
        },
        {
            "start_logit": 7.51171875,
            "end_logit": 0.95263671875,
            "text": " human immunodeficiency virus type 1 and in treatment-naive persons with human immunodeficiency virus type 1",
            "probability": 0.003269195556640625
        },
        {
            "start_logit": 7.51171875,
            "end_logit": 0.292236328125,
            "text": " human immunodeficiency virus type 1 and in treatment-naive persons with human immunodeficiency virus",
            "probability": 0.0016956329345703125
        },
        {
            "start_logit": 7.51171875,
            "end_logit": -0.607421875,
            "text": " human immunodeficiency virus type 1 and in treatment-naive persons with human immunodeficiency",
            "probability": 0.000690460205078125
        },
        {
            "start_logit": 7.51171875,
            "end_logit": -1.5458984375,
            "text": " human immunodeficiency virus type 1 and in treatment-naive persons with human immunodeficiency virus type 1,",
            "probability": 0.0002682209014892578
        },
        {
            "start_logit": 7.51171875,
            "end_logit": -1.61328125,
            "text": " human",
            "probability": 0.00025200843811035156
        },
        {
            "start_logit": 7.51171875,
            "end_logit": -1.7392578125,
            "text": " human ",
            "probability": 0.00022232532501220703
        },
        {
            "start_logit": -1.18359375,
            "end_logit": 6.57421875,
            "text": " multidrug-resistant human immunodeficiency virus",
            "probability": 0.00015163421630859375
        },
        {
            "start_logit": -1.798828125,
            "end_logit": 6.57421875,
            "text": "immunodeficiency virus",
            "probability": 8.183717727661133e-05
        },
        {
            "start_logit": -2.2421875,
            "end_logit": 6.57421875,
            "text": "resistant human immunodeficiency virus",
            "probability": 5.2809715270996094e-05
        },
        {
            "start_logit": -2.294921875,
            "end_logit": 6.57421875,
            "text": " virus",
            "probability": 5.0008296966552734e-05
        },
        {
            "start_logit": -2.5078125,
            "end_logit": 6.57421875,
            "text": " heavily treatment-experienced persons with multidrug-resistant human immunodeficiency virus",
            "probability": 4.0531158447265625e-05
        },
        {
            "start_logit": -2.638671875,
            "end_logit": 6.57421875,
            "text": " persons with multidrug-resistant human immunodeficiency virus",
            "probability": 3.546476364135742e-05
        },
        {
            "start_logit": -1.18359375,
            "end_logit": 4.15625,
            "text": " multidrug-resistant human immunodeficiency virus type 1",
            "probability": 1.3530254364013672e-05
        },
        {
            "start_logit": -1.50390625,
            "end_logit": 4.15625,
            "text": " type 1",
            "probability": 9.775161743164062e-06
        },
        {
            "start_logit": -1.798828125,
            "end_logit": 4.15625,
            "text": "immunodeficiency virus type 1",
            "probability": 7.271766662597656e-06
        },
        {
            "start_logit": -2.2421875,
            "end_logit": 4.15625,
            "text": "resistant human immunodeficiency virus type 1",
            "probability": 4.708766937255859e-06
        },
        {
            "start_logit": -2.294921875,
            "end_logit": 4.15625,
            "text": " virus type 1",
            "probability": 4.410743713378906e-06
        }
    ],
    "64041701201352f04a000017_0001": [
        {
            "start_logit": 5.7421875,
            "end_logit": 5.74609375,
            "text": " cryptorchidism",
            "probability": 0.440673828125
        },
        {
            "start_logit": 4.8125,
            "end_logit": 5.74609375,
            "text": " defective abdominal wall muscles, urinary tract abnormalities, and bilateral cryptorchidism",
            "probability": 0.17529296875
        },
        {
            "start_logit": 4.4453125,
            "end_logit": 5.74609375,
            "text": " bilateral cryptorchidism",
            "probability": 0.1204833984375
        },
        {
            "start_logit": 3.98046875,
            "end_logit": 5.74609375,
            "text": " urinary tract abnormalities, and bilateral cryptorchidism",
            "probability": 0.075927734375
        },
        {
            "start_logit": 4.8125,
            "end_logit": 4.73828125,
            "text": " defective abdominal wall muscles",
            "probability": 0.0634765625
        },
        {
            "start_logit": 3.44921875,
            "end_logit": 5.74609375,
            "text": " absent or defective abdominal wall muscles, urinary tract abnormalities, and bilateral cryptorchidism",
            "probability": 0.044677734375
        },
        {
            "start_logit": 4.8125,
            "end_logit": 3.576171875,
            "text": " defective abdominal wall muscles, urinary tract abnormalities",
            "probability": 0.0199737548828125
        },
        {
            "start_logit": 3.44921875,
            "end_logit": 4.73828125,
            "text": " absent or defective abdominal wall muscles",
            "probability": 0.01629638671875
        },
        {
            "start_logit": 2.17578125,
            "end_logit": 5.74609375,
            "text": " abdominal wall muscles, urinary tract abnormalities, and bilateral cryptorchidism",
            "probability": 0.0124969482421875
        },
        {
            "start_logit": 3.98046875,
            "end_logit": 3.576171875,
            "text": " urinary tract abnormalities",
            "probability": 0.00865936279296875
        },
        {
            "start_logit": 3.44921875,
            "end_logit": 3.576171875,
            "text": " absent or defective abdominal wall muscles, urinary tract abnormalities",
            "probability": 0.00508880615234375
        },
        {
            "start_logit": 2.17578125,
            "end_logit": 4.73828125,
            "text": " abdominal wall muscles",
            "probability": 0.0045623779296875
        },
        {
            "start_logit": 4.8125,
            "end_logit": 1.6953125,
            "text": " defective abdominal wall muscles, urinary",
            "probability": 0.0030384063720703125
        },
        {
            "start_logit": 4.8125,
            "end_logit": 1.25390625,
            "text": " defective abdominal wall muscles, urinary tract",
            "probability": 0.0019550323486328125
        },
        {
            "start_logit": 2.17578125,
            "end_logit": 3.576171875,
            "text": " abdominal wall muscles, urinary tract abnormalities",
            "probability": 0.0014247894287109375
        },
        {
            "start_logit": 3.98046875,
            "end_logit": 1.6953125,
            "text": " urinary",
            "probability": 0.0013227462768554688
        },
        {
            "start_logit": -0.150634765625,
            "end_logit": 5.74609375,
            "text": " abnormalities, and bilateral cryptorchidism",
            "probability": 0.0012187957763671875
        },
        {
            "start_logit": -0.180908203125,
            "end_logit": 5.74609375,
            "text": " congenital condition characterized by the triad of absent or defective abdominal wall muscles, urinary tract abnormalities, and bilateral cryptorchidism",
            "probability": 0.0011854171752929688
        },
        {
            "start_logit": -0.21484375,
            "end_logit": 5.74609375,
            "text": " tract abnormalities, and bilateral cryptorchidism",
            "probability": 0.0011444091796875
        },
        {
            "start_logit": 5.7421875,
            "end_logit": -0.258544921875,
            "text": " cryptorchidism.",
            "probability": 0.0010929107666015625
        }
    ],
    "64041701201352f04a000017_0002": [
        {
            "start_logit": 5.515625,
            "end_logit": 6.0234375,
            "text": " bilateral cryptorchidism",
            "probability": 0.4580078125
        },
        {
            "start_logit": 4.62109375,
            "end_logit": 6.0234375,
            "text": " cryptorchidism",
            "probability": 0.1865234375
        },
        {
            "start_logit": 4.37890625,
            "end_logit": 6.0234375,
            "text": " absence of abdominal wall muscles, urological abnormalities, and bilateral cryptorchidism",
            "probability": 0.1474609375
        },
        {
            "start_logit": 3.55859375,
            "end_logit": 6.0234375,
            "text": " deficiency or absence of abdominal wall muscles, urological abnormalities, and bilateral cryptorchidism",
            "probability": 0.064453125
        },
        {
            "start_logit": 3.1328125,
            "end_logit": 6.0234375,
            "text": " urological abnormalities, and bilateral cryptorchidism",
            "probability": 0.042266845703125
        },
        {
            "start_logit": 2.833984375,
            "end_logit": 6.0234375,
            "text": " abdominal wall muscles, urological abnormalities, and bilateral cryptorchidism",
            "probability": 0.031402587890625
        },
        {
            "start_logit": 4.37890625,
            "end_logit": 3.7734375,
            "text": " absence of abdominal wall muscles",
            "probability": 0.01555633544921875
        },
        {
            "start_logit": 4.37890625,
            "end_logit": 3.599609375,
            "text": " absence of abdominal wall muscles, urological abnormalities",
            "probability": 0.01299285888671875
        },
        {
            "start_logit": 1.8544921875,
            "end_logit": 6.0234375,
            "text": " congenital disease characterized by deficiency or absence of abdominal wall muscles, urological abnormalities, and bilateral cryptorchidism",
            "probability": 0.01177978515625
        },
        {
            "start_logit": 3.55859375,
            "end_logit": 3.7734375,
            "text": " deficiency or absence of abdominal wall muscles",
            "probability": 0.0068206787109375
        },
        {
            "start_logit": 3.55859375,
            "end_logit": 3.599609375,
            "text": " deficiency or absence of abdominal wall muscles, urological abnormalities",
            "probability": 0.005718231201171875
        },
        {
            "start_logit": 3.1328125,
            "end_logit": 3.599609375,
            "text": " urological abnormalities",
            "probability": 0.0037517547607421875
        },
        {
            "start_logit": 2.833984375,
            "end_logit": 3.7734375,
            "text": " abdominal wall muscles",
            "probability": 0.0033111572265625
        },
        {
            "start_logit": 2.833984375,
            "end_logit": 3.599609375,
            "text": " abdominal wall muscles, urological abnormalities",
            "probability": 0.002777099609375
        },
        {
            "start_logit": 3.55859375,
            "end_logit": 2.5390625,
            "text": " deficiency",
            "probability": 0.001983642578125
        },
        {
            "start_logit": 1.8544921875,
            "end_logit": 3.7734375,
            "text": " congenital disease characterized by deficiency or absence of abdominal wall muscles",
            "probability": 0.0012416839599609375
        },
        {
            "start_logit": 1.8544921875,
            "end_logit": 3.599609375,
            "text": " congenital disease characterized by deficiency or absence of abdominal wall muscles, urological abnormalities",
            "probability": 0.0010423660278320312
        },
        {
            "start_logit": -0.57080078125,
            "end_logit": 6.0234375,
            "text": " muscles, urological abnormalities, and bilateral cryptorchidism",
            "probability": 0.0010423660278320312
        },
        {
            "start_logit": 5.515625,
            "end_logit": -0.224853515625,
            "text": " bilateral cryptorchidism.",
            "probability": 0.0008840560913085938
        },
        {
            "start_logit": 5.515625,
            "end_logit": -0.52099609375,
            "text": " bilateral",
            "probability": 0.0006594657897949219
        }
    ],
    "64041701201352f04a000017_0003": [
        {
            "start_logit": 5.3828125,
            "end_logit": 5.79296875,
            "text": " cryptorchidism",
            "probability": 0.313232421875
        },
        {
            "start_logit": 5.12109375,
            "end_logit": 5.79296875,
            "text": " deficiency of the abdominal muscles, malformations of the urinary tract, and bilateral cryptorchidism",
            "probability": 0.2420654296875
        },
        {
            "start_logit": 4.9296875,
            "end_logit": 5.79296875,
            "text": " bilateral cryptorchidism",
            "probability": 0.1990966796875
        },
        {
            "start_logit": 4.4296875,
            "end_logit": 5.79296875,
            "text": " malformations of the urinary tract, and bilateral cryptorchidism",
            "probability": 0.1207275390625
        },
        {
            "start_logit": 5.12109375,
            "end_logit": 3.744140625,
            "text": " deficiency of the abdominal muscles",
            "probability": 0.03125
        },
        {
            "start_logit": 5.12109375,
            "end_logit": 3.419921875,
            "text": " deficiency of the abdominal muscles, malformations of the urinary tract",
            "probability": 0.02252197265625
        },
        {
            "start_logit": 2.689453125,
            "end_logit": 5.79296875,
            "text": " urinary tract, and bilateral cryptorchidism",
            "probability": 0.0213165283203125
        },
        {
            "start_logit": 5.12109375,
            "end_logit": 2.798828125,
            "text": " deficiency of the abdominal muscles, malformations",
            "probability": 0.01214599609375
        },
        {
            "start_logit": 4.4296875,
            "end_logit": 3.419921875,
            "text": " malformations of the urinary tract",
            "probability": 0.01131439208984375
        },
        {
            "start_logit": 4.4296875,
            "end_logit": 2.798828125,
            "text": " malformations",
            "probability": 0.0060577392578125
        },
        {
            "start_logit": 5.12109375,
            "end_logit": 1.935546875,
            "text": " deficiency of the abdominal muscles, malformations of the urinary",
            "probability": 0.00510406494140625
        },
        {
            "start_logit": 5.12109375,
            "end_logit": 1.263671875,
            "text": " deficiency",
            "probability": 0.0026073455810546875
        },
        {
            "start_logit": 4.4296875,
            "end_logit": 1.935546875,
            "text": " malformations of the urinary",
            "probability": 0.0025653839111328125
        },
        {
            "start_logit": 2.689453125,
            "end_logit": 3.419921875,
            "text": " urinary tract",
            "probability": 0.0019817352294921875
        },
        {
            "start_logit": 5.12109375,
            "end_logit": 0.94189453125,
            "text": " deficiency of the abdominal muscles, malformations of the urinary tract, and bilateral",
            "probability": 0.0018911361694335938
        },
        {
            "start_logit": 5.12109375,
            "end_logit": 0.8701171875,
            "text": " deficiency of the abdominal muscles, malformations of the urinary tract,",
            "probability": 0.0017633438110351562
        },
        {
            "start_logit": 4.9296875,
            "end_logit": 0.94189453125,
            "text": " bilateral",
            "probability": 0.0015611648559570312
        },
        {
            "start_logit": -0.281494140625,
            "end_logit": 5.79296875,
            "text": " abdominal muscles, malformations of the urinary tract, and bilateral cryptorchidism",
            "probability": 0.00109100341796875
        },
        {
            "start_logit": 4.4296875,
            "end_logit": 0.94189453125,
            "text": " malformations of the urinary tract, and bilateral",
            "probability": 0.0009474754333496094
        },
        {
            "start_logit": 4.4296875,
            "end_logit": 0.8701171875,
            "text": " malformations of the urinary tract,",
            "probability": 0.0008826255798339844
        }
    ],
    "64041701201352f04a000017_0004": [
        {
            "start_logit": 5.84765625,
            "end_logit": 5.7265625,
            "text": " cryptorchidism",
            "probability": 0.54736328125
        },
        {
            "start_logit": 4.4375,
            "end_logit": 5.7265625,
            "text": " hypoplasia of the abdominal wall musculature, urinary tract anomalies, and cryptorchidism",
            "probability": 0.133056640625
        },
        {
            "start_logit": 4.25,
            "end_logit": 5.7265625,
            "text": " urinary tract anomalies, and cryptorchidism",
            "probability": 0.11029052734375
        },
        {
            "start_logit": 3.0390625,
            "end_logit": 5.7265625,
            "text": " absence or hypoplasia of the abdominal wall musculature, urinary tract anomalies, and cryptorchidism",
            "probability": 0.032867431640625
        },
        {
            "start_logit": 4.4375,
            "end_logit": 4.31640625,
            "text": " hypoplasia of the abdominal wall musculature, urinary tract anomalies",
            "probability": 0.0323486328125
        },
        {
            "start_logit": 2.86328125,
            "end_logit": 5.7265625,
            "text": " abdominal wall musculature, urinary tract anomalies, and cryptorchidism",
            "probability": 0.027679443359375
        },
        {
            "start_logit": 4.25,
            "end_logit": 4.31640625,
            "text": " urinary tract anomalies",
            "probability": 0.026824951171875
        },
        {
            "start_logit": 2.716796875,
            "end_logit": 5.7265625,
            "text": " congenital disorder characterized by absence or hypoplasia of the abdominal wall musculature, urinary tract anomalies, and cryptorchidism",
            "probability": 0.02386474609375
        },
        {
            "start_logit": 4.4375,
            "end_logit": 3.814453125,
            "text": " hypoplasia of the abdominal wall musculature",
            "probability": 0.019622802734375
        },
        {
            "start_logit": 3.0390625,
            "end_logit": 4.31640625,
            "text": " absence or hypoplasia of the abdominal wall musculature, urinary tract anomalies",
            "probability": 0.00801849365234375
        },
        {
            "start_logit": 2.86328125,
            "end_logit": 4.31640625,
            "text": " abdominal wall musculature, urinary tract anomalies",
            "probability": 0.0067291259765625
        },
        {
            "start_logit": 2.716796875,
            "end_logit": 4.31640625,
            "text": " congenital disorder characterized by absence or hypoplasia of the abdominal wall musculature, urinary tract anomalies",
            "probability": 0.00579833984375
        },
        {
            "start_logit": 3.0390625,
            "end_logit": 3.814453125,
            "text": " absence or hypoplasia of the abdominal wall musculature",
            "probability": 0.004848480224609375
        },
        {
            "start_logit": 2.86328125,
            "end_logit": 3.814453125,
            "text": " abdominal wall musculature",
            "probability": 0.00408172607421875
        },
        {
            "start_logit": 4.4375,
            "end_logit": 2.171875,
            "text": " hypoplasia of the abdominal wall musculature, urinary",
            "probability": 0.003803253173828125
        },
        {
            "start_logit": 2.716796875,
            "end_logit": 3.814453125,
            "text": " congenital disorder characterized by absence or hypoplasia of the abdominal wall musculature",
            "probability": 0.00351715087890625
        },
        {
            "start_logit": 4.25,
            "end_logit": 2.171875,
            "text": " urinary",
            "probability": 0.003154754638671875
        },
        {
            "start_logit": 5.84765625,
            "end_logit": 0.316162109375,
            "text": " cryptorchidism in males",
            "probability": 0.0024356842041015625
        },
        {
            "start_logit": 4.4375,
            "end_logit": 1.439453125,
            "text": " hypoplasia",
            "probability": 0.0018253326416015625
        },
        {
            "start_logit": 0.130859375,
            "end_logit": 5.7265625,
            "text": " musculature, urinary tract anomalies, and cryptorchidism",
            "probability": 0.0017976760864257812
        }
    ],
    "640c85e9201352f04a000026_0001": [
        {
            "start_logit": 3.20703125,
            "end_logit": 2.349609375,
            "text": "B-cell non-Hodgkin lymphoma",
            "probability": 0.201416015625
        },
        {
            "start_logit": 2.80859375,
            "end_logit": 2.349609375,
            "text": "Mantle cell lymphoma (Mantle cell lymphoma) is a relatively rare B-cell non-Hodgkin lymphoma",
            "probability": 0.13525390625
        },
        {
            "start_logit": 3.20703125,
            "end_logit": 1.9375,
            "text": "B-cell non-Hodgkin lymphoma, typically presenting with extensive lymphadenopathy",
            "probability": 0.1336669921875
        },
        {
            "start_logit": 3.20703125,
            "end_logit": 1.9345703125,
            "text": "B-cell",
            "probability": 0.1331787109375
        },
        {
            "start_logit": 2.80859375,
            "end_logit": 1.9345703125,
            "text": "Mantle cell lymphoma (Mantle cell lymphoma) is a relatively rare B-cell",
            "probability": 0.08941650390625
        },
        {
            "start_logit": 1.482421875,
            "end_logit": 2.349609375,
            "text": "Hodgkin lymphoma",
            "probability": 0.035980224609375
        },
        {
            "start_logit": 2.80859375,
            "end_logit": 0.951171875,
            "text": "Mantle cell lymphoma",
            "probability": 0.033477783203125
        },
        {
            "start_logit": 1.2783203125,
            "end_logit": 2.349609375,
            "text": " non-Hodgkin lymphoma",
            "probability": 0.02935791015625
        },
        {
            "start_logit": 2.80859375,
            "end_logit": 0.69091796875,
            "text": "Mantle cell lymphoma (Mantle cell lymphoma)",
            "probability": 0.02581787109375
        },
        {
            "start_logit": 1.5302734375,
            "end_logit": 1.9375,
            "text": " lymphadenopathy",
            "probability": 0.0250244140625
        },
        {
            "start_logit": 1.482421875,
            "end_logit": 1.9375,
            "text": "Hodgkin lymphoma, typically presenting with extensive lymphadenopathy",
            "probability": 0.0238189697265625
        },
        {
            "start_logit": 3.20703125,
            "end_logit": 0.0595703125,
            "text": "B-cell non",
            "probability": 0.020416259765625
        },
        {
            "start_logit": 1.2783203125,
            "end_logit": 1.9375,
            "text": " non-Hodgkin lymphoma, typically presenting with extensive lymphadenopathy",
            "probability": 0.0193939208984375
        },
        {
            "start_logit": 2.80859375,
            "end_logit": 0.308837890625,
            "text": "Mantle cell lymphoma (Mantle cell lymphoma",
            "probability": 0.017608642578125
        },
        {
            "start_logit": 2.80859375,
            "end_logit": 0.28369140625,
            "text": "Mantle cell",
            "probability": 0.0171661376953125
        },
        {
            "start_logit": 2.80859375,
            "end_logit": 0.0595703125,
            "text": "Mantle cell lymphoma (Mantle cell lymphoma) is a relatively rare B-cell non",
            "probability": 0.01371002197265625
        },
        {
            "start_logit": 3.20703125,
            "end_logit": -0.38720703125,
            "text": "B-cell non-Hodgkin",
            "probability": 0.0130767822265625
        },
        {
            "start_logit": 0.7939453125,
            "end_logit": 1.9375,
            "text": " extensive lymphadenopathy",
            "probability": 0.01195526123046875
        },
        {
            "start_logit": 3.20703125,
            "end_logit": -0.5029296875,
            "text": "B",
            "probability": 0.011627197265625
        },
        {
            "start_logit": 2.80859375,
            "end_logit": -0.38720703125,
            "text": "Mantle cell lymphoma (Mantle cell lymphoma) is a relatively rare B-cell non-Hodgkin",
            "probability": 0.00878143310546875
        }
    ],
    "640c85e9201352f04a000026_0002": [
        {
            "start_logit": 6.65625,
            "end_logit": 4.23828125,
            "text": " mantle cell",
            "probability": 0.744140625
        },
        {
            "start_logit": 6.65625,
            "end_logit": 2.166015625,
            "text": " mantle cell lymphoma",
            "probability": 0.09381103515625
        },
        {
            "start_logit": 6.65625,
            "end_logit": 0.99755859375,
            "text": " mantle cell lymphoma (Mantle cell lymphoma), chronic lymphocytic leukemia",
            "probability": 0.029205322265625
        },
        {
            "start_logit": 6.65625,
            "end_logit": 0.77001953125,
            "text": " mantle cell lymphoma (Mantle cell lymphoma",
            "probability": 0.023284912109375
        },
        {
            "start_logit": 2.837890625,
            "end_logit": 4.23828125,
            "text": " follicular lymphoma (follicular lymphoma), mantle cell",
            "probability": 0.016448974609375
        },
        {
            "start_logit": 6.65625,
            "end_logit": 0.33544921875,
            "text": " mantle",
            "probability": 0.0150909423828125
        },
        {
            "start_logit": 6.65625,
            "end_logit": 0.273193359375,
            "text": " mantle cell lymphoma (Mantle cell",
            "probability": 0.01416778564453125
        },
        {
            "start_logit": 6.65625,
            "end_logit": 0.1590576171875,
            "text": " mantle cell lymphoma (Mantle cell lymphoma), chronic lymphocytic leukemia (chronic lymphocytic leukemia), lymphocyte-predominant Hodgkin lymphoma",
            "probability": 0.0126495361328125
        },
        {
            "start_logit": 6.65625,
            "end_logit": -0.0124664306640625,
            "text": " mantle cell lymphoma (Mantle cell lymphoma), chronic lymphocytic leukemia (chronic lymphocytic leukemia), lymphocyte",
            "probability": 0.01065826416015625
        },
        {
            "start_logit": 6.65625,
            "end_logit": -0.135009765625,
            "text": " mantle cell lymphoma (Mantle cell lymphoma), chronic lymphocytic leukemia (chronic lymphocytic leukemia",
            "probability": 0.0093994140625
        },
        {
            "start_logit": 2.03125,
            "end_logit": 4.23828125,
            "text": " diffuse large cell lymphoma, follicular lymphoma (follicular lymphoma), mantle cell",
            "probability": 0.00732421875
        },
        {
            "start_logit": 1.6064453125,
            "end_logit": 4.23828125,
            "text": "B-cell lymphoma, including diffuse large cell lymphoma, follicular lymphoma (follicular lymphoma), mantle cell",
            "probability": 0.00478363037109375
        },
        {
            "start_logit": 1.5,
            "end_logit": 4.23828125,
            "text": " large cell lymphoma, follicular lymphoma (follicular lymphoma), mantle cell",
            "probability": 0.004306793212890625
        },
        {
            "start_logit": 1.087890625,
            "end_logit": 4.23828125,
            "text": " lymphoma, follicular lymphoma (follicular lymphoma), mantle cell",
            "probability": 0.002857208251953125
        },
        {
            "start_logit": 1.0205078125,
            "end_logit": 4.23828125,
            "text": "follicular lymphoma), mantle cell",
            "probability": 0.00266265869140625
        },
        {
            "start_logit": 2.837890625,
            "end_logit": 2.392578125,
            "text": " follicular lymphoma",
            "probability": 0.0025920867919921875
        },
        {
            "start_logit": 2.837890625,
            "end_logit": 2.166015625,
            "text": " follicular lymphoma (follicular lymphoma), mantle cell lymphoma",
            "probability": 0.0020656585693359375
        },
        {
            "start_logit": 0.54833984375,
            "end_logit": 4.23828125,
            "text": " lymphoma, including diffuse large cell lymphoma, follicular lymphoma (follicular lymphoma), mantle cell",
            "probability": 0.001659393310546875
        },
        {
            "start_logit": 0.471435546875,
            "end_logit": 4.23828125,
            "text": " lymphoma (follicular lymphoma), mantle cell",
            "probability": 0.0015411376953125
        },
        {
            "start_logit": 2.03125,
            "end_logit": 2.392578125,
            "text": " diffuse large cell lymphoma, follicular lymphoma",
            "probability": 0.0011548995971679688
        }
    ],
    "640c85e9201352f04a000026_0003": [
        {
            "start_logit": 3.083984375,
            "end_logit": 2.052734375,
            "text": "B-cell",
            "probability": 0.282958984375
        },
        {
            "start_logit": 3.083984375,
            "end_logit": 1.841796875,
            "text": "B-cell non-Hodgkin's lymphoma",
            "probability": 0.229248046875
        },
        {
            "start_logit": 2.232421875,
            "end_logit": 2.052734375,
            "text": "Mantle cell lymphoma (Mantle cell lymphoma) is a subtype of B-cell",
            "probability": 0.12078857421875
        },
        {
            "start_logit": 2.232421875,
            "end_logit": 1.841796875,
            "text": "Mantle cell lymphoma (Mantle cell lymphoma) is a subtype of B-cell non-Hodgkin's lymphoma",
            "probability": 0.09783935546875
        },
        {
            "start_logit": 3.083984375,
            "end_logit": -0.01059722900390625,
            "text": "B-cell non-Hodgkin's lymphoma seen predominantly in males.",
            "probability": 0.035980224609375
        },
        {
            "start_logit": 2.232421875,
            "end_logit": 0.63427734375,
            "text": "Mantle cell lymphoma",
            "probability": 0.0292510986328125
        },
        {
            "start_logit": 2.232421875,
            "end_logit": 0.548828125,
            "text": "Mantle cell lymphoma (Mantle cell lymphoma)",
            "probability": 0.0268402099609375
        },
        {
            "start_logit": 3.083984375,
            "end_logit": -0.3408203125,
            "text": "B",
            "probability": 0.0258026123046875
        },
        {
            "start_logit": 0.75537109375,
            "end_logit": 1.841796875,
            "text": " non-Hodgkin's lymphoma",
            "probability": 0.0223388671875
        },
        {
            "start_logit": 2.232421875,
            "end_logit": 0.341796875,
            "text": "Mantle cell lymphoma (Mantle cell lymphoma",
            "probability": 0.021820068359375
        },
        {
            "start_logit": 3.083984375,
            "end_logit": -0.55419921875,
            "text": "B-cell non",
            "probability": 0.0208740234375
        },
        {
            "start_logit": 2.232421875,
            "end_logit": -0.005565643310546875,
            "text": "Mantle cell",
            "probability": 0.01541900634765625
        },
        {
            "start_logit": 3.083984375,
            "end_logit": -1.025390625,
            "text": "B-cell non-Hodgkin's",
            "probability": 0.013031005859375
        },
        {
            "start_logit": 2.232421875,
            "end_logit": -0.3408203125,
            "text": "Mantle cell lymphoma (Mantle cell lymphoma) is a subtype of B",
            "probability": 0.01102447509765625
        },
        {
            "start_logit": 2.232421875,
            "end_logit": -0.5009765625,
            "text": "Mantle cell lymphoma (Mantle cell",
            "probability": 0.00939178466796875
        },
        {
            "start_logit": 2.232421875,
            "end_logit": -0.55419921875,
            "text": "Mantle cell lymphoma (Mantle cell lymphoma) is a subtype of B-cell non",
            "probability": 0.00890350341796875
        },
        {
            "start_logit": -0.1702880859375,
            "end_logit": 1.841796875,
            "text": "Hodgkin's lymphoma",
            "probability": 0.00885009765625
        },
        {
            "start_logit": -0.50830078125,
            "end_logit": 2.052734375,
            "text": "Mantle cell lymphoma) is a subtype of B-cell",
            "probability": 0.007793426513671875
        },
        {
            "start_logit": -0.50830078125,
            "end_logit": 1.841796875,
            "text": "Mantle cell lymphoma) is a subtype of B-cell non-Hodgkin's lymphoma",
            "probability": 0.006313323974609375
        },
        {
            "start_logit": 2.232421875,
            "end_logit": -1.025390625,
            "text": "Mantle cell lymphoma (Mantle cell lymphoma) is a subtype of B-cell non-Hodgkin's",
            "probability": 0.00556182861328125
        }
    ],
    "6415bb3c690f196b5100000e_0001": [
        {
            "start_logit": 7.4453125,
            "end_logit": 6.6953125,
            "text": " 8%",
            "probability": 0.9326171875
        },
        {
            "start_logit": 7.4453125,
            "end_logit": 3.814453125,
            "text": " 8% and 10-12%",
            "probability": 0.05218505859375
        },
        {
            "start_logit": 7.4453125,
            "end_logit": 0.8974609375,
            "text": " 8% and 10",
            "probability": 0.0028324127197265625
        },
        {
            "start_logit": 7.4453125,
            "end_logit": 0.74462890625,
            "text": " 8% and 10-12",
            "probability": 0.002422332763671875
        },
        {
            "start_logit": 7.4453125,
            "end_logit": 0.5615234375,
            "text": " 8% and 10-12%,",
            "probability": 0.0020236968994140625
        },
        {
            "start_logit": 4.125,
            "end_logit": 3.814453125,
            "text": "12%",
            "probability": 0.0018873214721679688
        },
        {
            "start_logit": 4.05078125,
            "end_logit": 3.814453125,
            "text": " 10-12%",
            "probability": 0.001758575439453125
        },
        {
            "start_logit": 7.4453125,
            "end_logit": -0.01091766357421875,
            "text": " 8% and 10-12%, respectively.",
            "probability": 0.001140594482421875
        },
        {
            "start_logit": 7.4453125,
            "end_logit": -0.57861328125,
            "text": " 8% and 10-12%, respectively",
            "probability": 0.0006470680236816406
        },
        {
            "start_logit": 7.4453125,
            "end_logit": -0.76416015625,
            "text": " 8",
            "probability": 0.0005364418029785156
        },
        {
            "start_logit": -0.0289764404296875,
            "end_logit": 6.6953125,
            "text": " time and costs by online counseling with about 8%",
            "probability": 0.000530242919921875
        },
        {
            "start_logit": -0.433837890625,
            "end_logit": 6.6953125,
            "text": "%",
            "probability": 0.00035309791564941406
        },
        {
            "start_logit": -1.1015625,
            "end_logit": 6.6953125,
            "text": " online counseling with about 8%",
            "probability": 0.00018107891082763672
        },
        {
            "start_logit": -1.4638671875,
            "end_logit": 6.6953125,
            "text": " reduced time and costs by online counseling with about 8%",
            "probability": 0.00012636184692382812
        },
        {
            "start_logit": -1.7138671875,
            "end_logit": 6.6953125,
            "text": " costs by online counseling with about 8%",
            "probability": 9.846687316894531e-05
        },
        {
            "start_logit": 4.05078125,
            "end_logit": 0.8974609375,
            "text": " 10",
            "probability": 9.5367431640625e-05
        },
        {
            "start_logit": 7.4453125,
            "end_logit": -2.50390625,
            "text": " 8% and",
            "probability": 9.393692016601562e-05
        },
        {
            "start_logit": 4.125,
            "end_logit": 0.74462890625,
            "text": "12",
            "probability": 8.821487426757812e-05
        },
        {
            "start_logit": 4.05078125,
            "end_logit": 0.74462890625,
            "text": " 10-12",
            "probability": 8.159875869750977e-05
        },
        {
            "start_logit": -1.9345703125,
            "end_logit": 6.6953125,
            "text": " estimated reduced time and costs by online counseling with about 8%",
            "probability": 7.909536361694336e-05
        }
    ],
    "63f03ae6f36125a42600001d_0001": [
        {
            "start_logit": 7.6953125,
            "end_logit": 6.6328125,
            "text": " PDE4B",
            "probability": 0.984375
        },
        {
            "start_logit": 7.6953125,
            "end_logit": 2.220703125,
            "text": " PDE4B subtype",
            "probability": 0.01192474365234375
        },
        {
            "start_logit": 7.6953125,
            "end_logit": -0.376220703125,
            "text": " PDE4B subtype, in patients with idiopathic pulmonary fibrosis.",
            "probability": 0.0008907318115234375
        },
        {
            "start_logit": 7.6953125,
            "end_logit": -0.4736328125,
            "text": " PDE4",
            "probability": 0.0008082389831542969
        },
        {
            "start_logit": 7.6953125,
            "end_logit": -0.9765625,
            "text": " P",
            "probability": 0.00048828125
        },
        {
            "start_logit": 7.6953125,
            "end_logit": -1.3408203125,
            "text": " PDE4B subtype,",
            "probability": 0.000339508056640625
        },
        {
            "start_logit": -1.091796875,
            "end_logit": 6.6328125,
            "text": " preferential inhibitor of the PDE4B",
            "probability": 0.0001499652862548828
        },
        {
            "start_logit": 7.6953125,
            "end_logit": -2.357421875,
            "text": " PDE",
            "probability": 0.00012242794036865234
        },
        {
            "start_logit": 7.6953125,
            "end_logit": -2.7890625,
            "text": " PDE4B subtype, in patients with idiopathic pulmonary fibrosis",
            "probability": 7.969141006469727e-05
        },
        {
            "start_logit": -1.78125,
            "end_logit": 6.6328125,
            "text": "4B",
            "probability": 7.545948028564453e-05
        },
        {
            "start_logit": -1.892578125,
            "end_logit": 6.6328125,
            "text": "DE4B",
            "probability": 6.759166717529297e-05
        },
        {
            "start_logit": -1.91015625,
            "end_logit": 6.6328125,
            "text": " oral preferential inhibitor of the PDE4B",
            "probability": 6.61015510559082e-05
        },
        {
            "start_logit": -2.09375,
            "end_logit": 6.6328125,
            "text": "B",
            "probability": 5.525350570678711e-05
        },
        {
            "start_logit": -2.734375,
            "end_logit": 6.6328125,
            "text": ", placebo-controlled trial, we investigated the efficacy and safety of BI 1015550, an oral preferential inhibitor of the PDE4B",
            "probability": 2.9087066650390625e-05
        },
        {
            "start_logit": -2.76171875,
            "end_logit": 6.6328125,
            "text": ", an oral preferential inhibitor of the PDE4B",
            "probability": 2.8431415557861328e-05
        },
        {
            "start_logit": -2.8515625,
            "end_logit": 6.6328125,
            "text": ", we investigated the efficacy and safety of BI 1015550, an oral preferential inhibitor of the PDE4B",
            "probability": 2.586841583251953e-05
        },
        {
            "start_logit": -3.052734375,
            "end_logit": 6.6328125,
            "text": " the PDE4B",
            "probability": 2.110004425048828e-05
        },
        {
            "start_logit": -3.626953125,
            "end_logit": 6.6328125,
            "text": " safety of BI 1015550, an oral preferential inhibitor of the PDE4B",
            "probability": 1.1920928955078125e-05
        },
        {
            "start_logit": -0.98095703125,
            "end_logit": 2.220703125,
            "text": " subtype",
            "probability": 2.0265579223632812e-06
        },
        {
            "start_logit": -1.091796875,
            "end_logit": 2.220703125,
            "text": " preferential inhibitor of the PDE4B subtype",
            "probability": 1.8477439880371094e-06
        }
    ],
    "63f03ae6f36125a42600001d_0002": [
        {
            "start_logit": 7.140625,
            "end_logit": 2.884765625,
            "text": " phosphodiesterase 4B",
            "probability": 0.734375
        },
        {
            "start_logit": 7.140625,
            "end_logit": 1.486328125,
            "text": " phosphodiesterase 4",
            "probability": 0.181396484375
        },
        {
            "start_logit": 7.140625,
            "end_logit": -0.2197265625,
            "text": " phosphodiesterase 4B inhibitor, in healthy males and patients with idiopathic pulmonary fibrosis.",
            "probability": 0.033050537109375
        },
        {
            "start_logit": 7.140625,
            "end_logit": -1.021484375,
            "text": " phosphodiesterase 4B inhibitor",
            "probability": 0.0147705078125
        },
        {
            "start_logit": 7.140625,
            "end_logit": -1.09765625,
            "text": " p",
            "probability": 0.0137176513671875
        },
        {
            "start_logit": 7.140625,
            "end_logit": -1.3046875,
            "text": " phosphodiesterase 4B inhibitor,",
            "probability": 0.0111541748046875
        },
        {
            "start_logit": 7.140625,
            "end_logit": -2.263671875,
            "text": " phosphodiesterase 4B inhibitor, in healthy males and patients with idiopathic pulmonary fibrosis",
            "probability": 0.004268646240234375
        },
        {
            "start_logit": 7.140625,
            "end_logit": -2.36328125,
            "text": " phosphodiesterase",
            "probability": 0.0038700103759765625
        },
        {
            "start_logit": 7.140625,
            "end_logit": -3.6171875,
            "text": " phosphodiesterase 4B inhibitor, in healthy males",
            "probability": 0.0011043548583984375
        },
        {
            "start_logit": 7.140625,
            "end_logit": -3.8203125,
            "text": " phosphodiesterase 4B inhibitor, in healthy males and patients with idiopathic pulmonary",
            "probability": 0.0009016990661621094
        },
        {
            "start_logit": 7.140625,
            "end_logit": -4.09765625,
            "text": " phosphodiesterase 4B inhibitor, in healthy",
            "probability": 0.000682830810546875
        },
        {
            "start_logit": -0.66259765625,
            "end_logit": 2.884765625,
            "text": " 4B",
            "probability": 0.0003006458282470703
        },
        {
            "start_logit": -1.7021484375,
            "end_logit": 2.884765625,
            "text": "hosphodiesterase 4B",
            "probability": 0.00010597705841064453
        },
        {
            "start_logit": -0.66259765625,
            "end_logit": 1.486328125,
            "text": " 4",
            "probability": 7.396936416625977e-05
        },
        {
            "start_logit": -2.09765625,
            "end_logit": 2.884765625,
            "text": "B",
            "probability": 7.170438766479492e-05
        },
        {
            "start_logit": -2.134765625,
            "end_logit": 2.884765625,
            "text": ", a preferential phosphodiesterase 4B",
            "probability": 6.896257400512695e-05
        },
        {
            "start_logit": -2.296875,
            "end_logit": 2.884765625,
            "text": " preferential phosphodiesterase 4B",
            "probability": 5.8531761169433594e-05
        },
        {
            "start_logit": -2.798828125,
            "end_logit": 2.884765625,
            "text": " studies of BI 1015550, a preferential phosphodiesterase 4B",
            "probability": 3.552436828613281e-05
        },
        {
            "start_logit": -2.935546875,
            "end_logit": 2.884765625,
            "text": "Phase I studies of BI 1015550, a preferential phosphodiesterase 4B",
            "probability": 3.081560134887695e-05
        },
        {
            "start_logit": -1.7021484375,
            "end_logit": 1.486328125,
            "text": "hosphodiesterase 4",
            "probability": 2.6166439056396484e-05
        }
    ],
    "63f03ae6f36125a42600001d_0003": [
        {
            "start_logit": 6.421875,
            "end_logit": 5.7265625,
            "text": " phosphodiesterase 4",
            "probability": 0.98193359375
        },
        {
            "start_logit": 6.421875,
            "end_logit": 0.9072265625,
            "text": " phosphodiesterase 4 (phosphodiesterase 4",
            "probability": 0.0079193115234375
        },
        {
            "start_logit": 6.421875,
            "end_logit": -0.11883544921875,
            "text": " phosphodiesterase 4 (phosphodiesterase 4) inhibitor that has antifibrotic properties.",
            "probability": 0.0028438568115234375
        },
        {
            "start_logit": 6.421875,
            "end_logit": -1.0458984375,
            "text": " phosphodiesterase 4 (phosphodiesterase 4) inhibitor",
            "probability": 0.0011224746704101562
        },
        {
            "start_logit": 6.421875,
            "end_logit": -1.25,
            "text": " p",
            "probability": 0.0009164810180664062
        },
        {
            "start_logit": -0.56298828125,
            "end_logit": 5.7265625,
            "text": " 4",
            "probability": 0.0009093284606933594
        },
        {
            "start_logit": -0.57373046875,
            "end_logit": 5.7265625,
            "text": "Introduction: BI 1015550 is a phosphodiesterase 4",
            "probability": 0.0008988380432128906
        },
        {
            "start_logit": 6.421875,
            "end_logit": -1.6611328125,
            "text": " phosphodiesterase 4 (phosphodiesterase 4) inhibitor that has antifibrotic",
            "probability": 0.0006079673767089844
        },
        {
            "start_logit": 6.421875,
            "end_logit": -1.7685546875,
            "text": " phosphodiesterase",
            "probability": 0.0005450248718261719
        },
        {
            "start_logit": 6.421875,
            "end_logit": -2.0625,
            "text": " phosphodiesterase 4 (phosphodiesterase 4)",
            "probability": 0.00040650367736816406
        },
        {
            "start_logit": 6.421875,
            "end_logit": -2.2890625,
            "text": " phosphodiesterase 4 (p",
            "probability": 0.000324249267578125
        },
        {
            "start_logit": -1.6884765625,
            "end_logit": 5.7265625,
            "text": "hosphodiesterase 4",
            "probability": 0.0002951622009277344
        },
        {
            "start_logit": 6.421875,
            "end_logit": -2.552734375,
            "text": " phosphodiesterase 4 (phosphodiesterase 4) inhibitor that has antifibrotic properties",
            "probability": 0.0002486705780029297
        },
        {
            "start_logit": 6.421875,
            "end_logit": -2.619140625,
            "text": " phosphodiesterase 4 (phosphodiesterase",
            "probability": 0.00023353099822998047
        },
        {
            "start_logit": 6.421875,
            "end_logit": -3.16796875,
            "text": " phosphodiesterase 4 ",
            "probability": 0.00013518333435058594
        },
        {
            "start_logit": -2.5546875,
            "end_logit": 5.7265625,
            "text": " BI 1015550 is a phosphodiesterase 4",
            "probability": 0.00012409687042236328
        },
        {
            "start_logit": -2.6875,
            "end_logit": 5.7265625,
            "text": " a phosphodiesterase 4",
            "probability": 0.00010859966278076172
        },
        {
            "start_logit": 6.421875,
            "end_logit": -3.58203125,
            "text": " phosphodiesterase 4 (",
            "probability": 8.863210678100586e-05
        },
        {
            "start_logit": -3.361328125,
            "end_logit": 5.7265625,
            "text": ": BI 1015550 is a phosphodiesterase 4",
            "probability": 5.549192428588867e-05
        },
        {
            "start_logit": 0.59716796875,
            "end_logit": 0.9072265625,
            "text": "phosphodiesterase 4",
            "probability": 2.3484230041503906e-05
        }
    ],
    "63f03ae6f36125a42600001d_0004": [
        {
            "start_logit": 6.75390625,
            "end_logit": 5.72265625,
            "text": " PDE4B",
            "probability": 0.9892578125
        },
        {
            "start_logit": 6.75390625,
            "end_logit": -0.04461669921875,
            "text": " PDE4B Inhibitor and a Clinical Drug Candidate for the Oral Treatment of Idiopathic Pulmonary Fibrosis.",
            "probability": 0.003101348876953125
        },
        {
            "start_logit": 6.75390625,
            "end_logit": -0.5703125,
            "text": " PDE4B Inhibitor",
            "probability": 0.0018291473388671875
        },
        {
            "start_logit": 6.75390625,
            "end_logit": -0.70654296875,
            "text": " PDE4",
            "probability": 0.0015954971313476562
        },
        {
            "start_logit": 6.75390625,
            "end_logit": -0.9287109375,
            "text": " P",
            "probability": 0.001277923583984375
        },
        {
            "start_logit": 6.75390625,
            "end_logit": -1.984375,
            "text": " PDE4B Inhibitor and a Clinical Drug Candidate for the Oral Treatment of Idiopathic Pulmonary Fibrosis",
            "probability": 0.0004448890686035156
        },
        {
            "start_logit": 6.75390625,
            "end_logit": -2.0234375,
            "text": " PDE",
            "probability": 0.0004279613494873047
        },
        {
            "start_logit": -1.18359375,
            "end_logit": 5.72265625,
            "text": "DE4B",
            "probability": 0.0003533363342285156
        },
        {
            "start_logit": -1.35546875,
            "end_logit": 5.72265625,
            "text": "4B",
            "probability": 0.00029754638671875
        },
        {
            "start_logit": -1.478515625,
            "end_logit": 5.72265625,
            "text": "B",
            "probability": 0.0002624988555908203
        },
        {
            "start_logit": -2.16796875,
            "end_logit": 5.72265625,
            "text": "BI 1015550 is a PDE4B",
            "probability": 0.00013196468353271484
        },
        {
            "start_logit": 6.75390625,
            "end_logit": -3.203125,
            "text": " PDE4B Inhibitor and a Clinical Drug Candidate",
            "probability": 0.00013196468353271484
        },
        {
            "start_logit": 6.75390625,
            "end_logit": -3.455078125,
            "text": " PDE4B Inhibitor and a Clinical Drug Candidate for the Oral Treatment of Idiopathic Pulmonary",
            "probability": 0.00010204315185546875
        },
        {
            "start_logit": -2.697265625,
            "end_logit": 5.72265625,
            "text": " a PDE4B",
            "probability": 7.76052474975586e-05
        },
        {
            "start_logit": 6.75390625,
            "end_logit": -3.76953125,
            "text": " PDE4B Inhibitor and a Clinical Drug Candidate for the",
            "probability": 7.468461990356445e-05
        },
        {
            "start_logit": 6.75390625,
            "end_logit": -4.35546875,
            "text": " PDE4B Inhibitor and",
            "probability": 4.1544437408447266e-05
        },
        {
            "start_logit": 6.75390625,
            "end_logit": -4.609375,
            "text": " PDE4B Inhibitor and a Clinical Drug Candidate for the Oral",
            "probability": 3.236532211303711e-05
        },
        {
            "start_logit": -0.49853515625,
            "end_logit": -0.04461669921875,
            "text": ".",
            "probability": 2.205371856689453e-06
        },
        {
            "start_logit": -1.18359375,
            "end_logit": -0.04461669921875,
            "text": "DE4B Inhibitor and a Clinical Drug Candidate for the Oral Treatment of Idiopathic Pulmonary Fibrosis.",
            "probability": 1.1324882507324219e-06
        },
        {
            "start_logit": -1.35546875,
            "end_logit": -0.04461669921875,
            "text": "4B Inhibitor and a Clinical Drug Candidate for the Oral Treatment of Idiopathic Pulmonary Fibrosis.",
            "probability": 9.5367431640625e-07
        }
    ],
    "63f03ae6f36125a42600001d_0005": [
        {
            "start_logit": 5.59765625,
            "end_logit": 5.16015625,
            "text": " phosphodiesterase 4",
            "probability": 0.9140625
        },
        {
            "start_logit": 5.59765625,
            "end_logit": 2.34375,
            "text": " phosphodiesterase 4 inhibitor showing a preferential enzymatic inhibition of PDE4B",
            "probability": 0.0546875
        },
        {
            "start_logit": 5.59765625,
            "end_logit": 0.314453125,
            "text": " phosphodiesterase 4 inhibitor showing a preferential enzymatic inhibition of PDE4",
            "probability": 0.007205963134765625
        },
        {
            "start_logit": 5.59765625,
            "end_logit": -0.0254058837890625,
            "text": " phosphodiesterase 4 inhibitor showing a preferential enzymatic inhibition of PDE4B.",
            "probability": 0.005107879638671875
        },
        {
            "start_logit": 3.078125,
            "end_logit": 2.34375,
            "text": " PDE4B",
            "probability": 0.00440216064453125
        },
        {
            "start_logit": -0.3818359375,
            "end_logit": 5.16015625,
            "text": " 4",
            "probability": 0.0023097991943359375
        },
        {
            "start_logit": 5.59765625,
            "end_logit": -0.98583984375,
            "text": " phosphodiesterase 4 inhibitor",
            "probability": 0.0019626617431640625
        },
        {
            "start_logit": 5.59765625,
            "end_logit": -1.017578125,
            "text": " p",
            "probability": 0.0018939971923828125
        },
        {
            "start_logit": 5.59765625,
            "end_logit": -1.2880859375,
            "text": " phosphodiesterase 4 inhibitor showing a preferential enzymatic inhibition of P",
            "probability": 0.0014467239379882812
        },
        {
            "start_logit": 5.59765625,
            "end_logit": -1.7763671875,
            "text": " phosphodiesterase",
            "probability": 0.0008873939514160156
        },
        {
            "start_logit": -1.369140625,
            "end_logit": 5.16015625,
            "text": "hosphodiesterase 4",
            "probability": 0.0008602142333984375
        },
        {
            "start_logit": 5.59765625,
            "end_logit": -2.00390625,
            "text": " phosphodiesterase 4 inhibitor showing a preferential enzymatic inhibition of PDE",
            "probability": 0.0007076263427734375
        },
        {
            "start_logit": -1.5771484375,
            "end_logit": 5.16015625,
            "text": "BI 1015550 is a novel phosphodiesterase 4",
            "probability": 0.0006995201110839844
        },
        {
            "start_logit": 5.59765625,
            "end_logit": -2.03515625,
            "text": " phosphodiesterase 4 inhibitor showing a preferential enzymatic inhibition",
            "probability": 0.0006856918334960938
        },
        {
            "start_logit": 5.59765625,
            "end_logit": -2.11328125,
            "text": " phosphodiesterase 4 inhibitor showing a preferential enzymatic inhibition of",
            "probability": 0.0006341934204101562
        },
        {
            "start_logit": 3.078125,
            "end_logit": 0.314453125,
            "text": " PDE4",
            "probability": 0.0005774497985839844
        },
        {
            "start_logit": 5.59765625,
            "end_logit": -2.4453125,
            "text": " phosphodiesterase 4 inhibitor showing a preferential enzymatic",
            "probability": 0.0004551410675048828
        },
        {
            "start_logit": 3.078125,
            "end_logit": -0.0254058837890625,
            "text": " PDE4B.",
            "probability": 0.0004127025604248047
        },
        {
            "start_logit": -2.427734375,
            "end_logit": 5.16015625,
            "text": " novel phosphodiesterase 4",
            "probability": 0.0002994537353515625
        },
        {
            "start_logit": -2.564453125,
            "end_logit": 5.16015625,
            "text": " a novel phosphodiesterase 4",
            "probability": 0.00026035308837890625
        }
    ],
    "63f03ae6f36125a42600001d_0006": [
        {
            "start_logit": 7.69921875,
            "end_logit": 6.609375,
            "text": " PDE4B",
            "probability": 0.99609375
        },
        {
            "start_logit": 7.69921875,
            "end_logit": 0.1424560546875,
            "text": " PDE4",
            "probability": 0.0015392303466796875
        },
        {
            "start_logit": 7.69921875,
            "end_logit": -0.82763671875,
            "text": " P",
            "probability": 0.0005841255187988281
        },
        {
            "start_logit": 7.69921875,
            "end_logit": -1.6474609375,
            "text": " PDE4B by BI 1015550 and its anticipated improved tolerability in humans,",
            "probability": 0.0002562999725341797
        },
        {
            "start_logit": 7.69921875,
            "end_logit": -1.8369140625,
            "text": " PDE4B by BI 1015550 and its anticipated improved tolerability in humans, plus its anti-inflammatory and antifibrotic potential,",
            "probability": 0.0002124309539794922
        },
        {
            "start_logit": 7.69921875,
            "end_logit": -2.099609375,
            "text": " PDE4B by BI 1015550 and its anticipated improved tolerability in humans, plus its anti-inflammatory and antifibrotic",
            "probability": 0.00016415119171142578
        },
        {
            "start_logit": 7.69921875,
            "end_logit": -2.177734375,
            "text": " PDE",
            "probability": 0.00015175342559814453
        },
        {
            "start_logit": 7.69921875,
            "end_logit": -2.1875,
            "text": " PDE4B by BI 1015550 and its anticipated improved tolerability in humans, plus its anti-inflammatory and antifibrotic potential",
            "probability": 0.00015056133270263672
        },
        {
            "start_logit": 7.69921875,
            "end_logit": -2.205078125,
            "text": " PDE4B by BI 1015550 and its anticipated improved tolerability in humans, plus its anti-inflammatory",
            "probability": 0.00014710426330566406
        },
        {
            "start_logit": -1.33203125,
            "end_logit": 6.609375,
            "text": "DE4B",
            "probability": 0.00011914968490600586
        },
        {
            "start_logit": -1.345703125,
            "end_logit": 6.609375,
            "text": "4B",
            "probability": 0.00011730194091796875
        },
        {
            "start_logit": -1.794921875,
            "end_logit": 6.609375,
            "text": " preferential inhibition of PDE4B",
            "probability": 7.456541061401367e-05
        },
        {
            "start_logit": -1.9462890625,
            "end_logit": 6.609375,
            "text": "B",
            "probability": 6.431341171264648e-05
        },
        {
            "start_logit": -1.951171875,
            "end_logit": 6.609375,
            "text": "In summary, the unique preferential inhibition of PDE4B",
            "probability": 6.377696990966797e-05
        },
        {
            "start_logit": 7.69921875,
            "end_logit": -3.220703125,
            "text": " PDE4B by BI 1015550",
            "probability": 5.328655242919922e-05
        },
        {
            "start_logit": -2.65234375,
            "end_logit": 6.609375,
            "text": ", the unique preferential inhibition of PDE4B",
            "probability": 3.159046173095703e-05
        },
        {
            "start_logit": -2.990234375,
            "end_logit": 6.609375,
            "text": " unique preferential inhibition of PDE4B",
            "probability": 2.2590160369873047e-05
        },
        {
            "start_logit": -3.14453125,
            "end_logit": 6.609375,
            "text": " summary, the unique preferential inhibition of PDE4B",
            "probability": 1.9490718841552734e-05
        },
        {
            "start_logit": -1.33203125,
            "end_logit": 0.1424560546875,
            "text": "DE4",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -1.345703125,
            "end_logit": 0.1424560546875,
            "text": "4",
            "probability": 1.7881393432617188e-07
        }
    ],
    "63eeeaaaf36125a426000004_0001": [
        {
            "start_logit": 6.8828125,
            "end_logit": 6.03515625,
            "text": "Recessive dystrophic epidermolysis bullosa",
            "probability": 0.8408203125
        },
        {
            "start_logit": 6.8828125,
            "end_logit": 3.955078125,
            "text": "Recessive dystrophic epidermolysis bullosa (Recessive dystrophic epidermolysis bullosa)",
            "probability": 0.10443115234375
        },
        {
            "start_logit": 6.8828125,
            "end_logit": 2.55078125,
            "text": "Recessive dystrophic epidermolysis bullosa (Recessive dystrophic epidermolysis bullosa",
            "probability": 0.025787353515625
        },
        {
            "start_logit": 6.8828125,
            "end_logit": 2.033203125,
            "text": "Recessive dystrophic epidermolysis bullosa (Recessive dystrophic epidermolysis bullosa) is a lifelong genodermatosis",
            "probability": 0.01528167724609375
        },
        {
            "start_logit": 6.8828125,
            "end_logit": 1.0859375,
            "text": "Recessive dystrophic epidermolysis bullosa (Recessive dystrophic epidermolysis bullosa) is a lifelong genodermatosis associated with blistering",
            "probability": 0.0059356689453125
        },
        {
            "start_logit": 3.396484375,
            "end_logit": 3.955078125,
            "text": "Recessive dystrophic epidermolysis bullosa)",
            "probability": 0.0032024383544921875
        },
        {
            "start_logit": 3.396484375,
            "end_logit": 2.55078125,
            "text": "Recessive dystrophic epidermolysis bullosa",
            "probability": 0.0007848739624023438
        },
        {
            "start_logit": 2.826171875,
            "end_logit": 2.859375,
            "text": " Recessive dystrophic epidermolysis bullosa",
            "probability": 0.000606536865234375
        },
        {
            "start_logit": 6.8828125,
            "end_logit": -1.236328125,
            "text": "Recessive dystrophic epidermolysis bullosa (Recessive dystrophic epidermolysis bullosa) is a lifelong genodermatosis associated with blistering,",
            "probability": 0.0005831718444824219
        },
        {
            "start_logit": 6.8828125,
            "end_logit": -1.2373046875,
            "text": "Recessive dystrophic epidermolysis",
            "probability": 0.0005807876586914062
        },
        {
            "start_logit": 3.396484375,
            "end_logit": 2.033203125,
            "text": "Recessive dystrophic epidermolysis bullosa) is a lifelong genodermatosis",
            "probability": 0.0004687309265136719
        },
        {
            "start_logit": -0.88330078125,
            "end_logit": 6.03515625,
            "text": " dystrophic epidermolysis bullosa",
            "probability": 0.0003552436828613281
        },
        {
            "start_logit": -1.1611328125,
            "end_logit": 6.03515625,
            "text": " epidermolysis bullosa",
            "probability": 0.00026917457580566406
        },
        {
            "start_logit": -1.1650390625,
            "end_logit": 6.03515625,
            "text": "dermolysis bullosa",
            "probability": 0.00026917457580566406
        },
        {
            "start_logit": 3.396484375,
            "end_logit": 1.0859375,
            "text": "Recessive dystrophic epidermolysis bullosa) is a lifelong genodermatosis associated with blistering",
            "probability": 0.00018215179443359375
        },
        {
            "start_logit": 3.396484375,
            "end_logit": 0.92431640625,
            "text": "Recessive dystrophic epidermolysis bullosa) is a lifelong genodermatosis associated with blistering, wounding, and scarring",
            "probability": 0.0001544952392578125
        },
        {
            "start_logit": 3.396484375,
            "end_logit": 0.1673583984375,
            "text": "Recessive dystrophic epidermolysis bullosa) is a lifelong genodermatosis associated with blistering, wounding",
            "probability": 7.241964340209961e-05
        },
        {
            "start_logit": 1.234375,
            "end_logit": 2.033203125,
            "text": " genodermatosis",
            "probability": 5.3822994232177734e-05
        },
        {
            "start_logit": -0.8515625,
            "end_logit": 3.955078125,
            "text": "(Recessive dystrophic epidermolysis bullosa)",
            "probability": 4.571676254272461e-05
        },
        {
            "start_logit": -0.88330078125,
            "end_logit": 3.955078125,
            "text": " dystrophic epidermolysis bullosa (Recessive dystrophic epidermolysis bullosa)",
            "probability": 4.4286251068115234e-05
        }
    ],
    "63eeeaaaf36125a426000004_0002": [
        {
            "start_logit": 7.3203125,
            "end_logit": 7.26171875,
            "text": " epidermolysis bullosa",
            "probability": 0.9560546875
        },
        {
            "start_logit": 3.59375,
            "end_logit": 7.26171875,
            "text": " dystrophic epidermolysis bullosa",
            "probability": 0.023193359375
        },
        {
            "start_logit": 3.1640625,
            "end_logit": 7.26171875,
            "text": " Recessive dystrophic epidermolysis bullosa",
            "probability": 0.014984130859375
        },
        {
            "start_logit": 0.3017578125,
            "end_logit": 7.26171875,
            "text": " topical molecular corrective therapy promoting wound healing in patients with Recessive dystrophic epidermolysis bullosa",
            "probability": 0.000858306884765625
        },
        {
            "start_logit": 0.00695037841796875,
            "end_logit": 7.26171875,
            "text": " safely tolerated, topical molecular corrective therapy promoting wound healing in patients with Recessive dystrophic epidermolysis bullosa",
            "probability": 0.0006403923034667969
        },
        {
            "start_logit": 7.3203125,
            "end_logit": -0.08984375,
            "text": " epidermolysis bullosa.",
            "probability": 0.0006160736083984375
        },
        {
            "start_logit": -0.0408935546875,
            "end_logit": 7.26171875,
            "text": "dermolysis bullosa",
            "probability": 0.0006108283996582031
        },
        {
            "start_logit": 7.3203125,
            "end_logit": -0.5693359375,
            "text": " epidermolysis",
            "probability": 0.0003809928894042969
        },
        {
            "start_logit": -0.521484375,
            "end_logit": 7.26171875,
            "text": " molecular corrective therapy promoting wound healing in patients with Recessive dystrophic epidermolysis bullosa",
            "probability": 0.00037789344787597656
        },
        {
            "start_logit": -0.56591796875,
            "end_logit": 7.26171875,
            "text": " wound healing in patients with Recessive dystrophic epidermolysis bullosa",
            "probability": 0.00036072731018066406
        },
        {
            "start_logit": -0.7548828125,
            "end_logit": 7.26171875,
            "text": " easily administered, safely tolerated, topical molecular corrective therapy promoting wound healing in patients with Recessive dystrophic epidermolysis bullosa",
            "probability": 0.0002987384796142578
        },
        {
            "start_logit": -0.7783203125,
            "end_logit": 7.26171875,
            "text": " bullosa",
            "probability": 0.00029206275939941406
        },
        {
            "start_logit": 7.3203125,
            "end_logit": -1.1416015625,
            "text": " epi",
            "probability": 0.00021529197692871094
        },
        {
            "start_logit": -1.28515625,
            "end_logit": 7.26171875,
            "text": " tolerated, topical molecular corrective therapy promoting wound healing in patients with Recessive dystrophic epidermolysis bullosa",
            "probability": 0.00017571449279785156
        },
        {
            "start_logit": -1.478515625,
            "end_logit": 7.26171875,
            "text": "B-VEC is an easily administered, safely tolerated, topical molecular corrective therapy promoting wound healing in patients with Recessive dystrophic epidermolysis bullosa",
            "probability": 0.00014448165893554688
        },
        {
            "start_logit": -2.001953125,
            "end_logit": 7.26171875,
            "text": ", topical molecular corrective therapy promoting wound healing in patients with Recessive dystrophic epidermolysis bullosa",
            "probability": 8.565187454223633e-05
        },
        {
            "start_logit": -2.1171875,
            "end_logit": 7.26171875,
            "text": ", safely tolerated, topical molecular corrective therapy promoting wound healing in patients with Recessive dystrophic epidermolysis bullosa",
            "probability": 7.617473602294922e-05
        },
        {
            "start_logit": -2.134765625,
            "end_logit": 7.26171875,
            "text": " promoting wound healing in patients with Recessive dystrophic epidermolysis bullosa",
            "probability": 7.49826431274414e-05
        },
        {
            "start_logit": 7.3203125,
            "end_logit": -2.4453125,
            "text": " epiderm",
            "probability": 5.841255187988281e-05
        },
        {
            "start_logit": -2.427734375,
            "end_logit": 7.26171875,
            "text": " healing in patients with Recessive dystrophic epidermolysis bullosa",
            "probability": 5.620718002319336e-05
        }
    ],
    "64138ce8201352f04a000042_0001": [
        {
            "start_logit": 4.66015625,
            "end_logit": 3.0,
            "text": " renal failure",
            "probability": 0.8642578125
        },
        {
            "start_logit": 4.66015625,
            "end_logit": 0.1817626953125,
            "text": " renal failure accompanied by patchy alopecia",
            "probability": 0.05169677734375
        },
        {
            "start_logit": 4.66015625,
            "end_logit": -0.181884765625,
            "text": " renal failure accompanied by patchy alopecia.",
            "probability": 0.035797119140625
        },
        {
            "start_logit": 1.1171875,
            "end_logit": 3.0,
            "text": " progressive renal failure",
            "probability": 0.024993896484375
        },
        {
            "start_logit": 4.66015625,
            "end_logit": -1.9814453125,
            "text": " renal",
            "probability": 0.0059356689453125
        },
        {
            "start_logit": -0.537109375,
            "end_logit": 3.0,
            "text": " Hairpatches\"/Hairpatches\" homozygotes die in utero, while Hairpatches\"/+ heterozygotes exhibit progressive renal failure",
            "probability": 0.004791259765625
        },
        {
            "start_logit": -1.1083984375,
            "end_logit": 3.0,
            "text": " utero, while Hairpatches\"/+ heterozygotes exhibit progressive renal failure",
            "probability": 0.002696990966796875
        },
        {
            "start_logit": -1.5107421875,
            "end_logit": 3.0,
            "text": " heterozygotes exhibit progressive renal failure",
            "probability": 0.0018033981323242188
        },
        {
            "start_logit": 1.1171875,
            "end_logit": 0.1817626953125,
            "text": " progressive renal failure accompanied by patchy alopecia",
            "probability": 0.001495361328125
        },
        {
            "start_logit": -1.984375,
            "end_logit": 3.0,
            "text": " mouse mutation. Hairpatches\"/Hairpatches\" homozygotes die in utero, while Hairpatches\"/+ heterozygotes exhibit progressive renal failure",
            "probability": 0.0011243820190429688
        },
        {
            "start_logit": 1.1171875,
            "end_logit": -0.181884765625,
            "text": " progressive renal failure accompanied by patchy alopecia.",
            "probability": 0.0010356903076171875
        },
        {
            "start_logit": -2.083984375,
            "end_logit": 3.0,
            "text": " homozygotes die in utero, while Hairpatches\"/+ heterozygotes exhibit progressive renal failure",
            "probability": 0.0010194778442382812
        },
        {
            "start_logit": -2.150390625,
            "end_logit": 3.0,
            "text": " die in utero, while Hairpatches\"/+ heterozygotes exhibit progressive renal failure",
            "probability": 0.0009503364562988281
        },
        {
            "start_logit": -2.173828125,
            "end_logit": 3.0,
            "text": ", while Hairpatches\"/+ heterozygotes exhibit progressive renal failure",
            "probability": 0.0009288787841796875
        },
        {
            "start_logit": 0.1217041015625,
            "end_logit": 0.1817626953125,
            "text": " patchy alopecia",
            "probability": 0.0005521774291992188
        },
        {
            "start_logit": 0.1217041015625,
            "end_logit": -0.181884765625,
            "text": " patchy alopecia.",
            "probability": 0.0003840923309326172
        },
        {
            "start_logit": -0.537109375,
            "end_logit": 0.1817626953125,
            "text": " Hairpatches\"/Hairpatches\" homozygotes die in utero, while Hairpatches\"/+ heterozygotes exhibit progressive renal failure accompanied by patchy alopecia",
            "probability": 0.0002853870391845703
        },
        {
            "start_logit": -0.537109375,
            "end_logit": -0.255126953125,
            "text": " Hairpatches\"/Hairpatches\" homozygotes die in utero",
            "probability": 0.0001842975616455078
        },
        {
            "start_logit": 1.1171875,
            "end_logit": -1.9814453125,
            "text": " progressive renal",
            "probability": 0.00017178058624267578
        },
        {
            "start_logit": -0.8837890625,
            "end_logit": 0.003704071044921875,
            "text": "Hairpatches\" (Hairpatches\")",
            "probability": 0.0001690387725830078
        }
    ],
    "64138ce8201352f04a000042_0002": [
        {
            "start_logit": 3.8515625,
            "end_logit": 1.9189453125,
            "text": " renal disease",
            "probability": 0.4345703125
        },
        {
            "start_logit": 3.8515625,
            "end_logit": 1.443359375,
            "text": " renal disease and alopecia",
            "probability": 0.27099609375
        },
        {
            "start_logit": 3.8515625,
            "end_logit": -0.09136962890625,
            "text": " renal disease and alopecia in the mouse.",
            "probability": 0.058258056640625
        },
        {
            "start_logit": 3.8515625,
            "end_logit": -0.1903076171875,
            "text": " renal disease and alopecia in the mouse. A potential model for a newly described heritable human disorder.",
            "probability": 0.052825927734375
        },
        {
            "start_logit": 3.8515625,
            "end_logit": -0.41015625,
            "text": " renal",
            "probability": 0.0423583984375
        },
        {
            "start_logit": 3.8515625,
            "end_logit": -0.62939453125,
            "text": " renal disease and alopecia in the mouse",
            "probability": 0.034027099609375
        },
        {
            "start_logit": 1.1787109375,
            "end_logit": 1.9189453125,
            "text": " progressive renal disease",
            "probability": 0.030059814453125
        },
        {
            "start_logit": 1.1787109375,
            "end_logit": 1.443359375,
            "text": " progressive renal disease and alopecia",
            "probability": 0.018646240234375
        },
        {
            "start_logit": 3.8515625,
            "end_logit": -1.306640625,
            "text": " renal disease and alopecia in the mouse. A potential model for a newly described heritable human disorder",
            "probability": 0.0172882080078125
        },
        {
            "start_logit": 0.263671875,
            "end_logit": 1.443359375,
            "text": " alopecia",
            "probability": 0.007480621337890625
        },
        {
            "start_logit": -0.5927734375,
            "end_logit": 1.9189453125,
            "text": "Hairpatches, a single gene mutation characterized by progressive renal disease",
            "probability": 0.005100250244140625
        },
        {
            "start_logit": 3.8515625,
            "end_logit": -2.560546875,
            "text": " renal disease and alopecia in",
            "probability": 0.00494384765625
        },
        {
            "start_logit": 1.1787109375,
            "end_logit": -0.09136962890625,
            "text": " progressive renal disease and alopecia in the mouse.",
            "probability": 0.00402069091796875
        },
        {
            "start_logit": 3.8515625,
            "end_logit": -2.822265625,
            "text": " renal disease and alopecia in the mouse. A potential model",
            "probability": 0.0037899017333984375
        },
        {
            "start_logit": 1.1787109375,
            "end_logit": -0.1903076171875,
            "text": " progressive renal disease and alopecia in the mouse. A potential model for a newly described heritable human disorder.",
            "probability": 0.0036449432373046875
        },
        {
            "start_logit": -0.5927734375,
            "end_logit": 1.443359375,
            "text": "Hairpatches, a single gene mutation characterized by progressive renal disease and alopecia",
            "probability": 0.003177642822265625
        },
        {
            "start_logit": 1.1787109375,
            "end_logit": -0.41015625,
            "text": " progressive renal",
            "probability": 0.0029277801513671875
        },
        {
            "start_logit": 1.1787109375,
            "end_logit": -0.62939453125,
            "text": " progressive renal disease and alopecia in the mouse",
            "probability": 0.0023517608642578125
        },
        {
            "start_logit": 0.263671875,
            "end_logit": -0.09136962890625,
            "text": " alopecia in the mouse.",
            "probability": 0.0016107559204101562
        },
        {
            "start_logit": 0.263671875,
            "end_logit": -0.1903076171875,
            "text": " alopecia in the mouse. A potential model for a newly described heritable human disorder.",
            "probability": 0.001461029052734375
        }
    ],
    "63f9cd0b33942b094c000010_0001": [
        {
            "start_logit": 5.43359375,
            "end_logit": 4.91796875,
            "text": " metastasis potential of colorectal cancer",
            "probability": 0.63134765625
        },
        {
            "start_logit": 4.59375,
            "end_logit": 4.91796875,
            "text": " colorectal cancer",
            "probability": 0.273681640625
        },
        {
            "start_logit": 5.43359375,
            "end_logit": 2.271484375,
            "text": " metastasis",
            "probability": 0.044647216796875
        },
        {
            "start_logit": 1.626953125,
            "end_logit": 4.91796875,
            "text": " cancer",
            "probability": 0.0140533447265625
        },
        {
            "start_logit": 1.0537109375,
            "end_logit": 4.91796875,
            "text": " HSPA12A pre-RNA by SRSF11 contributes to metastasis potential of colorectal cancer",
            "probability": 0.0079193115234375
        },
        {
            "start_logit": 5.43359375,
            "end_logit": 0.322021484375,
            "text": " metastasis potential",
            "probability": 0.0063629150390625
        },
        {
            "start_logit": 5.43359375,
            "end_logit": 0.161376953125,
            "text": " metastasis potential of colorectal cancer.",
            "probability": 0.0054168701171875
        },
        {
            "start_logit": 0.4443359375,
            "end_logit": 4.91796875,
            "text": "SRSF11 contributes to metastasis potential of colorectal cancer",
            "probability": 0.004302978515625
        },
        {
            "start_logit": 5.43359375,
            "end_logit": -0.66845703125,
            "text": " metastasis potential of colorectal",
            "probability": 0.0023670196533203125
        },
        {
            "start_logit": 4.59375,
            "end_logit": 0.161376953125,
            "text": " colorectal cancer.",
            "probability": 0.0023403167724609375
        },
        {
            "start_logit": -0.53564453125,
            "end_logit": 4.91796875,
            "text": " contributes to metastasis potential of colorectal cancer",
            "probability": 0.0016145706176757812
        },
        {
            "start_logit": -0.65283203125,
            "end_logit": 4.91796875,
            "text": "Alternative splicing of HSPA12A pre-RNA by SRSF11 contributes to metastasis potential of colorectal cancer",
            "probability": 0.0014362335205078125
        },
        {
            "start_logit": -0.8388671875,
            "end_logit": 4.91796875,
            "text": " potential of colorectal cancer",
            "probability": 0.001190185546875
        },
        {
            "start_logit": 4.59375,
            "end_logit": -0.66845703125,
            "text": " colorectal",
            "probability": 0.0010223388671875
        },
        {
            "start_logit": -1.3076171875,
            "end_logit": 4.91796875,
            "text": " of colorectal cancer",
            "probability": 0.0007448196411132812
        },
        {
            "start_logit": -1.5712890625,
            "end_logit": 4.91796875,
            "text": " pre-RNA by SRSF11 contributes to metastasis potential of colorectal cancer",
            "probability": 0.0005736351013183594
        },
        {
            "start_logit": 1.0537109375,
            "end_logit": 2.271484375,
            "text": " HSPA12A pre-RNA by SRSF11 contributes to metastasis",
            "probability": 0.0005602836608886719
        },
        {
            "start_logit": 0.4443359375,
            "end_logit": 2.271484375,
            "text": "SRSF11 contributes to metastasis",
            "probability": 0.0003044605255126953
        },
        {
            "start_logit": -2.50390625,
            "end_logit": 4.91796875,
            "text": " to metastasis potential of colorectal cancer",
            "probability": 0.00022542476654052734
        },
        {
            "start_logit": -2.955078125,
            "end_logit": 4.91796875,
            "text": "PA12A pre-RNA by SRSF11 contributes to metastasis potential of colorectal cancer",
            "probability": 0.00014328956604003906
        }
    ],
    "63f9cd0b33942b094c000010_0002": [
        {
            "start_logit": 6.61328125,
            "end_logit": 4.55859375,
            "text": " metastasis",
            "probability": 0.80810546875
        },
        {
            "start_logit": 6.61328125,
            "end_logit": 3.03125,
            "text": " metastasis in colorectal cancer",
            "probability": 0.1748046875
        },
        {
            "start_logit": 6.61328125,
            "end_logit": 0.0186767578125,
            "text": " metastasis in colorectal cancer.",
            "probability": 0.00862884521484375
        },
        {
            "start_logit": 2.439453125,
            "end_logit": 3.03125,
            "text": " colorectal cancer",
            "probability": 0.002696990966796875
        },
        {
            "start_logit": 6.61328125,
            "end_logit": -1.79296875,
            "text": " metastasis in colorectal",
            "probability": 0.0014095306396484375
        },
        {
            "start_logit": -0.205078125,
            "end_logit": 4.55859375,
            "text": " associated with metastasis",
            "probability": 0.0008816719055175781
        },
        {
            "start_logit": -0.51953125,
            "end_logit": 4.55859375,
            "text": "PTBP1 is associated with metastasis",
            "probability": 0.0006456375122070312
        },
        {
            "start_logit": 6.61328125,
            "end_logit": -2.65625,
            "text": " metastasis in",
            "probability": 0.0005946159362792969
        },
        {
            "start_logit": -0.60205078125,
            "end_logit": 4.55859375,
            "text": "RBFOX2 and PTBP1 is associated with metastasis",
            "probability": 0.0005946159362792969
        },
        {
            "start_logit": -0.626953125,
            "end_logit": 4.55859375,
            "text": "Alternative microexon splicing by RBFOX2 and PTBP1 is associated with metastasis",
            "probability": 0.0005784034729003906
        },
        {
            "start_logit": -0.205078125,
            "end_logit": 3.03125,
            "text": " associated with metastasis in colorectal cancer",
            "probability": 0.00019216537475585938
        },
        {
            "start_logit": -0.51953125,
            "end_logit": 3.03125,
            "text": "PTBP1 is associated with metastasis in colorectal cancer",
            "probability": 0.00014066696166992188
        },
        {
            "start_logit": 2.439453125,
            "end_logit": 0.0186767578125,
            "text": " colorectal cancer.",
            "probability": 0.00013315677642822266
        },
        {
            "start_logit": -0.60205078125,
            "end_logit": 3.03125,
            "text": "RBFOX2 and PTBP1 is associated with metastasis in colorectal cancer",
            "probability": 0.0001291036605834961
        },
        {
            "start_logit": -0.626953125,
            "end_logit": 3.03125,
            "text": "Alternative microexon splicing by RBFOX2 and PTBP1 is associated with metastasis in colorectal cancer",
            "probability": 0.00012612342834472656
        },
        {
            "start_logit": -2.3203125,
            "end_logit": 4.55859375,
            "text": " with metastasis",
            "probability": 0.0001061558723449707
        },
        {
            "start_logit": -2.96875,
            "end_logit": 4.55859375,
            "text": " microexon splicing by RBFOX2 and PTBP1 is associated with metastasis",
            "probability": 5.5909156799316406e-05
        },
        {
            "start_logit": -3.091796875,
            "end_logit": 4.55859375,
            "text": "BP1 is associated with metastasis",
            "probability": 4.935264587402344e-05
        },
        {
            "start_logit": -1.8056640625,
            "end_logit": 3.03125,
            "text": " cancer",
            "probability": 3.8743019104003906e-05
        },
        {
            "start_logit": -3.384765625,
            "end_logit": 4.55859375,
            "text": " is associated with metastasis",
            "probability": 3.6716461181640625e-05
        }
    ],
    "63f9cd0b33942b094c000010_0003": [
        {
            "start_logit": 0.28515625,
            "end_logit": -0.1695556640625,
            "text": "CRC cells.",
            "probability": 0.1591796875
        },
        {
            "start_logit": -0.1212158203125,
            "end_logit": -0.1695556640625,
            "text": " microexon splicing in CRC cells.",
            "probability": 0.10601806640625
        },
        {
            "start_logit": -0.268310546875,
            "end_logit": -0.1695556640625,
            "text": "PTBP1, as regulators of microexon splicing in CRC cells.",
            "probability": 0.09149169921875
        },
        {
            "start_logit": -0.66015625,
            "end_logit": -0.1695556640625,
            "text": "RBFOX2 and PTBP1, as regulators of microexon splicing in CRC cells.",
            "probability": 0.0618896484375
        },
        {
            "start_logit": 0.28515625,
            "end_logit": -1.1337890625,
            "text": "CRC cells",
            "probability": 0.060699462890625
        },
        {
            "start_logit": -0.97216796875,
            "end_logit": -0.1695556640625,
            "text": ".",
            "probability": 0.045318603515625
        },
        {
            "start_logit": -0.1212158203125,
            "end_logit": -1.103515625,
            "text": " microexon splicing",
            "probability": 0.041717529296875
        },
        {
            "start_logit": -0.5673828125,
            "end_logit": -0.65673828125,
            "text": " such cells.",
            "probability": 0.041717529296875
        },
        {
            "start_logit": -0.1212158203125,
            "end_logit": -1.1337890625,
            "text": " microexon splicing in CRC cells",
            "probability": 0.04046630859375
        },
        {
            "start_logit": -0.268310546875,
            "end_logit": -0.986328125,
            "text": "PTBP1,",
            "probability": 0.04046630859375
        },
        {
            "start_logit": 0.28515625,
            "end_logit": -1.6201171875,
            "text": "CRC cells. RBFOX2 and PTBP1 were found to directly bind to microexon-containing pre-mRNAs",
            "probability": 0.037322998046875
        },
        {
            "start_logit": -0.5673828125,
            "end_logit": -0.78466796875,
            "text": " such cells. Differential microexon splicing",
            "probability": 0.0367431640625
        },
        {
            "start_logit": -0.268310546875,
            "end_logit": -1.103515625,
            "text": "PTBP1, as regulators of microexon splicing",
            "probability": 0.035980224609375
        },
        {
            "start_logit": -0.268310546875,
            "end_logit": -1.1337890625,
            "text": "PTBP1, as regulators of microexon splicing in CRC cells",
            "probability": 0.034912109375
        },
        {
            "start_logit": 0.28515625,
            "end_logit": -1.7041015625,
            "text": "CRC",
            "probability": 0.034332275390625
        },
        {
            "start_logit": -0.779296875,
            "end_logit": -0.78466796875,
            "text": " Differential microexon splicing",
            "probability": 0.0296783447265625
        },
        {
            "start_logit": -0.66015625,
            "end_logit": -0.986328125,
            "text": "RBFOX2 and PTBP1,",
            "probability": 0.02734375
        },
        {
            "start_logit": 0.28515625,
            "end_logit": -1.9580078125,
            "text": "CRC cells. RBFOX2 and PTBP1 were found to directly bind to microexon-",
            "probability": 0.0266265869140625
        },
        {
            "start_logit": -0.66015625,
            "end_logit": -1.103515625,
            "text": "RBFOX2 and PTBP1, as regulators of microexon splicing",
            "probability": 0.0243072509765625
        },
        {
            "start_logit": -0.66015625,
            "end_logit": -1.1337890625,
            "text": "RBFOX2 and PTBP1, as regulators of microexon splicing in CRC cells",
            "probability": 0.023590087890625
        }
    ],
    "63f9cd0b33942b094c000010_0004": [
        {
            "start_logit": 2.625,
            "end_logit": 2.810546875,
            "text": "CRC metastasis",
            "probability": 0.642578125
        },
        {
            "start_logit": 1.2275390625,
            "end_logit": 2.810546875,
            "text": " metastasis",
            "probability": 0.15869140625
        },
        {
            "start_logit": 2.625,
            "end_logit": -0.10443115234375,
            "text": "CRC metastasis through the regulation of microexon splicing.",
            "probability": 0.0347900390625
        },
        {
            "start_logit": -0.5029296875,
            "end_logit": 2.810546875,
            "text": " altered expression of RBFOX2 and PTBP1 might influence CRC metastasis",
            "probability": 0.028106689453125
        },
        {
            "start_logit": 2.625,
            "end_logit": -0.49951171875,
            "text": "CRC metastasis through the regulation of microexon splicing",
            "probability": 0.023406982421875
        },
        {
            "start_logit": -0.84814453125,
            "end_logit": 2.810546875,
            "text": " influence CRC metastasis",
            "probability": 0.0198974609375
        },
        {
            "start_logit": 2.625,
            "end_logit": -1.0634765625,
            "text": "CRC",
            "probability": 0.01332855224609375
        },
        {
            "start_logit": -1.5224609375,
            "end_logit": 2.810546875,
            "text": "RBFOX2 and PTBP1 might influence CRC metastasis",
            "probability": 0.0101470947265625
        },
        {
            "start_logit": -1.623046875,
            "end_logit": 2.810546875,
            "text": "PTBP1 might influence CRC metastasis",
            "probability": 0.00916290283203125
        },
        {
            "start_logit": 1.2275390625,
            "end_logit": -0.10443115234375,
            "text": " metastasis through the regulation of microexon splicing.",
            "probability": 0.00860595703125
        },
        {
            "start_logit": -1.724609375,
            "end_logit": 2.810546875,
            "text": "Our data thus suggest that altered expression of RBFOX2 and PTBP1 might influence CRC metastasis",
            "probability": 0.00827789306640625
        },
        {
            "start_logit": -1.796875,
            "end_logit": 2.810546875,
            "text": " thus suggest that altered expression of RBFOX2 and PTBP1 might influence CRC metastasis",
            "probability": 0.00771331787109375
        },
        {
            "start_logit": 1.2275390625,
            "end_logit": -0.49951171875,
            "text": " metastasis through the regulation of microexon splicing",
            "probability": 0.005779266357421875
        },
        {
            "start_logit": -2.11328125,
            "end_logit": 2.810546875,
            "text": "C metastasis",
            "probability": 0.005603790283203125
        },
        {
            "start_logit": -2.1328125,
            "end_logit": 2.810546875,
            "text": " CRC metastasis",
            "probability": 0.005512237548828125
        },
        {
            "start_logit": -2.205078125,
            "end_logit": 2.810546875,
            "text": " data thus suggest that altered expression of RBFOX2 and PTBP1 might influence CRC metastasis",
            "probability": 0.005123138427734375
        },
        {
            "start_logit": -2.5,
            "end_logit": 2.810546875,
            "text": " suggest that altered expression of RBFOX2 and PTBP1 might influence CRC metastasis",
            "probability": 0.0038204193115234375
        },
        {
            "start_logit": 2.625,
            "end_logit": -2.419921875,
            "text": "CR",
            "probability": 0.0034236907958984375
        },
        {
            "start_logit": 2.625,
            "end_logit": -2.478515625,
            "text": "CRC metastasis through the",
            "probability": 0.00324249267578125
        },
        {
            "start_logit": 0.111328125,
            "end_logit": -0.10443115234375,
            "text": " regulation of microexon splicing.",
            "probability": 0.00281524658203125
        }
    ],
    "63f56f7533942b094c000002_0001": [
        {
            "start_logit": 7.21484375,
            "end_logit": 5.75390625,
            "text": " aspartoacylase Gene",
            "probability": 0.9912109375
        },
        {
            "start_logit": 7.21484375,
            "end_logit": -0.0767822265625,
            "text": " aspartoacylase Gene.",
            "probability": 0.00290679931640625
        },
        {
            "start_logit": 7.21484375,
            "end_logit": -0.29443359375,
            "text": " aspartoacylase",
            "probability": 0.0023441314697265625
        },
        {
            "start_logit": 7.21484375,
            "end_logit": -1.265625,
            "text": " as",
            "probability": 0.0008864402770996094
        },
        {
            "start_logit": 7.21484375,
            "end_logit": -1.6708984375,
            "text": " aspartoacyl",
            "probability": 0.0005903244018554688
        },
        {
            "start_logit": 7.21484375,
            "end_logit": -2.537109375,
            "text": " aspar",
            "probability": 0.0002491474151611328
        },
        {
            "start_logit": 7.21484375,
            "end_logit": -2.56640625,
            "text": " asparto",
            "probability": 0.00024139881134033203
        },
        {
            "start_logit": -1.2197265625,
            "end_logit": 5.75390625,
            "text": "Cribriform Appearance of White Matter in Canavan Disease Associated with Novel Mutations of aspartoacylase Gene",
            "probability": 0.00021469593048095703
        },
        {
            "start_logit": -1.3662109375,
            "end_logit": 5.75390625,
            "text": "partoacylase Gene",
            "probability": 0.00018656253814697266
        },
        {
            "start_logit": -1.828125,
            "end_logit": 5.75390625,
            "text": " Gene",
            "probability": 0.00011676549911499023
        },
        {
            "start_logit": -2.22265625,
            "end_logit": 5.75390625,
            "text": " Appearance of White Matter in Canavan Disease Associated with Novel Mutations of aspartoacylase Gene",
            "probability": 7.897615432739258e-05
        },
        {
            "start_logit": -2.490234375,
            "end_logit": 5.75390625,
            "text": "acylase Gene",
            "probability": 6.0558319091796875e-05
        },
        {
            "start_logit": -2.513671875,
            "end_logit": 5.75390625,
            "text": " Associated with Novel Mutations of aspartoacylase Gene",
            "probability": 5.91278076171875e-05
        },
        {
            "start_logit": -2.58203125,
            "end_logit": 5.75390625,
            "text": " Novel Mutations of aspartoacylase Gene",
            "probability": 5.513429641723633e-05
        },
        {
            "start_logit": -2.59765625,
            "end_logit": 5.75390625,
            "text": "toacylase Gene",
            "probability": 5.429983139038086e-05
        },
        {
            "start_logit": -2.71484375,
            "end_logit": 5.75390625,
            "text": " of aspartoacylase Gene",
            "probability": 4.8279762268066406e-05
        },
        {
            "start_logit": -2.921875,
            "end_logit": 5.75390625,
            "text": " White Matter in Canavan Disease Associated with Novel Mutations of aspartoacylase Gene",
            "probability": 3.910064697265625e-05
        },
        {
            "start_logit": -2.95703125,
            "end_logit": 5.75390625,
            "text": " Mutations of aspartoacylase Gene",
            "probability": 3.784894943237305e-05
        },
        {
            "start_logit": -2.958984375,
            "end_logit": 5.75390625,
            "text": " with Novel Mutations of aspartoacylase Gene",
            "probability": 3.784894943237305e-05
        },
        {
            "start_logit": -2.990234375,
            "end_logit": 5.75390625,
            "text": "Cribriform Appearance of White Matter in Canavan Disease Associated with Novel Mutations of aspartoacylase Gene",
            "probability": 3.6776065826416016e-05
        }
    ],
    "63f56f7533942b094c000002_0002": [
        {
            "start_logit": 7.2265625,
            "end_logit": 5.49609375,
            "text": " aspartoacylase",
            "probability": 0.90478515625
        },
        {
            "start_logit": 7.2265625,
            "end_logit": 2.6484375,
            "text": " aspartoacylase or aspartoacylase",
            "probability": 0.052642822265625
        },
        {
            "start_logit": 7.2265625,
            "end_logit": 1.927734375,
            "text": " aspartoacylase or aspartoacylase gene",
            "probability": 0.025665283203125
        },
        {
            "start_logit": 7.2265625,
            "end_logit": 0.328369140625,
            "text": " aspartoacyl",
            "probability": 0.0051727294921875
        },
        {
            "start_logit": 7.2265625,
            "end_logit": -0.634765625,
            "text": " as",
            "probability": 0.001979827880859375
        },
        {
            "start_logit": 7.2265625,
            "end_logit": -0.7939453125,
            "text": " aspartoacylase or as",
            "probability": 0.00168609619140625
        },
        {
            "start_logit": 7.2265625,
            "end_logit": -0.8876953125,
            "text": " aspartoacylase or",
            "probability": 0.0015344619750976562
        },
        {
            "start_logit": 3.458984375,
            "end_logit": 2.6484375,
            "text": " aspartoacylase",
            "probability": 0.0012187957763671875
        },
        {
            "start_logit": 7.2265625,
            "end_logit": -1.3115234375,
            "text": " aspartoacylase or aspartoacylase gene that possibly accounts for the severe form of Canavan disease,",
            "probability": 0.0010023117065429688
        },
        {
            "start_logit": 7.2265625,
            "end_logit": -1.3388671875,
            "text": " aspartoacylase or aspartoacyl",
            "probability": 0.0009756088256835938
        },
        {
            "start_logit": 7.2265625,
            "end_logit": -1.4638671875,
            "text": " asparto",
            "probability": 0.0008611679077148438
        },
        {
            "start_logit": 7.2265625,
            "end_logit": -1.802734375,
            "text": " aspar",
            "probability": 0.0006127357482910156
        },
        {
            "start_logit": 3.458984375,
            "end_logit": 1.927734375,
            "text": " aspartoacylase gene",
            "probability": 0.0005917549133300781
        },
        {
            "start_logit": 7.2265625,
            "end_logit": -1.9501953125,
            "text": " aspartoacylase or aspartoacylase gene that possibly",
            "probability": 0.0005307197570800781
        },
        {
            "start_logit": 7.2265625,
            "end_logit": -2.44921875,
            "text": " aspartoacylase or aspartoacylase gene that possibly accounts for the severe form of",
            "probability": 0.0003218650817871094
        },
        {
            "start_logit": 7.2265625,
            "end_logit": -2.69140625,
            "text": " aspartoacylase or aspartoacylase gene that",
            "probability": 0.00025153160095214844
        },
        {
            "start_logit": -1.423828125,
            "end_logit": 5.49609375,
            "text": " the aspartoacylase",
            "probability": 0.00015866756439208984
        },
        {
            "start_logit": -1.7666015625,
            "end_logit": 5.49609375,
            "text": "Genetic analysis revealed novel mutations in the aspartoacylase",
            "probability": 0.00011342763900756836
        },
        {
            "start_logit": -2.283203125,
            "end_logit": 5.49609375,
            "text": "ase",
            "probability": 6.717443466186523e-05
        },
        {
            "start_logit": -2.3125,
            "end_logit": 5.49609375,
            "text": "partoacylase",
            "probability": 6.562471389770508e-05
        }
    ],
    "63f56f7533942b094c000002_0003": [
        {
            "start_logit": 6.5859375,
            "end_logit": 3.609375,
            "text": " aspartoacylase (aspartoacylase)",
            "probability": 0.498046875
        },
        {
            "start_logit": 6.5859375,
            "end_logit": 3.55859375,
            "text": " aspartoacylase",
            "probability": 0.471435546875
        },
        {
            "start_logit": 6.5859375,
            "end_logit": -0.041168212890625,
            "text": " aspartoacylase (aspartoacylase).",
            "probability": 0.012908935546875
        },
        {
            "start_logit": 6.5859375,
            "end_logit": -0.65673828125,
            "text": " aspartoacyl",
            "probability": 0.00699615478515625
        },
        {
            "start_logit": 6.5859375,
            "end_logit": -0.9365234375,
            "text": " aspartoacylase (aspartoacylase",
            "probability": 0.005279541015625
        },
        {
            "start_logit": 6.5859375,
            "end_logit": -2.068359375,
            "text": " as",
            "probability": 0.0017004013061523438
        },
        {
            "start_logit": 6.5859375,
            "end_logit": -2.513671875,
            "text": " aspartoacylase (asparto",
            "probability": 0.0010900497436523438
        },
        {
            "start_logit": 6.5859375,
            "end_logit": -2.6015625,
            "text": " asparto",
            "probability": 0.00099945068359375
        },
        {
            "start_logit": 6.5859375,
            "end_logit": -2.80078125,
            "text": " aspar",
            "probability": 0.0008192062377929688
        },
        {
            "start_logit": -1.171875,
            "end_logit": 3.609375,
            "text": "aspartoacylase)",
            "probability": 0.0002129077911376953
        },
        {
            "start_logit": -1.7744140625,
            "end_logit": 3.609375,
            "text": " leukodystrophy resulting from mutations in the gene encoding aspartoacylase (aspartoacylase)",
            "probability": 0.00011664628982543945
        },
        {
            "start_logit": -1.7744140625,
            "end_logit": 3.55859375,
            "text": " leukodystrophy resulting from mutations in the gene encoding aspartoacylase",
            "probability": 0.00011044740676879883
        },
        {
            "start_logit": -1.8984375,
            "end_logit": 3.55859375,
            "text": "Canavan disease (Canavan disease) is an inherited leukodystrophy resulting from mutations in the gene encoding aspartoacylase",
            "probability": 9.822845458984375e-05
        },
        {
            "start_logit": -1.958984375,
            "end_logit": 3.609375,
            "text": " the gene encoding aspartoacylase (aspartoacylase)",
            "probability": 9.673833847045898e-05
        },
        {
            "start_logit": -1.958984375,
            "end_logit": 3.55859375,
            "text": " the gene encoding aspartoacylase",
            "probability": 9.226799011230469e-05
        },
        {
            "start_logit": -2.119140625,
            "end_logit": 3.609375,
            "text": "partoacylase (aspartoacylase)",
            "probability": 8.273124694824219e-05
        },
        {
            "start_logit": -2.119140625,
            "end_logit": 3.55859375,
            "text": "partoacylase",
            "probability": 7.832050323486328e-05
        },
        {
            "start_logit": -2.2109375,
            "end_logit": 3.609375,
            "text": "anavan disease) is an inherited leukodystrophy resulting from mutations in the gene encoding aspartoacylase (aspartoacylase)",
            "probability": 7.528066635131836e-05
        },
        {
            "start_logit": -2.2109375,
            "end_logit": 3.55859375,
            "text": "anavan disease) is an inherited leukodystrophy resulting from mutations in the gene encoding aspartoacylase",
            "probability": 7.18235969543457e-05
        },
        {
            "start_logit": -2.62890625,
            "end_logit": 3.609375,
            "text": " an inherited leukodystrophy resulting from mutations in the gene encoding aspartoacylase (aspartoacylase)",
            "probability": 4.941225051879883e-05
        }
    ],
    "63f56f7533942b094c000002_0004": [
        {
            "start_logit": 7.49609375,
            "end_logit": 5.91796875,
            "text": " aspartoacylase",
            "probability": 0.9384765625
        },
        {
            "start_logit": 7.49609375,
            "end_logit": 2.578125,
            "text": " aspartoacylase (aspartoacylase) gene",
            "probability": 0.03338623046875
        },
        {
            "start_logit": 7.49609375,
            "end_logit": 2.044921875,
            "text": " aspartoacylase (aspartoacylase)",
            "probability": 0.01947021484375
        },
        {
            "start_logit": 7.49609375,
            "end_logit": 0.497314453125,
            "text": " aspartoacylase (aspartoacylase",
            "probability": 0.004146575927734375
        },
        {
            "start_logit": 7.49609375,
            "end_logit": -0.4375,
            "text": " aspartoacyl",
            "probability": 0.0016307830810546875
        },
        {
            "start_logit": 7.49609375,
            "end_logit": -0.6259765625,
            "text": " aspartoacylase (aspartoacylase) gene,",
            "probability": 0.0013513565063476562
        },
        {
            "start_logit": 7.49609375,
            "end_logit": -1.091796875,
            "text": " as",
            "probability": 0.0008492469787597656
        },
        {
            "start_logit": 7.49609375,
            "end_logit": -2.572265625,
            "text": " aspar",
            "probability": 0.00019240379333496094
        },
        {
            "start_logit": -1.3525390625,
            "end_logit": 5.91796875,
            "text": ". Because Canavan disease is caused by mutations of the aspartoacylase",
            "probability": 0.0001354217529296875
        },
        {
            "start_logit": -2.04296875,
            "end_logit": 5.91796875,
            "text": "partoacylase",
            "probability": 6.759166717529297e-05
        },
        {
            "start_logit": -2.4609375,
            "end_logit": 5.91796875,
            "text": "ase",
            "probability": 4.464387893676758e-05
        },
        {
            "start_logit": -2.736328125,
            "end_logit": 5.91796875,
            "text": " neurological disease that lacks effective therapy. Because Canavan disease is caused by mutations of the aspartoacylase",
            "probability": 3.3736228942871094e-05
        },
        {
            "start_logit": -2.896484375,
            "end_logit": 5.91796875,
            "text": " lacks effective therapy. Because Canavan disease is caused by mutations of the aspartoacylase",
            "probability": 2.8789043426513672e-05
        },
        {
            "start_logit": -3.001953125,
            "end_logit": 5.91796875,
            "text": " Canavan disease is caused by mutations of the aspartoacylase",
            "probability": 2.586841583251953e-05
        },
        {
            "start_logit": -3.0078125,
            "end_logit": 5.91796875,
            "text": "acylase",
            "probability": 2.586841583251953e-05
        },
        {
            "start_logit": -0.625,
            "end_logit": 2.578125,
            "text": "aspartoacylase) gene",
            "probability": 9.894371032714844e-06
        },
        {
            "start_logit": -0.625,
            "end_logit": 2.044921875,
            "text": "aspartoacylase)",
            "probability": 5.841255187988281e-06
        },
        {
            "start_logit": -1.3525390625,
            "end_logit": 2.578125,
            "text": ". Because Canavan disease is caused by mutations of the aspartoacylase (aspartoacylase) gene",
            "probability": 4.76837158203125e-06
        },
        {
            "start_logit": -1.3525390625,
            "end_logit": 2.044921875,
            "text": ". Because Canavan disease is caused by mutations of the aspartoacylase (aspartoacylase)",
            "probability": 2.8014183044433594e-06
        },
        {
            "start_logit": -2.04296875,
            "end_logit": 2.578125,
            "text": "partoacylase (aspartoacylase) gene",
            "probability": 2.384185791015625e-06
        }
    ],
    "63f56f7533942b094c000002_0005": [
        {
            "start_logit": 7.41796875,
            "end_logit": 5.625,
            "text": " aspartoacylase gene",
            "probability": 0.9716796875
        },
        {
            "start_logit": 7.41796875,
            "end_logit": 1.1455078125,
            "text": " aspartoacylase",
            "probability": 0.01096343994140625
        },
        {
            "start_logit": 7.41796875,
            "end_logit": 0.94873046875,
            "text": " aspartoacylase gene probably",
            "probability": 0.0090179443359375
        },
        {
            "start_logit": 7.41796875,
            "end_logit": -0.11029052734375,
            "text": " aspartoacylase gene probably underlay the Canavan disease in this patient, and the result has enabled prenatal diagnosis for this family.",
            "probability": 0.0031280517578125
        },
        {
            "start_logit": 7.41796875,
            "end_logit": -0.90771484375,
            "text": " aspartoacyl",
            "probability": 0.0014104843139648438
        },
        {
            "start_logit": 7.41796875,
            "end_logit": -1.30078125,
            "text": " as",
            "probability": 0.0009508132934570312
        },
        {
            "start_logit": 7.41796875,
            "end_logit": -1.44921875,
            "text": " aspartoacylase gene probably underlay the Canavan disease in this patient,",
            "probability": 0.0008196830749511719
        },
        {
            "start_logit": 7.41796875,
            "end_logit": -1.9345703125,
            "text": " asparto",
            "probability": 0.0005049705505371094
        },
        {
            "start_logit": 7.41796875,
            "end_logit": -2.046875,
            "text": " aspar",
            "probability": 0.0004508495330810547
        },
        {
            "start_logit": 7.41796875,
            "end_logit": -2.1484375,
            "text": " aspartoacylase gene probably underlay the Canavan disease in this patient, and the result",
            "probability": 0.00040721893310546875
        },
        {
            "start_logit": 7.41796875,
            "end_logit": -2.3984375,
            "text": " aspartoacylase gene probably underlay the Canavan disease in this patient, and the result has enabled prenatal diagnosis for this family",
            "probability": 0.0003159046173095703
        },
        {
            "start_logit": 7.41796875,
            "end_logit": -2.880859375,
            "text": " aspartoacylase gene probably underlay the Cana",
            "probability": 0.00019621849060058594
        },
        {
            "start_logit": 7.41796875,
            "end_logit": -2.94921875,
            "text": " aspartoacylase gene probably underlay the Canavan disease in this patient, and the result has enabled prenatal diagnosis",
            "probability": 0.00018286705017089844
        },
        {
            "start_logit": -1.5810546875,
            "end_logit": 5.625,
            "text": " compound heterozygous variants of the aspartoacylase gene",
            "probability": 0.00011986494064331055
        },
        {
            "start_logit": -2.04296875,
            "end_logit": 5.625,
            "text": " gene",
            "probability": 7.50422477722168e-05
        },
        {
            "start_logit": -2.109375,
            "end_logit": 5.625,
            "text": "partoacylase gene",
            "probability": 7.045269012451172e-05
        },
        {
            "start_logit": -2.501953125,
            "end_logit": 5.625,
            "text": "The compound heterozygous variants of the aspartoacylase gene",
            "probability": 4.774332046508789e-05
        },
        {
            "start_logit": -2.875,
            "end_logit": 5.625,
            "text": "acylase gene",
            "probability": 3.2782554626464844e-05
        },
        {
            "start_logit": -2.94140625,
            "end_logit": 5.625,
            "text": " the aspartoacylase gene",
            "probability": 3.081560134887695e-05
        },
        {
            "start_logit": -3.033203125,
            "end_logit": 5.625,
            "text": "toacylase gene",
            "probability": 2.8014183044433594e-05
        }
    ],
    "63eeeb70f36125a426000005_0001": [
        {
            "start_logit": 5.98046875,
            "end_logit": 4.97265625,
            "text": "DLBCL",
            "probability": 0.97509765625
        },
        {
            "start_logit": 5.98046875,
            "end_logit": -0.0635986328125,
            "text": "DLBCL after CAR T-Cell Therapy.",
            "probability": 0.006343841552734375
        },
        {
            "start_logit": 0.475830078125,
            "end_logit": 4.97265625,
            "text": " DLBCL",
            "probability": 0.003971099853515625
        },
        {
            "start_logit": 5.98046875,
            "end_logit": -0.60888671875,
            "text": "DLBCL after CAR T-Cell Therapy",
            "probability": 0.0036716461181640625
        },
        {
            "start_logit": 5.98046875,
            "end_logit": -1.1708984375,
            "text": "DLB",
            "probability": 0.0020923614501953125
        },
        {
            "start_logit": -0.419921875,
            "end_logit": 4.97265625,
            "text": " Refractory DLBCL",
            "probability": 0.0016231536865234375
        },
        {
            "start_logit": 5.98046875,
            "end_logit": -1.6640625,
            "text": "DLBCL after CAR",
            "probability": 0.0012788772583007812
        },
        {
            "start_logit": 5.98046875,
            "end_logit": -1.6875,
            "text": "DLBCL after CAR T-Cell",
            "probability": 0.0012493133544921875
        },
        {
            "start_logit": -0.72216796875,
            "end_logit": 4.97265625,
            "text": " Relapsed or Refractory DLBCL",
            "probability": 0.0011968612670898438
        },
        {
            "start_logit": 5.98046875,
            "end_logit": -1.7548828125,
            "text": "DL",
            "probability": 0.0011692047119140625
        },
        {
            "start_logit": -1.4091796875,
            "end_logit": 4.97265625,
            "text": "Glofitamab Treatment in Relapsed or Refractory DLBCL",
            "probability": 0.0006017684936523438
        },
        {
            "start_logit": 5.98046875,
            "end_logit": -2.517578125,
            "text": "DLBCL after CAR T",
            "probability": 0.0005435943603515625
        },
        {
            "start_logit": -1.6689453125,
            "end_logit": 4.97265625,
            "text": "BCL",
            "probability": 0.0004649162292480469
        },
        {
            "start_logit": -2.201171875,
            "end_logit": 4.97265625,
            "text": " in Relapsed or Refractory DLBCL",
            "probability": 0.0002734661102294922
        },
        {
            "start_logit": -2.236328125,
            "end_logit": 4.97265625,
            "text": "CL",
            "probability": 0.00026297569274902344
        },
        {
            "start_logit": -2.541015625,
            "end_logit": 4.97265625,
            "text": " or Refractory DLBCL",
            "probability": 0.0001938343048095703
        },
        {
            "start_logit": -3.37109375,
            "end_logit": 4.97265625,
            "text": "itamab Treatment in Relapsed or Refractory DLBCL",
            "probability": 8.469820022583008e-05
        },
        {
            "start_logit": 0.475830078125,
            "end_logit": -0.0635986328125,
            "text": " DLBCL after CAR T-Cell Therapy.",
            "probability": 2.580881118774414e-05
        },
        {
            "start_logit": 0.30078125,
            "end_logit": -0.0635986328125,
            "text": " CAR T-Cell Therapy.",
            "probability": 2.1576881408691406e-05
        },
        {
            "start_logit": 0.475830078125,
            "end_logit": -0.60888671875,
            "text": " DLBCL after CAR T-Cell Therapy",
            "probability": 1.4960765838623047e-05
        }
    ],
    "63eeeb70f36125a426000005_0002": [
        {
            "start_logit": 0.630859375,
            "end_logit": 0.312744140625,
            "text": " CAR T treatment. We report nine consecutive patients with progressive DLBCL",
            "probability": 0.1693115234375
        },
        {
            "start_logit": 0.2705078125,
            "end_logit": 0.312744140625,
            "text": "DLBCL",
            "probability": 0.1180419921875
        },
        {
            "start_logit": 0.630859375,
            "end_logit": -0.21923828125,
            "text": " CAR T treatment.",
            "probability": 0.09942626953125
        },
        {
            "start_logit": 0.630859375,
            "end_logit": -0.399658203125,
            "text": " CAR T treatment. We report nine consecutive patients with progressive DLBCL after preceding CAR T-cell therapy.",
            "probability": 0.08306884765625
        },
        {
            "start_logit": 0.630859375,
            "end_logit": -0.48583984375,
            "text": " CAR T treatment",
            "probability": 0.07623291015625
        },
        {
            "start_logit": -0.380615234375,
            "end_logit": 0.312744140625,
            "text": " progressive DLBCL",
            "probability": 0.061553955078125
        },
        {
            "start_logit": 0.2705078125,
            "end_logit": -0.399658203125,
            "text": "DLBCL after preceding CAR T-cell therapy.",
            "probability": 0.057952880859375
        },
        {
            "start_logit": 0.630859375,
            "end_logit": -1.0693359375,
            "text": " CAR T treatment. We report nine consecutive patients with progressive DLBCL after preceding CAR T-cell therapy",
            "probability": 0.04254150390625
        },
        {
            "start_logit": -0.990234375,
            "end_logit": 0.312744140625,
            "text": ". We report nine consecutive patients with progressive DLBCL",
            "probability": 0.033447265625
        },
        {
            "start_logit": -0.380615234375,
            "end_logit": -0.399658203125,
            "text": " progressive DLBCL after preceding CAR T-cell therapy.",
            "probability": 0.03021240234375
        },
        {
            "start_logit": 0.2705078125,
            "end_logit": -1.0693359375,
            "text": "DLBCL after preceding CAR T-cell therapy",
            "probability": 0.0296630859375
        },
        {
            "start_logit": -0.421875,
            "end_logit": -0.399658203125,
            "text": " T-cell therapy.",
            "probability": 0.02899169921875
        },
        {
            "start_logit": -0.60693359375,
            "end_logit": -0.21923828125,
            "text": "CD20xCD3 antibody glofitamab in patients who progressed after CAR T treatment.",
            "probability": 0.0288543701171875
        },
        {
            "start_logit": 0.630859375,
            "end_logit": -1.5185546875,
            "text": " CAR T",
            "probability": 0.027130126953125
        },
        {
            "start_logit": -0.60693359375,
            "end_logit": -0.48583984375,
            "text": "CD20xCD3 antibody glofitamab in patients who progressed after CAR T treatment",
            "probability": 0.0221099853515625
        },
        {
            "start_logit": -0.7626953125,
            "end_logit": -0.399658203125,
            "text": " CAR T-cell therapy.",
            "probability": 0.0206146240234375
        },
        {
            "start_logit": -0.990234375,
            "end_logit": -0.21923828125,
            "text": ".",
            "probability": 0.0196685791015625
        },
        {
            "start_logit": 0.630859375,
            "end_logit": -1.8837890625,
            "text": " CAR T treatment. We report nine consecutive patients with progressive DLBCL after preceding CAR T-cell",
            "probability": 0.0188446044921875
        },
        {
            "start_logit": -0.990234375,
            "end_logit": -0.399658203125,
            "text": ". We report nine consecutive patients with progressive DLBCL after preceding CAR T-cell therapy.",
            "probability": 0.016448974609375
        },
        {
            "start_logit": -1.72265625,
            "end_logit": 0.312744140625,
            "text": "xCD3 antibody glofitamab in patients who progressed after CAR T treatment. We report nine consecutive patients with progressive DLBCL",
            "probability": 0.016082763671875
        }
    ],
    "63eeeb70f36125a426000005_0003": [
        {
            "start_logit": 6.046875,
            "end_logit": 5.6953125,
            "text": "DLBCL",
            "probability": 0.94189453125
        },
        {
            "start_logit": 6.046875,
            "end_logit": 2.1796875,
            "text": "DLBCL relapsing after CAR",
            "probability": 0.0279998779296875
        },
        {
            "start_logit": 6.046875,
            "end_logit": 1.123046875,
            "text": "DLBCL relapsing after CAR T-cell therapy",
            "probability": 0.0097503662109375
        },
        {
            "start_logit": 6.046875,
            "end_logit": -0.039215087890625,
            "text": "DLBCL relapsing after CAR T-cell therapy and can enhance residual CAR T-cell activity.",
            "probability": 0.0030460357666015625
        },
        {
            "start_logit": 0.2607421875,
            "end_logit": 5.6953125,
            "text": " DLBCL",
            "probability": 0.002895355224609375
        },
        {
            "start_logit": 6.046875,
            "end_logit": -0.289794921875,
            "text": "DLBCL relapsing after CAR T-cell therapy and can enhance residual CAR",
            "probability": 0.0023708343505859375
        },
        {
            "start_logit": 6.046875,
            "end_logit": -0.55126953125,
            "text": "DLBCL relapsing",
            "probability": 0.0018253326416015625
        },
        {
            "start_logit": 6.046875,
            "end_logit": -0.6455078125,
            "text": "DLBCL relapsing after CAR T-cell therapy and can enhance residual CAR T-cell activity",
            "probability": 0.0016622543334960938
        },
        {
            "start_logit": 6.046875,
            "end_logit": -0.76708984375,
            "text": "DLBCL relapsing after CAR T",
            "probability": 0.00147247314453125
        },
        {
            "start_logit": 6.046875,
            "end_logit": -1.1240234375,
            "text": "DLB",
            "probability": 0.0010280609130859375
        },
        {
            "start_logit": 6.046875,
            "end_logit": -1.1875,
            "text": "DLBCL relapsing after CAR T-cell",
            "probability": 0.0009655952453613281
        },
        {
            "start_logit": 2.67578125,
            "end_logit": 2.1796875,
            "text": " CAR",
            "probability": 0.0009622573852539062
        },
        {
            "start_logit": 6.046875,
            "end_logit": -1.2275390625,
            "text": "DLBCL relapsing after",
            "probability": 0.0009288787841796875
        },
        {
            "start_logit": -1.11328125,
            "end_logit": 5.6953125,
            "text": "BCL",
            "probability": 0.0007319450378417969
        },
        {
            "start_logit": 6.046875,
            "end_logit": -1.4873046875,
            "text": "DL",
            "probability": 0.0007152557373046875
        },
        {
            "start_logit": -1.65625,
            "end_logit": 5.6953125,
            "text": "CL",
            "probability": 0.00042510032653808594
        },
        {
            "start_logit": 6.046875,
            "end_logit": -2.01953125,
            "text": "DLBCL relapsing after CAR T-cell therapy and can enhance residual CAR T",
            "probability": 0.0004203319549560547
        },
        {
            "start_logit": -1.7685546875,
            "end_logit": 5.6953125,
            "text": " well tolerated and effective in patients with DLBCL",
            "probability": 0.00037980079650878906
        },
        {
            "start_logit": 6.046875,
            "end_logit": -2.185546875,
            "text": "DLBCL relapsing after CAR T-cell therapy and can enhance residual CAR T-cell",
            "probability": 0.0003552436828613281
        },
        {
            "start_logit": 2.67578125,
            "end_logit": 1.123046875,
            "text": " CAR T-cell therapy",
            "probability": 0.0003337860107421875
        }
    ],
    "63eeeb70f36125a426000005_0004": [
        {
            "start_logit": 5.48046875,
            "end_logit": 3.92578125,
            "text": "DLBCL",
            "probability": 0.97900390625
        },
        {
            "start_logit": 5.48046875,
            "end_logit": -0.4931640625,
            "text": "DLBCL.",
            "probability": 0.011810302734375
        },
        {
            "start_logit": 0.38134765625,
            "end_logit": 3.92578125,
            "text": " nuclear export selinexor, and several new agents have been investigated for DLBCL",
            "probability": 0.0059814453125
        },
        {
            "start_logit": -1.0439453125,
            "end_logit": 3.92578125,
            "text": "BCL",
            "probability": 0.001438140869140625
        },
        {
            "start_logit": -1.91796875,
            "end_logit": 3.92578125,
            "text": "tesirine, oral selective inhibitor of nuclear export selinexor, and several new agents have been investigated for DLBCL",
            "probability": 0.0005993843078613281
        },
        {
            "start_logit": -2.15234375,
            "end_logit": 3.92578125,
            "text": " oral selective inhibitor of nuclear export selinexor, and several new agents have been investigated for DLBCL",
            "probability": 0.00047397613525390625
        },
        {
            "start_logit": -2.873046875,
            "end_logit": 3.92578125,
            "text": " DLBCL",
            "probability": 0.00023102760314941406
        },
        {
            "start_logit": -2.92578125,
            "end_logit": 3.92578125,
            "text": "selinexor, and several new agents have been investigated for DLBCL",
            "probability": 0.00021886825561523438
        },
        {
            "start_logit": 0.38134765625,
            "end_logit": -0.1829833984375,
            "text": " nuclear export",
            "probability": 9.78708267211914e-05
        },
        {
            "start_logit": 0.10113525390625,
            "end_logit": -0.1829833984375,
            "text": "tafasitamab combined with lenalidomide, CD19 antibody drug conjugate loncastuximab tesirine, oral selective inhibitor of nuclear export",
            "probability": 7.444620132446289e-05
        },
        {
            "start_logit": 0.38134765625,
            "end_logit": -0.4931640625,
            "text": " nuclear export selinexor, and several new agents have been investigated for DLBCL.",
            "probability": 7.212162017822266e-05
        },
        {
            "start_logit": 0.38134765625,
            "end_logit": -1.412109375,
            "text": " nuclear export selinexor",
            "probability": 2.872943878173828e-05
        },
        {
            "start_logit": 0.10113525390625,
            "end_logit": -1.3486328125,
            "text": "tafasitamab combined with lenalidomide, CD19 antibody drug conjugate loncastuximab tesirine",
            "probability": 2.3066997528076172e-05
        },
        {
            "start_logit": -1.107421875,
            "end_logit": -0.1829833984375,
            "text": " lenalidomide, CD19 antibody drug conjugate loncastuximab tesirine, oral selective inhibitor of nuclear export",
            "probability": 2.2172927856445312e-05
        },
        {
            "start_logit": 0.10113525390625,
            "end_logit": -1.5087890625,
            "text": "tafasitamab combined with lenalidomide, CD19 antibody drug conjugate loncas",
            "probability": 1.9729137420654297e-05
        },
        {
            "start_logit": -0.2861328125,
            "end_logit": -1.1279296875,
            "text": "CD19",
            "probability": 1.9550323486328125e-05
        },
        {
            "start_logit": 0.10113525390625,
            "end_logit": -1.625,
            "text": "tafasitamab combined with lenalidomide",
            "probability": 1.7583370208740234e-05
        },
        {
            "start_logit": 0.38134765625,
            "end_logit": -1.916015625,
            "text": " nuclear export selinexor,",
            "probability": 1.7404556274414062e-05
        },
        {
            "start_logit": -1.0439453125,
            "end_logit": -0.4931640625,
            "text": "BCL.",
            "probability": 1.728534698486328e-05
        },
        {
            "start_logit": 0.10113525390625,
            "end_logit": -1.673828125,
            "text": "tafasitamab",
            "probability": 1.6748905181884766e-05
        }
    ],
    "63eeeb70f36125a426000005_0005": [
        {
            "start_logit": 6.4453125,
            "end_logit": 6.97265625,
            "text": "Hodgkin lymphoma",
            "probability": 0.552734375
        },
        {
            "start_logit": 6.1953125,
            "end_logit": 6.97265625,
            "text": " non-Hodgkin lymphoma",
            "probability": 0.430419921875
        },
        {
            "start_logit": 2.7734375,
            "end_logit": 6.97265625,
            "text": "B-cell non-Hodgkin lymphoma",
            "probability": 0.01404571533203125
        },
        {
            "start_logit": -0.76806640625,
            "end_logit": 6.97265625,
            "text": " lymphoma",
            "probability": 0.0004050731658935547
        },
        {
            "start_logit": 6.4453125,
            "end_logit": -0.3330078125,
            "text": "Hodgkin lymphoma.",
            "probability": 0.00037026405334472656
        },
        {
            "start_logit": -0.982421875,
            "end_logit": 6.97265625,
            "text": "NP30179, a first-in-human, phase 1 trial in relapsed/refractory B-cell non-Hodgkin lymphoma",
            "probability": 0.00032782554626464844
        },
        {
            "start_logit": 6.1953125,
            "end_logit": -0.3330078125,
            "text": " non-Hodgkin lymphoma.",
            "probability": 0.00028824806213378906
        },
        {
            "start_logit": 6.4453125,
            "end_logit": -0.82470703125,
            "text": "Hodgkin",
            "probability": 0.0002262592315673828
        },
        {
            "start_logit": 6.1953125,
            "end_logit": -0.82470703125,
            "text": " non-Hodgkin",
            "probability": 0.00017690658569335938
        },
        {
            "start_logit": -1.6279296875,
            "end_logit": 6.97265625,
            "text": " relapsed/refractory B-cell non-Hodgkin lymphoma",
            "probability": 0.00017142295837402344
        },
        {
            "start_logit": 6.1953125,
            "end_logit": -1.0634765625,
            "text": " non",
            "probability": 0.00013887882232666016
        },
        {
            "start_logit": 6.4453125,
            "end_logit": -1.3720703125,
            "text": "Ho",
            "probability": 0.00013136863708496094
        },
        {
            "start_logit": 6.1953125,
            "end_logit": -1.3720703125,
            "text": " non-Ho",
            "probability": 0.0001024007797241211
        },
        {
            "start_logit": -2.18359375,
            "end_logit": 6.97265625,
            "text": "179, a first-in-human, phase 1 trial in relapsed/refractory B-cell non-Hodgkin lymphoma",
            "probability": 9.846687316894531e-05
        },
        {
            "start_logit": -2.322265625,
            "end_logit": 6.97265625,
            "text": "kin lymphoma",
            "probability": 8.553266525268555e-05
        },
        {
            "start_logit": 6.1953125,
            "end_logit": -1.654296875,
            "text": " non-",
            "probability": 7.665157318115234e-05
        },
        {
            "start_logit": -2.517578125,
            "end_logit": 6.97265625,
            "text": "gkin lymphoma",
            "probability": 7.033348083496094e-05
        },
        {
            "start_logit": -2.544921875,
            "end_logit": 6.97265625,
            "text": ", a first-in-human, phase 1 trial in relapsed/refractory B-cell non-Hodgkin lymphoma",
            "probability": 6.872415542602539e-05
        },
        {
            "start_logit": -2.568359375,
            "end_logit": 6.97265625,
            "text": ", phase 1 trial in relapsed/refractory B-cell non-Hodgkin lymphoma",
            "probability": 6.711483001708984e-05
        },
        {
            "start_logit": -2.57421875,
            "end_logit": 6.97265625,
            "text": " phase 1 trial in relapsed/refractory B-cell non-Hodgkin lymphoma",
            "probability": 6.663799285888672e-05
        }
    ]
}
